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Abstract 
 
   N-myristoyltransferase (NMT) is a monomeric enzyme, which is ubiquitous in 
eukaryotes, catalysing an irreversible co-translational transfer of myristate to a particular 
set of proteins containing an N-terminal glycine. The work presented in this thesis 
illustrates the use of synthesised small molecules as a probe to investigate the role of 
NMT in parasites. 
   Chapter 1 looks at the two parasitic diseases that this project targets: malaria and 
visceral leishmaniasis, which are caused by Plasmodium falciparum (Pf) and Leishmania 
donovani (Ld) respectively. Additionally, biological evidence to show that NMT is a 
promising drug target in these parasites is presented.  
   Chapter 2 describes a piggy-back strategy, which was applied to discover a 
benzofuran compound with moderate inhibition against PfNMT. This molecule was re-
synthesised and then validated as a hit by an optimised scintillant proximity assay. 
   Chapter 3 details the process of drug design based on the inhibition data against 
PfNMT and structural information of the related enzymes, in which a library of 150 
benzofuran analogues was generated. Importantly, the cell inhibition results provided 
strong evidence to chemically validate NMT as a drug target in P. falciparum, leading to 
the identification of a lead candidate.  
   Chapter 4 gives the initial structure-activity relationships for LdNMT inhibitors, 
whereby the whole library of the PfNMT inhibitors was screened against LdNMT. In 
addition, combined with the parasite inhibition assay, two compounds were determined 
to be the early lead candidates for LdNMT inhibitors.   
   Chapter 5 provides an overview of the work detailed in this thesis and suggests 
the future directions that will continue the advancement of this project.  
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1 Introduction and overview 
 
1.1 Parasitic diseases 
 
Parasitic diseases are infectious diseases caused by parasites, which affect all 
living organisms and cause mild discomfort or even death[1]. Approximately 240 parasitic 
diseases are reported to be spread from insects to humans[2]; among them, malaria and 
visceral leishmaniasis are most prevalent and deadly[3].   
 
1.1.1   Malaria 
 
Malaria, a tropical disease, remains one of the most severe global health 
problems of our time, with 3 billion people at risk, approximately 243 million cases and 
863,000 attributed deaths reported globally in 2008[4]. It is caused by micro-organisms of 
the genus Plasmodium that are transmitted to human hosts via female Anopheles 
mosquitoes. There are five different species that can infect humans: P. vivax, P. ovale, P. 
malariae, P. Knowlesi and P. falciparum; of which falciparum malaria causes most 
mortality (93%)[4], mainly in children below the age of five.  
 
1.1.1.1   Global distribution 
 
Malaria has a broad distribution in both the tropics and subtropics. The 
countries of sub-Saharan Africa account for the majority of all malaria cases, with the 
remainder mostly clustered in India, Brazil, Afghanistan, Sri Lanka, Thailand, Indonesia, 
Vietnam and Cambodia[5] (Figure 1.1).  
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Figure 1.1  Distribution of malaria risk areas in the world in 2007
[5]
 
 
1.1.1.2   Life cycle of malaria parasites 
 
The life cycle of malaria parasites involves two hosts, the human and mosquito. 
Beginning with a bite of an infected female Anopheles mosquito, sporozoites are 
transmitted to a human host. The sporozoites migrate to the liver in ca. 30 minutes (in 
the case of P. falciparum)[6] and invade hepatocytes, maturing into schizonts (ca. 5 days 
in P. falciparum; P. vivax forms a dormant stage, which lasts for weeks or even years 
before continuing to schizonts[7]). Schizonts then replicate, leading to the rupture of 
hepatocytes and the release of merozoites. After initial replication in the liver (exo-
erythrocytic cycle), the extracellular merozoites rapidly infect red blood cells, where the 
parasites mature and replicate in a ca. 48 hour cycle (in the case of P. falciparum)[6], 
through immature and mature trophozoites, followed by schizonts which then rupture, 
releasing merozoites to infect more erythrocytes (asexual erythrocytic cycle). Blood 
stage parasites are mainly responsible for the clinical symptoms of malaria, such as fever, 
diarrhoea and vomiting; therefore most chemotherapeutic treatments of the disease 
target this stage. Some parasites differentiate into gametocytes, which in turn infect a 
healthy mosquito during its blood meal from an infected human host. For the period of 
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the sexual reproduction of parasites in a mosquito (sporogonic cycle), male and female 
gametes yield zygotes, which then develop into ookinetes and mature into oocysts. The 
oocysts grow and rupture to release sporozoites that migrate to the mosquito’s salivary 
glands, which can be delivered to a new human host to start another life cycle[8] (Figure 
1.2).   
 
Figure 1.2  Life cycle of malaria parasite 
(The Picture is from http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Malaria_il.htm) 
During a blood meal, the parasites (sporozoite form) from an infected mosquito are delivered into 
the bloodstream of the human host. After rapid invasion of the liver cells, the parasites develop 
and replicate in the exo-erythrocytic cycle. The rupture of schizonts releases merozoites which 
further infect red blood cells to undergo the erythrocytic cycle, a phase of asexual reproduction 
producing merozoites to infect more erythrocytes which accounts for the most clinical symptoms 
of malaria. Some merozoites differentiate into gametocytes which are ingested as a part of a 
healthy mosquito’s blood meal, to initiate the sexual reproduction called sporogonic cycle. The 
male and female gamates form a zygote and subsequently mature to oocyst. Sporozoites, once 
ruptured from oocysts, migrate to the mosquito’s salivary glands from where sporozoites return to 
another human host during a new bite.  
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1.1.1.3   Development of antimalarial drugs 
 
Attempts to develop vaccines for malaria are in their infancy because of the 
complexity of malaria parasites and lack of funding[9].In 2010, GSK Biologicals launched a 
phase III trial of its most promising vaccine candidate, known as RTS,S, in seven African 
countries along with the local leading research institutions[10]. Currently however, 
chemotherapy remains the only option for the treatment.  
Chloroquine (Figure 1.3) was used extensively in the treatment of all types of 
malaria for several decades as it was safe, highly effective and cheap. However, since 
chloroquine resistance was first reported in Thailand in 1957, resistance spread so fast 
that today chloroquine has lost its efficacy in most epidemic areas[11]. Systematic 
exploration of chemical space around the 4-aminoquinoline scaffold of chloroquine 
discovered a promising derivative AQ-13 (Figure 1.3), showing excellent inhibition 
against chloroquine-resistant P. falciparum parasites and satisfactory pharmacokinetics[12, 
13]. This molecule is currently in a phase II clinical trial[14]. Amodiaquine (Figure 1.3) is 
another effective agent for chloroquine-resistant parasites[15]. However, its p-
hydroxyanilino moiety was found to be oxidised by cytochrome P450 to a chemically 
reactive quinoneimine species in rats, thereby accounting for the observed toxicity in 
humans[16]. Regioisomers of amodiaquine, proposed and developed by O’Neill[17], 
successfully bypassed the formation of the toxic metabolite, resulting in the discovery of 
N-t-butyl isoquine[18] (Figure 1.3). Unfortunately, this molecule suffered from an 
unexpected side effect at the high dose regimen and discontinued in the phase I trial[19].  
Artemisinin (Figure 1.3), a plant-derived natural product initially identified by 
Chinese researchers[20, 21], was shown to be highly potent for multi-drug resistant malaria 
parasites. To overcome its poor bioavailability, subsequent work concentrated on the 
modification of the C-10 moiety, leading to the identification of artemisinin’s semi-
synthetic derivatives artemether, artesunate and dihydroartemisinin (Figure 1.3). At 
present, artemisinin-based combination therapies (ACT) are recommended by World 
Health Organization for malaria in regions where drug resistance against other 
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antimalarials is prevalent. Artemisone is a single-drug therapy, displaying less toxicity 
than current ACTs, now in a phase II clinical trial[6]. However, high costs could prevent it 
from being widely used in the future. The supply of artemisinin is a major drawback of 
this therapy category since purely chemical synthesis is generally too expensive [22-25] and 
sole extraction from natural plants is not ecologically friendly. With the rapid 
development of biotechnology, a combination of bioengineering and chemical synthesis 
becomes feasible: Keasling’s lab successfully transplanted the plant biosynthetic genes 
into yeasts to allow the production of artemisinic acid[26] (Figure 1.3), which can be 
simply converted to artemisinin in 5 steps[27]. 
Artemisinin’s unusual endoperoxide bridge is essential to its mechanism of 
action, which involves a complexation with haem (Fe2+) by the coordination of the 
peroxide bridge with iron. This binding interrupts the haemin detoxification process used 
by the parasite and thus frees the radical species which can kill the parasite[28]. Inspired 
by this mechanism, totally synthetic peroxide-containing compounds were designed and 
synthesised. Encouragingly, they were found to mimic the behaviour of artemisinin in 
parasites[29]. Among them, 1,2,4-trioxane OZ277 (Figure 1.3) exhibited comparable in-
vivo activity with current ACTs[30]. However, a phase II clinical study revealed that this 
compound had a 3-fold lower exposure in malaria patients compared with healthy 
volunteers[31]. Subsequent study found that its analogue or OZ439[32] (Figure 1.3) showed 
a longer half-life with enhanced  exposure than OZ277 in malaria patients [31] and the 
clinical evaluation of OZ439 is underway[6]. Given the stability concerns of the 1,2,4-
trioxolane moiety, O’Neill proposed a class of 1,2,4,5-tetraoxane compounds[33] which 
showed comparable inhibition and better stability than the 1,2,4-trioxolane series, 
leading to the discovery of another clinical candidate RKA182 (Figure 1.3). All the above 
drugs and clinical candidates are supposed to inhibit the growth of hemozoin, a key 
target for the development of the antimalarial drugs [34-36].   
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Figure 1.3  Structures of antimalarial drugs in clinical use 
Artemisinin resistance was first recorded in western Cambodia in 2009[37]. 
Therefore, it is urgent to develop new drugs, especially considering that no novel class of 
antimalarials has been introduced into clinical practice since 1996[38]. Funded by MMV 
(Medicines for Malaria Venture) and in cooperation with the pharmaceutical industry, 
more than five million compounds (natural products and synthetic molecules) have been 
screened for activity against malaria parasites[39, 40]; among them, Norvatis identified a 
synthetic compound related to the spiroindolone class and successfully optimised this 
molecule to NITD609 (Figure 1.3), possessing sub-nM parasite inhibition and satisfactory 
pharmacokinetics[41]. More excitingly, the compound was suggested to adopt a novel 
mechanism of action different from those of artemisinin and chloroquine[42]. Therefore, 
this molecule is viewed as a promising alternative to artemisinin if artemisinin resistance 
were to spread and is currently in a phase I clinical trial[43]. 
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1.1.2   Visceral leishmaniasis 
 
Visceral leishmaniasis (VL, also known as kala-azar) is another lethal parasitic 
disease, characterised by fever, weight loss, anemia and depression of the immune 
system, threatening about 200 million people with an estimated 500,000 cases annually 
and greater than 50,000 deaths reported in 2004[44]. The real burden of VL might be 
much higher than the number of reported cases because of serious underreporting[45] 
and poor access to diagnosis and treatment[46] in some developing countries. The disease 
is transmitted by a female Phlebotomine sandfly and caused by different species of 
Leishmania parasites.  
 
1.1.2.1   Global distribution 
 
90% of reported VL cases occur in just five countries: Bangladesh, Brazil, India, 
Nepal and Sudan[47, 48] (Figure 1.4). The interesting problem associated with the 
geography affects the choice of treatment. In South Asia and East Africa (Old World) 
where drug resistance is a major concern, humans are the main reservoir for disease 
transmission and L. donovani is the causative agent[49]; in contrast, in South America 
(New World), domestic dog infection is the principal route to transmit the disease and 
drug resistance is no longer a problem[48].   
 
Figure 1.4  Global distribution of visceral leishamaniasis in 2009
[48]
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1.1.2.2   Life cycle of leishmania parasites 
 
Beginning with a bite of a female Phlebotomine sandfly, promastigote parasites 
(the infective stage) are transmitted into a human host and phagocytised by 
macrophages to form amastigotes, the causative stage of leishmaniasis. After that, the 
amastigotes replicate inside cells, responsible for a variety of clinical symptoms, such as 
fever and weight loss. During another blood meal from an infected human, a healthy 
sandfly takes up the infected macrophages which are then converted back to 
promastigotes in fly’s midgut. The resulting promastigotes multiply and migrate to fly’s 
proboscis, which can be delivered to another human host to start a new life cycle[50] 
(Figure 1.5).   
 
Figure 1.5  Life cycle of leishmania parasites   
(The picture is from http://www.uni-tuebingen.de/modeling/Mod_Leish_Cycle_en.html) 
During a blood meal, promastigotes (infective stage) are transmitted from a female sandfly into a 
human host, where they are phagocytised and transformed into amastigotes (causative stage). 
Amastigotes continue to replicate inside cells, which are then taken up by a healthy sandfly during 
its blood meal. In fly’s midgut, amastigotes are converted back to promastigotes, which undergo a 
further replication and migrate to fly’s proboscis, where the parasites return to another human 
host during a new bite.  
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1.1.2.3   Development of antileishmanial drugs 
 
Although VL is one of the most severe tropical diseases in the world, its research 
into new drugs has stalled for a long time[49].  Despite the toxicity associated with 
gastrointestinal symptoms[51] and emerging clinical resistance[52, 53], antimony-based 
therapy (sodium stibogluconate, meglumine antimoniate, Figure 1.6), developed nearly 
70 years ago, is still widely used as the first-line antileishmanial treatment because it 
requires minimal monitoring. Miltefosine (Figure 1.6), originally used as an anti-cancer 
drug, was later identified to be the first oral drug for VL[54]. However, rat models 
demonstrated that miltefosine induced testicular changes[55], raising concerns of 
potential teratogenicity, thereby requiring careful use and monitoring especially for 
women in child-bearing age[56]. Amphotericin B (Figure 1.6), especially its liposomal 
formulation, is a breakthrough for the treatment of VL since it is safe and effective, 
requiring a low administrable dose[57]. However, the high cost of US $300 per patient is 
still prohibitive for most VL-epidemic countries[49]. Paromomycin (Figure 1.6), originally 
used as a broad spectrum antibiotic against bacteria and intestinal protozoa, showed 
good cure rates for the VL patients with minor toxicity[58]. In addition, the low cost (US 
$15 per treatment[49]) is a big advantage over other available drugs. However, resistance 
was observed in vitro[59]. Therefore, paromomycin is suggested for use in combination 
with other therapies to avoid future problems with clinical failure[60].  
Combination regimens have been intensively and successfully used for the 
treatment of malaria, thereby forming the rationale for the same approach applied to VL. 
Currently, clinical trials of a variety of combinations based on the five available 
antileishmanial drugs are underway[61] (data from http://clinicaltrials.gov/ct2/home). In 
terms of the novel agents, sitamaquine (Figure 1.6), an oral treatment of VL, was 
developed by the Walter Reed Army Institute and GSK[62], receiving promising efficacy 
and acceptable safety profile from a phase II clinical trial[63]; Institute Pasteur Korea 
screened a 26,500-compound library with diverse structures, leading to the 
identification of  CH872 (excellent inhibition and toxicity tolerance in vitro, Figure 1.6) as 
a good candidate to the VL drug discovery pipeline[64]; a therapeutic vaccine for VL via 
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(re-) activation of CD8+ T-cell responses is currently progressing through the final pre-
clinical stages, with the aim to conduct a phase I clinical trial in early 2011 (personal 
communication from Prof. D. Smith, York University). 
 
Figure 1.6  Structures of antileishmanial drugs in clinical use 
 
1.1.3   Summary 
 
Malaria and VL affect hundreds of millions of people worldwide and result in 
significant mortality and devastating social and economic consequences, especially in 
poor third world countries (Table 1.1). However, most available drugs that were 
developed decades ago, frequently suffer from resistance or severe toxicities. In terms of 
the antimalarials, ACT is currently heavily relied on to treat the disease and new 
treatments are still based on the structure of artemisinin or its key peroxide moiety (OZ 
series and RKA182), raising potential resistance concerns (Table 1.1). In fact, signs of 
artemisinin resistance were observed in western Cambodia in 2009[37] although it is not 
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yet a significant clinical problem. Nevertheless, it is still urgent to discover drug 
candidates with novel structures and inhibition mechanisms. The situation for VL is even 
more challenging, whereby high supply costs prevent amphotericin from being widely 
used and other available drugs are associated with severe toxicities or resistance (Table 
1.1). No novel compounds nor vaccines are expected to be approved until 2014 at the 
earliest[65, 31]. Thus, new strategies of chemotherapy are desperately needed.      
Table 1.1  Current situation of malaria and visceral leishmaniasis  
 Malaria Visceral leishmaniasis 
Global burden Billion people at risk 
243 million cases 
86300 deaths 
250 million people in threat 
500,000 cases 
>50,000 deaths 
Global distribution Sub-Saharan Africa, India, 
Brazil, Afghanistan, Sri Lanka, 
Thailand, 
Indonesia, Vietnam, Cambodia 
Bangladesh, Brazil, India, Nepal 
Sudan 
Transmission 
vector 
Female Anopheles mosquito 
and human host 
Female Phlebotomine sandfly, 
human host in south Asia, east 
Africa or dog host in South 
America 
Causative 
parasites 
P. falciparum (most deadly) 
P. vivax (most widespread, 
latent stage) 
L. donovani (infects human) 
L. infantum and L. chagasi 
(infect dog) 
Available drugs  
(their weakness) 
Artemisinin-based combination 
therapy (cost, supply shortage, 
potential resistance) 
Antimonials, Miltesofine 
(toxicity) 
Paromomycin (rapid drug 
resistance) 
Amphotericin B (cost) 
Novel drugs in 
clinical trial 
Artemisone 
OZ series (1,2,4-trioxane series) 
RKA182 (1,2,4,5-tetraoxane 
series) 
NITD609 (spiroindolone series) 
RTS,S  (Vaccine) 
Sitamaquine 
CD8+ T-cell vaccine 
Therapeutic 
challenges 
Circumventing drug resistance Cheap, safe, orally bioavailable 
drugs with minimal monitoring 
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1.2   N-myristoyltransferase 
 
N-myristoyltransferase (NMT) is a monomeric enzyme, ubiquitous in eukaryotes. 
NMT catalyses a co-translational transfer of a saturated 14-carbon acyl or myristate from 
myristoyl-Coenzyme A (myr-CoA) to a protein substrate containing an N-terminal glycine 
via an amide bond[66]. N-myristoylation plays a key role in protein trafficking, mediating 
protein-protein interactions and stabilising protein structures[67]. 
 
1.2.1   Mechanism of NMT 
 
N-myristoylation by NMT follows an ordered Bi-Bi mechanism, in which the 
binding of myr-CoA to NMT occurs prior to the binding of a protein substrate [68]; bound 
myr-CoA facilitates the opening of a second binding pocket for a protein substrate, 
followed by a transfer of myristate to the protein substrate via a nucleophilic addition-
elimination reaction, finally with the release of CoA and the myristoylated protein. 
 
Figure 1.7  The catalytic cycle of NMT 
The enzyme (shown in yellow) first binds myr-CoA, inducing a conformational change which is to 
accommodate the binding of a peptide substrate (coloured in green). Then the amide bond 
(drawn in cyan) is formed via a nucleophilic addition-elimination reaction, followed by the release 
of CoA and the myristoylated protein 
[68]
.  
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1.2.2   NMT is a promising drug target 
 
Lipid modification of cellular proteins in eukaryotes, which includes 
myristoylation, palmitoylation and prenylation, plays important roles in protein 
trafficking and signal transduction in living systems[69]. In general, myristoylation or 
prenylation produces transient interactions of proteins with membranes, a prerequisite 
for palmitoylation to yield dually lipidated proteins that have long-lived associations with 
cellular membranes[70]. Therefore, inhibition of myristoylation has the potential to 
disrupt multi-protein pathways, an attractive characteristic to prevent resistance. 
 
1.2.2.1   NMT is an anti-fungal target 
 
NMTs are well characterised in Saccharomyces cerevisiae[71], Candida albicans[72], 
Cryptococcus neoformans[73] and mammalian cells (NMT1[74] and NMT2[75]). Disruption of 
the yeast NMT gene was reported to cause recessive lethality in S. cerevisiae[71] and 
genetic studies  revealed that NMT was essential for the viability of C. neoformans[76] and 
C. albicans[77]. Researchers at Roche further showed that a lack of NMT resulted in a loss 
of ability of C. albicans to infect mice[78]. In addition, biochemical analysis showed high 
conservation of myr-CoA binding sites, but divergent peptide binding specificities 
between human and fungal NMTs[67], indicating a possibility to gain selectivity when 
targeting the peptide binding pocket[79]. As a consequence, NMT was viewed as a novel 
anti-fungal target by a number of pharmaceutical companies (Pfizer, Roche and SSP, 
merged into Boehringer Ingelheim in 2010), with the aim of developing selective non-
peptidic inhibitors. Several lead candidates were identified from these projects, showing 
both excellent potency and selectivity over human NMTs in vitro (Pfizer, unpublished 
data; Roche[80-83]; SSP[84]). Unfortunately, given a narrow spectrum of antifungal activity 
of these molecules, these projects were terminated; nevertheless this data proves the 
concept that targeting the peptide binding pocket of NMT to develop selective inhibitors 
is feasible.     
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1.2.2.2   Essentiality of NMT in parasites 
 
NMTs from parasitic organisms have been well characterised during the past 
decade, which include Plasmodium falciparum (Pf, most deadly species in malaria)[85], 
Plasmodium vivax (Pv, a latent but highly prevalent form of Plasmodium species), 
Leishmania major (Lm, causative agent of cutaneous leishmaniasis)[86], Leishmania 
donovani (Ld, causative agent of VL)[87] and Trypanosoma brucei (Tb, causative agent of 
African sleeping sickness)[86]. Myr-CoA analogues, the non-specific competitive NMT 
inhibitors, were reported to inhibit the growth of promastigotes of L. major parasites[86], 
indicating a correlation between the loss of parasite viability and reduced N-
myristoylation. In addition, disruption of the LmNMT gene resulted in the demise of 
promastigotes[86]. The same approach was applied to L. donovani promastigotes and the 
results revealed that the parasites required at least one allele of the NMT gene for 
successful propagation in culture[87]. However, current difficulties in transfecting and 
knocking down the NMT gene selectively in intracellular amastigotes prevent direct 
evidence of essentiality of NMT in this causative stage [87, 86]. As in T. brucei, NMT was 
shown to be crucial for the viability of both host bloodstream and insect procyclic forms, 
using the RNA interference technique[86]. Further studies demonstrated that after 
silencing the NMT gene, bloodstream form T. brucei parasites were not able to establish 
an infection in a mouse model, genetically validating NMT as an anti-trypanosomatid 
target[88]. Several PfNMT inhibitors were reported to be anti-parasitic [89, 85], but it is not 
conclusive to show that NMT is critical for the growth of Plasmodium parasites. 
Additionally, full cycle cultivation of the asexual blood stage in P. vivax is currently not 
available, limiting the biological research into vivax malaria[90].  
 
1.2.2.3   Myristoylated proteins in parasites 
 
Aside from the chemical approach leading to effective drugs, identification of 
downstream myristoylated proteins and study of their biological functions is equally 
important to validate NMT as a drug target for parasites. Table 1.2 summarises the 
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known myristoylated proteins in parasites and their corresponding functions determined 
so far. These proteins are also found to be palmitoylated in vivo except for ARF (ADP-
ribosylation factor) and ARL (ARF-like) proteins where there is no cysteine residue 
existing in the N-terminal motif to allow palmitoylation to occur. In Plasmodium, ARF1[91] 
was shown to activate PIP5K (Phosphatidyl-inositol 4-phosphate 5-kinase), a key 
component to regulate cell motility and signalling[92]; GRASP1 (Golgi re-assembly stacking 
protein 1), as the name suggests, maintains the function of Golgi to transport proteins 
although recent research reported that its analogue, GRASP2, did not actually need 
myristoylation to mediate protein trafficking in Plasmodium[93]; two members of the 
calcium-dependent protein kinase (CDPK) family: CDPK1[94] was shown to form a motor 
complex with GAP45 (45kDa gliding-associated protein) and MTIP (Myosin A tail domain-
interacting protein) to regulate parasite invasion[95] and CDPK4 was determined to be 
critical for the gametocyte differentiation[96]. In Leishmania, dual acylation of HASPB 
(hydrophilic acylated surface protein B) protein was found to allow the exposure of this 
variable antigen on the external surface of infective stages for immune recognition in 
vivo[97-99] and the same protein was later described to be essential for the differentiation 
of L. major parasites in their sand fly vector[100]; SMP1 (small myristoylated protein 1), 
initially characterised in a Triton X-100 insoluble membrane fraction[101], was thought to 
maintain a normal flagellum function in Leishmania[102]. In Trypanosome, both ARF1 and 
ARL1 proteins were proven to be critical for the viability of bloodstream trypanosomes 
[103-105]. All the above proteins and the processes in which they are involved suggest that 
N-myristoylation plays an important role in the biology of parasites. 
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Table 1.2  Characterised myristoylated proteins in parasites and their biological functions   
Protein Biological function Comment Reference 
P. falciparum 
ARF1 
Activates PIP5K, a key 
regulator of cell motility, 
secretion and cell signalling 
Only myristoylated, but not 
palmitoylated 
[92, 91] 
P. falciparum 
GRASP1 
Associated with Golgi 
assembly stacking 
Existence of PfGRASP2, which 
is not myristoylated, via a 
lower-eukaryote-like 
mechanism 
[93] 
P. falciparum 
CDPK1 
Regulates merozoites 
invasion 
Unusual kinase family in 
Plasmodium and involves 
three N-terminal membrane 
anchor motifs 
[95, 106, 
94] 
P. berghei 
CDPK4 
Regulates gamete 
formation and mosquito 
transmission 
Unusual kinase family in 
Plasmodium 
[96, 107] 
P. falciparum 
GAP45 
Facilitates merozoites to 
invade the host cell 
A substrate of PfCDPK1 [95, 108] 
P. falciparum 
AK2 
Important in adenine 
nucleotide metabolism 
- [109] 
L. major 
HASPB 
Essential for the 
differentiation of parasites 
in the sand fly vector 
Unusual transportation 
behaviour 
[97, 100, 
98, 99] 
L. major  
PPEF 
- Bioinformatics prediction [110-113] 
L. major 
SMP1 
Vital for normal flagellum 
function 
Marker of flagellum 
elongation during amastigote 
to promastigote 
differentiation 
[102, 101] 
T. brucei 
ARF1 
Essential in endocytosis 
and Golgi-lysosome 
trafficking 
Only myristoylated, but not 
palmitoylated 
[105] 
T. brucei 
ARL1 
Critical for the viability of 
bloodstream trypanosomes 
Only myristoylated, but not 
palmitoylated 
[103, 104] 
T. brucei 
CAP5.5 
- Strictly life-cycle-regulated 
and only expressed in the 
procyclic form trypanosomes 
[114] 
Abbreviations used: ARF, ADP ribosylation factor; PIP5K, Phosphatidyl-inositol 4-phosphate 5-
kinase; GRASP, Golgi re-assembly stacking protein; CDPK, calcium-dependent protein kinase; 
GAP45, 45kDa gliding-associated protein; AK, adenylate kinase; HASP, hydrophilic acylated surface 
protein; PPEF, protein phosphatase with EF-hand; SMP, small myristoylated protein; ARL, ARF-like; 
CAP5.5, a novel cytoskeletal-associated protein 
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1.2.3   Current NMT inhibitors 
 
As described in Section 1.2.1, there are two binding pockets in NMT. One is the 
myr-CoA binding pocket and the other is the peptide binding pocket. Most reported 
NMT inhibitors so far target the peptide binding pocket.   
 
1.2.3.1   Peptidomimetic CaNMT inhibitors  
 
As mentioned in Section 1.2.2.1, CaNMT was viewed as a promising anti-fungal 
target. Searle (merged into Pfizer in 2000) started from the synthesis of an octapeptide 
(GLYASKLS-NH2, N-terminal octapeptide from a protein substrate), undergoing a partial 
replacement by ω-aminoalkyl and phenyl groups at the left side, to produce dipeptide 
inhibitor Sc-01 with high inhibition, but moderate selectivity of 18-fold over human 
NMT1[115]. Swapping ω-aminoalkyl by imidazole provided Sc-58272, showing comparable 
potency but much improved selectivity[116]. Although little antifungal activity was 
observed possibly because of the biological instability of the peptidomimetic in cells, Sc-
58272 was successfully co-crystalised with CaNMT to map the peptide binding pocket 
(PDB code: 1IYK)[117].  
 
Figure 1.8  Structures of peptidomimetic CaNMT inhibitors 
 
1.2.3.2   Non-peptidic CaNMT inhibitors  
 
              Two main series of non-peptidic inhibitors have been documented using either 
benzofuran or benzothiazole as the scaffold. The benzofuran series was developed by 
identifying a hit compound or RO-01 (Figure 1.9) from a random screening[83]. The hit 
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was then modified to give RO-09-4609 (Figure 1.9) showing sub-µM enzyme inhibition 
and high selectivity over human NMT1. The secondary amine (highlighted with a red 
circle in Figure 1.9) in the C-4 side chain was found to interact with the C-terminal Leu of 
CaNMT[83]. To improve the anti-fungal activity of RO-09-4609, subsequent efforts focused 
on the modification of the C-2 side chain. With the aid of 3D-quantitative structure-
activity relationship studies (3D-QSAR)[118, 119], RO-09-4746 and RO-02 (Figure 1.9) were 
discovered, showing much improved enzyme inhibition and antifungal activity[80-82]. 
However, poor pharmacokinetic (PK) profiles such as a short half life (t1/2) and low area 
under curve (AUC) [80, 81], indicated that these compounds might not be stable in vivo, 
responsible for the weak in-vivo efficacy observed in rats[81]. The project was later ceased 
given the narrow antifungal spectrum of this compound series. 
Figure 1.9  The evolution of the benzofuran CaNMT inhibitors 
The secondary amine highlighted with a red circle was observed to involve a hydrogen bond with 
the C-terminal Leu of CaNMT. 
A benzothiazole series was developed by identifying CP-123457 (Figure 1.10) as 
a hit from a high throughput screening (HTS). The ester group was then replaced to 
enhance the antifungal activity, followed by the exploration of different linkers and N-
substitutions on the right hand side of the scaffold, resulting in the identification of UK-
362091 with IC50 value of 11 nM and excellent selectivity over human NMT1 (Figure 
1.10). An interaction between the secondary amine (highlighted with a red circle in 
Figure 1.10) and the C-terminal Leu of CaNMT was observed (Mr. A. Bell, Pfizer, 
unpublished data). Interestingly, a new cavity induced by naphthyl (highlighted in blue, 
Figure 1.10) in UK-362091 upon binding was found from the co-crystal structure, 
compared with its free amine analogue UK-370485 (Figure 1.11, Mr. A. Bell, Pfizer, 
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unpublished results). Inspired by the structure of UK-362091, SSP, a Japanese 
pharmaceutical company which is now a part of Boehringer Ingelheim, adopted 
combinatorial chemistry to discover FTR1335 (Figure 1.10) as their best candidate[84]. 
Furthermore, FTR1335 was shown to be competitive with the peptide substrate and 
non-competitive with myr-CoA using an enzyme kinetic assay[120]. However, the resulting 
antifungal activities were not high enough for the further optimisation.   
 
Figure 1.10  Development of the benzothiazole CaNMT inhibitors 
The secondary amine highlighted with a red circle was observed to involve a hydrogen bond with 
the C-terminal Leu of CaNMT. Blue-coloured naphthyl was found to open up a new cavity on 
binding with CaNMT. 
 
 
Figure 1.11  Creation a new cavity by naphthyl in benzothiazole analogue UK-362091   
On comparison of the binding modes of the two structurally similar compounds (light green and 
dark green for UK-370485 and UK-362091 respectively), an orientation change of nearby amino 
acids (Tyr 210 and Phe 420) in the peptide binding pocket was noticed, which generates a new 
cavity occupied by naphthyl in compound UK-362091 (Pfizer, unpublished data). 
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1.2.3.3   Benzothiazole series for PfNMT 
 
Partnering with Pfizer, benzothiazole analogues were further researched against 
PfNMT in our group[89, 121]. Compound UK-370509 (Figure 1.12) was initially identified as 
a hit and the following work concentrated on the systematic variation of the 
composition of the right hand side chain (highlighted in red, Figure 1.12). However, only 
a small improvement of enzyme potency was achieved, whereby compounds FM-54 and 
FM-72 (Figure 1.12) were found to be most active[122]. Additionally, the low selectivity 
over both human NMTs and poor solubility significantly restricts the further 
investigation of this series.   
 
Figure 1.12  Study of benzothiazole series as PfNMT inhibitors 
The red-coloured moiety was the side chain being systematically studied in the previous 
project
[122]
.    
 
1.2.3.4   Sulphonamide series for TbNMT 
 
Screening of a library with 60,000 drug-like compounds[123] at Dundee University 
identified DDD64558, a pyrazole sulphonamide derivative, as a hit against TbNMT 
(Figure 1.13)[124]. Following work was undertaken to explore phenyl substitutions, leading 
to the discovery of DDD85602 (Figure 1.13), in which the terminal amine (highlighted 
with a red circle, Figure 1.13) was found to be essential to maintain the inhibitory activity. 
Subsequent rigidification of DDD85602 provided DDD85646 (Figure 1.13), the most 
active inhibitor, possessing low nano-molar range of potency against both the enzyme 
and parasites. More importantly, a tight correlation between the reduced activity of 
TbNMT and the inhibition of the Trypanosoma parasites was achieved, chemically 
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validating NMT as a target in T. brucei[124]. However, its low selectivity over human NMTs 
raises toxicity concerns although an in-vivo mouse model suggested that all mice were 
able to survive at the highest therapeutic dose (50 mg kg-1)[124]. The major drawback is 
that this molecule failed to cross the blood-brain barrier to kill the parasites in brain. 
Nevertheless it is still an exciting example of early-stage drug discovery conducted by an 
academic institution tackling tropical parasitic diseases, which are typically not viewed as 
a profitable market by the pharmaceutical industry.   
 
Figure 1.13  Identification of sulphonamide TbNMT inhibitors 
The terminal amine highlighted with a red circle was speculated to involve a hydrogen bond with 
the C-terminal Val of TbNMT. MRC-5 cell line is derived from a normal lung tissue of a 14-week-old 
male fetus
[125]
.  
 
1.3   Design and synthesis of parasite NMT inhibitors – PhD Project 
 
1.3.1   Target evaluation of PfNMT and LdNMT 
  
As stated in section 1.2.2, NMT is an attractive anti-parasitic target. By the time 
this project started in 2007, NMT from P. falciparum was well characterised[85]. A traffic 
light system, first proposed by Fairlamb[126], is shown below to evaluate the targetability 
of PfNMT at that stage (Table 1.3). Firstly, in terms of target validation, neither genetic 
(manipulation of the NMT gene in Plasmodium was not possible then) nor chemical 
validation had been achieved by then. However, research on the myristoylated proteins 
in P. falciparum suggested that N-myristoylation is important to keep parasites live 
(described in section 1.2.2.3). Secondly, it is essential for a medicinal chemistry project 
to have reliable biological assays in place so that compounds can be properly evaluated 
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and the structure-activity relationships can be derived. A scintillation proximity assay 
(SPA, detailed in section 2.1.2) was developed “in house”[107, 89] as a robust enzyme assay 
which was successfully employed in HTS by the Dundee Drug Discovery Unit to identify 
hits against TbNMT[124]. Fluorescent-activated cell sorting assay (FACS, detailed in section 
3.4.1) was also established to assess cell growth inhibition (Dr. A. Holder and Dr. D. Moss, 
National Institute for Medical Research). Thirdly, there are two NMTs characterised from 
human, known as HsNMT1 and HsNMT2, raising potential toxicity concerns although 
some evidence showed that selective inhibition is possible[107, 89]. Fourthly, with respect 
to resistance potential, there has been no NMT isoform found in parasitic organisms so 
far. In addition, inhibition of myristoylation is thought to disrupt multi-protein pathways 
in parasites (described in section 1.2.2), thereby reducing the possibility of developing 
resistance. Finally, there was no crystal structure of Plasmodium NMT when the project 
started; however, this is a desirable tool to direct rational inhibitor design as the project 
moves forward.   
Table 1.3  Traffic light system
[126]
 used to evaluate PfNMT as an anti-malarial target in 2007 
Criteria Comment 
Target validation No genetic or chemical validation; downstream proteins 
associated with biological pathways of parasites 
Assay feasibility Well developed enzyme[89] and cell-based assays[127] 
Toxicity concern Existence of human homologues and selective inhibition is 
possible[107, 89] 
Resistance potential Single gene copy and the potential to avoid resistance 
Structural information No Plasmodium NMT crystal structure 
Red represents that no information has been obtained; Amber indicates that only little 
information has been achieved and more progress is required; Green means that information or 
concept has been well understood and established. 
NMT was characterised from L. donovani in 2009[87], the causative agent of VL. 
The same target evaluation approach is applied to LdNMT (Table 1.4). Compared with 
PfNMT, the situation for LdNMT is more challenging. A major hurdle is the lack of a 
simple and reliable cell-based assay. In addition, there was little biological or chemical 
evidence at that time to show N-myristoylation is important for Leishmania parasites to 
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survive.   
Table 1.4  Traffic light system
[126]
 used to evaluate LdNMT as an anti-leishmanial target in 2009 
Criteria Comment 
Target validation weak genetic validation[87]; no chemical validation; weak 
functional knowledge of the downstream proteins 
Assay feasibility Well developed enzyme assay;  lack of a reliable cell-based 
assay 
Toxicity concern Existence of human homologues 
Resistance potential Single gene copy and the potential to avoid resistance 
Structural information Structure of LdNMT with myr-CoA analogue[87]  
Red represents that no information has been obtained; Amber indicates that only little 
information has been achieved and more progress is required; Green means that information or 
concept has been well understood and established. 
 
1.3.2   Project aim 
 
According to the results of target evaluation, the primary aim of this project is to 
identify potent and selective inhibitors for PfNMT and use small molecules to chemically 
investigate the targetability of NMT in P. falciparum. The project primarily comprises the 
hit identification and hit-to-lead development in the typical process of drug discovery 
(Figure 1.14) and the work presented in this thesis aims to a progress towards 
discovering lead candidates.  
 
Figure 1.14  Process of typical drug discovery 
Once a hit was validated, an iterative process involving library synthesis, 
biological evaluation (collaboration with Dr. A. Holder and Dr. D. Moss, NIMR) and 
structural information (collaboration with Prof. A. Wilkinson and Dr. J. Brannigan, 
University of York) would be carried out to generate lead compounds (Figure 1.15). 
Specifically the requirements were to: 
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1. Find inhibitors with excellent enzyme inhibition (at least sub-µM range of IC50s) 
and good selectivity (at least 100-fold) over human NMTs. 
2. Obtain a co-crystal structure of an inhibitor bound to the enzyme to rationalise 
the experimental SARs and direct future inhibitor design. 
3. Use small molecules as a probe to chemically validate whether NMT is a target 
in P. falciparum. 
 
Figure 1.15  Hit-to-lead development cycle 
In 2009, pursuing LdNMT inhibitors was included as a minor project. Given the 
high similarity of the primary sequence between PfNMT and LdNMT, a piggy-back 
strategy was adopted (detailed in Section 2.1). The library of PfNMT inhibitors generated 
from the development cycle (Figure 1.15) was screened against LdNMT, followed by the 
parasite growth inhibition tests (collaboration with Prof. D. Smith and Dr. D. Pappe, 
University of York), with the purpose to identify good hits or early lead candidates 
against LdNMT. Specifically the aims were to: 
1. Screen the library of PfNMT inhibitors to yield the preliminary SARs for LdNMT 
inhibitors. 
2. Select good hits or early lead candidates with the aid of antileishmanial activity 
tests.
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2 Hit Identification of PfNMT inhibitors 
 
2.1 Screen Strategy       
 
Given a molecular target, which is PfNMT in this project, the hit identification 
frequently relies on two strategies: high throughput screening (HTS) and piggy-back 
approach. HTS is well known to be able to identify new chemical entities, both synthetic 
compounds and natural products. However, lack of access to HTS facilities, the high costs 
and difficulty of dealing with large numbers of resulting hits prevent this strategy being 
widely used in academia (Table 2.1). A piggy-back approach is most useful when a 
molecular target present in one indication has been pursued for other indications as it 
would accelerate the process to identify good hits[128]. Therefore, it is a cost efficient 
strategy to start medicinal chemistry projects, particular in academic environments[129]. 
However, as the definition of “piggy-back” suggests, it is most likely to produce 
molecules that are closely related to the starting points. Moreover, the emerging 
structure-activity relationships (SARs) are unlikely to be the same as those observed for 
the original indication[130].  
Table 2.1  Comparison between HTS and piggy-back approach  
 HTS Piggy-back approach 
Examples in 
parasitic 
diseases 
TbNMT by Dundee University[123, 
124];  antimalarial targets by 
Norvatis[131, 40] and GSK[39] 
PfPFT (protein farnesyltransferase) 
by Yale University[129] 
Advantages 
Identifies new chemical class of 
inhibitors 
Cost efficient; accelerates the 
process of hit identification 
Disadvantages 
Costly; limited availability 
outside industry 
Starts with exsiting chemical 
entities; SARs might be disease-
specific[130] 
By the time this project started, CaNMT inhibitors had been intensively studied 
[82, 84] and the Dundee group was developing TbNMT inhibitors (unpublished at that time). 
Given the resources available to us, it was therefore the most feasible and economical to 
use a piggy-back strategy to identify hit compounds, where a molecular target present in 
C. albicans and T. brucei (NMT here) is being investigated in P. falciparum. In addition, 
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sequence alignment among these three NMTs reveals high similarities (Figure 2.1), 
increasing the chances of finding good hits using this approach.  
 Figure 2.1  Sequence alignments of CaNMT, PfNMT and TbNMT 
 The sequences of various NMT proteins have been aligned with the program MultAlign (Version 
5.4.1.(Corpet 1988)). The colour codes are as follows: Red = exact match, blue = AA of similar 
properties, black = no match, with a consensus level of 90% high and 50% low. The consensus 
symbols are as follows: ! = any of IV, $ = any of LM, % = any of FY and # = any of NDQEBZ. 
A small library (25 compounds) of reported CaNMT and TbNMT inhibitors (either 
kindly supplied by Dundee Drug Discovery Unit or synthesised “in house”) was screened 
using a developed scintillation proximity assay (SPA, detailed in Section 2.3), resulting in 
the discovery of a hit or compound 1 which displayed moderate inhibition. Compound 1, 
also known as RO-09-4609, was initially developed by Roche for its antifungal project, 
exhibiting sub-µM inhibition against CaNMT and excellent selectivity over human 
NMT1[82] (Figure 1.15). 
 
Figure 2.2  Structure of the hit compound  
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2.2   Re-synthesis of the hit  
 
To validate compound 1 as a hit, the first step is to re-synthesise this compound. 
Retro-synthetic analysis breaks compound 1 into two parts: the benzofuran scaffold and 
the C-4 side chain, as shown in Scheme 2.1.      
Scheme 2.1  Retro-synthetic analysis of the hit compound 
 
2.2.1   Synthesis of the benzofuran scaffold 
 
Although various methods have been developed to make benzofurans[132], the 
synthesis of ethyl benzofuran-2-carboxylates remains problematic due to the hydrolysis 
of the ester group. Ether 4, the precursor of benzofuran 3, could be easily obtained by 
reacting compound 5 with ethyl bromoacetate under basic conditions (Scheme 2.1). The 
following methods were attempted to achieve the benzofuran formation. 
P(MeNCH2CH2)3N, a non-ionic base, was applied to synthesise benzofuran 
derivatives without having the hydrolysis issue[133]. However, it is not practicable to get 
the benzofuran scaffold in large quantities because of the high cost of this base.  
Sodium hydride was reported to successfully convert a variety of 2-
mercaptophenyl ketones to 2,3-disubstituted benzo[b]thiophenes in 40-80% yields[134], 
implying that the strong base could act a similar manner to afford benzofuran. 
Disappointingly, no desired conversion was observed when ether 4 was reacted under 
such conditions.  
The Belanger group developed an improved method to produce benzofuran 3 
using sodium ethoxide in ethanol[135]. The isolated by-products were also discussed in 
the same paper (Scheme 2.2): carboxylic acids 6 and 8 were the hydrolysis products; 
subsequent decarboxylation of acid 6 gave benzofuran 7; diketone 9 was formed via 
another mode of cyclisation, which was observed when toluene was used as the 
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solvent[136].  
 
Scheme 2.2  Possible products in the cyclisation reaction using NaOEt as the base
[135]
 
Initial trials of Belanger’s protocol gave around 20% yields of benzofuran 3 and 
two by-products, benzofuran 7 and acid 8, were isolated. Study of the reaction 
parameters suggested that the temperature and amounts of NaOEt were two key factors 
to improve the yields.    
Table 2.2A presents the yields of the benzofuran scaffolds at different 
temperatures. It is clear that low temperature is necessary to form benzofuran (Table 
2.2A, entry 3). Although maintaining a low temperature throughout the reaction resulted 
in a high selectivity between the desired product 3 and its decarboxylated by-product 7, 
nearly half of the starting material was recovered (Table 2.2A, entry 4). Instead, such 
selectivity could be achieved by varying the amount of the base. Table 2.2B shows that 
1.5 eq. of NaOEt gives an optimal result. In addition, the concentration of NaOEt was 
also found to affect the said selectivity, whereby a higher base concentration leads to a 
lower selectivity (Table 2.2B, entries 3 vs. 5 and 4 vs. 6).     
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Table 2.2  Comparison of different conditions used to make benzofuran 
(A) 2.0 equivalents of NaOEt in ethanol 
Entry Temperature Time Product(s)a Overall yields b 
1 80 °C 18 h 4 + 7 + unknown 10% 
2 25 °C 18 h 4 + unknown 0% 
3 -15 ~ 7 °C 18 h 8 + 3 + 7 69% (35% for 3; 34% for 7) 
4 -15 °C 15 h 8 + 3 + 7 33% (30% for 3; 3% for 7) 
 
(B) Defined temperature (-15 - 7 °C) in ethanol 
Entry Equivalent(s) Concentration (mol / L) 
Overall yields 
b 
Ratio between 3 and 
7 
1 1.0 0.6 0% - 
2 1.5 0.6 73% 10 : 1 
3 2.0 0.6 70% 3 : 1 
4 6.0 0.6 68% 1 : 1 
5 2.0 1.2 70% 1 : 1 
6 6.0 1.2 62% 1 : 12 
a
 The products were separated via silica chromatography. 
b
 Overall isolated yields of benzofuran 
scaffolds, including 3 and 7.   
The optimised conditions: 1.5 eq. and 0.6M of NaOEt in EtOH, -15 ~ 7 °C, overall yields: 73%. 
 
2.2.2   Incorporation of the C-4 side chain 
 
The process of adding 1,3-dibromo propane to the benzofuran core involves a 
SN2 substitution under mild conditions. However, it suffered from both moderate yields 
even when a large excess of the reagents were used, and a difficult separation due to the 
similar polarities between the desired product 2 and the allyl by-product 10, which was 
unavoidable under basic conditions (Scheme 2.3).  
 
Scheme 2.3  Addition of trimethylene linker on the benzofuran scaffold  
Further amination on compound 2 was achieved in another straightforward SN2 
reaction. Initial trials in refluxing ethanol could only give reasonable yields of 50% even 
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when a large excess (100 eq.) of amine was used. Therefore, a range of solvents were 
screened and DMF was found to be best where only 4 eq. of amine was needed to 
ensure a full conversion (Scheme 2.4).  
Scheme 2.4  Amination on bromopropyl benzofuran 2  
 
2.2.3   Summary 
 
Hit compound 1 was successfully made in a 4-step synthesis (Scheme 2.5): 2,6-
dihydroxy acetophenone 5 was initially coupled with ethyl bromoacetate, followed by 
cyclisation under basic conditions to produce benzofuran 3. Treatment of an excess of 
1,3-dibromopropane with benzofuran 3 in the presence of potassium carbonate in DMF 
gave O-bromopropyl compound 2, which was further aminated to yield compound 1.  
Scheme 2.5  (a) ethyl bromoacetate, K2CO3, acetone, 60 °C, 3 hr, 89%; (b) Na, EtOH,  -18 °C to 7 °C, 
18 hr, 70%; (c) 1,3-dibromopropane, K2CO3, DMF, r. t., 5 hr, 64%; (d) (3-aminomethyl) pyridine, 
DMF, 80 °C, 3 hr, 90%.  
 
2.3   Activity confirmation of the re-synthesised hit compound 
 
The inhibitory activity of the re-synthesised hit or compound 1 was tested via a 
scintillation proximity assay (SPA), which was developed in our group[89].  
 
2.3.1   Principles of SPA 
 
The basis of SPA is to monitor the transfer of a radiolabelled substrate to a 
second substrate with an affinity tag (biotin in this case) which is subsequently captured 
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by a coated bead (streptavidin in this case). The bead, to which is attached a scintillant, 
ensures that the radiolabel on the product is close enough to the scintillant to allow the 
detection by a scintillation counter. In addition, the use of a scintillant that is 
immobilised on a solid support prevents the need to separate products from reactants, 
which significantly simplifies the work-up procedure used in a normal scintillation 
assay[84].  
The procedure of the assay is described in detail in Figure 2.3. NMT, tritium 
labelled myr-CoA and biotinylated peptide are incubated together, where they are 
expected to follow a Bi-Bi mechanism (Section 1.2.1) to form a radiolabelled 
myristoylated peptide. Then, both the myristoylated and un-reacted peptides are 
captured by the streptavidin-coated scintillation beads. Radiation from tritium in the 
myristoylated peptide is sufficiently close to the scintillant and the absorption from 3H-
decay results in the emission of a detectable photon, which is quantified and displayed in 
a scintillation counter.    
The existence of an inhibitor blocks the myristoylation to occur, thus decreasing 
the signal recorded by the scintillation counter. Therefore, a weak signal indicates a good 
inhibitor and vice versa (Figure 2.3). A plot of enzyme activity against an inhibitor’s 
concentration gives an inhibition curve from which an IC50 value can be determined. The 
IC50 is a measure of the effectiveness of a compound, which represents how much of this 
compound is needed to inhibit a given biological process (N-myristoylation in this case) 
by half.  
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Figure 2.3  Mechanism of SPA 
The radiolabelled (coloured in red) myr-CoA, biotinylated (shown in green) peptide and the 
enzyme are added together to form a radiolabelled myristoylated peptide; A streptavidin-coated 
bead incorporating a scintillant is expected to bind both myristoylated and unreacted peptides via 
the biotin functional group; Radiation from 
3
H of the myristoylated peptide is then sufficiently 
close to the scintillant and the absorption from 
3
H-decay leads to the emission of a photon, which 
can be detected and quantified by a scintillation counter
[107]
.  
 
2.3.2   Assay development 
 
The buffer conditions, including pH value, percentage of DMSO, and the 
selection of peptide substrates had been well documented previously in our group[107, 122] 
and so were used without further modification. The purpose here was to optimise 
incubation time, the enzyme and substrate concentrations to develop a robust assay for 
the NMTs investigated in this project.  
Enzyme concentration and incubation time 
In general, larger amounts of enzyme are expected to give higher signal. 
However, upon increase of the enzyme concentration, substrate depletion might occur, 
represented by the amount of signal reaching a plateau (Figure 2.4A). This meant that 
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under the conditions used in these assays, linearity was maintained only up to a PfNMT 
concentration of 1.7 nM (Figure 2.4B). Time-course experiments, where PfNMT 
concentration was fixed at 1.7 nM, showed that the signal increased linearly with the 
time up to 40 min (Figure 2.4C and 2.4D). Under these conditions, the amount of 
enzyme was rate-limiting and the gradient could be used to provide the initial velocity of 
reaction, an accurate and effective way to determine the inhibitory activities of test 
molecules[137].  
 
Figure 2.4  Signal dependence on enzyme concentration and incubation time  
(A, B) After 30 min incubation, signal intensity was found to be dependent on the enzyme 
concentration and the signal linearity was maintained up to a PfNMT concentration of 1.7 nM. 
Above this concentration of enzyme, substrate depletion was thought to be responsible for the 
observed leveling off of the curve. (C, D) Signal intensity was dependent on the incubation time at 
a fixed enzyme concentration (1.7 nM of PfNMT), where a linear response was maintained up to 
40 minutes.  
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The same approach was applied to determine the optimal enzyme concentration 
and incubation time for three other investigated enzymes (Ld, Hs1 and Hs2 NMTs) and 
the results are listed in Table 2.3. To simplify the assay conditions and allow better 
comparisons, the incubation time was uniformly set at 30 min for the four NMTs 
employed in this study. 
Table 2.3  Optimal enzyme concentration and incubation time for the investigated NMTs  
 PfNMT LdNMT HsNMT1 HsNMT2 
Concentration (nM)a 1.7 1.0 1.0 4.0 
Incubation time (min)b 40 30 30 60 
a
 Upper limit of the enzyme concentration to maintain a linear curve; 
b
 Upper end of the 
incubation time to keep the signal curve as a straight line. 
Concentration of myr-CoA and peptide 
Targeting the peptide binding pocket to find inhibitors that are selective over 
human NMTs was achieved in previous CaNMT projects. Therefore, the enzyme assay 
was designed to find inhibitors which are competitive with the peptide substrate. In 
theory, myr-CoA concentration in the assay should be well above its KM
app, ensuring a full 
occupancy of the myr-CoA binding pocket to efficiently open up the peptide binding 
pocket; peptide concentration should be ideally below or around its KM
app to find 
molecules which are competitive with the peptide substrate[138].  
To verify the KM
app for each substrate, a kinetic analysis was performed for each 
enzyme and is illustrated in Figure 2.5 for PfNMT. These data showed that for PfNMT, the 
KM
app of myr-CoA was 19.3 nM and the KM
app for peptide was 1.04 µM, similar to the 
previous data[107, 122]. 
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Figure 2.5  Km
app
 determinations for myr-CoA and peptide in PfNMT 
The Km
app
 of myr-CoA was determined using 500 - 0.2 nM myr-CoA with 500 nM peptide substrate 
while the Km
app 
of the peptide was measured over the range of 10 µM - 14 nM with a fixed myr-
CoA concentration of 62.5 nM. The initial rates of reaction (cpm/min) were fitted to the Michaelis 
Menten equation as a function of either myr-CoA or peptide concentration, allowing the Km and 
Vmax to be determined respectively. Each measurement was done once due to the safety and cost 
considerations and the obtained values were consistent with the reported data
[107, 122]
.    
The kinetic parameters of investigated NMTs are listed in Table 2.4. Given the 
use of radioactive myr-CoA in the assay, it is desirable to use the minimal amount of myr-
CoA while at the same time ensuring the concentration well above its KM. The 
concentration was thus chosen to be 62.5 nM, under which conditions approximately 80% 
of myr-CoA pocket in enzymes (PfNMT and LdNMT) would be occupied and sufficient 
signal intensity was obtained. In addition, the amount of streptavidin beads required to 
quench the assay was found to be proportional to the amount of peptide used[107]. 
Considering that the KM
app values of peptide for test NMTs were between 0.29 and 1.56 
µM, combining with the cost considerations of the beads, the peptide concentration was 
uniformly set at 0.5 µM in the assay. 
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Table 2.4  Kinetic data of investigated NMTs 
 PfNMT LdNMT HsNMT1 HsNMT2 
Mw 56 kDa 51 kDa 56 kDa 56 kDa 
KM
app (myr-CoA) 19.3 nM 17.5 nM n.d. n.d. 
KM
app (peptide) 1.04 µM 0.29 µM 1.56 µM 0.30 µM 
Data was tested using the same method applied to PfNMT and each measurement was done only 
once due to safety and cost considerations; 
  
n.d., not determined 
Optimised conditions 
Based on the above discussion, the optimal conditions for the assay are listed in 
Table 2.5, providing not only a high signal-to-noise ratio (generally greater than 30), but 
also the potential to identify selective inhibitors.   
Table 2.5  Optimised conditions of SPA for investigated NMTs  
 PfNMT LdNMT HsNMT1 HsNMT2 
[enzyme]  1.7 nM 1.0 nM 1.0 nM 4.0 nM 
[myr-CoA] 62.5 nM 
[peptide] 0.5 µM 
Incubation time  30 min 
Signal-to-noise 
ratio 
30 40 40 20 
 
2.3.3   Activity confirmation of the hit compound 
 
The inhibitory activity of the re-synthesised hit compound was tested by SPA and 
the IC50 value was found to be 51.4 µM against PfNMT (Figure 2.6), which was in 
accordance with the result of the screening hit (IC50: 47.0 µM). In addition, the molecule 
displayed nearly no inhibition against both human NMTs. Therefore, compound 1 was 
validated as a hit compound because of its promising inhibitory activity and selectivity 
over human NMTs.  
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Compound 
Enzyme IC50 (µM) 
PfNMT HsNMT1 HsNMT2 
1 51.4 NI (0%)a >1000 (1.3%)a 
a
 The number in parentheses was the percentage inhibition values of a compound at 100 µM in 
triplicate; the variation was generally <10%. The IC50 value is estimated from these to give a 
comparative indication of potency. NI: no inhibition. 
Figure 2.6  Activity determination of the re-synthesised hit  
 
2.4   Summary 
 
A piggy-back strategy was applied to screen a small library of reported NMT 
inhibitors against PfNMT, leading to the discovery of compound 1 that showed moderate 
inhibition. Compound 1 was re-synthesised in 4 steps and evaluated by a scintillant 
proximity assay, which was optimised “in house”. The resulting moderate inhibition 
against PfNMT and excellent selectivity over human NMTs validated compound 1 as a hit 
for PfNMT inhibitors (Figure 2.7). 
 
Figure 2.7  Structure of the validated hit  
 
 
 
 
Chapter 3 – PfNMT inhibitors 
-49- | P a g e  
 
3 Design and synthesis of PfNMT inhibitors 
 
Based on the structure of hit compound 1, two locations were identified as areas 
that were promising for modification: the C-4 trimethylene side chain and the C-2 ester. 
The aim was to discover inhibitors showing high potency against PfNMT and excellent 
selectivity over human NMTs (Scheme 3.1).   
 
Scheme 3.1  Strategy to design PfNMT inhibitors based on the structure of the hit compound: 
synthetic elaboration of the C-4 and C-2 positions 
 
3.1   The first generation of PfNMT inhibitors 
 
3.1.1   Optimisation of the flexible chain at the C-4 position 
 
Exploration of the C-4 side chain was first carried out by analysing side chains 
with varied length, different basicity of hetero atom X and a range of R1 groups (Scheme 
3.2). 
 
Scheme 3.2  Strategy to develop the flexible chains at the C-4 position as the first generation of 
PfNMT inhibitors 
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3.1.1.1   Synthesis 
 
Scheme 3.3 outlines the general synthetic route to make benzofuran analogues 
13-32 with different length, basicity and varied R1 groups at the C-4 side chain. 
Compounds 13-31 were prepared using the method to synthesise hit compound 1 
(Section 2.2) and compound 32 was obtained by the de-benzylation of compound 16 in 
good yields under conventional hydrogenation conditions.   
Scheme 3.3  (a) various alkyl dibromides, K2CO3, DMF, r.t., 5 hr, 30-76%; (b) R
1
NH(H), DMF, 80 ˚C, 3 
hr, 45-97%; (c) 10% Pd/C, 1,4-cyclohexadiene, EtOH, 80 ˚C, 1 hr, 67%. 
For full structural information of compounds 13-31 with different R
1
 groups, please refer to the 
following SAR part, Section 3.1.1.2 or Appendix. Only the synthetic route is described here.  
Compounds 33 and 34 with diverse basicity of the C-4 side chain were then 
made to assess whether the inhibitory activity is dependent on the basicity (Scheme 3.4).   
 
Scheme 3.4  (a) benzyl 3-bromopropyl ether, K2CO3, DMF, r.t., 5 hr, 80%; (b) N,N-dimethyl 
benzylamine, CH3CN, 85 ˚C, 16 hr, 90%. 
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3.1.1.2   Structure-activity relationships 
 
Investigation of the C-4 side chain length 
The inhibitory activities of compounds with varied length of the C-4 side chain 
are compared in Table 3.1. The results clearly demonstrate that a trimethylene linker 
between the ether attachment point and the nitrogen (1 and 15) is optimal.  
Table 3.1  Optimal length of the C-4 side chain in the first generation of PfNMT inhibitors 
                                                                           
Compound n IC50 (µM)
a Compound n IC50 (µM) 
13 2 ~220 (31.0%)b 14 2 NI (0%)b 
15 3 9.0 1 3 51.4 
30 4 ~130 (43.8%)b 31 4 ~300 (25.0%)b 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition. 
The importance of X 
The amino group on the reported inhibitor was found to interact with the C-
terminal Leu of ScNMT[139], playing an important role in exerting inhibition; a similar 
interaction was also observed in the CaNMT project[83]. Therefore, it was interesting to 
examine whether such interaction would occur in PfNMT. Four representative inhibitors, 
with the C-4 side chains ranging from basic, weakly basic, neutral to charged, were thus 
assessed (Table 3.2). Sufficient basicity of the C-4 side chain was found to be essential in 
maintaining the inhibitory activity since compound 16 showed far higher potency than 
other three compounds. However, whether such interaction with the C-terminal Leu of 
PfNMT is via an ionic or hydrogen bond is not clear[124].  
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Table 3.2  Dependence of inhibition on the basicity of the C-4 side chain 
 
Compound X-R1 IC50 (µM)
a Compound X-R1 IC50 (µM)
a 
16 
 
8.5 20 
 
~107 
(48.4%)b 
33 
 
~146 
(40.7%)b 
34 
 
~220 
(31.2%)b 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
Variation of R1 groups 
The effects of different N-substituents were then studied (Table 3.3). Among the 
alkyl R1 variants, t-Bu (15) was found to be the right size while smaller (19, 23 and 32) or 
bigger ones (18, 24 and 29) resulted in a significant drop in activity. In addition, insertion 
of an extra nitrogen atom (29) was not favoured by PfNMT. Of the different aromatic R1 
groups, benzyl (16) was the best. Electronic deficiency (1, 17, 21, 27 and 28) led to a loss 
of inhibition by at least 5-fold; addition of electron-rich groups on the phenyl ring, such 
as methyl (25 and 26), failed to improve the potency; β-naphthyl (22) might be too big to 
be accommodated by the binding pocket, accounting for a 20-fold loss of inhibition (22 
vs. 16).  
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Table 3.3  Exploration of R
1
 groups in the C-4 side chain of the first generation of PfNMT 
inhibitors 
 
Compound R1 IC50 (µM)
a Compound R1 IC50 (µM)
a 
15 
 
9.0 18 
 
84.4 
19 
 
~108 
(48.1%)b 
23 
 
102.0 
24 
 
51.0 29 
 
~490 
(17.0%)b 
32 
 
~143 
(41.1%)b 
1 
 
51.4 
16 
 
8.5 17 
 
54.5 
21 
 
~370 
(21.2%)b 
25 
 
 
13.0 
26 
 
31.6 27 
 
 
>100 
28 
 
>100 22 
 
 
~180 
(35.6%)b 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
 
3.1.2   Comparison of the C-4 versus C-5 attachment in benzofuran 
 
Considering that the C-4 side chains of compounds 15 and 16 were determined 
to be optimal, it was interesting to study the influence of the PfNMT inhibition when the 
side chain was changed from the C-4 to C-5 position (Scheme 3.5).   
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Scheme 3.5  Relocation of the side chain from the C-4 to C-5 position of the benzofuran scaffold 
 
3.1.2.1   Synthesis 
 
2,5-Dihydroxy-acetophenone 37 was selectively benzylated to give compound 38, 
which was then coupled with ethyl bromoacetate to form ether 39, the precursor of 
benzofuran. Base-catalysed cyclisation of ether 39, followed by the deprotection under 
conventional hydrogenation conditions afforded benzofuran 41, which was then 
attached with a trimethylene linker and finally aminated to yield target compounds 35 
and 36 (Scheme 3.6).  
Scheme 3.6  (a) benzyl bromide, K2CO3, acetone, 60 ˚C, 3 hr, 100%; (b) ethyl bromoacetate, K2CO3, 
DMF, 80 ˚C, 4 hr, 55%; (c) Na/EtOH, -18 ˚C to 7 ˚C, 18 hr, 44%; (d) Pd/C, 1,4-cyclohexadiene, EtOH, 
80 ˚C, 100%; (e) 1,3-dibromopropane, K2CO3, DMF, r.t., 5 h, 50%; (f) R
1
NH2, DMF, 80 ˚C, 3 hr, 90% 
for 35 and 70% for 36.  
 
3.1.2.2   Activity evaluation 
 
Surprisingly, reposition of the side chain from the C-4 to C-5 position of the 
benzofuran scaffold resulted in a total loss of the inhibitory activity (Table 3.4), indicating 
that the C-4 position of the side chain is critical.  
 
 
Chapter 3 – PfNMT inhibitors 
-55- | P a g e  
 
Table 3.4  Inhibitory activity comparison between the C-4 and C-5 side chain of benzofuran    
                                                                                                                                                                                                                                                                                   
R1 Compound IC50 (µM)
a Compound IC50 (µM)
 a 
 
35 NI (0%)b 15 9.0 
 
36 NI (0%)b 16 8.5 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. NI: no inhibition. 
 
3.1.3   Preliminary studies of heterocyclic cores other than benzofuran 
 
Given the fact that the furan oxygen of hit compound 1 involves a hydrogen 
bond with His227 in CaNMT[82], it was therefore worthwhile to assess the importance of 
benzofuran in PfNMT inhibitors and preliminary studies of heterocyclic scaffolds other 
than benzofuran was conducted. 
 
3.1.3.1   Synthesis 
 
Apart from benzofuran, there are other heterocyclic scaffolds, reported as 
readily prepared in literature, such as benzoxazole[140], benzothiazole[140], 
benzoimidazole[140]and benzothiophene[134]. As stated before, the C-4 position of the side 
chain in benzofuran is crucial to maintain the inhibitory activity. However, because of the 
restriction in the commercial availability of starting material, there are no such desired 
sites to modify in the scaffolds 43 and 44 (illustrated as red eclipses, Scheme3.7). In 2008, 
the Svete group developed a facile method to make 8-hydroxyimidazo[1,2-a]pyridine 
45[141] (Scheme 3.7), which is a good mimic to benzofuran containing the C-4 side chain. 
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Scheme 3.7  Heterocyclic scaffolds as alternatives to benzofuran  
The arrow indicates the desired modified site. 
Cyclocondensation of 2-aminopyridin-3-ol 46 with ethyl bromopyruvate under 
thermal conditions gave 8-hydroxyimidazo[1,2-a]pyridine 45 directly[141], which was then 
incorporated with the side chains to yield compounds 48 and 49 (Scheme 3.8).  
Scheme 3.8  (a) ethyl bromopyruvate, THF, 65 °C, 24 hr, 15%; (b) 1,3-dibromopropane, K2CO3, 
DMF, r.t., 5 hr, 24%; (c) R
1
NH2, DMF, 80 °C, 3 hr, 90% for 48 and 70% for 49.  
 
3.1.3.2   Activity evaluation 
 
Imidazo[1,2-a]pyridine inhibitors (48 and 49) were far less potent than their 
benzofuran counterparts (Table 3.5), indicating that the benzofuran core might be 
important. Current thought is that the difference of either electronic flow or aromacity 
between benzofuran and imidazo[1,2-a]pyridine is responsible for this huge discrepancy 
of the inhibitory activities. 
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Table 3.5  Inhibitory activity comparison between imidazo[1,2-a]pyridine and benzofuran 
inhibitors 
                                                                            
R1 Compound IC50 (µM)
a Compound IC50 (µM)
a 
 
48 ~180 (35.7%)b 15 9.0 
 
49 NI (0%)b 16 8.5 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition.  
 
3.1.4   Exploration of the C-2 side chain 
 
So far, two optimal C-4 side chains had been determined and attention was thus 
turned to the study of the C-2 side chain (Scheme 3.9).  
Scheme 3.9  Strategy to design the C-2 side chain as the first generation of PfNMT inhibitors  
 
3.1.4.1   Essentiality of the C-2 side chain 
 
To assess the importance of the C-2 side chain, compounds 51-53 were 
synthesised from benzofuran 7, a by-product from making the desired benzofuran 
scaffold, according to the method to make hit compound 1 (Scheme 3.10).  
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Scheme 3.10  (a) 1,3-dibromopropane, K2CO3, DMF, r.t., 5 hr, 30%; (b) R
1
NH2, DMF, 80 °C, 3 hr,  
70% - 90%. 
The comparison between ethyl ester and hydrogen at the C-2 position are listed 
in Table 3.6. There is no doubt that the presence of the C-2 side chain is necessary to 
keep the inhibition.  
Table 3.6  Investigation of the necessity of the C-2 side chain 
                                                                                    
R1 Compound IC50 (µM)
a Compound IC50 (µM)
 a 
 
15 9.0 51 ~100 (50.0%)b 
 
1 47.0 52 NI (0%)b 
 
16 8.5 53 ~163 (28.0%)b 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition.  
 
3.1.4.2   Synthesis of the C-2 side chains other than ester 
 
Ester has the potential to be broken down by esterases in the body, thereby 
always considered as a problematic functional group by medicinal chemists. To 
overcome this problem, a variety of functional groups (Y) other than ester such as amide, 
ketone, ether, etc., were investigated (Scheme 3.11).  
Chapter 3 – PfNMT inhibitors 
-59- | P a g e  
 
 
Scheme 3.11  Strategy to make the C-2 side chain other than ester 
Amide series 
Synthesis of the target compound is straightforward, with the formation of 
amide 54 as a key step (Scheme 3.12).   
Scheme 3.12  Synthetic analysis of the amide series in the first generation of PfNMT inhibitors 
Direct conversion from ester to amide was first reported by Weinreb[142], in 
which Lewis acid AlMe3 was used to activate the carbonyl of ester. However, the dangers 
involved with handling extremely flammable reagent AlMe3 and the resulting moderate 
yields, prevented this reaction from being a robust method to generate amide at the C-2 
position (Scheme 3.13). Encouragingly, indirect transition via carboxylic acid 55, which 
could be readily synthesised from the hydrolysis of ester 2 by lithium hydroxide, gave 
both milder coupling conditions and improved yields (Scheme 3.13). 
 
Scheme 3.13  Model study of amide formation at the C-2 position 
The PyBOP/DIPEA (benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate and N,N-diisopropylethylamine) system is used to activate the 
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carboxylic acid moiety. The carboxylic acid is firstly deprotonated by DIPEA to give the 
carboxylate anion, which then attacks PyBOP to form 57. After that, intermediate 57 is 
decomposed upon the involvement of benzotriazole anion to afford 58, the activated 
form of the carboxylic acid. Finally, intermediate 58 undergoes a substitution with amine 
to generate the desired amide (Scheme 3.14).  
 
Scheme 3.14  Mechanism of carboxylic acid activation by PyBOP/DIPEA to form an amide
[143]
 
In summary, ester 2 was treated with LiOH to afford carboxylic acid 55, which 
was then reacted with amines under PyBOP/DIPEA conditions to form an amide bond, 
followed by the amination to yield a set of amide compounds 59-65 (Scheme 3.15).  
 
Scheme 3.15  (a) LiOH, THF/H2O, r.t., 18 hr, 90%; (b) PyBOP, DIPEA, R
2
NH(H), DMF/DCM, r.t., 3 hr, 
50% - 70%; (c) R
1
NH2 , DMF, 80 ˚C, 3 hr, 70% - 90%;  
For full structural information of compounds 59-65 with different R
1
 and R
2
 groups, please refer 
to the following SAR part, Section 3.1.4.3 or Appendix. Only the synthetic route is described here.  
Ketone series 
The key intermediate towards the desired ketone molecules is compound 66, 
which was proposed to be made by a base-catalysed cyclisation of compound 67, readily 
synthesised from starting material 5 (Scheme 3.16). 
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Scheme 3.16  Retro-synthetic analysis of the ketone series in the first generation of PfNMT 
inhibitors 
Interestingly, the reaction anticipated to provide ether 69 actually gave ketone 
70 directly, indicating the possibility of one-pot reaction to make compound 70 (Scheme 
3.17).  
 
Scheme 3.17  One-pot reaction to make 2-ketone benzofuran 70 
However, there was still half of starting material left even extending the reaction 
time or increasing the amount of base when acetone was used as the solvent. In 
addition, the polarities of compounds 5 and 70 were found to be extremely similar, 
increasing the difficulty of the purification. Therefore, several other solvents were 
screened and acetonitrile was shown to be optimal to drive such conversion into 
completion (data not shown here). 
In summary, 2,6-dihydroxy acetophenone 5 was reacted with α-halogenated 
methyl ketones under  basic conditions to form benzofurans 70 and 71, which were then 
functionalised with  the side chains to generate ketone molecules 72-75 (Scheme 3.18).    
 
Scheme 3.18  (a) R
2
COCH2X (X=Cl or Br), K2CO3, CH3CN, 80 ˚C, 24 hr, 20% - 40%; (b) 1,3-
dibromopropane, K2CO3, DMF, r.t., 5 hr, 40% - 50%; (c) R
1
NH2, DMF, 80 °C, 3 hr, 80% - 90%. 
For full structural information of compounds 72-75 with different R
1
 and R
2
 groups, please refer 
to the following SAR part, Section 3.1.4.3 or Appendix. Only the synthetic route is described here.  
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Reduction of ketone 70 was also attempted. However, neither conventional 
reducing agents (NaBH4 and LiAlH4) nor Lewis acid triggered environment
[144] was able to 
afford the reduced forms of ketone 70 (Scheme 3.19).  
 
Scheme 3.19  Trials of reducing the C-2 ketone benzofuran 
Ether series 
Scheme 3.20 outlines the retro-synthetic analysis of the proposed ether 
compounds. Compound 78 required for a Mitsunobu reaction can be prepared in a 
simple two-step procedure involving reduction and SN2 substitution. The Mitsunobu 
reaction to make the C-2 ether is considered to be the key step.  
Scheme 3.20  Retro-synthetic analysis of the ether series in the first generation of PfNMT 
inhibitors 
Unfortunately, this Mitsunobu reaction generally afforded yields of less than 
20%, even screening a range of azo reagents and phosphine ligands. In most cases, the 
conditions of diisopropyl azodicarboxylate (DIAD) and triphenylphosphine (PPh3) in THF 
were found to give the best yields (ca. 25%), thus employed in the following Mitsunobu 
reactions.   
In addition, chemical instability is another hurdle to explore the ether series. 
Some of the ether compounds were observed to decompose under weakly acidic 
conditions (pH=3), which are not suitable for further study from a medicinal chemistry 
perspective. Scheme 3.21A suggests that electron rich phenyl substituents R3, such as 
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methyl and methoxy, have detrimental effects on the stability of the resulting ethers. 
Aside from the electronic dependence, scheme 3.21B indicates that the size of R1 affects 
the stability as well, whereby bigger R1 (t-Bu and 4-Me benzyl in this case) contributes to 
the stable ethers.  
Scheme 3.21  Chemical instability amongst the ether series    
To sum up the synthesis, ester 3 was reduced to alcohol 79, which was then 
added to a trimethylene side chain to form compound 78. This compound underwent 
either a Mitsunobu reaction, followed by amination to generate ether compounds 80-85 
or direct amination to yield compounds 86 and 87 (Scheme 3.22).  
Scheme 3.22  (a) LiAlH4, THF, 0 ˚C - r.t., 70%; (b) 1,3-dibromopropane, K2CO3, DMF, r.t., 5 hr, 40%; 
(c) DIAD, PPh3, ArOH, THF, r.t., 4 hr, 15% - 25%; (d) R
1
NH2, DMF, 80 ˚C, 3 hr, 70% - 95%. 
For full structural information of compounds 80-87 with different R
1
 and R
3
 groups, please refer 
to the following SAR part, Section 3.1.4.3 or Appendix. Only the synthetic route is described here.  
Thio ether series 
Thio ether was reported to be formed by reacting alcohol with aromatic thiol in 
TFA environment [80, 145]. When the same conditions were applied to compounds 86 and 
87, only the former gave the desired product 88. The colour of the reaction containing 
compound 87 turned to dark blue immediately after the addition of TFA, suggesting the 
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existence of the carbocation, which is thought to complicate the reaction (Scheme 3.23).  
 
Scheme 3.23  (a) thiophenol, 20% TFA in DCM, r.t., 2.5 hr, 17% 
The t-Bu moiety in compound 87 was speculated to be vulnerable under strong 
acidic conditions (20% TFA), with the tendency to form a t-Bu carbocation. To remove 
such potential effect, bromide 78 was used instead of compound 87 under the same TFA 
conditions. However, decomposition was still observed, indicating that it could be the C-
2 alcohol rather than the t-Bu to be instable under TFA conditions (Scheme 3.24, method 
1). The formation of compound 88 could be rationalised that the stabilising effect of the 
phenyl ring in the C-4 side chain of compound 86 would shield the C-2 alcohol from 
being attacked. To circumvent the strong acidic conditions and given that thiophenol 
(pKa = 8.2) is more acidic than phenol (pKa = 9.9), a Mitsunobu reaction was therefore 
attempted. Unfortunately, no desired conversion was observed (Scheme 3.24, method 2).  
Scheme 3.24  Trials of converting the C-2 alcohol to the C-2 thio ether 
To sum up, only compound 88 was able to be generated from the thio ether 
series.  
 
3.1.4.3   Structure-activity relationships 
 
 
Re-assess the suitable size of R1 
Interestingly, the results presented in Table 3.7a showed that compounds with  
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t-Bu (59, 72 and 80) in the C-4 side chain were much more potent than their benzyl 
counterparts (60, 73 and 81) when phenyl was used as R2. Given that t-Bu is much 
smaller than benzyl, it is likely that bulky groups for both R1 and R2 are not tolerated by 
the enzyme. The hypothesis is further supported by two pieces of evidence: firstly, 
tuning aromatic R1 (91-93) failed to display any inhibitory activity; secondly, replacing the 
phenyl ring by another bulky group cyclohexyl as R2 (62) only marginally improved the 
potency (Table 3.7b).  
Table 3.7  Interdependence between the C-2 and the C-4 side chains in first generation of 
PfNMT inhibitors                                                                                                                     
                               
Y Compound IC50 (µM)
a Compound IC50 (µM)
a 
-CONH- 59 9.2       60 (R’=Me) NI (0%)b 
-CO- 72 10.6       73 (R’=H) NI (0%)b 
-CH2O- 80 1.4       81 (R
’=Me) 98.3 
-CH2S- - -       88 (R
’=H) ~170 (37.1%)b 
 
Compound R1 IC50 (µM)
a Compound R1 IC50 (µM)
a 
91 
 
NI (0%)b 92 
 
NI (0%)b 
93 
 
NI (0%)b    
 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition.  
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Given the above findings, it was interesting to investigate the other three 
combinations of R1 and R2: “big R1 – small R2”, “small R1 - big R2” and “small R1 – small R2”, 
where any R groups with the physical size smaller than t-Bu were considered “small” 
(including t-Bu) and any R groups with the physical size bigger than Ph were considered 
“big” (including Ph).  
Big R1 - Small R2 
The inhibitory activities of this category of compounds (86, 75 and 16) were 
diverse (Table 3.8), but at least they were all more active than big R1 – big R2 
combinations, where no inhibition could be observed. 
Table 3.8  Big R
1
 – Small R
2
 combination in the first generation of PfNMT inhibitors 
 
Compound Y-R2 IC50 (µM)
a Compound Y-R2 IC50 (µM)
a 
86 
 
~230 
(30.0%)b 
75 
 
71.5 
16 
 
8.5    
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The number in parentheses was the percentage inhibition values of a 
compound at 100 µM in triplicate; the variation was generally <10%. The IC50 value is estimated 
from these to give a comparative indication of potency. 
Small R1 - Big R2 
A set of compounds with t-Bu – Ph combination (59, 72 and 80) are listed in 
Table 3.7a and all of them showed IC50s in the single-digit µM range. It was interesting to 
assess whether t-Bu would be the right size for R1. Amide series was chosen because of 
synthetic accessibility. Amides 94-96 with various sizes of R1 were prepared and their 
inhibitory activities were measured. The results showed that t-Bu derivative 72 was most 
active among compounds with small R1 groups (Table 3.9).  
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Table 3.9  Small R
1
 – Big R
2
 combination in the first generation of PfNMT inhibitors 
 
Compound R1 IC50 (µM)
a Compound R1 IC50 (µM)
a 
94 
 
~182 
(45.4%)b 
95 
 
67.4 
96 
 
~215 
(31.7%)b 
72 
 
10.6 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
Small R1 - Small R2 
Compounds of this combination were generally more active than the ones with 
big R1 – small R2 combination (87, 74 in Table 3.10 vs. 86, 75 in Table 3.8), suggesting that 
small R1, especially t-Bu, is favoured by the enzyme.    
Table 3.10  Small R
1
 – Small R
2
 combination in the first generation of PfNMT inhibitors 
 
Compound Y-R2 IC50 (µM)
a Compound Y-R2 IC50 (µM)
a 
87  30.0 74  53.2 
15  9.0 63  63.6 
a  
The IC50 values were averaged from two independent dose-response curves. 
Summary 
To conclude, when incorporating variations of the C-2 side chain (except ethyl 
ester), a small R1 group, especially t-Bu, is much more favourable to inhibit PfNMT than 
the big R1 counterparts. Therefore this reduced the two optimal C-4 side chain identified 
in Section 3.1.1.2 to one, with t-Bu as R1 group being more generally preferred. This was 
then used for the subsequent inhibitor development (Scheme 3.25).  
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Scheme 3.25  t-Bu was determined to be an optimal R
1
 group in the first generation of PfNMT 
inhibitors 
Activity dependence on the size of R2 
Inhibitory activities of compounds with varied R2 substitutions are listed in Table 
3.11. With regard to the amide series, activity peaked when R2 was phenyl (59); either a 
smaller R2 (63) or a bigger one (64) resulted in a loss of potency; addition of an extra 
methylene to phenyl provided slightly less activity (61 vs. 59); removing aromaticity of R2 
was found to reduce the activity by 4-fold (59 vs. 62), indicating a possible π-π 
interaction with the enzyme. Of the ether series, compound 80 was the most active 
inhibitor identified so far, with an IC50 value of 1.4 µM; either α or β naphthyl analogue 
(84 and 85) failed to improve the potency; interestingly, the α-isomer (84) was 4-fold 
more active than the β-isomer (85), suggesting that such R2 might sit in a shallow but 
relatively wide enzyme pocket. In the ketone series, it was clear that the bigger R2 was 
favoured by the enzyme (72 vs. 74).     
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Table 3.11  Exploration of R
2
 in the C-2 side chain in the first generation PfNMT inhibitors 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
63 
 
63.6 62 
 
30.0 
59 
 
9.2 61 
 
15.5 
64 
 
56.9    
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
87  30.0 80  
1.4 
84 
 
2.1 85 
 
8.2 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
74  53.2 72  
10.6 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
To sum up, phenyl as R2 was found to be generally optimal in the investigated 
amide, ether and ketone series in terms of its suitable size and a potential π-π 
interaction with the enzyme (Scheme 3.26). And the next step was to study the suitable 
phenyl substituents.  
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Scheme 3.26  Phenyl group was selected as an optimal R
2
 group in the first generation of 
PfNMT inhibitors 
Investigation of phenyl substituents  
A common scenario in drug design is to find an optimal phenyl substituent in an 
active compound for the potency maximisation. Given so many available substituents 
and different positions on the ring, the number of possible compounds is very large. 
Therefore, it is highly advantageous that compounds might be worth synthesising can be 
determined at an early stage. A rational approach based on the hydrophobic constant π 
of the substituent (more positive the value, more hydrophobic the substituent) and 
Hammett constant σ of the substituent (more positive the value, more electron-
withdrawing the substituent) was initially proposed and utilised by Topliss[146, 147]. The 
approach starts by selecting three substituents with good discrimination between π and 
σ (4-Cl, +π+σ; 4-Me, +π-σ; 4-OMe, -π-σ), aiming to determine the desired group of 
substituents. Further tuning based on Hansch’s aromatic substituent constants[148] leads 
to the discovery of the optimal substituent.   
Given the synthetic ease, amide series was selected to fully investigate the 
optimal phenyl R3 substituents. Compounds 97-101 were thus prepared and their 
inhibitory activities were measured (Table 3.12). It appeared that Cl or +π+σ system, was 
not favoured in either para or meta-position (97, 100 vs. 59); 4-Me or +π-σ system, had 
no effect on the inhibitory activity (99 vs. 59); but 4-OMe or -π-σ system, was found to 
slightly increase the activity (98 vs. 59). However, further enhancement of -σ effect to 4-
NMe2 failed to improve the potency (101 vs. 98), indicating that -π-σ system possibly has 
only trivial influence over the inhibitory activity. 
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Table 3.12  Different phenyl R
3
 substitutions in the amide series in the first generation of 
PfNMT inhibitors 
 
Compound R3 IC50 (µM)
a Compound R3 IC50 (µM)
a 
59 H 9.2 97 4-Cl 17.2 
98 4-OCH3 6.8 99 4-Me 9.7 
100 3-Cl 14.0 101 4-NMe2 6.8 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
Considering the stability issue in the ether series and the commercial availability 
of substituted 2-bromo acetophenones to form the ketone series, only chlorinated 
derivatives (82, 83 and 102) were synthesised. Introduction of chlorine on the phenyl 
group had a negative effect on inhibition (82 and 83 vs. 80; 102 vs. 72, Table 3.13), a 
similar trend to the results from the amide series.  
Table 3.13  Exploration of phenyl R
3
 substitutions in the ether and ketone series in the first 
generation of PfNMT inhibitors   
 
Compound R3 IC50 (µM)
a Compound R3 IC50 (µM)
a 
80 H 1.4 82 4-Cl 2.3 
83 3-Cl 8.4    
 
Compound R3 IC50 (µM)
a Compound R3 IC50 (µM)
a 
72 H 10.6 102 4-Cl 28.9 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
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To sum up, phenyl with no substitution remained to be an optimal R2 group 
(Scheme 3.27). No improved activity was achieved when R3 substituents with varied π 
and σ were added, indicating that neither of these two parameters are critical to for 
excellent inhibition against the enzyme. 
 
Scheme 3.27  Phenyl with no substitution was determined to be an optimal R
2
 in the first 
generation of PfNMT inhibitors 
 
3.1.5   Summary of the first generation of PfNMT inhibitors  
 
Achievement 
By optimising the C-4 side chain, compounds 15 and 16 were discovered. During 
the study of functional groups other than ester at the C-2 position, t-Bu in the C-4 side 
chain was found to give much more PfNMT inhibition than its benzyl counterpart. 
Among these inhibitors, ether 80 was the most active inhibitor with an IC50 value of 1.4 
µM, a 40-fold enhancement over the hit compound 1. In addition, compounds 59 and 72 
were also identified as the best inhibitors from the amide and ketone series respectively 
(Scheme 3.28).   
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Scheme 3.28  Summary of the development of the first generation of PfNMT inhibitors 
Problems to solve 
Aside from pursuing high potency against PfNMT, obtaining excellent selectivity 
over human NMTs (at least greater than 100-fold) is equally important. The three good 
inhibitors described in Scheme 3.28 were measured against both human NMTs (Table 
3.14). However, all of these molecules displayed moderate selectivity: compound 80 
showed 30-fold over HsNMT1 while compounds 59 and 72 gave only 8-fold over 
HsNMT2.    
Table 3.14  Moderate selectivity was observed in the first generation of PfNMT inhibitors   
 
Compound Y-R2 
Enzyme IC50s (µM)
a 
PfNMT HsNMT1 HsNMT2 
72 
 
10.6 ~148 (40.3%)b 81.9 
59  9.2 ~446 (18.3%)
b ~77 (56.6%)b 
80  1.4 ~63 (61.4%)
b 44.4 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
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Given the highest inhibition and selectivity among the first generation of PfNMT 
inhibitors, the ether series is most promising. However, the Mitsunobu reaction required 
to form an ether bond suffered from low yields, significantly limiting the scale-up of the 
synthesis. In addition, the resulting ether was found to be acid labile, raising a big 
stability concern if this series would be progressed into the lead optimisation stage. 
Combined with the moderate selectivity described above, it was necessary to develop a 
second generation of PfNMT inhibitors, requiring higher potency, greater selectivity and 
more efficient synthesis. 
 
3.2   The second generation of PfNMT inhibitors  
 
3.2.1   Study of the rigid C-4 side chain 
 
The first generation of PfNMT inhibitors is based on the flexible chain or 
trimethylene chain at the C-4 position of the benzofuran scaffold. The rigid chain at the 
same position was thus studied to examine whether it would lead to better inhibition or 
selectivity (Scheme 3.29). 
 
Scheme 3.29  Strategy to develop an alternative C-4 side chain other than trimethylene one 
 
3.2.1.1   Synthesis 
 
Alternative C-4 side chains (compounds 109-111, including two rings and one 
constrained trimethylene) were constructed in excellent yields using the Mitsunobu 
reaction, followed by deprotection in 5% TFA. Different sizes of R1 were then added to 
compound 109 via a reductive-amination reaction in good yields (Scheme 3.30). 
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Scheme 3.30  (a) DIAD, PPh3, N-Boc-4-OH piperidine (103) or N-Boc-3-OH piperidine (104) or N-
Boc-2,2-dimethyl propan-1-ol (105), THF, r.t., 4 hr, >95%; (b) 5% TFA in DCM, r.t., 2 hr, quantitative; 
(c) i. ketone or aldehyde, HOAc, THF/DMF, r.t., 2 hr; ii. NaBH(OAc)3, THF/DMF, r.t., 12 hr, 55-87%. 
For full structural information of compounds 112-116 with different R
1
 groups, please refer to the 
following SAR part, Section 3.2.1.2 or Appendix. Only the synthetic route is described here.  
 
3.2.1.2   Activity Evaluation 
 
The inhibitory activities of compounds with various C-4 side chains are listed in 
Table 3.15. Encouragingly, the results showed that compound 109 with a piperidine 
moiety had the comparable potency with inhibitor 15 containing the optimal 
trimethylene side chain. Relocation of amino group in the piperidine resulted in a total 
loss of activity (110 vs. 109), supporting the previous SAR (Table 3.1) that a 3-carbon 
distance is an optimal length between the ether oxygen and the amino group. Direct 
comparison between the two primary amines (111 vs. 32) indicates that increasing the 
steric hindrance of the trimethylene side chain is harmful to the potency.    
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Table 3.15  Comparison of different C-4 side chains 
 
Compound R IC50 (µM)
a Compound R IC50 (µM)
a 
15 
 
9.0 109 
 
16.5 
110 
 
NI (0%)b 111 
 
>1000 
(7.1%)b 
32 
 
~220 
(41.1%)b 
   
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition.  
A range of R1 groups were added to the amino group of piperidine to investigate 
their effects on inhibition (Table 3.16). The results demonstrate that a smaller R1 gives 
better potency with the exception of i-Pr compound 114, which displayed slightly better 
activity than 109. However, the synthesis of i-Pr attachment was found to be highly 
dependent on the composition of the C-2 side chain (Section 3.2.2.1, ketone series). 
Therefore, 4-piperidinol was selected as an optimal rigid C-4 side chain, possessing 
comparable inhibitory activity with the previously optimal C-4 trimethylene side chain.  
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Table 3.16  Examination of various R
1
 on the 4-piperidinol side chain in the second generation 
of PfNMT inhibitors   
 
Compound R1 IC50 (µM)
a Compound R1 IC50 (µM)
a 
109 
 
16.5 112 
 
50.0 
113 
 
27.0 114 
 
8.0 
115 
 
~208 
(32.5%)b 
116 
 
>500 
(14.7%)b 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
 
3.2.1.3   Comparison between the 4-piperidinol and trimethylene side chains  
 
The two optimal C-4 side chains identified so far are compared based on their 
molecular weight, rotatable bonds and synthetic ease (Table 3.17). With regard to the 
physiochemical properties, the 4-piperidinol side chain possesses lower molecular 
weight and fewer rotatable bonds. In addition, synthesis of the trimethylene side chain 
relies on chromatography to separate the desired product from its allyl by-product, 
while incorporation of the 4-piperidinol side chain involves a Mitsunobu reaction, which 
has been successfully performed in excellent yields with no need of chromatography 
(data not shown here)[149]. To conclude, 4-piperidinol is more drug-like and easier to 
synthesise than its trimethylene counterpart, therefore selected as an optimal C-4 side 
chain in the second generation of PfNMT inhibitors.      
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Table 3.17  Comparison between piperidine and trimethylene side chains 
C-4 side chain Molecular weight Rotatable bonds Synthesis 
 
114.1 4 
Chromatography, 
moderate yields 
 
84.1 1 
No chromatography, 
excellent yields 
 
3.2.2   Initial C-2 optimisation 
 
Since 4-piperidinol was identified to be an optimal C-4 side chain in the second 
generation of PfNMT inhibitors, attention was then focused on the study of the C-2 side 
chains by starting with the non-ester series (Scheme 3.31).    
 
Scheme 3.31  Strategy to develop the optimal C-2 side chain in the second generation of PfNMT 
inhibitors 
 
3.2.2.1   Synthesis 
 
Ketone series 
4-Piperidinol was incorporated to benzofuran 70 in excellent yields using the 
Mitsunobu reaction, followed by the Boc removal to yield compound 117. Different sizes 
of R1 were then incorporated to compound 117 via a reductive-amination reaction 
(Scheme 3.32). However, the N-i-Pr derivative was not produced under these conditions, 
only compounds 118 and 119 being prepared at that stage.   
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Scheme 3.32  (a) DIAD, PPh3, N-Boc-4-OH piperidine (103), THF, r.t., 4 hr, >95%; (b) 5% TFA in 
DCM, r.t., 2 hr, quantitative; (c) i. ketone or aldehyde, HOAc, THF/DMF, r.t., 2 hr; ii. NaBH(OAc)3, 
THF/DMF, r.t., 12 hr, 78% for 118 and 50% for 119. 
Amide series 
Ester 106 was hydrolysed in the presence of LiOH to give carboxylic acid 120, 
which was then reacted with various sizes of amines under PyBOP/DIPEA conditions to 
form an amide bond, followed by deprotection to generate compounds 121-132 
(Scheme 3.33). 
 
Scheme 3.33  (a) LiOH, THF/H2O, r.t., 18 hr, 90%; (b) PyBOP, DIPEA, R2N(H)H, DMF/DCM, r.t., 3 hr, 
50%-70%; (c) 5% TFA in DCM, r.t., 2 hr, quantitative. 
For full structural information of compounds 121-132 with different R
2
 groups, please refer to the 
following SAR part, Section 3.2.2.2 or Appendix. Only the synthetic route is described here.  
Ether series 
Scheme 3.34 outlines the retro-synthetic route for the ether compounds. 
Compound 133 required for the Mitsunobu reaction or SN2 substitution is proposed to 
be prepared in a two-step procedure (Scheme 3.34).  
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Scheme 3.34  Retro-synthetic analysis of the ether series as the second generation of PfNMT 
inhibitors 
Selection of a suitable protecting group was found to be critical.  Boc was 
initially used, towards the synthesis of the precursors of desired ethers, compounds 136 
and 137 (Scheme 3.35). A range of deprotection conditions were then attempted; 
however, none of them worked: high concentration of acids (at least 1M) was required 
to remove Boc[150], under which conditions the ether bond was not able to survive; 
neutral conditions which involved 20% of ceric ammonium nitrate (CAN) in silica[151] was 
not capable to achieve the conversion (Scheme 3.35).    
Scheme 3.35  Study of Boc used as a protecting group to make the ether series in the second 
generation of PfNMT inhibitors 
A variety of other protecting groups were also screened. Fmoc 
(fluorenylmethyloxycarbonyl), a base labile group, was found not to work under 
Mitsunobu conditions to form the ether bond; Cbz (carbobenzyloxy), a neutral 
protecting group, could not tolerate the reducing agent which was used to convert ester 
134 to alcohol 133 (Scheme 3.34); Tr (trityl), an acid labile group which is removed under 
weakly acidic conditions, under which the degradation of the C-2 ether bond was found 
not to occur, was finally utilised to provide the desired ether compounds.  
Summarising the synthesis, key intermediate 140 was prepared in a 
straightforward 2-step reaction in good yields. Representative phenol and alkyl halides 
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were reacted with compound 140 under Mitsunobu and basic conditions respectively, to 
form the ether bond, followed by the removal of Tr under weakly acidic conditions to 
yield ether compounds 142-145. However, because of the steric hindrance of the Tr 
group, above ether formation experienced low to moderate yields. In addition, alcohol 
141 was prepared under the same deprotection conditions (Scheme 3.36).  
 
Scheme 3.36  (a) DIAD, PPh3, N-Tr-4-OH piperidine (138), THF, r.t., 4 hr, 65%; (b) LiAlH4, THF, 0˚C - 
r.t., quantitative; (c) 0.1% TFA, 0.2% H2O in DCM, r.t., 12 hr, 60%-90%; (d) DIAD, PPh3, phenol, 
THF, r.t., 4 hr, 5%; (e) NaH, R
2
X (X=Br or I), DMF, r.t., 15%-40%. 
For full structural information of compounds 143-145 with different R
2
 groups, please refer to the 
following SAR part, Section 3.2.2.2 or Appendix. Only the synthetic route is described here.  
Amine series 
Direct alkylation of amine by alcohol was reported by Zaragoza where 
phosphonium iodide 146, a readily synthesised agent, was used to furnish the 
conversion[152]. The same conditions were applied to a model study in which alcohol 147 
was successfully converted to amine 148 in good yields. However, compound 135 
remained unreacted under these conditions (Scheme 3.37).  
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Scheme 3.37  Direct alkylation of amine by alcohol 
The proposed mechanism[152] is shown in Scheme 3.38. The compound 146 is 
deprotonated by DIPEA and then undergoes a Michael addition by an alcohol to form 
intermediate 150. Thermolysis of this intermediate leads to the P-C bond cleavage and 
the release of MeCN, to afford alkoxyphosphonium iodide 151, which further 
decomposes to yield alkyl iodide 152. Finally, the active species 152 alkylates the amine 
to form the desired product. Based on this mechanism, the failure to provide target 
amine from compound 135 (Scheme 3.37) could be a result of the bulky C-4 side chain in 
alcohol 135 that blocks the Michael addition occurring, therefore stopping the rest of 
the steps to generate the desired amine. 
 
Scheme 3.38  Proposed mechanism for the direct alkylation of amine by alcohol 
Another approach to produce amine is an indirect way via aldehyde stage 
(Scheme 3.39). Alcohol 135 was oxidised to aldehyde 153 by activated manganese 
dioxide, followed by a reductive-amination and then deprotection to generate the C-2 
amines 154 and 155. Primary amine 156 was further hydrogenated from compound 154. 
However, this route is only suitable for small-scale synthesis because at least 50 
equivalents of MnO2 are required to drive the reaction complete in the oxidation step, 
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which is neither environmentally nor economically friendly.  
Scheme 3.39  (a) MnO2, DCM, r.t., 24 hr, 77%; (b) i. R
2
NH2, HOAc, THF, r.t., 2 hr; ii. NaBH(OAc)3, 
THF, r.t., 12 hr, 50% for 154 and 80% for 155; (c) 5% TFA in DCM, r.t., 2 hr, quantitative; (d) Pd/C, 
1,4-cyclohexadiene, EtOH, 80 ˚C, 4 hr, 38%. 
 
3.2.2.2   Structure-activity relationships 
 
 
Determination of suitable R1 
A range of R1 groups were added to the amino group of piperidine, aiming to 
investigate their effects on inhibition (Table 3.18). It is clear that a smaller R1 gives better 
potency, which is consistent with the results in the C-2 ethyl ester series (Table 3.16). 
Table 3.18  Study of R
1
 on 4-piperidinol side chain in the second generation of PfNMT inhibitors 
 
Compound R1 IC50 (µM)
a Compound R1 IC50 (µM)
a 
117 H 22.0 118  
~133 
(43.0%)b 
119 
 
NI (0%)b    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of a 
compound at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition. 
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Given the two different series (ethyl ester and phenyl ketone) ending up with a 
similar inhibition trend regarding the size of R1, the facts further support that 4-
piperidinol with no N-substituent is an optimal C-4 side chain in the second generation 
of PfNMT inhibitors (Scheme 3.40).  
 
Scheme 3.40  Hydrogen was determined to be an optimal R
1
 on piperidine in the second 
generation of PfNMT inhibitors 
Activity Evaluation of the C-2 side chain 
Inhibitory activities of amide series with various R2 substitutions are listed in 
Table 3.19. None of compounds containing alkyl groups (121-125) were good inhibitors 
although it seemed to follow a trend that bigger R2 leads to better inhibition. Compound 
126 with phenyl was at least 4-fold more active than 124 and 125, indicating a possible 
π-π interaction with the enzyme which was described earlier (Table 3.11). Branches on 
the aromatic rings were found to reduce the activity to a large extent (127, 129 vs. 126). 
Interestingly, insertion of a methylene group between amide and the aromatic ring 
improved the potency significantly (130 vs. 129), indicating the importance of such 
spacer. Compounds with different length of the alkyl spacer were thus prepared and 
their inhibitory activities were measured. The results showed that mono-methylene is an 
optimal length of the spacer (128 vs. 157 and 158). In addition, rigidification of the 
mono-methylene spacer failed to improve the potency (131 vs. 128). Among the 
compounds in the amide series, compound 130 displayed an IC50 value of 2.3 µM, similar 
potency to the most active compound from the first generation of PfNMT inhibitors (IC50: 
1.4 µM).   
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Table 3.19  Investigation of R
2
 in the amide series in the second generation of PfNMT inhibitors 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
121 
 
~410 
(19.6%)b 
122 
 
~294 
(25.4%)b 
123 
 
~292 
(25.5%)b 
124 
 
~130 
(43.5%)b 
125 
 
~146 
(40.7%)b 
126 
 
28.8 
128 
 
13.0 157 
 
37.2 
158 
 
~144 
(40.9%)b 
127 
 
~318 
(23.9%)b 
129 
 
>100 130 
 
2.3 
131 
 
21.0 132 
 
~138 
(42.1%)b 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
Inhibitory activities of the ether compounds (141-145) with different R2 groups 
are listed in Table 3.20. The results suggested that a big R2, especially an aromatic group, 
is favoured by the enzyme (145 and 142 vs. 141, 143 and 144). Interestingly, little 
difference was observed between compounds with and without a mono-methylene 
spacer (142 vs. 145), which was in contrast to the previous findings from the amide 
series (Table 3.19).  
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Table 3.20  Examination of R
2
 in the ether series in the second generation of PfNMT inhibitors 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
141 H 
>1000 
(3.9%)b 
143 
 
>500 
(15.1%)b 
144 
 
~418 
(19.3%)b 
142 
 
6.6 
145 
 
7.1    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
Amine compounds (154-156) were generally poor inhibitors against PfNMT 
(Table 3.21). However, the rule that bigger R2 results in better enzyme inhibition was still 
followed.  
Table 3.21  Exploration of R
2
 in the amine series in the second generation of PfNMT inhibitors 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
156 H NI (0%)b 154 
 
~124 
(44.6%)b 
155 
 
50    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition. 
To conclude, the trend that a bigger R2, especially an aromatic ring, leads to 
better enzyme inhibition was observed in three investigated series (amide, ether and 
amine), therefore emerging as a clear SAR for the second generation of PfNMT inhibitors. 
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3.2.2.3 Summary 
 
Achievement 
4-Piperidinol was identified as an optimal rigid C-4 side chain, which made the 
molecule more drug-like and easier to synthesise while maintaining a similar potency to 
its trimethylene counterpart. Further exploration of the non-ester C-2 side chain resulted 
in the discovery of inhibitor 130 with an IC50 value of 2.3 µM (Scheme 3.41), comparable 
with the most active inhibitor or compound 80 from the first generation of PfNMT 
inhibitors (IC50: 1.4 µM).  
Scheme 3.41  Development of the initial second generation of PfNMT inhibitors  
Problems to solve 
Four good inhibitors described in Scheme 3.41 were measured against both 
human NMTs (Table 3.22). However disappointedly, moderate selectivity over human 
NMTs, generally less than 25-fold, was obtained. 
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Table 3.22  Selectivity data of the good inhibitors from the initial second generation of PfNMT 
inhibitors 
 
Compound Y-R2 
Enzyme IC50 (µM)
a 
PfNMT HsNMT1 HsNMT2 
117 
 
22.0 ~78 (56%)b ~89 (52.8%) 
142 
 
6.6 ~153 (39.6%) ~92 (52.1%) 
145 
 
7.1 ~87 (53.6%) ~89 (53.0%) 
130 
 
2.3 ~58 (63.2%) 50.0 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition. 
Compound 130 was the most promising compound out of the above second 
generation of PfNMT inhibitors, showing low single-digit µM of the IC50 and moderate 
selectivity. From a synthetic perspective, much higher yields were achieved in the 
preparation of compound 130 than compound 80, the best inhibitor of the first 
generation. However, relatively high molecular weight of compound 130 (Mw: 414), 
toxicity concerns associated with naphthyl[153] and scarcity of the commercially available 
naphthyl derivatives and their heterocyclic mimics significantly limited the further 
development based on this structure. 
 
3.2.3   Breakthrough 
 
At that stage, it seemed that the project was stagnant where conventional non-
ester functionalities had been exhausted, but the IC50 values of inhibitors were still in the 
µM range and only moderate selectivity over human NMTs were achieved. Therefore,  
revisiting the data obtained was necessary. 
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Table 3.23 compares the activity of compounds with three different functional 
groups Y.  Ester 109 was far more potent than amide 121 and ether 144 when R2 was 
fixed as ethyl (ethyl amine was not available at that time, so i-Pr amine was used instead). 
Combined with the rule that bigger R2 leads to better enzyme inhibition, it was likely that 
ester coupled with a big R2 would give high potency. Although ester might be hydrolysed 
by a range of esterases in the cell or body, it should be chemically stable under enzyme 
assay conditions, therefore worthwhile to be investigated. 
Table 3.23   Activity comparison among different series for the second generation of PfNMT 
inhibitors 
 
Compound Y-R2 IC50 (µM)
a Compound Y-R2 IC50 (µM)
a 
121 
 
~410 
(19.6)b 
144 
 
~418 
(19.3%)b 
109 
 
16.5    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
 
3.2.3.1   Synthesis of the C-2 ester 
 
A range of methods were attempted to convert carboxylic acid 120 to ester. 
Deprotonating the acid using a strong base (NaH in this case) followed by SN2 
substitution with electrophilic R2X afforded the desired ester. However, the yields 
became poor when the size of R2 increases (Scheme 3.42). Highly acidic conditions to 
make acyl chloride, a conventional precursor of ester, were found to complicate the 
reaction because of the vulnerability of Boc under such conditions (Scheme 3.42). 
Different coupling reagents were screened as well: PyBOP/DIPEA was only able to make 
methyl ester; DCC/DMAP (N,N'-dicyclohexylcarbodiimide/4-Dimethylaminopyridine) 
failed to provide any conversion; but good to excellent yields were obtained when 
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EDCI/HOBt (1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide/N-Hydroxybenzotriazole) 
was employed (Scheme 3.42). The mechanism of such conversion is similar to the one of 
PyBOP/DIPEA (Scheme 3.14) and compound 159 is the activated form of the carboxylic 
acid. Interestingly, intermediate 159 was found to be chemically stable and could be 
isolated under weakly acidic conditions. Considering that the actual form of EDCI used 
for synthesis was an HCl salt, DIPEA was thus added to basify the reaction mixture, 
ensuring the conversion from intermediate 159 to the desired ester. 
Scheme 3.42  Trials of making the ester series 
Esterification of carboxylic acid 120 by alcohols with various sizes of R2 was 
conducted with the aid of the coupling reagents EDCI/HOBt, followed by the Boc-
removal to produce compounds 160-164. Additionally, acid 165 was prepared from the 
deprotection of 120 directly (Scheme 3.43).   
 
Scheme 3.43  (a) EDCI, HOBt, DIPEA, R
2
OH, CH3CN, r.t., 12 hr, 70-90%; (b) 5% TFA in DCM, r.t., 2 
hr, quantitative. 
For full structural information of compounds 160-164 with different R
2
 groups, please refer to the 
following SAR part, Section 3.2.3.2 or Appendix. Only the synthetic route is described here.  
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3.2.3.2   Activity evaluation 
 
Discovery of a sub-µM inhibitor 
Inhibitory activities of the ester series with different R2 groups are listed in Table 
3.24. As expected, the results suggest that big R2 in the ester series is generally favoured 
by the enzyme which is consistent with the previous results (Section 3.2.2.2). More 
excitingly, compound 162 is the first compound to reach the sub-µM range, with an IC50 
value of 0.27 µM. Introduction of a mono-methylene between R2 phenyl and the ester 
group dramatically improved the potency by 100-fold (162 vs. 161). It was thus 
worthwhile to investigate the most suitable length of such spacer and compounds 166 
and 167 were hence prepared. The results reveal that the mono-methylene is optimal 
and longer spacer results in poorer activity (166, 167 vs. 162). Increasing the ring size 
reduced the potency by 5-fold (164 vs. 162), a contrast to the results from the amide 
series whereby 130 containing naphthyl was 6-fold more active than 128 with phenyl 
(Table 3.19), indicating the different environments surrounding R2 between the ester and 
amide series. In addition, aromaticity of R2 was determined to be critical and the 
removal of this led to a 30-fold reduction of activity (163 vs. 162), indicating the 
existence of a strong π-π interaction.     
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Table 3.24  Examination of R
2
 in the ester series in the second generation of PfNMT inhibitors 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM)
a 
165 
 
~443 
(18.4%)b 
160 
 
~98 
(50.6%)b 
109 
 
16.5 161 
 
24.4 
162 
 
0.27 163 
 
9.7 
166 
 
4.1 167 
 
36.2 
164 
 
1.4    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
Investigation of phenyl substituents 
Neither electronic nor hydrophobic effect of phenyl substitutions was found to 
improve enzyme inhibition in the amide series in the first generation of PfNMT inhibitors 
(Table 3.12). As mentioned above, the binding modes of R2 phenyl with the enzyme 
between the ester and amide series might be different. Therefore it was thought 
valuable to study the effects of phenyl substitutions in the ester series in the second 
generation of PfNMT inhibitors. The Topliss approach was again applied and the same 
initial set of substituents: methyl, chlorine and methoxy, were employed.  
Interestingly, when compounds with methoxy on different phenyl positions were 
deprotected under acidic conditions, only compound with 3-methoxy could be made 
while the other two suffered from the decomposition (Scheme 3.44).  
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Scheme 3.44  Acid labile phenomena in some methylene esters  
The decomposition was accompanied with a dramatic colour change after the 
addition of TFA, indicating the existence of the carbocation. Scheme 3.45 illustrates the 
fates of carbocations with methoxy added on the different phenyl positions. 2-OMe 168 
and 4-OMe 170 can be stabilised by their resonance hybrids 169 and 171 respectively, 
responsible for the decomposition from their parent esters; in contrast, 3-OMe 172 lacks 
such stabilisation, therefore escaping a breakdown under acidic conditions.  
 
Scheme 3.45  Resonance theory to explain the acid labile observation in some methylene esters 
Seven derivatives 173-179 comprising methyl and chlorine at all three possible 
positions and methoxy at meta-position of phenyl were prepared and their inhibitory 
activities were measured (Table 3.25). Introduction of a para-substituent reduced the 
potency by at least 10-fold (173, 174 vs. 162), indicating that R2 might sit in a shallow 
enzyme pocket. Meta and ortho-substitutions (175-179) failed to improve the inhibition 
although these two positions seemed to be more tolerated by the enzyme than the 
para-ones. These compounds were also tested against both human NMTs to determine 
the selectivity (Table 3.25). The most active compound (162) displayed excellent 
selectivity (greater than 400-fold over both human NMTs) and the investigated phenyl 
substitutions showed little effects on the inhibition against both human NMTs.   
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Table 3.25  Enzyme inhibition data of compounds with different phenyl R
3
 substituents in the 
ester series in the second generation of PfNMT inhibitors 
 
Compound R3 
Enzyme IC50 (µM)
a 
PfNMT HsNMT1 HsNMT2 
162 H 0.27 ~140 (41.7)b ~87 (53.4%)b 
173 4-Cl 
4-Me 
3-Cl 
3-Me 
3-OMe 
2-Cl 
5.6 ~150 (40%)b ~84 (54.2%)b 
174 2.1 ~136 (42.4%)b ~73 (57.8%)b 
175 0.99 ~79 (55.8%)b ~77 (56.5%)b 
176 0.62 ~96 (50.1%)b ~92 (52.1%)b 
177 0.68 >100 182 
178 0.98 ~221 (31.2%)b ~148 (40.4%)b 
179 2-Me 1.9 ~239 (29.5%)b ~74 (57.6%)b 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition. 
Other interesting analogues 
Given the fact that N-i-Pr piperidine 114 was slightly more active than piperidine 
109 in the C-2 ethyl ester series (Table 3.16), N-i-Pr piperidine 180 was hence prepared 
via a reductive-amination from 162 and evaluated against PfNMT. Unfortunately, such i-
propylation to the piperidine side chain failed to give the expected activity enhancement, 
but a 5-fold loss of enzyme potency observed instead (180 vs. 162, Figure 3.1).  
Considering the similar activity between the trimethylene and 4-piperidinol side 
chains at the C-4 position of the benzofuran scaffold, compound 181 was synthesised via 
esterification and amination from compound 55. The resulting ester 181 showed an IC50 
value of 1.6 µM (Figure 3.1), equally potent with the best compound 80 (IC50: 1.4 µM) in 
the first generation of PfNMT inhibitors, but it was still 6-fold less active than inhibitor 
162. Additionally, compound 181 displayed moderate selectivity of 25-fold over both 
human NMTs, which was shared by the other first generation of PfNMT inhibitors (Table 
3.14). Apart from simple synthesis and drug-like properties mentioned earlier (Table 
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3.17), 4-piperidinol possesses excellent selectivity, hence supporting the superiority of 4-
piperidinol over the trimethylene side chain as an optimal C-4 side chain. 
Figure 3.1  Other interesting analogues based on the structure of sub-µM inhibitor 162  
The reversed ester 182 was another interesting molecule to look at. The initial 
synthesis trial used Boc as a protecting group; however it failed at the Boc-removal stage 
when decomposition occurred under TFA conditions. The strategy then moved to utilise 
a Tr group instead and made the target compound via esterification and acid-catalysed 
deprotection (Scheme 3.46). However, poor yields were obtained due to the steric 
hindrance of Tr. Regarding the inhibitory activity, reversing the ester lost the potency by 
35-fold (182 vs. 162, Figure 3.1), suggesting that the proper arrangement of methylene 
ester is essential.  
 
Scheme 3.46  Trials in synthesising reversed ester 182  
 
3.2.3.3   Summary 
 
Re-examinations of previous compounds containing varied Y linkage groups at 
the C-2 position suggested that ester could form the basis for a promising series. 
Investigation of R2 in the ester series led to the discovery of compound 162 with an IC50 
value of 0.27 µM, the first inhibitor to reach sub-µM range. In addition, the compound 
exhibited excellent selectivity over both human NMTs. Tunings of the electronic and 
hydrophobic effects of phenyl R3 substituents failed to improve the potency (Scheme 
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3.47). Preliminary attempts to design more active molecules based on the structure of 
162 were not successful. At this stage, aside from the role of Y linkage group, other 
moieties of benzofuran inhibitors had been established. Therefore, the next step would 
focus on the investigation of Y linkage group, aiming to understand its binding mode. 
Scheme 3.47  Development of the first sub-µM inhibitor  
 
3.2.4   Investigation of the role of Y linkage group 
 
3.2.4.1   Huge activity difference between the amide and ester series 
 
A 90-fold increase of inhibitory activity was observed in the ester series when R2 
was changed from phenyl to benzyl; in contrast, only a 2-fold improvement was seen in 
the amide series (Table 3.26).  
Table 3.26  Comparison of the amide and ester series in the second generation of PfNMT 
inhibitors 
                                                                                  
R2 Compound IC50 (µM)
a Compound IC50 (µM)
 a 
 
126 28.8 161 24.4 
 
128 13.0 162 0.27 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
The amide and ester groups are quite similar in terms of their propensities 
towards the dipole-dipole interaction and hydrogen bond. Given the fact that a partial 
double bond (38%) formed between nitrogen and carbonyl carbon restricts the rotation 
Chapter 3 – PfNMT inhibitors 
-97- | P a g e  
 
of C-N bond[154] while the C-O bond in the ester is more flexible (Figure 3.2), it is likely 
that the enhanced flexibility available to the ester analogues is beneficial within these 
inhibitors.  
 
Figure 3.2  Flexibility theory to explain the activity difference between the amide and ester 
series in the second generation of PfNMT inhibitors   
Aside from the flexibility assumption, it was also worthwhile to examine whether 
Y involves other interactions, such as the dipole-dipole interaction and hydrogen bond; 
additionally, phenyl with no substitution was determined to be an optimal terminal 
group of the C-2 side chain; it was therefore easier to re-define Y as a linkage group to 
connect the benzofuran scaffold and phenyl (Figure 3.3). Compounds with various Y 
linkage groups based on the generic structure of 185 were thus proposed, synthesised 
and evaluated against PfNMT.   
 
Figure 3.16  New definition of Y linkage group in the second generation of PfNMT inhibitors 
 
3.2.4.2   Synthesis 
 
Alkyl as the Y linkage group 
Compound 186 was designed to contain a flexible linker Y without any other 
possible interactions. Its intermediate alkenes 187 (mixture of cis and trans isomers), 
which were proposed to be prepared via a Wittig reaction from aldehyde 153 (Scheme 
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3.48), were also interesting for biological tests, with the purpose to study the effects of 
the geometric isomerism of Y on enzyme inhibition.      
 
Scheme 3.48  Synthetic analysis to make compounds containing alkyl as the Y linkage group 
The synthetic route was straightforward. Aldehyde 153 underwent a Wittig 
reaction, followed by the Boc-removal to generate alkenes 188 (trans-isomer) and 189 
(cis-isomer), which could only be separated by preparative HPLC. The latter was further 
hydrogenated to yield alkyl 186 in moderate yields (Scheme 3.49).   
 
Scheme 3.49  (a) benzyltriphenyl phosphonium bromide, NaOH, THF/H2O, r.t., 1 hr, 70% 
(including cis and trans); (b) 5% TFA in DCM, r.t., 2 hr, quantitative; (c) Pd/C, 1,4-cyclohexadiene, 
EtOH, 80 ˚C, 4 hr, 40%.   
Carbonyl dimethylene formation 
Compound 190 was proposed to mimic methylene ester (the series that showed 
the best inhibition so far). Its precursor or enone 191, synthesised in two steps involving 
a Mitsunobu reaction and aldol condensation (Scheme 3.50), was another interesting 
molecule for biological tests. 
Scheme 3.50  Retro-synthetic analysis to make compounds containing carbonyl dimethylene 
moiety 
Chapter 3 – PfNMT inhibitors 
-99- | P a g e  
 
To sum up the synthesis, N-Boc-4-hydroxyl-piperidine 103 was firstly added to 
methyl ketone 71 to form compound 192, which was then treated with benzaldehyde 
under basic conditions, followed by the Boc-removal to provide trans-enone 193 
exclusively. Hydrogenation of compound 193 finally afforded the desired compound 190 
(Scheme 3.51).  
Scheme 3.51  (a) DIAD, PPh3, N-Boc-4-OH piperidine (103), THF, r.t., 4 hr, 84%; (b) benzaldehyde, 
NaOH, EtOH/H2O, 3 hr, 45%; (c) 5% TFA in DCM, r.t., 2 hr, 90%; (d) Pd/C, 1,4-cyclohexadiene, 
EtOH, 80 ˚C, 40%.    
Methylene sulfanyl derivatives 
In 2000, the Petrov group[155, 156] reported a novel approach to synthesise 2-
benzofuransulfanyl derivatives 196 from the precursor 1,2,3-thiadiazole 195, which was 
prepared in two steps involving a thermal dehydration and Hurd Mori reaction[157, 158] 
from acetophenone 194 (Scheme 3.52). The route opens up a possibility to synthesise 4-
hydroxy-2-benzofuransulfanyl derivatives, a desired inhibitor pattern described earlier 
(Section 3.1.3).  
 
Scheme 3.52  Literature synthesis of 2-benzofuransulfanyl derivatives 
Carbazone 197 was prepared according to the literature method in moderate 
yields of 25%[156]. Thionyl chloride is usually used as both reagent and solvent for a 
normal Hurd Mori reaction. However, compound 197 was found to be insoluble in SOCl2 
at room temperature, under which conditions no desired conversion was observed; 
increasing the temperature helped dissolve the compound, but led to the formation of 
di-chloro compound 198 instead. Therefore, it was necessary to have another solvent to 
co-exist with SOCl2 to dissolve the starting material. A range of solvents were thus 
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screened and DMF was found to give the desired product (Scheme 3.53). 
 
Scheme 3.53  Optimisation of Mori-Hurd reaction conditions  
Base-catalysed alkylation of thiadiazole 199 was then conducted. Benzyl 
bromide was initially used. However, it was found to be too reactive and only O-
benzylated products 201 and 202 were isolated. Therefore, benzyl chloride, a less 
reactive alkylating reagent, was attempted. It was able to provide the desired product 
200, but in poor yields of 15% and three by-products 201-203 were isolated as well 
(Scheme 3.54a). Di-benzylated compound 203 could be removed by a careful control of 
the amount of benzyl chloride; however, O-benzylated products 201 and 202 were 
unavoidable even pre-refluxing compound 199 with the base for several hours before 
the addition of benzyl chloride. Possible explanation could be that the two adjacent 
hydroxyl groups stabilise the thiadiazole, resulting in only a partial breakdown by the 
base under thermal conditions to provide intermediate 204 (Scheme 3.54b).  
Scheme 3.54  Investigation of base-catalyzed alkylation of 1,2,3-thiadiazole 
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Compound 205 was prepared via a Mitsunobu reaction from compound 200.  
m-CPBA was reported to selectively oxidise the thioether to either sulfoxide or sulfone, 
depending on the equivalents of reagent used[159]. However, when the same conditions 
were applied to compound 205, sulfone 207 was the exclusive product no matter how 
much m-CPBA involved in the reaction (Scheme 3.55). Given a chiral center in sulfoxide 
206, the access to optically pure isomers might have proven to be difficult. Therefore, 
the sulfoxide 206 was not targeted at this stage.    
Scheme 3.55  Oxidation of the benzofuransulfanyl compound  
To conclude, 2,6-dihydroxy-acetophenone 1 was treated with ethyl carbazate 
under refluxing conditions to give ethylcarbozone 197, which then underwent a Hurd-
Mori reaction to form 1,2,3-thiadiazole 199, followed by base-catalysed alkylation to 
yield sulfanyl 200. Incorporation of the piperidine side chain on compound 200 provided 
compound 205, which was either deprotected to obtain sulfanyl 208, or oxidised and 
then deprotected to afford sulfone 209, a truncated mimic of methylene ester (Scheme 
3.56).   
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Scheme 3.56  (a) ethyl carbazate, EtOH/H2O, 80 ˚C, 24 hr, 24%; (b) SOCl2, DMF, -20 ˚C-r.t, 3 hr, 
54%; (c) benzyl chloride, K2CO3, acetone, 60 ˚C, 6 hr, 24%; (d) DIAD, PPh3, N-Boc-4-OH piperidine 
(103), THF, r.t., 4 hr, 50%; (e) 5% TFA in DCM, r.t., 2 hr, 90%; (f) m-CPBA, DCM, r.t., 1 hr, 50%.   
Bioisostere of methylene ester 
Aside from structural mimics, bioisosteres of the ester are another attractive 
area to investigate. In medicinal chemistry, bioisosteres are substituents or groups with 
similar physical or chemical properties which produce broadly similar biological 
properties to a chemical compound. Figure 3.4 lists a set of bioisosteres of ester 
reported by Cambridge Medchem Consulting[160]. From a synthetic perspective, 1,2,4-
oxadiazole is the most chemically tractable and has been successfully used in a number 
of biologically important molecules to mimic ester[161-164].  
 
Figure 3.4  Structures of bioisosteres of ester  
A one-pot reaction to make 1,2,4-oxodiazole was reported by Amarasinghe[165] in 
which ester 210 was formed in situ, followed by a dehydration under refluxing toluene 
conditions to provide the target compound (Scheme 3.57). However, no conversion 
occurred when the same conditions were applied to carboxylic acid 120.  
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Scheme 3.57  Proposed one-pot reaction to make 1,2,4-oxadiazole derivatives 
The one-pot reaction was then separated into two individual steps. Ester 211 
was readily prepared using an established EDCI/HOBt approach (Section 3.2.3.1), 
followed by the dehydration under thermal conditions in the presence of 4Å molecular 
sieves, to provide the target oxadiazole compounds 213 and 215 (Scheme 3.58).   
 
Scheme 3.58  (a) R
2
(NH2)C=N-OH, EDCI, HOBt, DIPEA, CH3CN, r.t., 12 hr, 70%; (b) 4Å molecular 
sieve, dry toluene, 110 ˚C, 4 hr, 95%; (c) 5% TFA in DCM, r.t., 2 hr, 90%.  
 
3.2.4.3   Structure-activity relationships 
 
Rigid Y linkage groups 
As for rigid Y linkage groups, all the compounds except cis-alkene 189 displayed 
similar inhibition with IC50 values around 20 µM, indicating that the ester group itself is 
not special (Table 3.27). The geometric flip of alkenes from trans to cis-isomer resulted in 
a 3-fold drop of potency (188 vs. 189).  
 
 
Chapter 3 – PfNMT inhibitors 
-104- | P a g e  
 
Table 3.27  Rigid Y linkage groups in the second generation of PfNMT inhibitors 
 
Compound Y IC50 (µM)
a Compound Y IC50 (µM)
a 
161 -COO- 24.4 126 -CONH- 28.8 
188 
 
26.1 189 
 
72.0 
117 -CO- 22.0 213 
 
17.9 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
Flexible Y linkage groups 
Table 3.28 is used to compare the inhibitors with flexible Y linkage groups. Only a 
flexible ethyl of linker Y (186) was not able to ensure good inhibition. Changing 
methylene to the hetero atom, especially oxygen, led to a significant activity 
enhancement (142, 208 vs. 186), signaling the probable existence of a hydrogen bond 
associated with the hetero atom. Replacing carbonyl by methylene resulted in a 25-fold 
loss of activity (142, 145 vs. 162), indicating the necessity of the carbonyl group. The 
reversal of methylene ester reduced the potency dramatically (182 vs. 162) and the swap 
between the hetero atom and methylene was also found to affect enzyme inhibition 
(142 vs. 208), suggesting that the proper atom arrangement of Y is crucial.  
Table 3.28  Flexible Y linkage groups in the second generation of PfNMT inhibitors 
 
Compound Y IC50 (µM)
a Compound Y IC50 (µM)
a 
162 -COOCH2- 0.27 186 -CH2CH2- 131.4 
142 -CH2O- 6.6 145 -CH2OCH2- 7.1 
182 -CH2OCO-  9.6 208 -SCH2-
b 38.2 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The structure has no methyl on the C-3 position of the benzofuran scaffold. 
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Mimic of methylene ester as the Y linkage group 
Compounds listed in Table 3.29 are designed to mimic methylene ester, to view 
the Y linkage group as a whole. The inhibitory activity plummeted by 50-fold when 
replacing the ester oxygen by methylene (190 vs. 162), suggesting the key role of this 
oxygen which could involve a hydrogen bond with the enzyme. Rigidification of the 
enone moiety gave a 3-fold improvement of activity (193 vs. 190), which appeared to 
contradict the previous findings that flexibility of Y was essential. It is possible that this 
rigid linker would direct the molecule into a proper enzyme pocket. Surprisingly, 
methylene sulfone 209 lost almost all the inhibitory activity. Shorter length of Y 
compared with methylene ester should not be a major contributor to such a dramatic 
loss of activity as even shorter one, C-2 phenyl ketone 171, displayed the inhibitory 
activity with an IC50 value of 22 µM. Therefore, it is likely that methylene sulfone (209) 
would be incompatible with the good binding to the enzyme. Oxodiazole 215, a 
bioisostere of methylene ester, failed to reach the comparable level of inhibition with 
compound 162.  
Table 3.29  Mimic of methylene ester as the Y linkage group in the second generation of PfNMT 
inhibitors 
 
Compound Y IC50 (µM)
a Compound Y 
IC50 
(µM)a 
190 -COCH2CH2- 10.2 193 trans -COCH=CH-  3.5
d 
209 -SO2CH2- 
~485 
(17.1%)b,c 
215 
 
2.0 
162 -COOCH2- 0.27    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The number in parentheses was the percentage inhibition values of a 
compound at 100 µM in triplicate. The IC50 value is estimated from these to give a comparative 
indication of potency; the variation was generally <10%. 
c
 The structure has no methyl on the C-3 
position of the benzofuran scaffold. 
d
 The compound only showed moderate selectivity, with the 
IC50s 43.9 µM and 39.5 µM against HsNMT1&2, respectively.  
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Summary 
In conclusion, all three components of methylene ester were determined to be 
essential to maintain the activity: the carbonyl group might involve a dipole-dipole 
interaction or hydrogen bond; the ester oxygen could participate in a key hydrogen bond; 
the mono-methylene spacer would improve the flexibility of linker Y (Figure 3.5). None 
of other Y linkage groups synthesised so far exhibited comparable inhibition, indicating 
that methylene ester would be optimal to give excellent PfNMT inhibition.  
 
Figure 3.5  Optimal role of methylene ester to give excellent inhibition   
All three components of methylene ester were proven to be important to ensure excellent 
inhibition. The carbonyl group could be involved in dipole-dipole interaction or hydrogen bond 
with the enzyme; the ester oxygen would act as a key hydrogen bond acceptor; the methylene 
group is thought to give sufficient flexibility.  
 
3.2.5   Summary of the second generation of PfNMT inhibitors 
 
4-Piperidinol was identified as an optimal C-4 side chain in the second 
generation of PfNMT inhibitors. Big R2 groups, especially aromatic groups, were found to 
be favoured by the enzyme. A great effort was put into the study of Y linkage groups and 
methylene ester was determined to be optimal (Scheme 3.59). Compound 162 was the 
best inhibitor against PfNMT so far, with an IC50 value of 0.27 µM and excellent 
selectivity over both human NMTs.  
 
Scheme 3.59  Summary of development of the second generation of PfNMT inhibitors 
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3.3   Co-crystal structure 
 
Excitingly, the structure of P. vivax NMT, a nonhydrolysable myr-CoA analogue [S-
(2-oxo)pentadecyl-CoA] and compound 177 was successfully obtained in collaboration 
with Dr. J. Brannigan and Prof. A. Wilkinson in York University, which is to our knowledge 
the first co-crystal structure of an inhibitor bound to a Plasmodium NMT. The structural 
interpretations in this section are based on the initial unpublished information; this is 
still being refined and so the exact interatomic distances are still preliminary although 
the main features are well defined and are unlikely to change.  
PvNMT shares 81% identity with PfNMT in primary sequence and only 2 out of 
23 residues, which form the ligand binding site (residues within 5Å of the ligand in the 
enzyme) in PvNMT, are different between these two enzymes (Y212 and Y334 in PvNMT 
are both replaced by Phe in PfNMT, Figure 3.6). Therefore, the structural information of 
PvNMT would be greatly valuable to rationalise the experimental SARs for PfNMT 
inhibitors and give directions for future inhibitor design. 
 
Figure 3.6  Alignment of PvNMT and PfNMT 
The sequences of various NMT proteins have been aligned with the program MultAlign (Version 
5.4.1.Corpet 1988). PvNMT shares 81% identity with PfNMT in primary sequence; out of 23 
residues forming the ligand binding pocket, only 2 residues are different between these two 
enzymes (Y212 and Y334 in PvNMT are replaced by Phe in PfNMT).The colour codes are as follows: 
red, exact match; blue underline, residues forming the ligand binding site; green star, different 
residues between these two enzymes out of the residues forming the ligand binding pocket.  
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3.3.1   Binding mode of compound 177 with PvNMT 
 
The inhibitor 177 is found to bind at the peptide binding pocket and the key 
interactions are illustrated in Figure 3.7. The secondary amino group of piperidine at the 
C-4 position of the benzofuran scaffold picks up a hydrogen bond with the C-terminal 
carboxylate (Leu 410), a conserved interaction found in both CaNMT[117] and TbNMT 
inhibitors[124]. The benzofuran moiety is surrounded by hydrophobic residues and the 
ring is stacked parallel to Tyr211 to involve a π-π interaction. The observed interactions 
regarding methylene ester are as follows: the carbonyl oxygen is found to participate in a 
hydrogen bond with Tyr334 via a water bridge; the ester oxygen is associated with 
another hydrogen bond with Tyr211; the methylene directs the attached meta-methoxy 
phenyl group to a proper enzyme pocket, where the aromatic ring captures a weak π-π 
interaction with Phe105 (4.2 Å of distance) and the meta-methoxy oxygen forms a 
hydrogen bond with Ser319.  
 
Figure 3.7  The schematic drawing of the interactions of inhibitor 177 with PvNMT 
The colour codes are as follows: oxygen atoms, red; nitrogen atoms, blue; carbon atoms of the key 
residues and the inhibitor are yellow and green respectively; residues not directly involved with 
the interactions are coloured orange; dashed magenta lines indicate hydrogen bond (HB) 
interactions and dashed brown lines represent π-π stackings; water molecules, red sphere.  
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3.3.2   Comparison of inhibition data between Pf and PvNMTs 
 
Given the high identity of primary sequence between these two Plasmodium 
NMTs, it is expected that PfNMT inhibitors discussed earlier would give similar potency 
against PvNMT. Although there is a broad similarity in inhibition of the two NMTs, there 
are some differences (Table 3.30). Most significant is that the most potent PfNMT 
inhibitor, compound 162, is 10-fold less potent against PvNMT. As shown in Figure 3.7, R2 
phenyl involves a weak π-π stacking with Phe105 in PvNMT, giving a mere 3-fold 
improvement over its cyclohexyl counterpart (162 vs. 163). However, the same 
aromacity of R2 is found to be responsible for a 35-fold activity enhancement in PfNMT. 
Such discrepancy could be explained as the different distances between R2 and Phe105 
in these two NMTs, whereby the distance in PfNMT is closer than the one in PvNMT, 
therefore giving a stronger π-π interaction.  
Table 3.30  Comparison of inhibition data between Pf and PvNMTs 
 
Compound Y IC50s (PfNMT, µM)
a IC50s (PvNMT, µM)
a 
162 -COOCH2- 0.27 2.9 
128 -CONHCH2- 19.2 15.7 
193 (trans) -COCH=CH- 3.5 14.2 
190 -COCH2CH2- 10.2 19.7 
145 -CH2OCH2- 7.1 11.0 
166 -COOCH2CH2- 4.1 7.8 
215 
 
2.0 3.4 
 
163 
 
9.7 7.3 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
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3.3.3   Proposed origin of selectivity 
 
Compound 177 displays excellent selectivity over human NMTs; while DDD85646, 
initially developed as a TbNMT inhibitor[124], is actually a universal NMT inhibitor, giving 
little selectivity (data not shown here). It was thus interesting to use the available 
structural information, with the purpose to rationalise the origin of selectivity.  
At the start of this project, there was no information on the structure of any 
parasite NMT; now that this has become available for Leishmania NMTs[87, 124] and 
Plasmodium NMT (discussed above), it is apparent that the residues forming the peptide 
binding pocket are highly similar. Obtaining selective inhibitors is therefore welcome 
news, but would not have been obvious from the structural data. It is likely to be the 
different geometry of some key residues rather than the amino-acid differences, which is 
responsible for the selectivity. The X-ray structure of unligated and inhibitor-complexed 
PvNMT shows that the residue Y211 in PvNMT undergoes a twist, moving the aromatic 
ring and relocating the main chain to gain a stacking interaction with the benzofuran 
core of 177 (Figure 3.8a); presumably the associated energy cost is offset by the resulting 
π-π stacking with the scaffold and a hydrogen bond with the ester oxygen of the inhibitor 
(Figure 3.7). However, when modelling the same inhibitor into the structure of HsNMT1 
with myr-CoA (PDB code: 3IU1), the equivalent tyrosine or Y296 in HsNMT1 is found to 
significantly clash with 177 (Figure 3.8b). Given the poor inhibition of 177 against 
HsNMT1, it is speculated that either the initial geometry of this residue is sufficiently 
different from that of PvNMT or the energy barrier required for the conformational 
change of Y296 in HsNMT1 is too high to be compensated by the resulting interactions, 
hence giving the selectivity. There are sequence differences between PvNMT and 
HsNMT1 in the region immediately “behind” that tyrosine (Figure 3.8a and 3.8b), which 
may be responsible for this difference in behaviour. In contrast to inhibitor 177, 
DDD85646 makes a minimal interaction with the corresponding tyrosine (Y217 in 
LmNMT and Y296 in HsNMT1) in both LmNMT (Figure 3.8c, PDB code: 2WSA) and 
HsNMT1 (Figure 3.8d, PDB code: 3IWE); this could be the reason that little selectivity is 
found for this inhibitor. It might be possible to validate this assumption by mutating this 
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particular tyrosine in PvNMT (Y211) and HsNMT1 (Y296); these studies are on-going and 
it will be interesting to see the effect of mutating this residue on the binding of 177 and 
DDD85646 by PvNMT and HsNMT1.  
 
Figure 3.8  Proposed origin of selectivity over human NMTs 
(a). Conformational change of Y212 in PvNMT after the binding of compound 177; (b). Modelling 
inhibitor 177 in HsNMT1; (c),(d). There is a minimal effect on the orientation of Y217 in LmNMT 
and Y296 in HsNMT1 upon the binding of DDD85646 in LmNMT and HsNMT1 respectively 
The colour codes are as follows: oxygen atoms, red; nitrogen atoms, blue; carbon atoms of 
residues and the inhibitor are yellow and green respectively; White carbons indicated the target 
Tyr residue before the insertion of the inhibitor, either compound 177 or DDD85646.   
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3.4   Evaluation of P. falciparum inhibition 
 
Current antimalarial drug development aims at blocking the erythrocytic cycle. 
Preliminary work reported that small molecule PfNMT inhibitors, when incubating with P. 
falciparum infected erythrocytes, resulted in a reduction of parasitemia [107, 89, 122]. In this 
project, selected compounds from the library of PfNMT inhibitors were tested against 
parasites to study the correlation between enzyme inhibition and parasite growth killing 
ability, aiming to assess whether NMT is a target in P. falciparum. The assay used in the 
project was known as fluorescent-activated cell sorting (FACS) assay, which was 
conducted by Dr. D. Moss in NIMR, in conjunction with Dr. A. Holder.  
 
3.4.1   Assay description 
 
The erythrocytic cycle is a complex multi-step process, where the asexual 
reproduction occurs. For P. falciparum this typically takes 48 hours. Most parasites 
invade fresh red blood cells within 2 hours. Sharp morphological transitions for the ring-
to-trophozoite and trophozoite-to-schizont stages occur at the 18- and 30-hour 
timepoints respectively[166] (Figure 3.9A). Near the end of one cycle (44-48 hour), 
schizonts mature to merozoites, which then invade healthy erythrocytes to start a new 
infection after cell rupture (Figure 3.9B).  
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Figure 3.9  Life stages of P. falciparum throughout the intraerythrocytic cycle
[166]
 
(A) Major morphological stages throughout the intraerythrocytic cycle are shown with the 
percentage representation of ring-, trophozoite- and schizont-stage parasites at every timepoint. 
The 2-hour invasion window is also indicated (gray area)
[166]
. (B) Detailed morphological stages 
throughout the intraerythrocytic cycle, where the merozoites grow first to a ring-shaped form and 
then to a larger trophozoite form. In the schizont stage, the parasites replicate rapidly to produce 
new merozoites which start a new infection after cell rupture. 
FACS assay is a flow cytometric approach to analyse cell populations based on 
the light scattering properties and fluorescent characteristics, allowing rapid separation 
of cells. This method has been used to study growth inhibition of intraerythrocytic 
protozoan parasites that are hydroethidine (HE)-stained, a red fluorescent stain initially 
used to investigate the viability of prokaryotes[167]. HE is taken up by the living cells and 
metabolically converted to ethidium by NADPH oxidase (Figure 3.10A). Ethidium then 
intercalates into DNA (Figure 3.10B) and the resulting red fluorescence distinguishes 
infected erythrocytes with viable parasites from uninfected or infected erythrocytes 
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containing dead parasites [168-170]. 
 
Figure 3.10  Detection of living cells by hydroethidine  
(A) Mechanism of hydroethidine oxidation to fluorescent ethidium (coloured red). (B) The stain 
process of the DNA helix with ethidium  
 
3.4.2   Selected compounds for parasite inhibition assay 
 
25 selected compounds from the library of PfNMT inhibitors with diverse 
enzyme potency were tested against P. falciparum parasites. Compounds 3, the 
benzofuran scaffold, and WR99210, a highly potent antimalarial, were used as the 
negative and positive controls respectively (Figure 3.11). 
Among the first generation of PfNMT inhibitors, the good inhibitors (15, 16, 56, 
72, 80 and 181), showing IC50 values of single-digit µM range, were chosen to investigate 
their inhibition behaviours against parasites. In addition, compounds suffering from a 
total loss of enzyme inhibition by either relocation of the C-4 side chain (36) or 
incorporation of phenyl instead of t-Bu at the terminal end of the C-4 side chain (57, 73 
and 81) were picked as well to find out whether these compounds would follow a similar 
trend in parasite inhibition (Figure 3.11). 
Compounds selected from the second generation of PfNMT inhibitors were 
more comprehensive, showing a wide IC50 coverage, from 0.27 to 28.8 µM (Figure 3.11). 
In terms of the structures, these inhibitors only differ in the C-2 side chain, thus forming 
a good group to systematically study the influence of the C-2 side chain on the ability to 
kill the parasites.  
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Figure 3.11  Structures of compounds selected for P. falciparum inhibition assay 
Compound names coloured in red indicate that they are poor PfNMT inhibitors 
 
3.4.3   Assay considerations 
 
3.4.3.1   Determination of negative and positive controls 
 
Establishment of good negative and positive controls is important in assay 
development. Compound 3, the bare benzofuran core, displayed no inhibitory effect 
against PfNMT at even 1 mM. As expected, no inhibition against parasites was observed 
at the highest concentration or 100 µM (Figure 3.12A), which is considered to the point 
at which any inhibition would come from the general toxicity of a test compound 
(personal communication, Dr. D. Moss, NIMR). Therefore, compound 3 was confirmed as 
Chapter 3 – PfNMT inhibitors 
-116- | P a g e  
 
a negative control for the FACS assay. Highly active reference compound WR99210 was 
treated under the same conditions and the resulting EC50 (0.24 nM, Figure 3.12B) was 
consistent with the literature value (0.15 nM)[171], hence supporting the FACS assay as a 
reliable method to determine the inhibition against parasites.  
 
Figure 3.12  Confirmation of negative and positive controls in P. falciparum inhibition assay 
(A) Compound 3 displayed no inhibition against the parasites up to 100 µM, hence acting as the 
negative control in FACS assay. (B) WR99210, a highly active antimalarial, served as a positive 
control and showed an EC50 value of 0.24 nM against P. falciparum, which was comparable with 
the literature data
[171]
.       
 
3.4.3.2   Trifluoroacetic acid effect 
 
All selected compounds from the library of PfNMT inhibitors were purified from 
preparative HPLC with the elution always containing 0.1% TFA. Therefore, they were 
actually TFA salts. It was reported that even low concentration of TFA (nM range) could 
alter the accuracy of biological studies[172], prompting us to examine the effect of TFA on 
the growth of parasites. Encouragingly, as illustrated in Figure 3.13, TFA had no 
significant effect on the parasites, showing no inhibition or toxicity for cell growth over 
the concentrations up to 1 mM. Therefore, these TFA salts were used in the FACS assay 
without further manipulation and the resulting inhibitory activities should only come 
from the molecules under test.   
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Figure 3.13  The effects of TFA on the growth of parasites   
Trifluoroacetic acid (TFA) demonstrated no inhibitory or toxic effects on P. falciparum infected 
erythrocytes at concentrations up to 1mM.  
 
3.4.4   Parasite inhibition results 
 
At that time, there had been no evidence to show in which stage(s) of the 
intraerythrocytic cycle N-myristoylation occurs (Figure 3.9). Given a highly metabolic 
activity in trophozoite stage[166], it was sensible that the inhibitors were added during this 
stage where myristoylation is expected to be happening.  
 
3.4.4.1   Inhibition data of the first generation of PfNMT inhibitors 
 
The inhibitory activities of compounds from the first generation of PfNMT 
inhibitors against parasites are summed up in Table 3.31. NMT inhibitors with the IC50 
values of low µM range were found to display the similar degree of parasite inhibition. 
However, compounds with little or no inhibition against the enzyme (36, 60, 73 and 81) 
unexpectedly exhibited good ability to kill parasites.  
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Table 3.31  Inhibition data of the compounds from the first generation of PfNMT inhibitors 
against P. falciparum 
Compound Structure 
IC50 µM 
(PfNMT) 
EC50 µM  
(P. falciparum) 
Comments on 
EC50 
15 
 
9.0 (16.9 ± 2.7)a 
Prediction;  
good fit b  
16 
 
8.5 6.8 ± 0.7 Hill slope 4.4 
36 
 
>100 7.3 ± 0.9 Hill slope 3.1 
59 
 
9.2 (1.2 ± 0.6)a 
Prediction;  
good fit 
60 
 
>100 (5.0)a 
Prediction; 
 poor fit b 
72 
 
10.6 (5.5)a 
Prediction;  
poor fit  
73 
 
>100 (1.3 ± 0.5)a 
Prediction;  
poor fit 
80 
 
1.4 (6.0)a 
Prediction;  
poor fit  
81 
 
98.3 (5.5)a 
Prediction;  
poor fit  
181 
 
1.5 (3.5)a 
Prediction;  
poor fit  
a
 The number in parentheses was calculated from the two single points of inhibitory data, using 
GraFit (version 7.0.1).  
b
 good fit: x < 0.3; poor fit: x>0.5, x = standard deviation error / EC50. 
Discrepancy between the enzyme and cell-based results in the C-4 side chain 
Compounds 15 and 16 showed similar enzyme inhibition. However, 16 
containing the N-Bn moiety at the C-4 side chain was 3-fold more potent than its N-t-Bu 
counterpart 15 against the parasites. Such discrepancies were even more exaggerated 
whereby the N-Bn derivatives (60, 73, and 81) exhibiting no inhibition for enzyme, 
displayed comparable or even better activity than their N-t-Bu equivalents (59, 72, and 
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80) in killing parasites (Table 3.31). In addition, relocation of the side chain from the C-4 
to the C-5 position of the benzofuran core led to a total loss of enzyme activity, but 
maintained the anti-parasitic activity (16 vs. 36, Table 3.31). Given that the NMTs used in 
this project are slightly different from the wild-type ones whereby the former ones are 
His-tag attached at the N-terminus, it is not conclusive that the above activity 
discrepancy is a result of an off-target effect at the moment. The measurements of these 
compounds against the recombinant NMTs without His-tag are badly needed. 
Correlation between the enzyme and cell-based results 
When plotting the enzyme pIC50 against the cell pEC50 of five good NMT 
inhibitors from the first generation of the library (15, 59, 72, 80 and 181, Table 3.31), no 
linear correlation was observed although these anti-NMT compounds were also found to 
be anti-Plasmodial (Figure 3.14). The poor correlation could be rationalised as an off-
target effect of this series. 
 
Figure 3.14  Correlation between PfNMT and P. falciparum inhibition for the selected 
compounds from the first generation of PfNMT inhibitors  
A poor correlation between enzyme and parasite inhibition was observed in the C-2 side chain 
(orange circle) 
 
3.4.4.2   Inhibition data of the second generation of PfNMT inhibitors 
 
The inhibitory activities of the compounds from the second generation of PfNMT 
inhibitors against parasites are listed in Table 3.32. Test compounds showing a broad 
range of enzyme inhibition, with the IC50 values from 0.27 to 28.8 µM, displayed a much 
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narrower EC50 range which was between 1.2 and 15.0 µM (Table 3.32). 
Table 3.32  Inhibition data of the compounds from the second generation of PfNMT inhibitors 
against P. falciparum 
Compound Structure 
IC50 µM 
(PfNMT) 
EC50 µM  
(P. falciparum) 
Comments on EC50 
109 
 
16.5 (15.0)a Prediction; poor fit b 
117 
 
22.0 5.3 ± 0.6 Hill slope 3.2 
124 
 
100 (4.0 ± 0.7)a Prediction; good fit b 
126 
 
28.8 (5.3 ± 1.1)a Prediction; good fit b 
128 
 
13.0 7.8 ± 0.8 Hill slope 3.1c;  
130 
 
2.3 2.4 ± 0.1 Steep Hill slope 12.4 
145 
 
7.1 4.5 ± 1.9 Hill slope2.1 
161 
 
24.4 (10.0)a Prediction; poor fit b 
162 
 
0.27 (1.2 ± 0.2)a Prediction; good fit b 
163 
 
9.7 3.2 ± 0.8 Hill slope 2.5 
173 
 
5.6 (3.5)a Prediction; poor fit b 
174 
 
2.1 (3.0)a Prediction; poor fit b 
190 
 
10.2 4.0 ± 0.3 Hill slope 4.7 
193 
 
3.5 2.5 ± 0.1 Hill slope 3.6 
215 
 
2.0 2.1 ± 0.1 Hill slope 4.8 
a
 The number in parentheses was calculated from the two single points of inhibitory data, using 
GraFit (version 7.0.1). 
b
 good fit: x < 0.3; poor fit: x>0.5, x = standard deviation error / EC50. 
c
 20% 
parasite inhibition even at the lowest concentration. 
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Figure 3.15 plots the enzyme pIC50s against the cell pEC50s of the test compounds 
(data listed in Table 3.32). In contrast to the previous set of inhibitors, a good correlation 
(R2 = 0.714) was observed. This is highly suggestive that the anti-Plasmodial effects are 
directly a result of NMT inhibition rather than an off-target effect. This is the first time to 
our knowledge that a series of compounds, covering a broad range of functional groups, 
such as ketone (117), amide (124, 126, 128 and 130), ether (145), ester (109, 161, 162, 
163, 173, 174) and the mimics of methylene ester (190, 193, 215), have been found to 
show good correlation between PfNMT inhibition and anti-Plasmodial ability. The results 
provide strong evidence from a chemical perspective to prove that NMT is a target in P. 
falciparum. In addition, the resulting good correlation indirectly suggests that methylene 
ester, currently the most promising Y linkage group, is able to survive under cell 
conditions.  
 
Figure 3.15  Correlation between PfNMT and P. falciparum inhibition for the selected 
compounds from the second generation of PfNMT inhibitors  
A good correlation between the enzyme and parasite inhibition was observed in the C-2 side chain 
(red circle) 
Considering that these inhibitors only differ at their C-2 side chains, it was hence 
worthwhile to study the influence of the C-4 side chain on parasite inhibition.   
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3.4.4.3   Investigation of the role of the C-4 side chain 
 
Figure 3.16 lists the structures of further compounds selected for the cell-based 
assay, whereby these inhibitors differ in the C-4 side chain while keeping their C-2 side 
chain fixed.  
 
Figure 3.16  Structures of compounds further selected for P. falciparum inhibition assay 
The inhibitory activities of these six compounds against parasites are listed in 
Table 3.33. It appeared that inhibitors containing 4-piperidinol without N-substitution 
generally displayed higher anti-parasitic activity than their N-substitution counterparts 
(109 vs. 112, 113 and 114; 162 vs. 180). 
Table 3.33  Inhibition data of the further compounds from the second generation of PfNMT 
inhibitors against P. falciparum 
Compound CLogPa pKaa 
pIC50 
(PfNMT) 
EC50 µM  
(P. falciparum) 
pEC50 
(P. 
falciparum) 
Comments 
on EC50 
109 2.41 9.82 4.78 (15.0)
b 4.89 
Prediction; 
poor fit c 
112 2.80 8.66 4.30 16.6 ± 0.4  4.78 Hill slope 5.2 
113 3.15 8.94 4.57 23.7 ± 1.4  4.62 Hill slope 3.4 
114 3.57 9.22 5.10 (40.0)
b  4.40 
Prediction; 
poor fit c 
162 3.78 9.82 6.57 (1.2 ± 0.2)
b 5.92 
Prediction; 
good fit c 
180 4.94 9.22 5.85 4.7 ± 0.2 5.33 Hill slope 4.5 
a
 The values were calculated using the in-house compound database. 
b
 The number in 
parentheses was calculated from the two single points of inhibitory data, using GraFit (version 
7.0.1). 
c
 good fit: x < 0.3; poor fit: x>0.5, x = standard deviation error / EC50. 
Aside from improving enzyme potency, tuning of physicochemical properties is 
also widely used to optimise cell inhibition [173-175]. N-substitution on the piperidine of 
the inhibitors resulted in a big change of either CLogP (calculated LogP) or pKa (Table 
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3.33). Combined with their enzyme inhibition data, these inhibitors formed a good group 
to identify the parameter(s) of the C-4 side chain to contribute to parasite inhibition. 
Among these three factors (CLogP, pKa and pIC50), CLogP is the only one to show good 
correlation with cell inhibition (Figure 3.17) and lower hydrophobicity of R1 leads to 
higher anti-parasitic activity, supporting that 4-piperidinol, possessing the lowest 
hydrophobicity among the series, is an optimised C-4 side chain of the inhibitors.    
 
Figure 3.17  Identification of factor(s) in the C-4 4-piperidinol series to affect parasite inhibition  
Good correlation between CLogP and parasite inhibition was observed in the C-4 side chain (green 
circle) 
 
3.5   Summary 
 
Starting from the hit compound 1, two generations of PfNMT inhibitors with 
different compositions at the C-4 position of the benzofuran scaffold were developed 
(Scheme 3.60). N-t-Bu trimethylene was identified as an optimal C-4 side chain for the 
first generation of inhibitors. Subsequent modification of the C-2 side chain led to the 
discovery of several promising inhibitors (72, 59, 80 and 181) showing good inhibition at 
low µM range against both the enzyme (PfNMT) and parasites (P. falciparum). However, 
moderate selectivity over human NMTs and poor correlation between enzyme potency 
and cell inhibition prevented these inhibitors from further optimisation. Rigidification of 
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the trimethylene side chain led to the discovery of 4-piperidinol as a favourable C-4 side 
chain for the second generation of PfNMT inhibitors. A great effort was then put into the 
investigation of Y linkage groups and methylene ester was determined to be a delicate 
combination to direct the attached R2 phenyl group to pick up a strong π-π interaction, 
which was unequivocally supported by the crystal structure. More importantly, a tight 
correlation between enzyme potency and parasite inhibition was observed in the second 
generation of PfNMT, chemically validating NMT as a target in P. falciparum.   
 
Scheme 3.60  Summary of development of PfNMT inhibitors 
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4.   Discovery of LdNMT inhibitors 
 
The piggy-back strategy was again used here to identify LdNMT inhibitors, 
whereby the whole library of PfNMT inhibitors (discussed in Chapter 3) was screened 
against LdNMT to generate the initial SARs. Enzyme inhibition data were then combined 
with the parasite growth inhibition results, aiming to discover good hits or early lead 
candidates. 
 
4.1   Structure-activity relationships 
 
The full enzyme inhibition data are listed in Appendix. The key SARs observed for 
LdNMT, especially the ones different from the ones suggested in PfNMT, are presented in 
this chapter. 
 
4.1.1   Identification of the C-4 side chain for LdNMT inhibitors 
 
4-Piperidinol is a favourable C-4 side chain 
Inhibitors with the trimethylene and 4-piperidinol side chains at the C-4 position 
of the benzofuran scaffold displayed comparable enzyme potency against PfNMT. 
However, as Table 4.1 suggests, across a range of representative C-2 side chains, 
compounds containing 4-piperidinol are generally more active than their trimethylene 
counterparts against LdNMT. Most significant is the pair of compounds 80 and 142, 
where a 22-fold activity difference was observed. These results reveal that 4-piperidinol 
is more favoured than trimethylene by LdNMT as the C-4 side chain.  
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Table 4.1  Identification of 4-piperidinol as a favourable C-4 side chain for LdNMT inhibitors  
                                                                        
-Y-R2 Compound IC50 (µM)
a Compound IC50 (µM)
a 
-COOEt 15 ~167 (37.5%)b 109 22.9 
-COPh 72 32.6 117 8.6 
-CH2OPh 80 56.0 142 2.6 
-CONHPh 56 ~132 (43.1%)b 126 94.8 
-CONHBn 58 >100 128 13.5 
-COOBn 181 14.6 162 4.7 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
There is little room for R1 substitution on C-4 4-piperidinol side chain 
Table 4.2 lists the inhibitory activities of three series of compounds (ethyl ester, 
phenyl ketone and benzyl ester) with various N-substituitions on the C-4 4-piperidinol 
side chain. The results show that 4-piperidinol without N-substitution is most active 
among the series and large R1 leads to a significant loss of activity. These findings are 
slightly different to the case with PfNMT where compound 114 was found to be 2-fold 
more active than compound 109 (Table 3.16).  
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Table 4.2  Investigation of R
1
 substitutions on the C-4 4-piperidinol side chain 
 
Compound R1 IC50 (µM)
a Compound R1 IC50 (µM) 
109 H 22.9 112 Me >100 
113 Et 
~116 
(46.4%)b 
114 i-Pr 117 
115 Bn NI (0%)b    
                                                                    
Compound R1 IC50 (µM) Compound R
1 IC50 (µM) 
117 H 8.6 162 H 4.7 
118 Me 68.8 180 i-Pr 12.5 
119 Bn NI (0%)b    
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. NI: no inhibition. 
 
4.1.2   Investigation of the C-2 side chain for LdNMT inhibitors 
 
Big and aromatic R2 is favoured 
Inhibition data for compounds with different sizes of R2 are presented in Table 
4.3. The rule that bigger R2 results in better potency is followed in LdNMT, which was 
also found for PfNMT. However, there are some differences between these two enzymes: 
compound 164, 6-fold less active than compound 162 against PfNMT (Table 3.24), was 
found to be 3-fold more potent than compound 162 for LdNMT; addition of a methylene 
spacer to the C-2 ester and amide was shown to improve the potency by similar extents 
(4-7 fold) against LdNMT (162 vs. 161; 128 vs. 126) while dramatic differences regarding 
the improvement factor between these two pairs were recorded for PfNMT (Table 3.26); 
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in contrast to a 35-fold activity difference for PfNMT between compounds 162 and 163, 
aromaticity of R2 was only responsible for a 3-fold improvement for LdNMT. 
Table 4.3  Examination of compounds with various sizes of R
2
 against LdNMT 
 
Compound R2 IC50 (µM)
a Compound R2 IC50 (µM) 
160  
~145 
(40.8%)b 
109 
 
22.9 
161 
 
19.8 162 
 
4.7 
163 
 
16.5 164 
 
1.9 
 
Compound R2 IC50 (µM) Compound R
2 IC50 (µM) 
121 
 
~216 
(31.7%)b 
123 
 
~161 
(38.3%)b 
124 
 
>100 126 
 
94.8 
128 
 
13.0 130 
 
5.3 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parentheses were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. IC50 values are estimated 
from these to give a comparative indication of potency. 
Comparison of the Y linkage groups 
Inhibitory activities of molecules containing varied Y linkers are listed in Table 4.4. 
Among the rigid Y linkage groups (Table 4.4A), ketone 117 and enone 193 displayed the 
best inhibition, with the IC50 values below 10 µM. The remaining compounds except cis-
alkene 189 possessed the similar inhibition against LdNMT. For the flexible Y linkage 
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groups (Table 4.4B), methylene ester is not optimal in LdNMT: reversed methylene ester 
182 even displayed higher potency than methylene ester 162; replacing the carbonyl by 
methylene even increased potency by 2-fold (145 vs. 162). The results suggest that 
inhibitors containing a methylene ether (142 and 145) are somewhat favoured by the 
enzyme; however, poor synthetic yields and chemical instability significantly limit their 
further optimisation. Surprisingly, compound 154, which shows little inhibition for 
PfNMT, was actually quite active against LdNMT with an IC50 value of 9.0 µM.  
Table 4.4  Investigation of effects of Y linkage groups on the inhibitory activity for LdNMT 
 
(A) Rigid Y linker 
Compound Y 
IC50 
(µM)a 
Compound Y IC50 (µM)
a 
161 -COO- 19.8 126 -CONH- 28.8 
188 -CH=CH- (trans) 20.8 189 -CH=CH- (cis) 68.8 
193 
-COCH=CH- 
(trans) 
9.7b 213 
 
26.8 
117 -CO- 8.6    
 
(B) Flexible Y linker 
Compound Y IC50 (µM)
a Compound Y IC50 (µM)
a 
162 -COOCH2- 4.7 128 -CONHCH2- 13.5 
142 -CH2O- 2.6 145 -CH2OCH2- 2.5 
182 -CH2OCO-  3.3 208 -SCH2- 25.1
c 
186 -CH2CH2- 30.9 154 -CH2NH- 9.0 
215 
 
10.2 209 -SO2CH2- >100
c 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The compound only has moderate selectivity, IC50s for HsNMT1&2 are 43.9 µM 
and 39.5 µM, respectively. 
c
 The actual structure has no methyl group at the C-3 position of the 
benzofuran scaffold. 
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Investigation of R3 substitution 
Table 4.5 shows the inhibition data of inhibitors with various phenyl 
substitutions R3: para-substitutions (173 and 174) resulted in a 4-fold loss of activity; 
ortho-substitutions (178 and 179) were slightly less potent than the parent compound 
162; meta-substitutions (175-177) were found to be promising since they displayed 
comparable or higher inhibition than compound 162. In general, introduction of phenyl 
substitutions appears to be more tolerated by LdNMT than PfNMT (Table 3.25). 
Moreover, addition of meta-OMe improved the inhibitory activity by 2-fold; this could 
imply that a hydrogen bond with the enzyme might be gained. 
Table 4.5  Inhibitory activities of compounds with different phenyl R
3
 substitutions against 
LdNMT 
 
Compound R3 IC50 (µM)
a Compound R3 IC50 (µM) 
162 H 4.7 173 4-Cl 16.4 
174 4-Me 21.1 175 3-Cl 4.1 
176 3-Me 2.8 177 3-OMe 2.2 
178 2-Cl 7.9 179 2-Me 6.1 
a 
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%.  
 
4.1.3   Summary 
 
The whole library of PfNMT inhibitors was screened against LdNMT. Surprisingly, 
the molecules with trimethylene were found to be generally poor LdNMT inhibitors. 
However, the inhibitors with 4-piperidinol were quite promising. In terms of the C-4 
piperidine side chain, hydrogen as R1 was shown to be superior to other substitutions 
(Figure 4.1). With regard to the C-2 side chain, aromaticity of R2 and the addition of 
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meta-OMe to the R2 phenyl contributed to the improved enzyme potency (Figure 4.1). 
However, the role of Y linkage group remained ambiguous and there were a number of 
candidate Y linkage groups based on the enzyme inhibition results (Table 4.4). With the 
purpose to select the early lead candidates for LdNMT inhibitors, it would be greatly 
helpful at that stage to have these molecules covering a variety of Y linkage groups 
tested in the cell-based assay. 
 
Figure 4.1  Summary of SARs for LdNMT inhibitors 
 
4.2   Evaluation of L. donovani inhibition  
 
 In collaboration with Prof. D. Smith and Dr. D. Pappe in York University, inhibitors 
containing various Y linkage groups were tested against L. Donovani amastigotes, aiming 
to select promising candidates for further optimisation. In addition, it was also 
interesting to know whether anti-LdNMT molecules would kill the parasites in cells. 
 
4.2.1   Assay description 
 
The development of new antileishmanial drugs has been impeded by the lack of 
a simple and reliable drug evaluation system because the parasites exist in two forms 
(which differs from the stages in malaria parasites), known as extracellular flagellated 
promastigotes and intracellular amastigotes within mammalian macrophages. These two 
different forms are exposed to extreme environmental changes such as pH and 
temperature[176]. Many studies still measure the antileishmanial activity using 
promastigotes, the form of parasites found in the sandfly vector, because it is easy to 
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grow in culture. However, since the development of cultured amastigotes, the actual 
causative form to infect human body[177], much attention has been turned to establishing 
a rapid assay using amastigotes for the discovery of antileishmanial agents[178, 179]. In this 
project, a fluorescent assay using Alamar blue (see below) was used to determine the 
inhibition against L. donovani amastigotes.  
Alamar Blue, an oxidation-reduction indicator, is reduced in the living cell, hence 
changing the colour from blue to red (Figure 4.2)[180]. The assay was initially developed to 
target promastigotes[181] and later axenic amastigotes[179], providing a simple, rapid and 
reproducible method for screening antileishmanial agents.  
 
Figure 4.2  Mechanism of the oxidation-reduction indicator Alamar Blue 
The oxidative form, as the name suggested, is coloured as blue while the reduced form is red.  
 
4.2.2   Selection strategy 
 
There are two types of amastigotes, known as the axenic and ex-vivo 
amastigotes. Given the sources available to our collaborators in York University, ex-vivo 
amastigotes, purified from the spleen of a 6-week-infected donor hamster, were used in 
this project. Compounds were tested against both ex-vivo amostigotes and macrophages 
to obtain the extracellular inhibitory activity and toxicity respectively, aiming to identify 
the promising hits with good activity and sufficient inhibition window, which determines 
the ratio between the macrophage toxicity and anti-leishmanial activity (Figure 4.3). The 
resulting hits would be further confirmed by an intracellular amastigote assay which is 
currently laborious, time consuming and difficult to scale up into a system for HTS[182].  
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Figure 4.3  Strategy to select promising LdNMT inhibitors using the cell-based assay 
A funnel representing the selection of hits or early lead candidates for LdNMT inhibitors is based 
on the results of inhibition against ex-vivo amastigotes and toxicity for macrophages.  
 
4.2.3   Compounds for L. donovani inhibition test 
 
As mentioned earlier, the role of Y linkage group in the inhibitors remained 
ambiguous while the SARs for the other parts of the inhibitors were relatively clear 
(Figure 4.1). Therefore, ten compounds which only differ in the Y linkage group were 
selected for analysis (Figure 4.4). Compound 3, the negative control used in P. falciparum 
inhibition assay, was also viewed as a negative control here while amphotericin B, 
currently the most effective first-line antileishmanial drug[48], was used as a positive 
control.  
Figure 4.4  Structures of compounds differing only in the Y linkage group selected for anti-
leishmanial activity assays  
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4.2.4   L. donovani inhibition results 
 
4.2.4.1   Negative and positive controls 
 
As expected, compound 3, the negative control in P. falciparum, had no 
considerable inhibition against L. donovani amastigotes at the highest concentration of 
75 µM (Figure 4.5A). Therefore, compound 3 was confirmed as a negative control for the 
assay. Amphotericin B, a highly active reference compound, was treated under the same 
conditions; and a good dose-response curve was obtained (Figure 4.5B), confirming the 
feasibility of the assay.  
 
Figure 4.5  Confirmation of negative and positive controls in the L. donovani amastigote assay 
(A) Compound 3 displayed little inhibition against amastigotes at even 75 µM, hence acting as a 
negative control in the assay. (B) Amphotericin B, currently the most effective first-line 
antileishmanial, served as a positive control, showed an EC50 value of 0.03 µM.       
 
4.2.4.2   Study of ex-vivo amastigote inhibition 
 
Both inhibitory activities against ex-vivo L. donovani amastigotes and toxicity for 
macrophages of test compounds are summarised in Table 4.6. With respect to parasite 
inhibition, compounds with enzyme IC50 at low µM range (2.6 to 19.8 µM) generally 
showed a similar range of EC50 (1.3 to 25.0 µM), indicating that anti-LdNMT could be also 
anti-leishmanial. Some EC50 values were observed to be lower than their corresponding 
IC50 values (compounds 161, 162, 190, 193 and 215). Such unexpected discrepancy can 
be rationalised by considering that IC50 values derived from the enzyme assay are 
actually apparent enzyme potency, which is found to change significantly with different 
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concentrations of assay components and varied peptide substrates (data not shown 
here). In terms of the macrophage toxicity, a viability threshold was found to exist since 
only two forms of marcophage, the live (intact cell) and the dead (lysed cell), were able 
to be detected during the experiments.  
Table 4.6  Ex-vivo L. donovani amastigote inhibition and macrophage toxicity data for the 
selected compounds 
Compound Structure 
IC50 µM 
(LdNMT) 
EC50 µM  
(L. donovani)
a
 
Comments on 
EC50 
Toxicity µM
b
 
128 
 
13.5 (15.0)c 
Prediction; 
poor fit d  
Between 8.3 
and 25 
142 
 
2.6 (1.9 ± 0.1)c 
Prediction; 
good fit d 
Between 8.3 
and 25 
145 
 
2.6 (11.0 ± 2.0)c 
Prediction; 
good fit 
Between 8.3 
and 25 
154 
 
9.0 (25.0)c 
Prediction; 
poor fit 
Between 8.3 
and 25 
161 
 
19.8 4.9 ± 1.1 Hill slope 0.9 
Between 25  
and 75 
162 
 
4.7 1.4 ± 0.3 Hill slope 1.1 ~8.3e 
182 
 
2.6 (15.0)c 
Prediction; 
poor fit  
Between 25 
and 75 
190 
 
18.2 (5.5)c 
Prediction; 
poor fit 
Between 8.3 
and 25 
193 
 
9.7 1.3 ± 0.02 Hill slope 4.4 
Between 8.3 
and 25 
215 
 
10.2 1.5 ± 0.04 Hill slope 4.2 
Between 8.3 
and 25 
a
 Ex-vivo L. donovani amastigotes; 
b
 bone marrow derived macrophage (BMDM); 
c
 The numbers in 
parentheses were calculated from the two single points of inhibitory data, using GraFit (version 
7.0.1); 
d
 good fit: x < 0.3; poor fit: x>0.5, x = standard deviation error / EC50; 
e
 macrophage started 
to round up.  
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The enzyme pIC50s are plotted against the cell pEC50s in Figure 4.6. However, a 
poor correlation was observed which was in contrast to the good correlation seen in P. 
falciparum (Figure 3.18). There are several possibilities for that. Firstly, high metabolic 
activity and/or slightly acidic assay environment (pH 6.5, tested in the cultures 
throughout the incubation period) in the ex-vivo amastigotes might result in the partial 
decomposition of compounds 145 and 182 under culture conditions, perhaps 
responsible for lower-than-expected cell inhibition of these two compounds. But it 
remains mysterious that compound 142, another acid-labile molecule, exhibited strong 
cell inhibition. Secondly, the ideal temperature to culture amastigotes is 37 °C[176]. 
However, ex vivo amastigotes, the amastigotes without macrophages, were found to 
only survive at 26 °C throughout the incubation period (personal communication, Dr. D. 
Pappe, York University), under which conditions amastigotes gradually differentiate into 
promastigotes[176]. Therefore, actual parasite inhibition under assay conditions could be 
the one against both ex-vivo amastigotes and promastigotes. Considering that the 
different susceptibilities of these two forms of parasites to antileishmanial reference 
drugs have been reported[183], it is possible that the test inhibitors in this project would 
display different extents of inhibition against amastigotes and promastigotes, thus 
accounting for the observed poor correlation between enzyme potency and cell 
inhibition. Thirdly, low cell absorption could contribute to the poor cell killing ability of 
compound 154, whereby the two secondary amino groups might prevent the molecules 
from being effectively absorbed into cells. Fourthly, there has been no confirmative 
evidence to date to show that NMT is critical for the viability of amastigotes although the 
enzyme has been reported to be essential in L.donovani promastigotes[87]. Lastly, some 
of these inhibitors might be off target in L. donovani amastigotes. Under this 
circumstance, the on-target studies of these molecules are badly required.  
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Figure 4.6  Correlation between LdNMT potency and L. donovani ex-vivo amastigote inhibition 
for inhibitors differing in the Y linkage group 
The dots with red circles indicate the compounds which are used to give the possible explanations 
to the poor correlation between enzyme potency and anti-leishmanial activity. 
 
4.2.4.3   Selection of the early lead candidates 
 
Figure 4.7 lists the structures of the four compounds which were selected based 
on their high anti-leishmanial activity and sufficient inhibition window (at least 5-fold), 
which is the ratio between the macrophage toxicity and anti-leishmanial activity. The 
evaluation of these four molecules in terms of the synthetic ease, stability and selectivity 
concerns was as follows.  
Figure 4.7  Structures of compounds with good antileshmanial activity and sufficient inhibition 
window   
Inhibitors containing the ether and enone moiety 
Low synthetic yields of 2% and acid lability significantly limited the further 
development of ether 142. Using carbonyl vinyl as the Y linkage group overcame the 
synthesis and stability issues. However, the resulting enone 193 suffered from poor 
selectivity over human NMTs (IC50s: 43.9 and 39.5 µM against HsNMT1 and HsNMT2 
Chapter 4 – LdNMT inhibitors 
-138- | P a g e  
 
respectively), raising potential toxicity concerns. In addition, the Michael acceptor 
moiety is always thought to be responsible for a range of false positives in the 
biochemical assays[184, 185], therefore discarding enone 193 as an early lead candidate.   
Inhibitors with the ester functional group 
Given the excellent selectivity over human NMTs, ester 162, the lead candidate 
of PfNMT inhibitors, was also found to be a promising LdNMT inhibitors. Therefore, it 
was worthwhile to investigate a range of esters and the compounds listed in Figure 4.8 
were further evaluated in cell-based assays.  
 
Figure 4.8  Structures of the ester series for L. donovani ex-vivo amastigote inhibition assays 
Table 4.7 presents the parasite inhibition and macrophage toxicity data of the 
ester series. Generally, higher enzyme potency leads to stronger cell inhibition except for 
compound 177, which gave the lower-than-expected antileishmanial activity. In addition, 
compounds 163 and 164 displayed macrophage toxicity at lower concentrations than 
other esters, indicating a toxicity concern of cyclohexyl or naphthalene as the R2 group.   
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Table 4.7  Ex-vivo L. donovani amastigote inhibition and macrophage toxicity data for esters  
Compound Structure 
IC50 µM 
(LdNMT) 
EC50 µM  
(L. donovani)
a
 
Comments on 
EC50 
Toxicity µM
b
 
109 
 
23.0 (4.6 ± 0.5)c 
Prediction; 
good fit d  
~25e 
161 
 
19.8 4.9 ± 1.1 Hill slope 0.9 
Between 25  
and 75 
162 
 
4.7 1.4 ± 0.3 Hill slope 1.1 ~8.3e 
163 
 
15.6 3.6 ± 0.7 Hill slope 5.1 
Between 2.8 
and 8.3 
164 
 
1.9 1.5 ± 0.2 Hill slope 1.5 
Between 2.8 
and 8.3 
173 
 
16.4 (4.0)c 
Prediction; 
poor fit d 
~8.3e 
177 
 
2.2 7.4 ± 2.9 Hill slope 1.2  
Between 8.3 
and 25 
a
 Ex-vivo L. donovani amastigotes; 
b
 bone marrow derived macrophage (BMDM); 
c
 The numbers in 
parentheses were calculated from the two single points of inhibitory data, using GraFit (version 
7.0.1); 
d
 good fit: x < 0.3; poor fit: x>0.5, x = standard deviation error / EC50; 
e
 macrophage started 
to round up. 
Figure 4.9 demonstrates the correlation between enzyme potency and parasite 
inhibition of the ester series. Interestingly, it shows a tight correlation if compound 177 is 
excluded from the series. The discrepancy of 177 might be a result of demethylases in L. 
donovani amastigotes, which remove methyl from the methoxy group. Or it could be 
that the ester in this particular compound is a better substrate for cellular esterases than 
the other ester compounds. Given that the only one series is included in these data, it is 
not fully conclusive that the antileishmanial effects are directly a result of the NMT 
inhibition rather than an off-target effect. However, the linear response is at least 
indicative of this and also suggests that these esters are able to survive under culture 
conditions. Therefore, ester 162 was selected as an early lead candidate of LdNMT 
inhibitors at this stage.  
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Figure 4.9  Correlation between LdNMT potency and L. donovani ex vivo amastigote inhibition 
for the ester series  
Inhibitors containing an oxadiazole moiety  
As mentioned earlier, oxadiazole is a bioisostere of ester. Given the excellent 
selectivity over human NMTs and leadlike properties (removing the stability concerns of 
the ester group), compound 215 was determined to be a second early lead candidate of 
LdNMT inhibitors. However, incorporation of oxadiazole was found to decrease the 
solubility by at least 5-fold (data not shown here), which should be bore in mind for 
future optimisation.  
 
4.3   Summary 
 
The whole library of PfNMT inhibitors was screened against LdNMT. The 
molecules with the trimethylene side chain generally showed poor inhibitory activity 
against LdNMT while the inhibitors with 4-piperidinol were found to be a promising class 
for further investigation. Subsequent SARs suggested that hydrogen and phenyl were the 
optimal R1 and R2 groups respectively, leaving the Y linkage group to be selected. With 
the aid of the amastigote growth inhibition and macrophage toxicity assays, combined 
with synthesis and selectivity considerations, ester 162 and oxadiazole 215 were 
determined to be the early lead candidates for LdNMT inhibitors.    
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Scheme 4.1  Identification of the early lead candidates for LdNMT inhibitors 
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5.   Final Summary 
 
This PhD project has the goal to identify, design and synthesise inhibitors against 
NMTs in P. faciparum and L. donovani, the causative agents of malaria and visceral 
leishmaniasis respectively, aiming to validate NMT as a target for anti-parasitic drugs.  
 
5.1   P. falciparum NMT inhibitors 
 
5.1.1   Achievements 
 
A piggy-back strategy of screening a 25-component library of reported NMT 
inhibitors was used to identify a hit or compound 1, based on a benzofuran core, which 
showed promising enzyme potency and scope for synthetic diversity. Subsequent effort 
focused on the modification of the C-2 and C-4 side chains of the scaffold, creating a 
library of 150 analogues. The potency against PfNMT and selectivity over human NMTs 
were measured in an optimised scintillation proximity assay, leading to the discovery of 
compound 162, a lead candidate for PfNMT inhibitors. The experimental SARs were then 
rationalised by the structural analysis of inhibitor 177 in PvNMT, which is to our 
knowledge the first co-crystal structure of an inhibitor bound to a Plasmodium NMT. 
More importantly, a tight correlation between enzyme potency and parasite inhibition 
was observed, providing strong evidence from a chemical perspective to validate NMT as 
a target in P. falciparum.       
Figure 5.1  Structures of key PfNMT inhibitors at each important stage of the thesis  
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The current situation of evaluating NMT as a target in P. falciparum is 
summarised in Table 5.1. Compared with the situation when the project started in 2007, 
several improvements have been achieved: 
 A lead candidate for PfNMT inhibitors with excellent enzyme potency and selectivity 
over human homologues was identified. 
 Cell inhibition results suggested that the anti-Plasmodial effects are directly a result 
of the NMT inhibition, chemically validating NMT as a target in P. falciparum.  
 The first co-crystal structure of an inhibitor bound to a Plasmodium NMT was 
obtained, which helps to rationalise the experimental SARs and gives the direction 
for future inhibitor design. 
Table 5.1  Traffic light system
[126]
 to evaluate PfNMT as an anti-malarial target in early 2011 
Criteria Comment 
Target validation No genetic validation but chemical evidence is achieved; 
downstream proteins associated with biological pathways of 
parasites 
Assay feasibility Well developed enzyme[89] and cell-based assays[127] 
Toxicity concern Existence of human homologues; selective inhibition is 
obtained 
Resistance potential Single gene copy and the potential to avoid resistance 
Structural information Co-crystal structure of a ligand in P. vivax NMT is available 
Red represents that no information has been obtained; Amber indicates that only little 
information has been achieved and more progress is required; Green means that information or 
concept has been well understood and established. 
Underlined text demonstrates the improvement compared with the situation of PfNMT as an 
antimalarial target when the project started in 2007. 
 
5.1.2   Future work 
 
As shown in Figure 5.2a, the function of Y linkage group is to direct the attached 
R2 group into a pocket. Interestingly, the residues (highlighted in red, Figure 5.2b) 
forming this pocket are highly conserved among the four parasite NMTs listed in Figure 
5.2b, indicating a similar shape of the pocket. Two “hot residues”, F105 and S319 in 
PvNMT, were identified to involve a π-π interaction and hydrogen bond with aromatic R2 
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respectively (Figure 3.7). Therefore, to maximise these two interactions is key to further 
improve enzyme potency. Clearly, this needs to be done without affecting selectivity 
over human NMTs, though it seems that the origin of this specificity for these inhibitors 
lies elsewhere (Section 3.3.3) 
 
Figure 5.2   The enzyme pocket containing the R
2
 group of the inhibitor in PvNMT 
(a) Close-up view of the PvNMT enzyme pocket containing R
2
 of inhibitor 177; the 3-methoxy-
phenyl ester sits in the middle of this pocket, involving a π-π interaction with F105 and a 
hydrogen bond with S319.  
(b) Comparison of the residues forming the observed (Pv and Lm NMTs) or expected (Pf and Ld 
NMTs) ligand binding pocket. The red-coloured residues, which form the pocket containing 
the R
2
 group, are highly conserved among the four parasite NMTs. 
The colour codes are as follows: oxygen atoms, red; nitrogen atoms, blue; carbon atoms of 
residues and the inhibitor are yellow and green, respectively; residues forming the pocket to 
accommodate the R
2
 group are presented as a surface model; other residues not directly involved 
with the interactions are displayed as a line model; water molecules, red stars.  
Compared with compound 177 in PvNMT, there is a missing hydrogen bond with 
S319 from the phenyl R2 of compound 162, currently the lead candidate of PfNMT 
inhibitors. Therefore, the short-term goal is to investigate the diverse phenyl 
substitutions or heterocycles with hydrogen bond donor properties to pick up the 
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missing interaction with PfNMT (216, Figure 5.3). However, acid lability described in 
Scheme 3.45 will possibly limit the full study of this ester series. Under this circumstance, 
it is also desirable to identify other good Y linkage groups to replace methylene ester 
(217, Figure 5.3).  
 
Figure 5.3  Future design for PfNMT inhibitors  
Aside from enhancing enzyme potency, the long-term goal should be to improve 
cell inhibition, aiming to identify the determinant factors other than enzyme IC50, such as 
CLogP described in Figure 3.17, and understand the structural influence on the cellular 
uptake behaviour.     
 
5.2   L. donovani NMT inhibitors  
 
5.2.1   Achievements 
 
A second piggy-back approach was applied to identify good hits or early lead 
candidates for LdNMT inhibitors whereby the 150-component library of PfNMT inhibitors 
was screened against LdNMT. The resulting SARs determined 4-piperidinol to be an 
optimal C-4 side chain. In addition, phenyl at the C-2 side chain was found to be 
important as well. L. donovani ex-vivo amastigote inhibition and macrophage toxicity 
assays were further conducted to select the promising Y linkage groups, resulting in the 
identification of compounds 162 and 215 with good anti-parasitic activity and sufficient 
inhibition window (at least greater than 5-fold), which determines the ratio between 
macrophage toxicity and its corresponding EC50 value (Figure 5.4).    
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Figure 5.4  Structures of the  early lead candidates for LdNMT inhibitors 
Table 5.2 lists the current situation of evaluating NMT as an anti-leishmanial 
target. Compared with the situation when LdNMT project started in 2009, several 
improvements have been achieved: 
 Two early lead candidates for LdNMT inhibitors with good enzyme potency and 
selectivity over human homologues were achieved. 
 LdNMT inhibitors were also found to kill parasites in the ex-vivo amastigote 
inhibition assays although there was no conclusive clue from the chemical aspect to 
show that NMT is a target in L. donovani. 
Table 5.2  Traffic light system
[126]
 to evaluate LdNMT as an anti-leishmania target in early 2011 
Criteria Comment 
Target validation weak genetic validation[87];LdNMT inhibitors show cell killing 
ability; weak functional knowledge of downstream proteins 
Assay feasibility Well developed enzyme assay;  Ex-vivo and intracellular 
amastigotes is available 
Toxicity concern Existence of human homologues; Selective inhibition is 
achieved 
Resistance potential Single gene copy and the potential to avoid resistance 
Structural information Structure of LdNMT with myr-CoA analogue[87] (PDB code: 
2WUU) 
Amber indicates that only little information has been achieved and more progress is required; 
Green means that information or concept has been well understood and established. 
Underlined text demonstrates the improvement compared with the situation of PfNMT as an 
antimalarial target when the project started in 2007. 
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5.2.2   Future work 
 
Given the conserved pocket containing the R2 group in LdNMT (described in 
Figure 5.2), the strategy for future PfNMT inhibitor design can also be applied, to 
discover more active LdNMT inhibitors (217, Figure 5.5). Given that there is no 
preference of the Y linkage group in terms of enzyme potency, it is likely that either an 
optimal Y has not been identified or the benzofuran scaffold is not favoured by the 
enzyme. Scaffold hopping studies are on-going in our group in an attempt to address this 
(218, Figure 5.5). In addition, obtaining a co-crystal structure of an inhibitor bound to 
LdNMT will be enormously helpful in the near future.     
 
Figure 5.5  Future design for LdNMT inhibitors  
Understanding the cell behaviour of inhibitors in parasites is even more 
challenging than just improving enzyme potency, since a poor correlation between 
enzyme potency and the cell killing ability has been observed (Figure 4.6). There are 
various explanations to such discrepancies, and a sub-group of the inhibitor variations 
does show an excellent correlation (ester series, Figure 4.9). However, from a chemistry 
point of view, to synthesise inhibitors with good stability, including chemical and 
biological stability, will be at the top of the agenda. More compounds with good stability 
and diverse functional groups will thus be badly needed to support the target validation.  
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6   Experimental Section 
 
6.1   Chemistry 
 
6.1.1   General Methods 
 
All solvents and reagents were purchased from commercial sources and used 
without further purification. 
The compounds were spotted on silica TLC plates (Merck, Si60, F254), visualized 
under UV-light at 254 nm or iodine over silica. 
Purification of the final products was performed on a Gilson semi-preparative 
Reverse Phase-HPLC system (Anachem Ltd., Luton, UK) equipped with a HICHROM C18 
Column (250 × 21.2 mm), #306 pumps and a Gilson 155 UV/Vis detector. UV detection 
was at 220 nm. The mobile phase consisted of water plus 0.1% TFA (solvent A) and 
methanol plus 0.1% TFA (solvent B) with a gradient of 30% B for 2 min changing to 98% B 
over 30 min, maintaining for 2 min , and then down to 2% B over 0.5 min at a flow rate 
of 12 mL/min. 
The purities of the reported compounds for biological assay tests were evaluated 
by analytical LC-MS which were carried out on a Waters 2767 system equipped with a 
photodiode array and a mass spectrometer using an X-BridgeTM C18 column (5 µM, 4.6 x 
100 mM). The mobile phase consisted of water plus 0.1% formic acid (solvent A) and 
methanol plus 0.1 formic acid (solvent B) with a gradient starting from 2% to 98% B over 
the first 10 min, maintaining for 2 min, and down to 2% B over 1 min followed by the 
maintenance period for another 4 min at 2% B at a flow rate of 1.2 mL/min.    
Considering that the actual forms of these compounds are TFA and water 
adducts, determination of the accurate chemical formulae might have proven to be 
difficult. Therefore, only Mass, NMR and LC-MS data, which are used to confirm the 
structures and purities of test compounds, are presented in this thesis.  
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One-dimensional 1H- and 13C-NMR spectra as well as two-dimensional NMR 
spectra were recorded on Bruker AV at 400, 500 MHz or 100, 125 MHz respectively. 
Chemical shifts were reported in ppm. 
Mass spectra were obtained from the Mass Spectrometry Service of Department 
of Chemistry, Imperial College London. 
 
6.1.2   Synthesis and characterisation of compounds 
 
Ethyl 3-methyl-4-(3-(pyridin-3-ylmethylamino)propoxy) 
benzofuran-2-carboxylate (1)[82]  
Compound 2 (8 mg, 0.023 mmol) was stirred with 3-
(aminomethyl)-pyridine (9.6 µL, 0.092 mmol) in DMF (1 mL) at 80 °C for 4 hours. The 
reaction mixture was diluted with EtOAc (10 mL), followed by partitioning with water (10 
mL). The aqueous layer was further extracted by EtOAc (2 x 5 mL). The combined organic 
layers were sequentially washed by saturated NH4Cl, water and brine (each 10 mL), dried 
over anhydrous sodium sulphate, evaporated under pressure to dryness. The residue 
was purified by semi-preparative reverse phase HPLC to give the title compound as a 
white solid (5.9 mg, 53% yield). 1H-NMR (CD3OD, 400 MHz): δ 8.82 (s, 1H), 8.74 (s, 1H), 
8.20 (d, J=8.0 Hz, 1H), 7.70 (dd, J=8.0, 5.2 Hz, 1H), 7.39 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.4 Hz, 
1H), 6.79 (d, J=8.0 Hz, 1H), 4.44 (s, 2H), 4.41 (q, J=7.2 Hz, 2H), 4.28 (t, J=5.6 Hz, 2H), 3.41 
(t, J=7.6 Hz, 2H), 2.70 (s, 3H), 2.38-2.31 (m, 2H), 1.43 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 
100 MHz): δ 160.48, 155.71, 155.04, 148.96, 148.69, 140.07, 139.52, 128.70, 125.74, 
124.88, 118.21, 104.63, 104.00, 64.65, 60.69, 47.96, 45.02, 25.78, 13.23, 10.38. 
Calculated exact mass for the protonated molecule (C21H25N2O4): 369.1814; measured 
accurate mass (ESI): 369.1806. LC-MS purity: 100%, tR = 11.74 min. 
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Ethyl 4-(3-bromopropoxy)-3-methylbenzofuran-2-carboxylate 
(2)[82]  
Compound 3 (100 mg, 0.45 mmol), potassium carbonate (326 mg, 
2.36 mmol) were suspended in DMF (2 mL). The mixture was stirred at room 
temperature for 30 minutes and 1,3-dibromopropane (240 µL, 2.36 mmol) was then 
added. The resulting mixture was allowed to stir at room temperature for 4 hours. The 
reaction mixture was added with 10 mL water and extracted with EtOAc 3×15 mL. The 
organic layer was then dried over anhydrous sodium sulphate, concentrated and purified 
by column chromatography on silica gel, eluting with hexane:ethyl acetate, 95:5 to give 
the title compound as a white solid (95 mg, 62% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.35 
(t, J=8.0 Hz, 1H), 7.17 (d, J=8.0 Hz, 1H), 6.68 (d, J=8.0 Hz, 1H), 4.47 (q, J=7.2 Hz, 2H), 4.26 
(t, J=5.6 Hz, 2H), 3.68 (t, J=6.4 Hz, 2H), 2.76 (s, 3H), 2.47-2.41 (m, 2H), 1.46 (t, J=7.2 Hz, 
3H).  
 
Ethyl 4-hydroxy-3-methylbenzofuran-2-carboxylate (3)[135] 
To a sodium ethoxide solution, prepared by dissolving sodium 
(225 mg, 9.8 mmol) in 20 mL anhydrous ethanol (purchased from 
Aldrich, with 3 Å molecular sieve over it) under a nitrogen atmosphere and cooled down 
to around -18 °C, compound 4 (1.55 g, 6.5 mmol) was added with stirring over a period 
of 5 min. The solution was stirred for 18 hours while the temperature was slowly 
warmed up to room temperature. The mixture was quenched by 20 mL water and 
extracted by 20 mL EtOAc immediately. The aqueous layer was further extracted by 2 × 
15 mL EtOAc. The above organic layer was combined and dried over anhydrous sodium 
sulphate, concentrated and purified by column chromatography on silica gel, eluting 
with hexane:ethyl acetate, 86:14, 80:20 to give the title compound as an light-yellow 
solid (670 mg,  46% yield). 1H-NMR (CD3COCD3, 400 MHz): δ 9.05 (s, 1H, OH), 7.25 (t, 
J=8.0 Hz, 1H), 6.99 (d, J=8.0 Hz, 1H), 6.69 (d, J=8.0 Hz, 1H), 4.36 (q, J=7.2 Hz, 2H), 2.73 (s, 
3H), 1.37 (t, J=7.2 Hz, 3H).  
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Ethyl 2-(2-acetyl-3-hydroxyphenoxy)acetate (4)[83] 
A solution of 2,6-dihydroxyacetophenone (5 g, 32.9 mmol) in 60 mL of 
acetone was added potassium carbonate (11.3 g, 82 mmol) and ethyl 
bromoacetate (3.82 mL, 34.5 mmol). The reaction mixture was stirred at 60 °C for 2 
hours. The solid was filtered off and the filtrate was concentrated. The residue was 
purified by column chromatography on silica gel, eluting with hexane:ethyl acetate, 
78:22 to obtain the title compound as a light-yellow solid (6.95 g, 89% yield). 1H-NMR 
(CDCl3, 400 MHz): δ 13.26 (s, 1H), 7.34 (t, J=8.0 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 6.26 (d, 
J=8.0 Hz, 1H), 4.72 (s, 2H), 4.31 (q, J=7.8 Hz, 2H), 2.82 (s, 3H), 1.33 (t, J=7.8 Hz, 3H).  
 
4-Hydroxy-3-methyl benzofuran (7)[135] 
The aqueous layer after the extraction with EtOAc in the preparation of 
compound 3, was acidified using 2 mL concentrated HCl (20 mmol) and 
then extracted with 20 mL EtOAc. The aqueous layer was further extracted with 2 × 15 
mL EtOAc. The combined organic layers were dried over anhydrous sodium sulphate, 
concentrated and purified by column chromatography on silica gel, eluting with 
hexane:ethyl acetate, 86:14, to give the title compound as a white solid (276 mg, 29% 
yield). 1H-NMR (CD3COCD3, 400 MHz): δ 8.89 (s, 1H, OH), 7.42 (s, 1H), 7.06 (t, J=8.0 Hz, 
1H), 6.94 (d, J=8.0 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 2.38 (s, 3H).  
 
Ethyl 4-(2-bromoethoxy)-3-methylbenzofuran-2-carboxylate (11)[82] 
Prepared from compound 3 (100 mg, 0.45 mmol), dibromoethane 
(0.28 mL, 2.4 mmol) and potassium carbonate (0.69 g, 5.0 mmol) 
in DMF (2 mL) according to the preparation of compound 2, the title compound was 
obtained as a white solid (55 mg, 37% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.34 (t, J=8.0 
Hz, 1H), 7.18 (d, J=8.0 Hz, 1H), 6.61 (d, J=8.0 Hz, 1H), 4.47 (q, J=7.2 Hz, 2H), 4.44 (t, J=6.0 
Hz, 2H), 3.76 (t, J=6.0 Hz, 2H), 2.81 (s, 3H), 1.46 (t, J= 7.2 Hz, 3H).  
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Ethyl 4-(4-bromobutoxy)-3-methylbenzofuran-2-carboxylate 
(12)[82]  
Prepared from compound 3 (100 mg, 0.45 mmol), 
dibromobutane (0.28 mL, 2.4 mmol) and potassium carbonate (0.69 g, 5.0 mmol) in DMF 
(2 mL) according to the preparation of compound 2, the title compound was obtained as 
a white solid (89 mg, 56% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.33 (t, J=8.0 Hz, 1H), 7.15 
(d, J=8.0 Hz, 1H), 6.63 (d, J=8.0 Hz, 1H), 4.46 (q, J=7.2 Hz, 2H), 4.14 (t, J=6.0 Hz, 2H), 3.54 
(t, J=6.4 Hz, 2H), 2.77 (s, 3H), 2.19-2.04 (m, 4H), 1.46 (t, J=7.2 Hz, 3H).  
 
 Ethyl 4-(2-(tert-butylamino)ethoxy)-3-methylbenzofuran-2-
carboxylate(13)[82]  
Prepared from compound 11 (13.1 mg, 0.04 mmol) and t-
butylamine (16.8 µL, 0.16 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as a white solid (9.5 mg, 
55% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.43 (t, J=8.0 Hz, 1H), 7.19 (d, J=8.0 Hz, 1H), 
6.85 (d, J=8.0 Hz, 1H), 4.43 (t, J=4.4 Hz, 2H), 4.41 (q, J=7.2 Hz, 3H), 3.59 (t, J=4.4 Hz, 2H), 
2.79 (s, 3H), 1.48 (s, 9H), 1.42 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 160.45, 
155.75, 154.49, 139.74, 128.67, 125.75, 118.45, 105.35, 104.37, 64.13, 60.74, 57.30, 
41.21, 24.33, 13.21, 10.35. Calculated exact mass for the protonated molecule 
(C18H26NO4): 320.1862; measured accurate mass (ESI): 320.1849. LC-MS purity: 94%, tR = 
11.67 min. 
 
Ethyl 3-methyl-4-(2-(pyridin-3-ylmethylamino)ethoxy) 
benzofuran-2-carboxylate (14)  
Prepared from compound 11 (10 mg, 0.031 mmol) and 3-
(aminomethyl)-pyridine (12.6 µL, 0.12 mmol) in DMF (1 mL), 
according to the preparation of compound 1, the title compound was obtained as a 
white solid (2.7 mg, 19% yield). 1H-NMR (CD3OD, 400 MHz): δ 8.79 (d, J=2.0 Hz, 1H), 8.72 
(dd, J=5.0, 1.6 Hz, 1H), 8.15 (dt, J=8.0, 1.6 Hz, 1H), 7.67 (dd, J=8.0, 5.0 Hz, 1H), 7.43 (t, 
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J=8.4 Hz, 1H), 7.20 (d, J=8.0 Hz, 1H), 6.87 (d, J=8.0 Hz, 1H), 4.51 (s, 2H), 4.51 (t, J=4.8 Hz, 
2H), 4.41 (q, J=7.2 Hz, 2H), 3.69 (t, J=4.8 Hz, 2H), 2.76 (s, 3H), 1.42 (t, J=7.2 Hz, 3H). 13C-
NMR (CD3OD, 125 MHz): δ 161.81, 157.18, 155.72, 151.66, 151.49, 141.17, 139.98, 
130.03, 129.12, 127.07, 125.74, 120.00, 106.91, 105.98, 65.24, 62.15, 50.04, 47.94, 
14.63, 11.71. Calculated exact mass for the protonated molecule (C20H23N2O4): 355.1658; 
measured accurate mass (ESI): 355.1645. LC-MS purity: 100%, tR = 11.34 min. 
 
Ethyl 4-(3-(tert-butylamino)propoxy)-3-methylbenzofuran-2-
carboxylate(15)[82]  
Prepared from compound 2 (5 mg, 0.015 mmol) and t-butylamine 
(6.2 µL, 0.06 mmol) in DMF (1 mL), according to the preparation 
of compound 1, the title compound was obtained as a white solid (2.9 mg, 45% yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.41 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.81 (d, J=8.0 
Hz, 1H), 4.41 (q, J=7.0 Hz, 2H), 4.29 (t, J=6.0 Hz, 2H), 3.29 (t, J=6.0 Hz, 2H), 2.76 (s, 3H), 
2.32-2.25 (m, 2H), 1.44 (s, 9H), 1.40 (t, J=7.0 Hz, 3H).  13C-NMR (CD3OD, 100 MHz): δ 
160.60, 155.75, 155.23, 139.70, 128.87, 125.85, 118.37, 104.75, 104.15, 64.77, 60.83, 
56.98, 38.81, 26.58, 24.58, 13.37, 10.52. Calculated exact mass for the protonated 
molecule (C19H28NO4): 334.2018; measured accurate mass (ESI): 334.2003. LC-MS purity: 
100%, tR = 12.28 min. 
 
Ethyl 4-(3-(benzylamino)propoxy)-3-methylbenzofuran-2-
carboxylate(16)[82]  
Prepared from compound 2 (10 mg, 0.029 mmol) and 
benzylamine (12.7 µL, 0.12 mmol) in DMF (1 mL), according to the preparation of 
compound 1, the title compound was obtained as an off-white solid (6.0 mg, 43% yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.54-7.48 (m, 5H), 7.40 (t, J=8.0 Hz, 1H), 7.14 (d, J=8.0 Hz, 
1H), 6.79 (d, J=8.0 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 4.30 (s, 2H), 4.27 (t, J=5.6 Hz, 2H), 3.33 
(t, J=6.0 Hz, 2H), 2.66 (s, 3H), 2.35-2.28 (m, 2H), 1.44 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 
100 MHz): δ 160.47, 155.70, 155.02, 139.50, 131.00, 129.58, 129.41, 128.99, 128.70, 
125.75, 118.21, 104.62, 103.97, 64.69, 60.69, 51.01, 44.50, 25.69, 13.24, 10.37. 
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Calculated exact mass for the protonated molecule (C22H26NO4): 368.1862; measured 
accurate mass (ESI): 368.1876. LC-MS purity: 100%, tR = 12.41 min. 
 
Ethyl 3-methyl-4-(3-(pyridin-2-ylmethylamino)propoxy) 
benzofuran-2-carboxylate (17)[82] 
Prepared from compound 2 (10 mg, 0.029 mmol) and 2-
(aminomethyl)-pyridine (12.0 µL, 0.12 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as a white solid (7.2 mg, 
52% yield). 1H-NMR (CD3OD, 400 MHz): δ 8.60 (d, J=4.8 Hz, 1H), 7.89 (dt, J=8.0, 1.6 Hz, 
1H), 7.49 (d, J=8.0 Hz, 1H), 7.41 (dd, J=8.0, 4.8 Hz, 1H), 7.41 (t, J=8.0 Hz, 1H), 7.14 (d, 
J=8.0 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 4.47 (s, 2H), 4.42 (q, J=7.2 Hz, 2H), 4.30 (t, J=6.0 Hz, 
2H), 3.41 (t, J=7.6 Hz, 2H), 2.70 (s, 3H), 2.41-2.34 (m, 2H), 1.43 (t, J=7.2 Hz, 3H). 13C-NMR 
(CD3OD, 100 MHz): δ 160.37, 155.70, 155.06, 151.04, 149.23, 139.49, 137.43, 128.71, 
125.80, 123.65, 122.69, 118.18, 104.63, 104.02, 64.87, 60.68, 50.44, 44.98, 25.73, 13.23, 
10.37. Calculated exact mass for the protonated molecule (C21H25N2O4): 369.1814; 
measured accurate mass (ESI): 369.1807. LC-MS purity: 100%, tR = 12.13 min. 
 
Ethyl 3-methyl-4-(3-(piperidin-1-yl)propoxy)benzofuran-2-
carboxylate(18)  
Prepared from compound 2 (10 mg, 0.029 mmol) and piperidine 
(11.5 µL, 0.12 mmol) in DMF (1 mL), according to the preparation of compound 1, the 
title compound was obtained as an off-white solid (12.0 mg, 90% yield). 1H-NMR (CD3OD, 
400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.79 (d, J=8.0 Hz,1H), 4.42 (q, 
J=7.2 Hz, 2H), 4.26 (t, J=6.0 Hz, 2H), 3.64 (d, J=12.4 Hz, 2H), 3.38 (t, J=6.0 Hz, 2H), 3.03 (td, 
J=12.4, 2.4 Hz, 2H), 2.76 (s, 3H), 2.39-2.32 (m, 2H), 2.02 (d, J=14.8 Hz, 2H), 1.91-1.77 (m, 
3H), 1.63-1.54 (m, 1H), 1.43 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 160.49, 
155.70, 155.05, 139.52, 128.71, 125.80, 118.22, 104.62, 103.97, 64.81, 60.69, 54.40, 
53.10, 23.77, 22.95, 21.24, 13.22, 10.41. Calculated exact mass for the protonated 
molecule (C20H28NO4): 364.2018; measured accurate mass (ESI): 364.2009. LC-MS purity: 
100%, tR = 11.88 min. 
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Ethyl 3-methyl-4-(3-(methylamino)propoxy)benzofuran-2-
carboxylate(19)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 
methylamine (33% wt solution in ethanol, 11.3 µL, 0.12 mmol) in DMF (1 mL), according 
to the preparation of compound 1, the title compound was obtained as a white solid (7.5 
mg, 64% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.14 (d, J=8.0 Hz, 1H), 
6.80 (d, J=8.0 Hz, 1H), 4.41 (q, J=7.2 Hz, 2H), 4.27 (t, J=5.6 Hz, 2H), 3.29 (t, J=7.6 Hz, 2H), 
2.80 (s, 3H), 2.76 (s, 3H), 2.33-2.26 (m, 2H), 1.43 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 
MHz): δ 160.50, 155.70, 155.09, 139.57, 128.70, 125.66, 118.24, 104.62, 104.01, 64.72, 
60.69, 46.53, 32.36, 25.70, 13.22, 10.37. Calculated exact mass for the protonated 
molecule (C16H22NO4): 292.1549; measured accurate mass (ESI): 292.1545. LC-MS purity: 
96%, tR = 11.73 min. 
 
Ethyl 3-methyl-4-(3-(phenylamino)propoxy)benzofuran-2-
carboxylate(20)  
Prepared from compound 2 (10 mg, 0.029 mmol) and aniline 
(10.9 µL, 0.12 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as a pale brown solid (9.5 
mg, 70% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.34-7.29 (m, 3H), 7.15 (d, J=8.0 Hz, 1H), 
7.08 (d, J=8.0 Hz, 2H), 7.07 (t, J=8.0 Hz, 1H), 6.58 (d, J=8.0 Hz, 1H), 4.46 (q, J=7.2 Hz, 2H), 
4.16 (t, J=6.0 Hz, 2H), 3.50 (t, J=7.6 Hz, 2H), 2.73 (s, 3H), 2.31-2.24 (m, 2H), 2.20 (s, NH), 
1.46 (t, J=7.2 Hz, 3H). 13C-NMR (CDCl3, 100 MHz): δ 160.46, 155.66, 155.18, 142.12, 
139.71, 129.81, 128.55, 126.37, 123.37, 118.65, 117.64, 105.35, 103.77, 65.26, 61.03, 
45.54, 27.38, 14.43, 11.38. Calculated exact mass for the protonated molecule 
(C21H24NO4): 354.1705; measured accurate mass (ESI): 354.1716. LC-MS purity: 100%, tR 
= 22.94 min (optimal gradient: from 2% to 98% B over the first 20 min, maintaining for 2 
min, and down to 2% B over 1 min followed by the maintenance period for another 4 
min at 2% B at a flow rate of 1.2 mL/min). 
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Ethyl 3-methyl-4-(3-(pyridin-4-ylmethylamino)propoxy) 
benzofuran-2-carboxylate (21) 
Prepared from compound 2 (10 mg, 0.029 mmol) and 4-
(aminomethyl)-pyridine (12.1 µL, 0.12 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as a yellow solid (4.8 mg, 
34% yield). 1H-NMR (CD3OD, 500 MHz): δ 8.72 (s, 2H), 7.67 (d, J=6.0 Hz, 2H), 7.38 (t, 
J=7.5 Hz, 1H), 7.11 (d, J=7.5 Hz, 1H), 6.78 (d, J= 7.5 Hz, 1H), 4.42 (s, 2H), 4.39 (q, J=7.2 Hz, 
2H), 4.27 (t, J=6.0 Hz, 2H), 3.39 (t, J=7.5 Hz, 2H), 2.69 (s, 3H), 2.36-2.30 (m, 2H), 1.40 (t, 
J=7.2 Hz, 3H). 13C-NMR (CD3OD, 125 MHz): δ 161.88, 157.14, 156.43, 149.88, 144.44, 
140.98, 130.11, 127.11, 126.30, 119.65, 106.10, 105.43, 66.05, 62.11, 50.87, 46.74, 
27.16, 14.64, 11.79. Calculated exact mass for the protonated molecule (C21H25N2O4): 
369.1814; measured accurate mass (ESI): 369.1814. LC-MS purity: 100%, tR = 11.65 min.  
 
Ethyl 3-methyl-4-(3-(naphthalen-1-ylmethyl-amino)-
propoxy)-benzofuran-2-carboxylate (22)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 1-
(aminomethyl)-naphthalin (17.0 µL, 0.12 mmol) in DMF (1 
mL), according to the preparation of compound 1, the title compound was obtained as a 
white solid (3.7 mg, 24% yield). 1H-NMR (CD3OD, 500 MHz): δ 8.16 (d, J=8.0 Hz, 1H), 8.00 
(d, J=8.0 Hz, 1H), 7.97 (d, J=8.0 Hz, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.66-7.62 (m, 1H), 7.60-
7.54 (m, 1H), 7.36 (t, J=8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 4.80 (s, 
2H), 4.40 (q, J=7.0 Hz, 2H), 4.25 (t, J=6.0 Hz, 2H), 3.42 (t, J=7.5 Hz, 2H), 2.56 (s, 3H), 2.35-
2.29 (m, 2H), 1.41 (t, J=7.0 Hz, 3H). 13C-NMR (CD3OD, 125 MHz): δ 161.88, 157.12, 156.39, 
140.92, 135.52, 132.71, 131.78, 130.38, 130.24, 130.09, 128.55, 128.34, 127.69, 127.11, 
126.52, 123.69, 119.63, 106.07, 105.41, 66.22, 62.11, 48.91, 46.52, 27.11, 14.67, 11.69. 
Calculated exact mass for the protonated molecule (C26H28NO4): 418.2018; measured 
accurate mass (ESI): 418.2036. LC-MS purity: 100%, tR = 19.14 min (gradient: from 2% to 
98% B over the first 20 min, maintaining for 2 min, and down to 2% B over 1 min 
followed by another 4 min at 2% B; flow rate: 1.2 mL/min). 
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Ethyl 3-methyl-4-[3-(propan-2-ylamino)propoxy]-1-benzofuran-2-
carboxylate (23)[82]  
Prepared from compound 2 (10 mg, 0.029 mmol) and 
isopropylamine (10.2 µL, 0.12 mmol) in DMF (1 mL), according to the preparation of 
compound 1, the title compound was obtained as a white solid (9.7 mg, 77% yield). 1H-
NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.14 (d, J=8.0 Hz, 1H), 6.80 (d, J=8.0 Hz, 
1H), 4.41 (q, J=7.2 Hz, 2H), 4.27 (t, J=6.0 Hz, 2H), 3.50-3.43 (m, 1H), 3.30 (d, J=8.0 Hz, 2H), 
2.76 (s, 3H), 2.32-2.25 (m, 2H), 1.43 (t, J=7.2 Hz, 3H), 1.39 (d, J=6.8 Hz, 6H). 13C-NMR 
(CD3OD, 100 MHz): δ 160.55, 155.77, 155.09, 139.53, 128.87, 125.79, 118.28, 104.61, 
104.04, 64.66, 60.76, 50.66, 42.19, 26.20, 17.89, 13.30, 10.45. Calculated exact mass for 
the protonated molecule (C18H26NO4): 320.1862; measured accurate mass (ESI): 
320.1858. LC-MS purity: 100%, tR = 12.66 min.  
 
Ethyl 4-(3-(cyclohexylamino)propoxy)-3-methylbenzofuran-2-
carboxylate(24)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 
cyclohexylamine (13.7 µL, 0.12 mmol) in DMF (1 mL), according 
to the preparation of compound 1, the title compound was obtained as a white solid 
(10.9 mg, 79% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.0 
Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 4.41 (q, J=7.2 Hz, 2H), 4.27 (t, J=6.0 Hz, 2H), 3.32 (t, J=8.0 
Hz, 2H), 3.21-3.10 (m, 1H), 2.75 (s, 3H), 2.32-2.25 (m, 2H), 2.20-2.11 (brd, 2H), 1.98-1.87 
(brd, 2H), 1.80-1.70 (m, 2H), 1.46-1.19 (m, 5H), 1.43 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 
100 MHz): δ 160.48, 155.72, 155.10, 139.54, 128.71, 125.72, 118.23, 104.60, 103.99, 
64.70, 60.69, 57.11, 41.77, 28.99, 26.00, 24.67, 24.03, 13.22, 10.38. Calculated exact 
mass for the protonated molecule (C21H30NO4): 360.2175; measured accurate mass (ESI): 
360.2186. LC-MS purity: 100%, tR = 12.71 min.  
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Ethyl 3-methyl-4-(3-(2-methylbenzylamino)propoxy) 
benzofuran-2-carboxylate (25)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 2-
methylbenzylamine (14.9 µL, 0.12 mmol) in DMF (1 mL), 
according to the preparation of compound 1, the title compound was obtained as a 
white solid (7.6 mg, 53% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.46 (d, J=7.6 Hz, 1H), 7.41 
(t, J=8.0 Hz, 1H), 7.37-7.29 (m, 3H), 7.14 (d, J=8.0 Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 4.42 (q, 
J=7.2 Hz, 2H), 4.35 (s, 2H), 4.29 (t, J=6.0 Hz, 2H), 3.41 (t, J=8.0 Hz, 2H), 2.70 (s, 3H), 2.47 
(s, 3H), 2.38-2.31 (m, 2H), 1.44 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 160.47, 
155.72, 155.05, 139.52, 137.56, 137.40, 130.88, 129.83, 129.52, 128.71, 126.48, 125.75, 
118.23, 104.63, 104.00, 64.76, 60.69, 48.71, 44.97, 25.69, 17.80, 13.23, 10.39. Calculated 
exact mass for the protonated molecule (C23H28NO4): 382.2018; measured accurate mass 
(ESI): 382.2007. LC-MS purity: 100%, tR = 12.52 min.   
 
Ethyl 3-methyl-4-(3-(4-methylbenzylamino)propoxy) 
benzofuran-2-carboxylate (26)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 4-
methylbenzylamine (15.2 µL, 0.12 mmol) in DMF (1 mL), according to the preparation of 
compound 1, the title compound was obtained as a white solid (8.2 mg, 57% yield). 1H-
NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 2H), 7.29 (d, J=8.0 Hz, 
2H), 7.13 (d, J=8.0 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 4.25 (s, 2H), 4.25 
(t, J=5.6 Hz, 2H), 3.30 (t, J=8.0 Hz, 2H), 2.61 (s, 3H), 2.39 (s, 3H), 2.33-2.26 (m, 2H), 1.44 (t, 
J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 160.46, 155.69, 154.99, 139.71, 139.47, 
129.55, 128.70, 127.85, 125.76, 118.19, 104.60, 103.94, 64.61, 60.68, 50.68, 44.14, 
25.64, 19.84, 13.25, 10.32. Calculated exact mass for the protonated molecule 
(C23H28NO4): 382.2018; measured accurate mass (ESI): 382.2023. LC-MS purity: 100%, tR 
= 12.68 min. 
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Ethyl 4-(3-(2-fluorobenzylamino)propoxy)-3-
methylbenzofuran-2-carboxylate (27)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 2-
fluorobenzylamine (13.7 µL, 0.12 mmol) in DMF (1 mL), 
according to the preparation of compound 1, the title compound was obtained as a 
white solid (8.2 mg, 57% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.62-7.51 (m, 2H), 7.40 (t, 
J=8.0 Hz, 1H), 7.36-7.24 (m, 2H), 7.14 (d, J=8.0 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H), 4.42 (q, 
J=7.2 Hz, 2H), 4.40 (s, 2H), 4.27 (t, J=5.6 Hz, 2H), 3.37 (t, J=8.0 Hz, 2H), 2.68 (s, 3H), 2.38-
2.28 (m, 2H), 1.44 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 160.47, 160.18, 155.70, 
155.02, 139.51, 132.07, 131.96, 128.70, 125.73, 124.90, 118.22, 115.6, 104.63, 103.99, 
64.67, 60.69, 44.74, 44.29, 25.63, 13.23, 10.36. Calculated exact mass for the protonated 
molecule (C22H25NO4F): 386.1768; measured accurate mass (ESI): 386.1771. LC-MS purity: 
100%, tR = 12.34 min.  
 
Ethyl 4-(3-(4-fluorobenzylamino)propoxy)-3-
methylbenzofuran-2-carboxylate (28)  
Prepared from compound 2 (10 mg, 0.029 mmol) and 4-
fluorobenzylamine (13.7 µL, 0.12 mmol) in DMF (1 mL), according to the preparation of 
compound 1, the title compound was obtained as a white solid (8.6 mg, 59% yield). 1H-
NMR (CD3OD, 400 MHz): δ 7.57 (dd, J=8.8, 5.2 Hz, 2H), 7.40 (t, J=8.0 Hz, 1H), 7.23 (t, 
J=8.8 Hz, 2H), 7.14 (d, J=8.0 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 4.30 (s, 
2H), 4.27 (t, J=5.6 Hz, 2H), 3.33 (t, J=8.0 Hz, 2H), 2.66 (s, 3H), 2.36-2.26 (m, 2H), 1.44 (t, 
J=7.2 Hz, 3H).  13C-NMR (CD3OD, 100 MHz): δ 162.26, 160.47, 155.71, 155.01, 139.52, 
131.97, 128.70, 127.16, 125.69, 118.21, 115.78, 104.62, 103.98, 64.66, 60.70, 50.16, 
44.45, 25.69, 13.22, 10.36. Calculated exact mass for the protonated molecule 
(C22H25NO4F): 386.1768; measured accurate mass (ESI): 386.1766. LC-MS purity: 100%, tR 
= 12.33 min.  
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Ethyl 3-methyl-4-(3-(piperazin-1-yl)propoxy)benzofuran-2-
carboxylate(29) 
Prepared from compound 2 (10 mg, 0.029 mmol) and piperazine 
(10 mg, 0.12 mmol) in DMF (1 mL), according to the preparation of compound 1, the title 
compound was obtained as a white solid (4.9 mg, 37% yield). 1H-NMR (CD3OD, 400 MHz): 
δ 7.39 (t, J=8.4 Hz, 1H), 7.12 (d, J=8.4 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.41 (q, J=7.2 Hz, 
2H), 4.25 (t, J=6.0 Hz, 2H), 3.45 (t, J=5.2 Hz, 4H), 3.23 (brd, 4H), 3.13 (t, J=7.6 Hz, 2H), 
2.76 (s, 3H), 2.29-2.22 (m, 2H), 1.42 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 
161.94, 157.15, 156.76, 140.88, 130.12, 127.32, 119.66, 105.81, 105.36, 66.57, 62.08, 
55.80, 50.48, 43.55, 26.26, 14.63, 11.79. Calculated exact mass for the protonated 
molecule (C19H27N2O4): 347.1971; measured accurate mass (ESI): 347.1956. LC-MS purity: 
100%, tR = 11.39 min.  
 
Ethyl 4-(4-(tert-butylamino)butoxy)-3-methylbenzofuran-2-
carboxylate(30)[82] 
Prepared from compound 12 (10.7 mg, 0.03 mmol) and tert-
butylamine (12.6 µL, 0.12 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as a white solid (6.8 mg, 
49% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.38 (t, J=8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 
6.78 (d, J=8.0 Hz, 1H), 4.40 (q, J=7.2 Hz, 2H), 4.21 (t, J=6.0 Hz, 2H), 3.10 (t, J=4.0 Hz, 2H), 
2.76 (s, 3H), 2.06-1.90 (m, 4H), 1.42 (t, J=7.2 Hz, 3H), 1.40 (s, 9H). 13C-NMR (CD3OD, 100 
MHz): δ 160.52, 155.73, 155.49, 139.42, 128.75, 125.94, 118.22, 104.27, 103.94, 67.08, 
60.65, 56.54, 41.00, 26.05, 24.41, 23.62, 13.23, 10.38. Calculated exact mass for the 
protonated molecule (C20H30NO4): 348.2175; measured accurate mass (ESI): 348.2165. 
LC-MS purity: 100%, tR = 12.45 min.  
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Ethyl 3-methyl-4-(4-(pyridin-3-ylmethylamino)butoxy) 
benzofuran-2-carboxylate (31)  
Prepared from compound 12 (26 mg, 0.07 mmol) and 3-
(aminomethyl)-pyridine (29.5 µL, 0.29 mmol) in DMF (1 
mL), according to the preparation of compound 1, the title compound was obtained as a 
white solid (13.6 mg, 39% yield). 1H-NMR (CD3OD, 400 MHz): δ 8.86 (s, 1H), 8.78 (d, J=4.8 
Hz, 1H), 8.33 (d, J=8.0 Hz, 1H), 7.80 (dd, J=8.0, 4.8 Hz, 1H), 7.36 (t, J=8.0 Hz, 1H), 7.09 (d, 
J=8.0 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 4.43 (s, 2H), 4.39 (q, J=7.2 Hz, 2H), 4.18 (t, J=5.2 Hz, 
2H), 3.27 (t, J=7.6 Hz, 2H), 2.72 (s, 3H), 2.07-1.97 (m, 4H), 1.41 (t, J=7.2 Hz, 3H). 13C-NMR 
(CD3OD, 100 MHz): δ 160.55, 155.71, 155.47, 147.34, 146.90, 142.24, 139.38, 129.65, 
128.72, 125.99, 125.53, 118.21, 104.24, 103.89, 67.00, 60.66, 47.56, 47.41, 25.91, 23.00, 
13.21, 10.39. Calculated exact mass for the protonated molecule (C22H27N2O4): 383.1971; 
measured accurate mass (ESI): 383.1956. LC-MS purity: 100%, tR = 12.07 min.  
 
Ethyl 4-(3-aminopropoxy)-3-methylbenzofuran-2-carboxylate 
(32)[82] 
 10% Palladium on carbon (6 mg, 0.005 mmol) and 1,4-
cyclohexadiene (50 µL, 0.54 mmol) were added to a solution of compound 16 (10 mg, 
0.027mmol) in ethanol (1 mL). The resulting mixture was stirred at 80 ˚C for 4 hours. 
After that, the reaction mixture was filtered off and the filtration was concentrated in 
vacuo, which was purified by semi-preparative reverse phase HPLC to give the title 
compound as a white solid (7.1 mg, 67% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.39 (t, 
J=8.4 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H), 4.41 (q, J=7.2 Hz, 2H), 4.26 (t, 
J=6.0 Hz, 2H), 3.23 (t, J=7.6 Hz, 2H), 2.75 (s, 3H), 2.30-2.23 (m, 2H), 1.42 (s, 3H). 13C-NMR 
(CD3OD, 100 MHz): δ 160.50, 155.70, 155.15, 139.50, 128.71, 125.78, 118.23, 104.57, 
103.99, 64.70, 60.69, 36.90, 27.00, 13.22, 10.33. Calculated exact mass for the 
protonated molecule (C15H20NO4): 278.1392; measured accurate mass (ESI): 278.1400. 
LC-MS purity: 97%, tR = 11.48 min.  
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Ethyl 3-methyl-4-(3-phenoxypropoxy)benzofuran-2-
carboxylate (33)[83]  
Prepared from compound 3 (10 mg, 0.045 mmol), benzyl 3-
bromopropyl ether (16 µL, 0.091 mmol) and potassium carbonate (39 mg, 0.27 mmol) in 
DMF (1 mL), according to the preparation of compound 2, the title compound was 
obtained as colourless oil (3.0 mg, 19% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.36 (t, J=8.0 
Hz, 1H), 7.31-7.29 (m, 2H), 7.25-7.18 (m, 2H), 7.07 (d, J=8.0 Hz, 1H), 6.73 (d, J=8.0 Hz, 
1H), 4.54 (s, 2H), 4.40 (q, J=7.2 Hz, 2H), 4.20 (t, J=6.0 Hz, 2H), 3.72 (t, J=6.0 Hz, 2H), 2.58 
(s, 3H), 2.18-2.12 (m, 2H), 1.42 (t, J=7.2 Hz, 3H). ). 13C-NMR (CD3OD, 100 MHz): δ 160.57, 
155.71, 139.24, 138.30, 128.69, 127.91, 127.41, 127.19, 126.23, 118.25, 103.98, 103.78, 
72.49, 65.89, 64.65, 60.59, 29.22, 13.25, 10.23. Calculated exact mass for the protonated 
molecule (C22H25O5): 369.1702; measured accurate mass (ESI): 369.1714. LC-MS purity: 
100%, tR = 23.99 min (gradient: from 2% to 98% B over the first 20 min, maintaining for 2 
min, and down to 2% B over 1 min, followed by 4 min at 2% B; flow rate: 1.2 mL/min). 
 
N-benzyl-3-(2-(ethoxycarbonyl)-3-methylbenzofuran-4-
yloxy)-N,N- dimethylpropan-1-aminium bromide (34) 
A solution of compound 2 (10 mg, 0.029 mmol) and N,N-
dimethyl benzylamine (4.4 µL, 0.029 mmol) in acetonitrile (1 mL) was stirred at 85 ˚C for 
16 hours. The reaction mixture was then cooled and a white solid precipitated. The solid 
was washed by ether and dried under pressure, to give the title compound as a white 
solid (12.4 mg, 90% yield).  1H-NMR (CD3OD, 400 MHz): δ 7.63-7.51 (m, 5H), 7.40 (t, J=8.4 
Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 4.67 (s, 2H), 4.40 (q, J=7.2 Hz, 2H), 
4.30 (t, J=5.6 Hz, 2H), 3.65-3.61 (m, 2H), 3.17 (s, 6H), 2.60 (s, 3H), 2.57-2.46 (m, 2H), 1.42 
(t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 400 MHz): δ 160.46, 155.69, 154.92, 139.51, 132.79, 
130.63, 128.73, 127.39, 125.74, 118.21, 104.69, 104.07, 68.20, 64.76, 61.74, 60.70, 
49.18, 22.55, 13.24, 10.46. Calculated exact mass for the protonated molecule 
(C24H30NO4): 396.2175; measured accurate mass (ESI): 396.2169. LC-MS purity: 100%, tR 
= 11.98 min.  
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Ethyl 5-(3-(tert-butylamino)propoxy)-3-methylbenzofuran-2-
carboxylate(35)  
Prepared from compound 42 (10 mg, 0.029 mmol) and t-
butylamine (12.3 µL, 0.12 mmol) in DMF (1 mL), according to the preparation for 
compound 1, the title compound was obtained as a white solid (7.0 mg, 54% yield). 1H-
NMR (CD3OD, 400 MHz): δ 7.46 (d, J=9.2 Hz, 1H), 7.21 (d, J=1.8 Hz, 1H), 7.14 (dd, J=9.2, 
1.8 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 4.21 (t, J=6.0 Hz, 2H), 3.25 (t, J=7.6 Hz, 2H), 2.57 (s, 
3H), 2.24-2.17 (m, 2H), 1.43 (t, J=7.2 Hz, 3H), 1.42 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 
160.46, 155.23, 149.60, 141.50, 129.37, 125.28, 117.72, 112.25, 103.07, 65.22, 60.79, 
56.72, 38.87, 26.52, 24.39, 13.23, 8.07. Calculated exact mass for the protonated 
molecule (C19H28NO4): 334.2018; measured accurate mass (ESI): 334.2024. LC-MS purity: 
100%, tR = 11.81 min.  
 
Ethyl 5-(3-(benzylamino)propoxy)-3-methylbenzofuran-2-
carboxylate(36) 
Prepared from compound 42 (10 mg, 0.029 mmol) and 
benzylamine (12.8 µL, 0.12 mmol) in DMF (1 mL), according to 
the preparation for compound 1, the title compound was obtained as a white solid (5.6 
mg, 40% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.54-7.48 (m, 5H), 7.46 (d, J=9.2 Hz, 1H), 
7.19 (d, J=1.8 Hz, 1H), 7.11 (dd, J=8.8, 1.8 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 4.28 (s, 2H), 
4.20 (t, J=5.6 Hz, 2H), 3.33 (m, 2H), 2.57 (s, 3H), 2.29-2.22 (m, 2H), 1.43 (t, J=7.2 Hz, 3H). 
13C-NMR (CD3OD, 100 MHz): δ 160.45, 155.18, 149.60, 141.51, 131.16, 129.52, 128.96, 
125.26, 117.68, 112.24, 104.96, 103.10, 65.42, 60.78, 51.07, 44.97, 25.77, 13.22, 8.06. 
Calculated exact mass for the protonated molecule (C22H26NO4): 368.1862; measured 
accurate mass (ESI): 368.1862. LC-MS purity: 100%, tR = 12.22 min.  
 
1-[5-(Benzyloxy)-2-hydroxyphenyl]ethan-1-one (38)[186]  
A solution of 2,5-dihydroxyacetophenone (2 g, 13.1 mmol) in 30 
mL of acetone was added potassium carbonate (5.4 g, 39.4 mmol) and benzyl bromide 
(1.64 mL, 13.8 mmol). The reaction mixture was stirred at 60 °C for 3 hrs. The solid was 
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filtered off and the filtrate was concentrated in vacuo, to give the title compound 
without further purification, as yellow oil (3.2 g, quantitative yield).  1H-NMR (CDCl3, 400 
MHz): δ 11.88 (s, 1H), 7.48-7.35 (m, 5H), 7.28 (d, J=3.2 Hz, 1H), 7.21 (dd, J=8.8, 3.2 Hz, 
1H), 6.95 (d, J=8.8 Hz, 1H), 5.07 (s, 2H), 2.61 (s, 3H).  
 
Ethyl 2-[2-acetyl-4-(benzyloxy)phenoxy]acetate (39)  
A solution of compound 38 (3.2 g, 13.1 mmol) in 5 mL of 
DMF was added potassium carbonate (9.0 g, 65.5 mmol) and ethyl bromoacetate (2.9 
mL, 26.2 mmol). The reaction mixture was stirred at 80 °C for 4 hours. The solid was 
filtered off and the filtrate was concentrated. The residue was purified by column 
chromatography on silica gel, eluting with hexane:ethyl acetate, 91:9, 84:16, to obtain 
the title compound as a off-white solid (2.37 g, 55% yield). 1H-NMR (CDCl3, 400 MHz): δ 
7.48-7.32 (m, 6H), 7.08 (dd, J=8.8, 3.2 Hz, 1H), 6.81 (d, J=8.8 Hz, 1H), 5.06 (s, 2H), 4.69 (s, 
2H), 4.29 (q, J=7.2 Hz, 2H), 2.74 (s, 3H), 1.32 (t, J=7.2 Hz, 3H).   
 
Ethyl 5-(benzyloxy)-3-methyl-1-benzofuran-2-carboxylate 
(40) 
Prepared from compound 39 (1.25 g, 3.9 mmol) and sodium (90 mg, 3.9 mmol) in 
ethanol (10 mL) according to the preparation of compound 3, the title compound was 
obtained as a pale-yellow solid (0.53 g, 44 % yield). 1H-NMR (CDCl3, 400 MHz): δ 7.50-
7.35 (m, 6H), 7.17 (dd, J=8.8, 2.4 Hz, 1H), 7.12 (d, J=2.4 Hz, 1H), 5.14 (s, 2H), 4.47 (q, 
J=7.2 Hz, 2H), 2.58 (s, 3H), 1.47 (t, J=7.2 Hz, 3H).  
 
Ethyl 5-hydroxy-3-methyl-1-benzofuran-2-carboxylate (41) 
1,4-Cyclohexadiene (0.33 mL) and 10% palladium on carbon 
(20 mg) was added to a solution of compound 40 (110 mg, 0.36 mmol) in ethanol (5 mL). 
The resulting mixture was stirred at 80 ˚C for 4 hours. After that, the reaction mixture 
was filtered off and the filtration was concentrated in vacuo, to give the title compound 
without further purification as an off-white solid (78 mg, quantitative yield). 1H-NMR 
(CD3COCD3, 400 MHz): δ 8.40 (brs, 1H), 7.41 (d, J=8.8 Hz, 1H), 7.08 (dd, J=8.8, 2.4 Hz, 1H), 
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7.05 (d, J=2.4 Hz, 1H), 4.39 (q, J=7.2 Hz, 2H), 2.52 (s, 3H), 1.40 (t, J=7.2 Hz 3H).  
 
Ethyl 5-(3-bromopropoxy)-3-methyl-1-benzofuran-2-
carboxylate (42) 
Prepared from compound 41 (78 mg, 0.36 mmol), 
dibromopropane (112 µL, 1.1 mmol) and potassium carbonate (276 mg, 2.2 mmol) in 
DMF (1 mL) according to the preparation of compound 2, the title compound was 
obtained as colourless oil (58 mg, 48% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.46 (d, J=8.8 
Hz, 1H), 7.08 (dd, J=8.8, 2.4 Hz, 1H), 7.05 (d, J=2.4 Hz, 1H), 4.47 (q, J=7.2 Hz, 2H), 4.18 (t, 
J=6.0 Hz, 2H), 3.66 (t, J=6.4 Hz, 2H), 2.58 (s, 3H), 2.41-2.34 (m, 2H), 1.46 (t, J=7.2 Hz, 3H). 
 
Ethyl 8-hydroxyimidazo[1,2-a]pyridine-2-carboxylate (45)[141]  
A suspension of 2-aminopyridin-3-ol (600 mg, 5.45 mmol) in 
anhydrous THF (12 mL) was treated with ethyl bromopyruvate 
(681 µL, 5.45 mmol) at room temperature and then heated at reflux temperature for 40 
hours. The resulting mixture was evaporated in vacuo to give the residue which was 
dissolved in DCM (30 mL), followed by partitioning with 5% NaHCO3 solution. The 
aqueous phase was further extracted with DCM (2 x 20 mL). The combined organic layers 
were dried over anhydrous sodium sulphate and evaporated in vacuo. The residue was 
purified by column chromatography over silica gel, eluting with hexane:ethyl acetate 
30:70, 0:100 to give the title compound as a yellow solid (180 mg, 15% yield). 1H-NMR 
(CD3SOCD3, 400 MHz): δ 10.63 (s, 1H, -OH), 8.53 (s, 1H), 8.06 (d, J=7.0 Hz, 1H), 6.81 (t, 
J=7.0 Hz, 1H), 6.55 (d, J=7.0 Hz, 1H), 4.31 (q, J=7.2 Hz, 2H), 1.32 (t, J=7.2 Hz, 1H). 
 
 Ethyl 8-(3-bromopropoxy)imidazo[1,2-a]pyridine-2-carboxylate 
(47) 
Prepared from compound 45 (93 mg, 0.45 mmol), 1, 3-
dibromopropane (91 µL, 0.90 mmol) and potassium carbonate (370 mg, 2.7 mmol) in 
DMF (2 mL) according to the preparation of compound 2, the title compound was 
obtained as an off-white solid (36 mg, 24% yield). 1H-NMR (CDCl3, 400 MHz): δ 8.20 (s, 
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1H), 7.82 (d, J=7.2 Hz, 1H), 6.81 (t, J=7.2 Hz, 1H), 6.58 (d, J=7.2 Hz, 1H), 4.47 (q, J=7.2 Hz, 
2H), 4.34 (t, J=6.0 Hz, 2H), 3.73 (t, J=6.0 Hz, 2H), 2.53-2.47 (m, 2H), 1.45 (t, J=7.2 Hz, 3H) 
 
Ethyl 8-(3-(tert-butylamino)propoxy)imidazo[1,2-a]pyridine-2-
carboxylate(48) 
Prepared from compound 47 (10 mg, 0.03 mmol) and t-
butylamine (13 µL, 0.12 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as yellow oil (11.6 mg, 90% 
yield). 1H-NMR (CD3OD, 400 MHz): δ 8.57 (s, 1H), 8.23 (d, J=7.2 Hz, 1H), 7.12 (t, J=7.2 Hz, 
1H), 7.03 (d, J=7.2 Hz, 1H), 4.47 (q, J= 7.2 Hz, 2H), 4.41 (t, J=5.6 Hz, 2H), 3.37 (t, J=7.2 Hz, 
2H), 2.36-2.29 (m, 2H), 1.44 (s, 9H), 1.44 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 
161.12, 146.72, 138.61, 132.49, 120.43, 118.89, 115.30, 106.27, 66.78, 61.22, 56.85, 
39.24, 26.01, 24.39, 13.18. Calculated exact mass for the protonated molecule 
(C17H26N3O3): 320.1974; measured accurate mass (ESI): 320.1990. LC-MS purity: 100%, tR 
= 9.87 min.  
 
Ethyl 8-(3-(benzylamino)propoxy)imidazo[1,2-a]pyridine-2-
carboxylate(49)  
Prepared from compound 47 (10 mg, 0.03 mmol) and 
benzylamine (13 µL, 0.12 mmol) in DMF (1 mL), according to the preparation of 
compound 1, the title compound was obtained as pale yellow oil (8.2 mg, 59% yield). 1H-
NMR (CD3OD, 400 MHz): δ 8.50 (s, 1H), 8.17 (d, J=7.2 Hz, 1H), 7.54-7.51 (m, 2H), 7.46-
7.44 (m, 3H), 7.01 (t, J=7.2 Hz, 1H), 6.91 (d, J=7.2 Hz, 1H), 4.46 (q, J=7.2 Hz, 2H), 4.37 (t, 
J=5.6 Hz, 2H), 4.34 (s, 2H), 3.44 (t, J=7.0 Hz, 2H), 2.38-2.32 (m, 2H), 1.44 (t, J=7.2 Hz, 3H). 
13C-NMR (CD3OD, 100 MHz): δ 161.97, 147.07, 139.40, 133.49, 131.15, 129.60, 129.23, 
128.85, 120.50, 118.70, 114.67, 106.16, 66.76, 61.06, 51.21, 44.75, 25.44, 13.23. 
Calculated exact mass for the protonated molecule (C20H24N3O3): 354.1818; measured 
accurate mass (ESI): 354.1817. LC-MS purity: 97%, tR = 10.78 min.  
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4-(3-Bromopropoxy)-3-methylbenzofuran (50) 
Prepared from compound 7 (75 mg, 0.51 mmol), 1,3-dibrompropane 
(0.27 mL, 2.6 mmol) and potassium carbonate (0.69 g, 5.0 mmol) in 
DMF (2 mL) according to the preparation of compound 2, the title compound was 
obtained as colourless oil (35 mg, 30% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.29 (d, J=1.2 
Hz, 1H), 7.19 (t, J=8.0 Hz, 1H), 7.09 (d, J=8.0 Hz, 1H), 6.65 (d, J=8.0 Hz, 1H), 4.24 (t, J=6.0 
Hz, 2H), 3.68 (t, J=6.4 Hz, 2H), 2.45-2.40 (m, 2H), 2.38 (d, J=1.2 Hz, 3H).  
 
N-tert-butyl-3-(3-methylbenzofuran-4-yloxy)propan-1-amine (51)  
Prepared from compound 50 (10 mg, 0.037 mmol) and t-
butylamine (15.8 µL, 0.15 mmol) in DMF (1 mL), according to the 
preparation for compound 1, the title compound was obtained as a 
white solid (7.6 mg, 55% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.38 (d, J=0.8 Hz, 1H), 7.18 
(t, J=8.0 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H), 6.72 (d, J=8.0 Hz, 1H), 4.24 (t, J=6.0 Hz, 2H), 3.27 
(t, J=8.0 Hz, 2H), 2.28-2.21 (m, 2H), 1.42 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 160.95, 
157.71, 144.16, 128.65, 121.89, 119.11, 108.40, 107.31, 68.18, 60.63, 42.62, 30.48, 
28.34, 12.89. Calculated exact mass for the protonated molecule (C16H24NO2): 262.1807; 
measured accurate mass (ESI): 262.1797. LC-MS purity: 90%, tR = 11.93 min.  
 
{3-[(3-Methyl-1-benzofuran-4-yl)oxy]propyl}(pyridin-3-
ylmethyl)amine (52) 
Prepared from compound 50 (10 mg, 0.037 mmol) and 3-
(aminomethyl)-pyridine (15.3 µL, 0.15 mmol) in DMF (1 mL), according to the 
preparation for compound 1, the title compound was obtained as pale yellow oil (5.6 mg, 
37% yield). 1H-NMR (CD3OD, 400 MHz): δ 8.81 (d, J=1.2 Hz, 1H), 8.74 (dd, J=4.8, 1.2 Hz, 
1H), 8.20 (dt, J=8.0, 1.2 Hz, 1H), 7.71 (dd, J=8.0, 4.8 Hz, 1H), 7.38 (d, J=1.2 Hz, 1H), 7.18 (t, 
J=8.0 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H), 6.71 (d, J=8.0 Hz, 1H), 4.43 (s, 2H), 4.24 (t, J=5.6 Hz, 
2H), 3.40 (t, J=7.6 Hz, 2H), 2.35-2.28 (m, 2H), 2.33 (d, J=1.2 Hz, 3H). 13C-NMR (CD3OD, 
100 MHz): δ 157.00, 153.17, 148.68, 148.41, 140.43, 140.18, 128.76, 124.96, 124.68, 
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117.95, 115.52, 104.50, 103.41, 64.35, 46.94, 45.11, 25.89, 8.93. Calculated exact mass 
for the protonated molecule (C18H21N2O2): 297.1603; measured accurate mass (ESI): 
297.1589. LC-MS purity: 100%, tR = 11.36 min.  
 
N-benzyl-3-(3-methylbenzofuran-4-yloxy) propan-1-amine 
(53) 
 Prepared from compound 50 (10 mg, 0.037 mmol) and 
benzylamine (16.4 µL, 0.15 mmol) in DMF (1 mL), according to the preparation for 
compound 1, the title compound was obtained as a white solid (6.6 mg, 44% yield). 1H-
NMR (CD3OD, 400 MHz): δ 7.54-7.48 (m, 5H), 7.37 (d, J=1.2 Hz, 1H), 7.18 (t, J=8.0 Hz, 1H), 
7.05 (d, J=8.0 Hz, 1H), 6.71 (d, J=8.0 Hz, 1H), 4.29 (s, 2H), 4.23 (t, J=5.6 Hz, 2H), 3.32 (t, 
J=6.0 Hz, 2H), 2.32-2.26 (m, 2H), 2.28 (d, J=1.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 
156.96, 153.62, 140.15, 131.00, 129.57, 129.39, 128.98, 124.67, 117.94, 115.23, 104.46, 
103.36, 64.60, 51.00, 44.62, 25.81, 8.93. Calculated exact mass for the protonated 
molecule (C19H22NO2): 296.1650; measured accurate mass (ESI): 296.1643. LC-MS purity: 
100%, tR = 12.21 min.  
 
4-(3-bromopropoxy)-3-methyl-1-benzofuran-2-carboxylic acid 
(55)[80] 
LiOH·H2O (1.49 g, 35.4 mmol) was added to a solution of 
compound 2 (2 g, 5.9 mmol) in THF/MeOH (40 mL, 1:1). The reaction mixture was stirred 
for 24 hours at room temperature. The volatile components were then evaporated in 
vacuo. The residue was dissolved in H2O (30 mL), followed by the addition of 3 mL 
concentrated HCl while stirring. Precipitation occurred in the resulting solution and title 
compound was collected as a white solid (1.66 g, 90% yield). 1H-NMR (CD3OD, 400 MHz): 
δ 7.35 (t, J=8.0 Hz, 1H), 7.17 (d, J=8.0 Hz, 1H), 6.68 (d, J=8.0 Hz, 1H), 4.26 (t, J=5.6 Hz, 2H), 
3.68 (t, J=6.4 Hz, 2H), 2.76 (s, 3H), 2.47-2.41 (m, 2H).  
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4-(3-(t-Butylamino)propoxy)-3-methyl-N-phenylbenzofuran-
2-carboxamide (59) 
To a solution of compound 55 (10 mg, 0.03 mmol) in 
DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 
0.037 mmol), PyBOP (19 mg, 0.037 mmol). The above mixture was stirred at room 
temperature for 30 minutes, followed by the addition of aniline (3.3 µL, 0.037 mmol). 
The resulting mixture was further stirred at room temperature for 3 hours. After that, 
the reaction mixture was diluted with DCM (15 mL) and partitioned with water (15 mL), 
and then the aqueous layer was further extracted by DCM (2 x 10 mL). The combined 
organic layers were washed by 5% NaHCO3 and brine, dried over anhydrous sodium 
sulphate and concentrated in vacuo. The residue was purified by column 
chromatography over silica gel, eluting with hexane:ethyl acetate, 87:13, 80:20, to afford 
the brominated precursor. After that, amination with t-butylamine (13.6 µL, 0.13 mmol) 
in DMF (1 mL) was carried out according to the preparation of compound 1, to afford the 
title compound as a white solid (5.6 mg, 38% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.72 (d, J=7.6 Hz, 2H), 7.44-7.37 (m, 3H), 7.22 (d, J=8.4 Hz, 1H), 7.18 (t, J=7.6 Hz, 1H), 
6.83 (d, J=8.0 Hz, 1H), 4.29 (t, J=6.0 Hz, 2H), 3.29 (t, J=8.4 Hz, 2H), 2.83 (s, 3H), 2.32-2.23 
(m, 2H), 1.43 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 160.44, 156.36, 156.30, 142.81, 
139.12, 129.83, 129.59, 125.76, 124.83, 122.41, 120.20, 106.09, 105.61, 66.00, 58.17, 
40.09, 27.90, 25.84, 11.59. Calculated exact mass for the protonated molecule 
(C23H29N2O3): 381.2178; measured accurate mass (ESI): 381.2196. LC-MS purity: 100%, tR 
= 12.07 min.  
 
3-Methyl-4-(3-(4-methylbenzylamino)propoxy)-N-phenyl-
benzo-furan-2-carboxamide (60) 
Prepared from a solution of compound 55 (15 mg, 0.05 
mmol) in DMF/DCM (1 mL, 1:1) was sequentially added 
DIPEA (9.2 µL, 0.055 mmol), PyBOP (28 mg, 0.055 mmol) and aniline (5 µL, 0.055 mmol), 
the brominated precursor was obtained. After that, amination with 4-methyl 
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benzylamine (25.3 µL, 0.2 mmol) in DMF (1 mL) was carried out according to the 
preparation of compound 59, to afford the title compound as a white solid (5.0 mg, 19% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.72 (d, J=8.4 Hz, 2H), 7.42-7.37 (m, 5H), 
7.29 (d, J=8.4 Hz, 2H), 7.21 (d, J=8.4 Hz, 1H), 7.18 (t, J=8.0 Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 
4.26 (t, J=5.6 Hz, 2H), 4.24 (s, 2H), 3.30 (t, J=8.0 Hz, 2H), 2.68 (s, 3H), 2.38 (s, 3H), 2.33-
2.26 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 160.44, 156.28, 142.74, 141.20, 139.13, 
130.99, 129.84, 129.56, 129.21, 125.75, 124.94, 122.40, 120.19, 106.07, 105.60, 66.06, 
52.12, 45.62, 27.09, 21.24, 11.54. Calculated exact mass for the protonated molecule 
(C27H29N2O3): 429.2178; measured accurate mass (ESI): 429.2169. LC-MS purity: 100%, tR 
= 12.73 min.  
 
N-benzyl-4-(3-(tert-butylamino)propoxy)-3-
methylbenzofuran-2-carboxamide (61) 
Prepared from a solution of compound 55 (30 mg, 0.1 mmol) 
in DMF/DCM (2 mL, 1:1) was sequentially added DIPEA (18.4 µL, 0.11 mmol), PyBOP (56 
mg, 0.11 mmol) and benzylamine (12.0 µL, 0.11 mmol), the brominated precursor was 
obtained. After that, the amination with t-butylamine (21 µL, 0.2 mmol) in DMF (1 mL), 
was carried out according to preparation of compound 59, to afford the title compound 
as a white solid (17.3 mg, 44% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.39-7.32 (m, 
5H), 7.26 (t, J=7.2 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.58 (s, 2H), 4.26 
(t, J=6.0 Hz, 2H), 3.27 (t, J=8.0 Hz, 2H), 2.77 (s, 3H), 2.29-2.22 (m, 2H), 1.42 (s, 9H). 13C-
NMR (CD3OD, 100 MHz): δ 162.33, 156.31, 156.27, 142.85, 140.17, 129.54, 129.35, 
128.50, 128.20, 123.81, 120.06, 105.93, 105.48, 65.94, 58.12, 43.53, 40.04, 27.85, 25.81, 
11.45. Calculated exact mass for the protonated molecule (C24H31N2O3): 395.2335; 
measured accurate mass (ESI): 395.2319. LC-MS purity: 100%, tR = 11.98 min.  
 
 
 
 
 
 
Chapter 6 – Experimental section 
-171- | P a g e  
 
4-(3-(t-Butylamino)propoxy)-N-cyclohexyl-3-
methylbenzofuran-2-carboxamide (62) 
Prepared from a solution of compound 55 (15 mg, 0.05 
mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (9.2 µL, 0.055 mmol), 
PyBOP (28 mg, 0.055 mmol) and cyclohexylamine (6.3 µL, 0.055 mmol), the brominated 
precursor was obtained. After that, the amination with tert-butylamine (21 µL, 0.2 mmol) 
in DMF (1 mL) was carried out according to the preparation of compound 59, to afford 
the title compound as a white solid (6.9 mg, 28% overall yield). 1H-NMR (CD3OD, 400 
MHz): δ 7.37 (t, J=8.0 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 4.28 (t, J=6.0 
Hz, 2H), 3.95-3.84 (m, 1H), 3.29 (t, J=8.0 Hz, 2H), 2.77 (s, 3H), 2.30-2.23 (m, 2H), 2.00-
1.90 (m, 2H), 1.90-1.80 (m, 2H), 1.76-1.67 (m, 1H), 1.48-1.38 (m, 4H), 1.43 (s, 9H), 1.35-
1.22 (m, 1H). 13C-NMR (CD3OD, 100 MHz): δ 161.48, 156.28, 156.18, 142.99, 129.21, 
123.39, 120.10, 105.95, 105.47, 65.92, 58.15, 49.71, 40.06, 33.76, 27.88, 26.56, 26.44, 
25.81, 11.44. Calculated exact mass for the protonated molecule (C23H35N2O3): 387.2648; 
measured accurate mass (ESI): 387.2659. LC-MS purity: 100%, tR = 12.50 min.  
 
N-t-butyl-4-(3-(t-butylamino)propoxy)-3-methylbenzofuran-2-
carboxamide (63) 
Prepared from a solution of compound 55 (10 mg, 0.03 mmol) 
in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 
0.037 mmol), PyBOP (19 mg, 0.037 mmol), the brominated precursor was obtained. 
After that, the amination with t-butyl amine (3.4 µL, 0.037 mmol) in DMF (1 mL) was 
carried out according to the method of compound 59, to afford the title compound as a 
white solid (5 mg, 35% overall  yield). 1H-NMR (CD3OD, 400 MHz): δ 7.37 (t, J=8.4 Hz, 1H), 
7.16 (d, J=8.4 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 4.28 (t, J=6.0 Hz, 2H), 3.29 (t, J=8.0 Hz, 2H), 
2.75 (s, 3H), 2.31-2.20 (m, 2H), 1.50 (s, 9H), 1.43 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 
161.83, 156.23, 155.95, 143.36, 129.12, 122.84, 120.11, 105.98, 105.48, 65.90, 58.18, 
52.64, 40.07, 29.10, 27.90, 25.81, 11.42. Calculated exact mass for the protonated 
molecule (C21H33N2O3): 361.2491; measured accurate mass (ESI): 361.2493. LC-MS purity: 
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100%, tR = 12.15 min.  
 
(4-benzylpiperazin-1-yl)(4-(3-(t-butylamino)propoxy)-3-
methylbenzofuran-2-yl) methanone (64) 
Prepared from a solution of compound 55 (10 mg, 0.03 mmol) 
in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 
µL, 0.037 mmol), PyBOP (19 mg, 0.037 mmol) and 1-benzyl piperazine (6.4 µL, 0.037 
mmol), the brominated precursor was obtained. After that, the amination with tert-
butylamine (13.6 µL, 0.13 mmol) in DMF (1 mL) was carried out according to the 
preparation of compound 59, to afford the title compound as a white solid (2.7 mg, 
16%overall  yield). 1H-NMR (CD3OD, 400 MHz): δ 7.59-7.51 (m, 5H), 7.40 (t, J=8.4 Hz, 1H), 
7.15 (d, J=8.4 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 4.43 (s, 2H), 4.29 (t, J=6.0 Hz, 2H), 3.44 (brd, 
4H), 3.33 (brd, 4H), 3.28 (t, J=8.0 Hz, 2H), 2.64 (s, 3H), 2.30-2.24 (m, 2H), 1.43 (s, 9H). 13C-
NMR (CD3OD, 100 MHz): δ 162.29, 156.37, 156.16, 142.64, 132.37, 131.48, 130.51, 
130.05, 129.51, 125.03, 119.40, 105.96, 105.73, 66.04, 61.78, 58.18, 52.69, 40.03, 27.88, 
25.81, 11.57. Calculated exact mass for the protonated molecule (C28H38N3O3): 464.2913; 
measured accurate mass (ESI): 464.2921. LC-MS purity: 100%, tR = 9.52 min.  
 
4-(3-(Benzylamino)propoxy)-N-cyclohexyl-3-
methylbenzofuran-2-carboxamide (65)  
Prepared from a solution of compound 55 (15 mg, 0.05 
mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (9.2 µL, 0.055 mmol), 
PyBOP (28 mg, 0.055 mmol) and cyclohexylamine (6.3 µL, 0.055 mmol), the brominated 
precursor was obtained. After that, the amination with benzyamine (22 µL, 0.2 mmol) in 
DMF (1 mL) was carried out according to the preparation of compound 59, to afford the 
title compound as a white solid (9.4 mg, 35% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.58-7.48 (m, 5H), 7.36 (t, J=8.4 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 
4.30 (s, 2H), 4.26 (t, J=6.0 Hz, 2H), 3.94-3.84 (m, 1H), 3.29 (t, J=8.0 Hz, 2H), 2.66 (s, 3H), 
2.34-2.27 (m, 2H), 2.00-1.90 (m, 2H), 1.90-1.81 (m, 2H), 1.77-1.66 (m, 1H), 1.49-1.38 (m, 
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4H), 1.35-1.22 (m, 1H). 13C-NMR (CD3OD, 100 MHz): δ 161.48, 156.23, 156.17, 142.93, 
132.38, 130.96, 130.83, 130.39, 129.18, 123.51, 120.10, 105.94, 105.48, 66.06, 52.40, 
49.71, 45.93, 33.78, 27.13, 26.57, 26.44, 11.44. Calculated exact mass for the protonated 
molecule (C24H31N2O3): 395.2335; measured accurate mass (ESI): 395.2334. LC-MS purity: 
96%, tR = 12.72 min.  
 
 2-Benzoyl-3-methyl-1-benzofuran-4-ol (70) 
A mixture of 2, 6-dihydroxy acetophenone (50 mg, 0.33 mmol), 2-
bromo-1-phenylethan-1-one (69 mg, 0.34 mmol) and potassium 
carbonate (136 mg, 1.0 mmol) in acetonitrile (3 mL) was stirred at reflux temperature for 
24 hours. The reaction mixture was filtered through a celite pad and the filtrate was 
concentrated in vacuo. The residue was purified by column chromatography over silica 
gel, eluting with hexane:ethyl acetate, 91:9, 84:16, to afford the title compound as a light 
yellow solid (34 mg, 41% yield). 1H-NMR (CD3COCD3, 400 MHz): δ 9.31 (brs, 1H), 8.07 (d, 
J=7.2 Hz, 2H), 7.68 (t, J=7.2 Hz, 1H), 7.61 (t, J=7.2 Hz, 2H), 7.33 (t, J=8.0 Hz, 1H), 7.06 (d, 
J=8.0 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 2.81 (s, 3H).  
 
 1-(4-Hydroxy-3-methyl-1-benzofuran-2-yl)ethan-1-one (71) 
Prepared from 2, 6-dihydroxy acetophone (2 g, 13.1 mmol), 1-
chloropropan-2-one (1.05 mL, 13.1 mmol) and potassium carbonate 
(5.4 g, 39.4 mmol) in acetonitrile (30 mL) according to the preparation of compound 70, 
the title compound was obtained as an off-white solid (420 mg, 17% yield). 1H-NMR 
(CD3COCD3, 400 MHz): δ 9.27 (brs, 1H), 7.32 (t, J=8.0 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H), 6.72 
(d, J=8.0 Hz, 1H), 2.76 (s, 3H), 2.53 (s, 3H).  
 
(4-(3-(t-Butylamino)propoxy)-3-methylbenzofuran-2-yl)-(phenyl)- 
methanone (72) 
Prepared from a solution of compound 70 (15 mg, 0.06 mmol), 
1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate (50 mg, 0.36 mmol) 
in DMF (1 mL) according to the preparation of compound 2, the brominated precursor 
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was obtained. After that, the amination with t-butylamine (14  µL, 0.12 mmol) in DMF (1 
mL) was carried out according to the preparation of compound 1, to afford the title 
compound as a white solid (5.3 mg, 24% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
8.01 (d, J=7.2 Hz, 2H), 7.66 (t, J=7.2 Hz, 1H), 7.56 (t, J=7.2 Hz, 2H), 7.46 (t, J=8.4 Hz, 1H), 
7.18 (d, J=8.4 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 4.32 (t, J=6.0 Hz, 2H), 3.30 (t, J=8.0 Hz, 2H), 
2.82 (s, 3H), 2.32-2.26 (m, 2H), 1.43 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 185.98, 
155.68, 155.47, 137.86, 132.40, 129.39, 129.18, 128.04, 127.27, 118.49, 104.84, 104.15, 
64.69, 56.78, 38.65, 26.46, 24.41, 10.97. Calculated exact mass for the protonated 
molecule (C23H28NO3): 366.2069; measured accurate mass (ESI): 366.2076. LC-MS purity: 
100%, tR = 12.70 min.  
 
(4-(3-(Benzylamino)propoxy)-3-methylbenzofuran-2-yl)-
(phenyl)-methanone (73) 
Prepared from a solution of compound 70 (15 mg, 0.06 
mmol), 1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate (50 mg, 0.36 
mmol) in DMF (1 mL), the brominated precursor was obtained. After that, the amination 
with benzylamine (14 µL, 0.12 mmol) in DMF (1 mL) was carried out according to the 
method of compound 72, to afford the title compound as an off-white solid (5.9 mg, 25% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.01 (d, J=7.2 Hz, 2H), 7.66 (t, J=7.2 Hz, 1H), 
7.58-7.43 (m, 8H), 7.17 (d, J=8.4 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 4.30 (s, 2H), 4.29 (t, J=6.0 
Hz, 2H), 3.36-3.33 (m, 2H), 2.70 (s, 3H), 2.36-2.29 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 
185.98, 155.68, 155.42, 146.98, 137.90, 132.40, 130.98, 129.56, 129.44, 129.38, 129.16, 
129.00, 128.05, 127.37, 118.47, 104.82, 104.15, 64.79, 51.01, 44.50, 25.70, 10.99. 
Calculated exact mass for the protonated molecule (C26H26NO3): 400.1913; measured 
accurate mass (ESI): 400.1922. LC-MS purity: 100%, tR = 12.90 min.  
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1-(4-(3-(t-Butylamino)propoxy)-3-methylbenzofuran-2-yl) 
ethanone (74)  
Prepared from a solution of compound 71 (18 mg, 0.09 mmol), 
1,3-dibrompropane (18.8 µL, 0.18 mmol) and potassium carbonate (75 mg, 0.54 mmol) 
in DMF (1 mL), the brominated precursor was obtained. After that, the amination with  
t-butylamine (25 µL, 0.24 mmol) in DMF (1 mL) was carried out according to the 
preparation of compound 72, to afford the title compound as a white solid (8.7 mg, 32% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.44 (t, J=8.4 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 
6.81 (d, J=8.0 Hz, 1H), 4.28 (t, J=6.0 Hz, 2H), 3.28 (t, J=8.0 Hz, 2H), 2.77 (s, 3H), 2.57 (s, 
3H), 2.31-2.24 (m, 2H), 1.42 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 191.40, 155.55, 
155.39, 146.94, 129.29, 124.64, 118.61, 104.76, 104.00, 64.63, 56.74, 47.42, 38.62, 
26.42, 24.40, 10.42. Calculated exact mass for the protonated molecule (C18H26NO3): 
304.1913; measured accurate mass (ESI): 304.1922. LC-MS purity: 100%, tR = 11.40 min.  
 
1-(4-(3-(Benzylamino)propoxy)-3-methylbenzofuran-2-yl) 
ethanone(75) 
Prepared from a solution of compound 71 (18 mg, 0.09 mmol), 
1,3-dibrompropane (18.8 µL, 0.18 mmol) and potassium carbonate (75 mg, 0.54 mmol) 
in DMF (1 mL), the brominated precursor was obtained. After that, the amination with 
benzylamine (28 µL, 0.24 mmol) in DMF (1 mL) was carried out according to the 
preparation of compound 72, to afford the title compound as a white solid (14.3 mg, 47% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.55-7.46 (m, 5H), 7.43 (t, J=8.4 Hz, 1H), 7.14 
(d, J=8.0 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.30 (s, 2H), 4.26 (t, J=6.0 Hz, 2H), 3.35-3.31 (m, 
2H), 2.66 (s, 3H), 2.57 (s, 3H), 2.37-2.26 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 192.77, 
156.89, 156.77, 148.28, 132.41, 130.98, 130.79, 130.66, 130.37, 126.17, 119.99, 106.14, 
105.40, 66.15, 52.28, 45.87, 27.82, 27.08, 11.83. Calculated exact mass for the 
protonated molecule (C21H24NO3): 338.1756; measured accurate mass (ESI): 338.1749. 
LC-MS purity: 100%, tR = 11.81 min.  
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[4-(3-bromopropoxy)-3-methyl-1-benzofuran-2-yl]methanol(78) 
Prepared from compound 79 (550 mg, 3.1 mmol), 1,3-
dibrompropane (0.63 mL, 6.2 mmol) and potassium carbonate 
(2.56 g, 18.6 mmol) in DMF (2 mL) according to the preparation of compound 2, the title 
compound was obtained as colourless oil (0.42 g, 46% yield). 1H-NMR (CDCl3, 400 MHz): 
δ 7.22 (t, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 6.66 (d, J=8.0 Hz, 1H), 5.12 (s, 2H), 4.24 (t, 
J=6.0 Hz, 2H), 3.67 (t, J=6.4 Hz, 2H), 2.45 (s, 3H), 2.44-2.39 (m, 2H). 
 
1-(4-Hydroxy-3-methyl-1-benzofuran-2-yl)ethan-1-one(79) 
LiAlH4 (0.26 g, 6.8 mmol) was added slowly to a solution of 
compound 3 (1g, 4.5 mmol) in anhydrous THF (20 mL) at 0 ˚C. The 
resulting mixture was gradually warmed up to room temperature for 2 hours. 100 µL of 
water was then added to the reaction mixture, followed by the filtration through a celite 
pad. The filtrate was concentrated in vacuo, to give the title compound as a light-yellow 
solid (0.55g, 68% yield) without further purification. 1H-NMR (CDCl3, 400 MHz): δ 7.24 (t, 
J=8.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 5.15 (s, 2H), 2.45 (s, 3H). 
 
N-t-butyl-3-(3-methyl-2-(phenoxymethyl)benzofuran-4-
yloxy)-propan-1-amine (80) 
 To a stirred solution of the compound of compound 78 
(29 mg, 0.1 mmol), phenol (24 mg, 0.25 mmol) and triphenylphosphine (65 mg, 0.25 
mmol) in anhydrous THF (2 mL) was added DIAD (47 µL, 0.25 mmol) at room 
temperature. The resulting mixture was stirred at the same temperature for 4 hours, and 
then concentrated in vacuo. The residue was purified by column chromatography over 
silica gel, eluting with hexane:ethyl acetate, 5:1 to afford the brominated precursor. After 
that, the amination with t-butylamine (11.5 µL, 0.11 mmol) in DMF (1 mL) was carried 
out according to the preparation of compound 1, to afford the title compound as a white 
solid (2.4 mg, 7% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.30 (t, J=8.0 Hz, 2H), 7.23 
(t, J=8.4 Hz, 1H), 7.08 (d, J=8.4 Hz, 1H), 7.03 (d, J=8.0 Hz, 2H), 6.98 (t, J=7.6 Hz, 1H), 6.75 
(d, J=8.0 Hz, 1H), 5.14 (s, 2H), 4.26 (t, J=6.0 Hz, 2H), 3.27 (t, J=8.0 Hz, 2H), 2.45 (s, 3H), 
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2.28-2.21 (m, 2H), 1.42 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 158.52, 155.82, 153.81, 
147.07, 129.11, 125.35, 120.97, 118.45, 114.78, 114.44, 104.32, 103.61, 64.28, 60.48, 
56.72, 38.67, 26.52, 24.40, 8.97. Calculated exact mass for the protonated molecule 
(C23H30NO3): 368.2226; measured accurate mass (ESI): 368.2227. LC-MS purity: 90%, tR = 
12.87 min.  
 
3-(3-methyl-2-(phenoxymethyl)benzofuran-4-yloxy)-N-(4-
methyl-benzyl)propan-1-amine (81) 
Prepared from compound 78 (50 mg, 0.17 mmol), phenol 
(40 mg, 0.42 mmol), triphenyl phosphine (110 mg, 0.42 mmol) and DIAD (80 µL, 0.42 
mmol) in anhydrous THF (2 mL), the brominated precursor was obtained. After that, the 
amination with 4-methyl benzylamine (23 µL, 0.18 mmol) in DMF (1 mL) was carried out 
according to the preparation of compound 80, to afford the title compound as a white 
solid (8.0 mg, 11% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.38 (d, J=8.0 Hz, 2H), 
7.33-7.27 (m, 4H), 7.21 (t, J=8.0 Hz, 1H), 7.08-7.02 (m, 3H), 6.98 (t, J=7.6 Hz, 1H), 6.72 (d, 
J=8.0 Hz, 1H), 5.12 (s, 2H), 4.23 (s, 2H), 4.20 (t, J=6.8 Hz, 2H), 3.28 (t, J=8.0 Hz, 1H), 2.36 
(s, 3H), 2.31 (s, 3H), 2.29-2.22 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 158.55, 155.80, 
153.77, 146.98, 139.71, 129.53, 129.13, 127.86, 125.32, 120.98, 114.77, 114.53, 104.29, 
103.62, 64.41, 60.50, 50.73, 44.32, 25.75, 19.81, 8.91. Calculated exact mass for the 
protonated molecule (C27H30NO3): 416.2226; measured accurate mass (ESI): 416.2232. 
LC-MS purity: decompose under weakly acidic or LC-MS conditions. 
 
N-t-butyl-3-(2-((4-chlorophenoxy)methyl)-3-methyl-
benzo-furan-4-yloxy)propan-1-amine (82) 
Prepared from compound 78 (50 mg, 0.17 mmol), 4-
chlorophenol (41 µL, 0.42 mmol), triphenyl phosphine (110 mg, 0.42 mmol) and DIAD 
(80 µL, 0.42 mmol) in anhydrous THF (2 mL), the brominated precursor was obtained. 
After that, the amination with t-butylamine (13.8 µL, 0.13 mmol) in DMF (1 mL) was 
carried out according to the preparation of compound 80, to afford the title compound 
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as a white solid (4.3 mg, 5% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.29 (d, J=8.8 Hz, 
2H), 7.24 (t, J=8.0 Hz, 1H), 7.08 (d, J=8.4 Hz, 1H), 7.03 (d, J=8.8 Hz, 2H), 6.76 (d, J=8.0 Hz, 
1H), 5.15 (s, 2H), 4.26 (t, J=6.0 Hz, 2H), 3.28 (t, J=8.0 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 
2H), 1.42 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 158.69, 157.26, 155.26, 148.12, 130.38, 
127.28, 126.88, 119.82, 117.82, 116.14, 105.73, 105.10, 65.74, 62.31, 58.17, 40.10, 
27.94, 25.83, 10.37. Calculated exact mass for the protonated molecule (C23H29NO3Cl): 
402.1836; measured accurate mass (ESI): 402.1831. LC-MS purity: 96%, tR = 13.34 min.  
 
N-t-butyl-3-(2-((3-chlorophenoxy)methyl)-3-
methylbenzofuran-4-yloxy)propan-1-amine (83) 
Prepared from compound (50 mg, 0.17 mmol), 3-
chlorophenol (44 µL, 0.42 mmol), triphenyl phosphine (110 mg, 0.42 mmol) and DIAD 
(80 µL, 0.42 mmol) in anhydrous THF (2 mL), the brominated precursor was obtained. 
After that, the amination with t-butylamine (11.5 µL, 0.11 mmol) in DMF (1 mL) was 
carried out according to the preparation of compound 80, to afford the title compound 
as a white solid (1.2 mg, 2% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.26 (t, J=8.4 Hz, 
1H), 7.20 (d, J=8.4 Hz, 1H), 7.07-7.05 (m, 2H), 6.98-6.96 (m, 1H), 6.96-6.94 (m, 1H), 6.73 
(d, J=8.0 Hz, 1H), 5.14 (s, 2H), 4.23 (t, J=6.0 Hz, 2H), 3.25 (t, J=8.0 Hz, 2H), 2.44 (s, 3H), 
2.26-2.18 (m, 2H), 1.39 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 160.76, 157.27, 155.25, 
147.96, 135.91, 131.61, 126.93, 122.38, 119.78, 116.50, 116.24, 114.78, 105.75, 105.07, 
65.70, 62.11, 58.15, 40.09, 27.95, 25.82, 10.41. Calculated exact mass for the protonated 
molecule (C23H29NO3Cl): 402.1836; measured accurate mass (ESI): 402.1842. LC-MS 
purity: 94%, tR = 13.40 min.  
 
t-Butyl[3-({3-methyl-2-[(naphthalen-1-yloxy)methyl]-1-
benzofuran-4-yl}oxy)propyl]amine (84) 
Prepared from compound 78 (50 mg, 0.17 mmol), 1-
naphthol (60.5 mg, 0.42 mmol), triphenyl phosphine (110 
mg, 0.42 mmol) and DIAD (80 µL, 0.42 mmol) in anhydrous THF (2 mL), the brominated 
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precursor was obtained. After that, the amination with t-butylamine (29 µL, 0.27 mmol) 
in DMF (1 mL) was carried out according to the preparation of compound 80, to afford 
the title compound as an off-white solid (11.2 mg, 12% overall yield). 1H-NMR (CD3OD, 
400 MHz): δ 8.18 (d, J=8.0 Hz, 1H), 7.81 (d, J=8.0 Hz, 1H), 7.49-7.39 (m, 4H), 7.25 (t, J=8.0 
Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 6.76 (d, J=8.0 Hz, 1H), 5.34 (s, 2H), 4.25 (t, J=6.0 Hz, 2H), 
3.25 (t, J=8.0 Hz, 2H), 2.48 (s, 3H), 2.28-2.21 (m, 2H), 1.40 (s, 9H). 13C-NMR (CD3OD, 100 
MHz): δ 157.29, 155.52, 155.26, 148.43, 136.10, 128.51, 127.39, 127.20, 126.90, 126.80, 
126.21, 122.87, 121.95, 119.93, 116.11, 107.11, 105.76, 105.08, 65.73, 62.44, 58.09, 
40.07, 27.90, 25.80, 10.45. Calculated exact mass for the protonated molecule 
(C27H32NO3): 418.2382; measured accurate mass (ESI): 418.2368. LC-MS purity: 95%, tR = 
13.64 min.  
 
t-Butyl[3-({3-methyl-2-[(naphthalen-2-yloxy)methyl]-1-
benzo-furan-4-yl}oxy)propyl]amine (85) 
Prepared from compound 78 (50 mg, 0.17 mmol), 2-
naphthol (60.5 mg, 0.42 mmol), triphenylphosphine 
(110 mg, 0.42 mmol) and DIAD (80 µL, 0.42 mmol) in anhydrous THF (2 mL), the 
brominated precursor was obtained. After that, the amination with t-butylamine (29 µL, 
0.27 mmol) in DMF (1 mL) was carried out according to the preparation of compound 80, 
to afford the title compound as a white solid (16.8  mg, 19% overall yield). 1H-NMR 
(CD3OD, 400 MHz): δ 7.79-7.76 (m, 3H), 7.46-7.41 (m, 2H), 7.34 (t , J=8.0 Hz, 1H), 7.26-
7.17 (m, 2H), 7.09 (d, J=8.0 Hz, 1H), 6.74 (d, J=8.0 Hz, 1H), 5.25 (s, 2H), 4.23 (t, J=6.0 Hz, 
2H), 3.24 (t, J=8.0 Hz, 2H), 2.48 (s, 3H), 2.27-2.20 (m, 2H), 1.40 (s, 9H). 13C-NMR (CD3OD, 
100 MHz): δ 157.77, 157.26, 155.26, 148.28, 136.02, 130.74, 130.49, 127.92, 126.83, 
124.89, 119.90, 116.09, 108.60, 105.70, 105.07, 65.72, 61.91, 58.08, 40.05, 27.88, 25.80, 
10.47. Calculated exact mass for the protonated molecule (C27H32NO3): 418.2382; 
measured accurate mass (ESI): 418.2368. LC-MS purity: 95%, tR = 13.52 min.  
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(4-(3-(benzylamino)propoxy)-3-methylbenzofuran-2-yl) 
methanol(86) 
Prepared from a solution of compound 78 (10 mg, 0.034 
mmol) and benzylamine (14.2 µL, 0.13 mmol) in DMF (1 mL), according to the 
preparation of compound 1, the title compound was obtained as a white solid (6.6 mg, 
44% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.38-7.23 (m, 5H), 7.16 (t, J=8.4 Hz, 1H), 7.00 (d, 
J=8.4 Hz, 1H), 6.68 (d, J=8.0 Hz, 1H), 4.62 (s, 2H), 4.14 (t, J=6.0 Hz, 2H), 3.81 (s, 2H), 2.86 
(t, J=7.6 Hz, 2H), 2.30 (s, 3H), 2.12-2.05 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 159.55, 
158.26, 154.22, 142.83, 132.12, 132.05, 130.81, 128.78, 122.58, 116.40, 107.66, 107.31, 
69.82, 57.79, 56.96, 49.47, 32.66, 12.71. Calculated exact mass for the protonated 
molecule (C20H24NO3): 326.1756; measured accurate mass (ESI): 326.1767. LC-MS purity: 
100%, tR = 10.71 min.  
 
(4-(3-(t-butylamino)propoxy)-3-methylbenzofuran-2-yl)methanol 
(87)  
Prepared from a solution of compound 78 (10 mg, 0.034 mmol) 
and t-butylamine (14 µL, 0.13 mmol) in DMF (1 mL), according to the preparation of 
compound 1, the title compound was obtained as a white solid (5.0 mg, 36% yield). 1H-
NMR (CD3OD, 400 MHz): δ 7.19 (t, J=8.4 Hz, 1H), 7.05 (d, J=8.4 Hz, 1H), 6.73 (d, J=8.0 Hz, 
1H), 4.64 (s, 2H), 4.25 (t, J=5.6 Hz, 2H), 3.30-3.26 (m, 2H), 2.43 (s, 3H), 2.28-2.21 (m, 2H), 
1.42 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 155.66, 153.77, 150.68, 124.90, 118.66, 
112.13, 104.26, 103.48, 64.24, 56.71, 53.83, 38.68, 26.55, 24.40, 8.88. Calculated exact 
mass for the protonated molecule (C17H26NO3): 292.1913; measured accurate mass (ESI): 
292.1919. LC-MS purity: 95%, tR = 9.97 min.  
 
Benzyl-[3-({3-methyl-2-[(phenylsulfanyl)methyl]-1-
benzofuran-4-yl}oxy)propyl]amine (88)  
To a solution of compound 86 (20 mg, 0.06 mmol) and 
benzenethiol (9.4 µL, 0.09 mmol) in anhydrous DCM (1 mL) was added TFA (0.2 mL). The 
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mixture was stirred at room temperature for 2.5 hours. After that, the reaction mixture 
was concentrated in vacuo and the residue was purified by semi-preparative reverse 
phase HPLC to give the title compound as a white solid (5.3 mg, 17% yield). 1H-NMR 
(CDCl3, 400 MHz): δ 9.63 (brs, 1H, NH), 7.41-7.23 (m, 10H), 7.11 (t, J=8.0 Hz, 1H), 7.04 (d, 
J=8.0 Hz, 1H), 6.48 (d, J=8.0 Hz, 1H), 4.13 (s, 2H), 3.99 (s, 2H), 3.97 (t, J=5.6 Hz, 2H), 3.09 
(brs, 2H), 2.01-1.99 (m, 2H), 1.96 (s, 3H). 13C-NMR (CDCl3, 100 MHz): δ 155.47, 153.16, 
147.53, 135.14, 131.80, 129.62, 128.90, 127.26, 124.76, 118.87, 112.61, 104.99, 103.60, 
64.58, 51.45, 44.57, 30.72, 25.79, 9.61. Calculated exact mass for the protonated 
molecule (C26H28NO2S): 418.1841; measured accurate mass (ESI): 418.1837. LC-MS purity: 
95%, tR = 13.42 min.  
 
{3-[(2-Benzoyl-3-methyl-1-benzofuran-4-yl)oxy]propyl} 
(pyridin-3-ylmethyl)amine (91) 
Prepared from a solution of compound 70 (15 mg, 0.06 
mmol), 1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate (50 mg, 0.36 
mmol) in DMF (1 mL), the brominated precursor was obtained. After that, the amination 
with 3-(aminomethyl)-pyridine (13 µL, 0.12 mmol) in DMF (1 mL) was carried out 
according to the method of compound 72, to afford the title compound as yellow oil (4.5 
mg, 19% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.78 (s, 1H), 8.72 (d, J=4.4 Hz, 1H), 
8.14 (d, J=8.0 Hz, 1H), 8.01 (d, J=7.2 Hz, 2H), 7.66 (t, J=7.6 Hz, 2H), 7.56 (t, J=7.6 Hz, 2H), 
7.46 (t, J=8.0 Hz, 1H), 7.18 (d, J=8.0 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 4.43 (s, 2H), 4.31 (t, 
J=5.6 Hz, 2H), 3.42 (t, J=8.0 Hz, 2H), 2.75 (s, 3H), 2.39-2.32 (m, 2H). 13C-NMR (CD3OD, 100 
MHz): δ 185.95, 155.68, 155.41, 149.39, 149.20, 146.99, 139.46, 137.88, 132.41, 129.39, 
129.71, 128.32, 128.05, 127.34, 124.66, 118.48, 104.86, 104.16, 64.74, 48.15, 45.01, 
25.79, 11.01. Calculated exact mass for the protonated molecule (C25H25N2O4): 401.1865; 
measured accurate mass (ESI): 401.1866. LC-MS purity: 100%, tR = 12.33 min.   
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{3-[(2-Benzoyl-3-methyl-1-benzofuran-4-yl)oxy]propyl}[(4-
methyl-phenyl) methyl]amine (92) 
Prepared from a solution of compound 70 (15 mg, 0.06 
mmol), 1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate (50 mg, 0.36 
mmol) in DMF (1 mL), the brominated precursor was obtained. After that, the amination 
with 4-methyl benzylamine (14 µL, 0.11 mmol) in DMF (1 mL) was carried out according 
to the preparation of compound 72, to afford the title compound as an off-white solid 
(5.3 mg, 22% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.01 (d, J=7.2 Hz, 2H), 7.66 (t, 
J=7.2 Hz, 1H), 7.56 (t, J=7.2 Hz, 2H), 7.45 (t, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 2H), 7.29 (d, 
J=8.0 Hz, 2H), 7.17 (d, J=8.0 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 4.28 (t, J=5.6 Hz, 2H), 4.25 (s, 
2H), 3.30 (t, J=8.0 Hz, 2H), 2.66 (s, 3H), 2.38 (s, 3H), 2.34-2.27 (m, 2H). 13C-NMR (CD3OD, 
100 MHz): δ 185.96, 155.67, 155.38, 146.96, 142.89, 139.78, 137.89, 132.40, 129.58, 
129.53, 129.37, 129.16, 128.05, 127.80, 127.36, 118.46, 104.81, 104.13, 64.72, 50.70, 
44.16, 25.66, 19.83, 10.94. Calculated exact mass for the protonated molecule 
(C27H28NO3): 414.2069; measured accurate mass (ESI): 414.2083. LC-MS purity: 100%, tR 
= 13.21 min.  
 
{3-[(2-Benzoyl-3-methyl-1-benzofuran-4-yl)oxy]propyl} 
[(4-fluoro-phenyl) methyl]amine (93) 
Prepared from a solution of compound 70 (15 mg, 0.06 
mmol), 1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate (50 mg, 0.36 
mmol) in DMF (1 mL), the brominated precursor was obtained. After that, the amination 
with 4-fluoro-benzylamine (15 µL, 0.12 mmol) in DMF (1 mL) was carried out according 
to the preparation of compound 72, to afford the title compound as an off-white solid 
(5.9 mg, 24% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.01 (d, J=7.6 Hz, 2H), 7.66 (t, 
J=7.6 Hz, 1H), 7.58-7.54 (m, 4H), 7.46 (t, J=8.0 Hz, 1H), 7.22 (t, J=7.6 Hz, 2H), 7.17 (d, 
J=8.0 Hz, 1H), 6.83 (d, J=8.0 Hz, 1H), 4.30 (s, 2H), 4.30 (t, J=5.6 Hz, 2H), 3.34 (t, J=8.0 Hz, 
2H), 2.73 (s, 3H), 2.36-2.29 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 185.95, 159.43, 
155.73, 155.40, 147.05, 137.88, 132.39, 131.88, 129.38, 129.16, 128.05, 127.25, 118.44, 
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115.79, 104.84, 104.16, 64.77, 50.18, 44.50, 25.71, 10.98. Calculated exact mass for the 
protonated molecule (C26H25NO3F): 418.1818; measured accurate mass (ESI): 418.1825. 
LC-MS purity: 100%, tR = 12.88 min.  
 
(3-Methyl-4-(3-(methylamino)propoxy)benzofuran-2-yl)(phenyl) 
methanone(94) 
 Prepared from a solution of compound 70 (15 mg, 0.06 mmol), 
1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate (50 mg, 0.36 mmol) 
in DMF (1 mL), the brominated precursor was obtained. After that, the amination with 
methylamine (33% w/w in ethanol, 14  µL, 0.11 mmol) in DMF (1 mL) was carried out 
according to the method of compound 72, to afford the title compound as yellow oil (2.0 
mg, 11% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.02 (d, J=7.2 Hz, 2H), 7.67 (t, J=7.2 
Hz, 1H), 7.56 (t, J=7.2 Hz, 2H), 7.47 (t, J=8.4 Hz, 1H), 7.19 (d, J=8.4 Hz, 1H), 6.86 (d, J=8.0 
Hz, 1H), 4.31 (t, J=6.0 Hz, 2H), 3.31 (t, J=8.0 Hz, 2H), 2.83 (s, 3H), 2.80 (s, 3H), 2.35-2.28 
(m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 186.02, 155.68, 155.46, 147.00, 137.86, 132.42, 
129.40, 129.17, 128.05, 127.42, 118.50, 104.86, 104.18, 64.81, 46.54, 32.37, 25.72, 
11.00. Calculated exact mass for the protonated molecule (C20H22NO3): 324.1600; 
measured accurate mass (ESI): 324.1602. LC-MS purity: 100%, tR = 12.35 min.  
 
(4-(3-(Isopropylamino)propoxy)-3-methylbenzofuran-2-yl)-
(phenyl)-methanone (95) 
Prepared from a solution of compound 70 (15 mg, 0.06 mmol), 
1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate 
(50 mg, 0.36 mmol) in DMF (1 mL), the brominated precursor was obtained. After that, 
the amination with isopropylamine (9.2  µL, 0.11 mmol) in DMF (1 mL) was carried out 
according to the preparation of compound 72, to afford the title compound as a white 
solid (4.1 mg, 20 % overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.02 (d, J=7.2 Hz, 2H), 
7.67 (t, J=7.2 Hz, 1H), 7.57 (t, J=7.2 Hz, 2H), 7.47 (t, J=8.4 Hz, 1H), 7.19 (d, J=8.4 Hz, 1H), 
6.85 (d, J=8.0 Hz, 1H), 4.31 (t, J=6.0 Hz, 2H), 3.53-3.42 (m, 1H), 3.33-3.30 (m, 2H), 2.83 (s, 
3H), 2.34-2.27 (m, 2H), 1.40 (d, J=6.4 Hz, 6H). 13C-NMR (CD3OD, 100 MHz): δ 187.42, 
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157.14, 156.88, 148.41, 139.27, 133.81, 130.81, 130.57, 129.45, 128.76, 119.90, 106.24, 
105.58, 66.18, 52.01, 43.54, 27.45, 19.23, 12.41. Calculated exact mass for the 
protonated molecule (C22H26NO3): 352.1913; measured accurate mass (ESI): 352.1927. 
LC-MS purity: 98%, tR = 12.59 min.  
 
(4-(3-(Cyclopropylamino)propoxy)-3-methylbenzofuran-2-yl)-
(phenyl)-methanone (96) 
Prepared from a solution of compound 70 (15 mg, 0.06 mmol), 
1,3-dibrompropane (12.5 µL, 0.12 mmol) and potassium carbonate 
(50 mg, 0.36 mmol) in DMF (1 mL), the brominated precursor was obtained. After that, 
the amination with cyclo-propylamine (8.0 µL, 0.11 mmol) in DMF (1 mL) was carried out 
according to the preparation of compound 72, to afford the title compound as yellow oil 
(2.0 mg, 16% yield). 1H-NMR (CD3OD, 400 MHz): δ 8.02 (d, J=7.2 Hz, 2H), 7.66 (t, J=7.2 Hz, 
1H), 7.56 (t, J=7.2 Hz, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.19 (d, J=8.4 Hz, 1H), 6.85 (d, J=8.0 Hz, 
1H), 4.31 (t, J=6.0 Hz, 2H), 3.43 (t, J=8.0 Hz, 2H), 2.91-2.85 (m, 1H), 2.83 (s, 3H), 2.38-2.28 
(m, 2H), 1.02-0.96 (m, 2H), 0.94-0.89 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 187.45, 
157.10, 156.87, 139.27, 138.74, 133.83, 130.82, 130.58, 129.46, 128.76, 119.90, 106.27, 
105.59, 66.17, 46.91, 31.31, 27.11, 12.39, 4.16. Calculated exact mass for the protonated 
molecule (C22H24NO3): 350.1756; measured accurate mass (ESI): 350.1745. LC-MS purity: 
97%, tR = 12.54 min.  
 
4-(3-(t-Butylamino)propoxy)-N-(4-chlorophenyl)-3-
methyl-benzofuran-2-carboxamide (97) 
Prepared from a solution of compound 55 (10 mg, 
0.03 mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 0.037 mmol), 
PyBOP (19 mg, 0.037 mmol) and 4-chloroaniline (4.7 mg, 0.037 mmol), the brominated 
precursor was obtained. After that, the amination with t-butylamine (13.6 µL, 0.13 mmol) 
in DMF (1 mL) was carried out according to the preparation of compound 59, to afford 
the title compound as a white solid (6.2 mg, 39%  overall yield). 1H-NMR (CD3OD, 400 
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MHz): δ 7.74 (d, J=8.8 Hz, 2H), 7.41 (t, J=8.4 Hz, 1H), 7.36 (d, J=8.8 Hz, 2H), 7.21 (d, J=8.4 
Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 4.28 (t, J=6.0 Hz, 2H), 3.28 (t, J=8.0 Hz, 2H), 2.81 (s, 3H), 
2.31-2.24 (m, 2H), 1.43 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 160.34, 156.37, 156.28, 
142.58, 138.09, 130.52, 129.76, 129.69, 125.15, 123.59, 120.15, 106.05, 105.60, 66.00, 
58.15, 40.06, 27.87, 25.82, 11.58. Calculated exact mass for the protonated molecule 
(C23H28N2O3Cl): 415.1788; measured accurate mass (ESI): 415.1780. LC-MS purity: 100%, 
tR = 12.77 min.  
 
4-(3-(t-Butylamino)propoxy)-N-(4-methoxyphenyl) 
-3-methylbenzofuran-2-carboxamide (98) 
Prepared from a solution of compound 55 (10 mg, 
0.03 mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 0.037 mmol), 
PyBOP (19 mg, 0.037 mmol) and 4-methoxy aniline (4.6 mg, 0.037 mmol), the 
brominated precursor was obtained. After that, the amination with t-butylamine (13.6 
µL, 0.13 mmol) in DMF (1 mL) was carried out according to the preparation of compound 
59, to afford the title compound as a white solid (2.9 mg, 19% overall yield). 1H-NMR 
(CD3OD, 400 MHz): δ 7.61 (d, J=9.2 Hz, 2H), 7.41 (t, J=8.4 Hz, 1H), 7.21 (d, J=8.4 Hz, 1H), 
6.96 (d, J=9.2 Hz, 2H), 6.83 (d, J=8.0 Hz, 1H), 4.29 (t, J=6.0 Hz, 2H), 3.82 (s, 3H), 3.29 (t, 
J=8.0 Hz, 2H), 2.82 (s, 3H), 2.31-2.24 (m, 2H), 1.44 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 
160.38, 158.39, 156.33, 156.28, 142.89, 131.91, 129.49, 124.49, 124.23, 120.19, 114.98, 
106.05, 105.57, 65.98, 58.16, 55.88, 40.08, 27.88, 25.82, 11.58. Calculated exact mass 
for the protonated molecule (C24H31N2O4): 411.2284; measured accurate mass (ESI): 
411.2301. LC-MS purity: 100%, tR = 11.98 min.  
 
4-(3-(t-Butylamino)propoxy)-3-methyl-N-p-tolyl 
benzofuran-2-carboxamide (99) 
Prepared from a solution of compound 55 (10 mg, 
0.03 mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 0.037 mmol), 
PyBOP (19 mg, 0.037 mmol) and 4-metyl aniline (4.0 mg, 0.037 mmol), the brominated 
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precursor was obtained. After that, the amination with t-butylamine (13.6 µL, 0.13 mmol) 
in DMF (1 mL) was carried out according to the preparation of compound 59, to afford 
the title compound as a white solid (5.1 mg, 34% overall yield). 1H-NMR (CD3OD, 400 
MHz): δ 7.59 (d, J=8.4 Hz, 2H), 7.42 (t, J=8.4 Hz, 1H), 7.23-7.20 (m, 3H), 6.83 (d, J=8.0 Hz, 
1H), 4.30 (t, J=6.0 Hz, 2H), 3.30 (t, J=8.0 Hz, 2H), 2.83 (s, 3H), 2.36 (s, 3H), 2.31-2.24 (m, 
2H), 1.44 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 160.40, 156.34, 156.28, 142.88, 136.46, 
135.60, 130.30, 129.53, 124.64, 122.49, 120.20, 106.08, 105.58, 65.98, 58.18, 40.08, 
27.90, 25.83, 20.96, 11.59. Calculated exact mass for the protonated molecule 
(C24H31N2O3): 395.2335; measured accurate mass (ESI): 395.2334. LC-MS purity: 100%, tR 
= 12.52 min.  
 
4-(3-(t-Butylamino)propoxy)-N-(3-chlorophenyl)-3-
methyl-benzo-furan-2-carboxamide (100) 
Prepared from a solution of compound 55 (10 mg, 0.03 
mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 0.037 mmol), 
PyBOP (19 mg, 0.037 mmol) and 3-chloro aniline (3.9 µL, 0.037 mmol), the brominated 
precursor was obtained. After that, the amination with t-butylamine (13.6 µL, 0.13 mmol) 
in DMF (1 mL) was carried out according to the preparation of compound 59, to afford 
the title compound as a white solid (6.3 mg, 40% overall yield). 1H-NMR (CD3OD, 400 
MHz): δ 7.94 (t, J=2 Hz, 1H), 7.64 (d, J=9.6 Hz, 1H), 7.42 (t, J=8.4 Hz, 1H), 7.36 (t, J=8.0 Hz, 
1H), 7.22 (d, J=8.4 Hz, 1H), 7.17 (d, J=10.0 Hz, 1H), 6.83 (d, J=8.0 Hz, 1H), 4.29 (t, J=6.0 Hz, 
2H), 3.30 (t, J=8.0 Hz, 2H), 2.83 (s, 3H), 2.32-2.25 (m, 2H), 1.44 (s, 9H). 13C-NMR (CD3OD, 
100 MHz): δ 160.39, 156.39, 156.31, 142.52, 140.75, 135.37, 131.08, 129.75, 125.35, 
121.91, 120.20, 106.09, 105.63, 66.02, 58.18, 40.09, 27.89, 25.84, 11.60. Calculated 
exact mass for the protonated molecule (C23H28N2O3Cl): 415.1788; measured accurate 
mass (ESI): 415.1792. LC-MS purity: 97%, tR = 12.30 min.  
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4-(3-(t-butylamino)propoxy)-N-(4-(dimethylamino) 
phenyl)-3-methylbenzofuran-2-carboxamide (101) 
Prepared from a solution of compound 55 (10 mg, 
0.03 mmol) in DMF/DCM (1 mL, 1:1) was sequentially added DIPEA (6.1 µL, 0.037 mmol), 
PyBOP (19 mg, 0.037 mmol) and N,N-dimethyl-p-phenylenediamine (5 mg, 0.037 mmol), 
the brominated precursor was obtained. After that, the amination with t-butylamine 
(13.6 µL, 0.13 mmol) in DMF (1 mL) was carried out according to the preparation of 
compound 59, to afford the title compound as an off-white solid (6.6 mg, 41%overall 
yield). 1H-NMR (CD3OD, 400 MHz): δ 7.94 (d, J=9.2 Hz, 2H), 7.50 (d, J=8.4 Hz, 2H), 7.44 (t, 
J=8.4 Hz, 1H), 7.23 (d, J=8.0 Hz, 1H), 6.85 (d, J=8.0 Hz, 1H), 4.31 (t, J=6.0 Hz, 2H), 3.30 (t, 
J=8.0 Hz, 2H), 3.26 (s, 6H), 2.84 (s, 3H), 2.34-2.24 (m, 2H), 1.44 (s, 9H). 13C-NMR (CD3OD, 
100 MHz): δ 160.44, 156.42, 156.35, 142.53, 141.87, 138.51, 129.80, 125.38, 123.52, 
120.36, 120.17, 106.06, 105.66, 66.04, 58.17, 45.90, 40.06, 27.87, 25.82, 11.59. 
Calculated exact mass for the protonated molecule (C25H34N3O3): 424.2600; measured 
accurate mass (ESI): 424.2604. LC-MS purity: 100%, tR = 10.47 min.  
 
(4-(3-(t-Butylamino)propoxy)-3-methylbenzofuran-2-yl)(4-chloro-
phenyl)methanone (102)  
Prepared from a solution of 2,6-dihydroxyl acetophenone (30 mg, 
0.2 mmol), 2-Bromo-4'-chloroacetophenone (51 mg, 0.22 mmol) 
and potassium carbonate (82 mg, 0.6 mmol) in acetonitrile (1 
mL), according to the preparation of compound 70, the benzofuran core was obtained. 
The resulting scaffold was then treated with 1,3-dibromopropane (14 µL, 0.14 mmol) 
and potassium carbonate (58 mg, 0.4 mmol) in DMF (1 mL), to afford the brominated 
precursor. After that, the amination with t-butylamine (15 µL, 0.14 mmol) in DMF (1 mL) 
was carried out according to the preparation of compound 72, to give the title 
compound as a white solid (1.3 mg, 2% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.05 
(d, J=8.4 Hz, 2H), 7.59 (d, J=8.4 Hz, 2H), 7.48 (t, J=8.4 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 6.86 
(d, J=8.4 Hz, 1H), 4.32 (t, J=6.0 Hz, 2H), 3.32-3.28 (m, 2H), 2.84 (s, 3H), 2.32-2.25 (m, 2H), 
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1.43 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 185.69, 157.07, 156.89, 148.20, 140.03, 
137.69, 132.30, 129.70, 129.14, 119.86, 106.28, 105.60, 66.09, 58.18, 40.05, 27.88, 
25.82, 12.37. Calculated exact mass for the protonated molecule (C23H27NO3Cl): 
400.1679; measured accurate mass (ESI): 400.1669. LC-MS purity: 95%, tR = 13.46 min.  
 
t-Butyl 4-hydroxypiperidine-1-carboxylate (103)[187] 
4-hydroxypiperidine (1 g, 9.9 mmol) was dissolved in THF (15 mL) 
and 10% NaOH (4 mL) was added. Di-tert-butyl-dicarbonate (2.37 g, 10.9 mmol) was 
added dropwise over 15 minutes and the resulting mixture was stirred for 24 hours. 
After that, the reaction was diluted with CHCl3 (40 mL) and partitioned with water (30 
mL). The aqueous layer was then extracted with CHCl3 (2 x 20 mL). The combined organic 
layers were washed with brine and dried over anhydrous sodium sulphate, concentrated 
in vacuo, to give the title compound as a white solid (2.17 g, quantitative yield). 1H-NMR 
(CDCl3, 400 MHz): δ 3.88 (brs, 3H), 3.07 (brs, 2H), 1.89 (brs, 2H), 1.67-1.54 (m, 2H), 1.47 
(s, 9H).  
 
 t-Butyl 3-hydroxypiperidine-1-carboxylate (104) 
Prepared from a solution of 3-hydroxypiperidine (0.5 g, 4.9 mmol) and  
Di-tert-butyl-dicarbonate (1.18 g, 5.4 mmol) in THF (10 mL) and 10% NaOH (2 mL), 
according to the preparation of compound 103, the title compound was obtained as a 
white solid (1.24 g, quantitative yield). 1H-NMR (CDCl3, 400 MHz): δ 3.78-3.71 (m, 2H), 
3.60-3.50 (m, 1H), 3.19-3.01 (m, 2H), 2.00-1.87 (m, 2H), 1.80-1.71 (m, 1H), 1.54-1.42 (m, 
1H), 1.47 (s, 9H). 
 
t -Butyl N-(3-hydroxy-2,2-dimethylpropyl)carbamate (105) 
Prepared from a solution of 3-amino-2,2-dimethylpropan-1-ol (0.5 g, 
4.8 mmol) and Di-tert-butyl-dicarbonate (1.16 g, 5.3 mmol) in THF (10 mL) and 10% 
NaOH (2 mL), according to the preparation of compound 103, the title compound was 
obtained as a white solid (1.01 g, quantitative yield). 1H-NMR (CDCl3, 400 MHz): δ 4.93 
(brs, 1H), 3.20 (s, 2H), 2.96 (d, J=6.0 Hz, 2H), 1.45 (s, 9H), 0.86 (s, 6H).  
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 t-Butyl 4-{[2-(ethoxycarbonyl)-3-methyl-1-benzofuran-4-yl]oxy} 
piperidine-1-carboxylate (106) 
To a stirred solution of compound 3 (2 g, 9.1 mmol), compound 
103 (4.56 g, 22.7 mmol) and triphenylphosphine (5.95 g, 22.7 
mmol) in anhydrous THF (20 mL) was added DIAD (4.34 mL, 22.7 mmol) dropwise at 
room temperature. The resulting mixture was stirred at the same temperature for 4 
hours, and then concentrated in vacuo. The residue was purified by column 
chromatography over silica gel, eluting with hexane: ethyl acetate, 5:1 to afford the title 
compound as colourless oil (3.52 g, 96% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.32 (t, J=8.0 
Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.65 (d, J=8.0 Hz, 1H), 4.74-4.69 (m, 1H), 4.46 (q, J=7.2 Hz, 
2H), 3.68-3.61 (m, 2H), 3.58-3.52 (m, 2H), 2.78 (s, 3H), 2.04-1.97 (m, 2H), 1.96-1.86 (m, 
2H), 1.50 (s, 9H), 1.46 (t, J=7.2 Hz, 3H).  
 
Ethyl 3-methyl-4-(piperidin-4-yloxy)benzofuran-2-carboxylate 
(109)[188]  
A mixture of compound 106 (10 mg, 0.025 mmol) and TFA (50 µL) 
in DCM (1 mL) was stirred at room temperature for 2 hours. The 
reaction mixture was evaporated under pressure to dryness, which was further purified 
by semi-preparative reverse phase HPLC to give the title compound as a white solid (9.8 
mg, 94% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.41 (t, J=8.4 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 
6.88 (d, J=8.0 Hz, 1H), 4.98-4.93 (m, 1H), 4.42 (q, J=7.2 Hz, 2H), 3.50-3.40 (m, 2H), 3.33-
3.28 (m, 2H), 2.80 (s, 3H), 2.34-2.24 (m, 2H), 2.22-2.12 (m, 2H), 1.43 (t, J=7.2 Hz, 3H). 13C-
NMR (CD3OD, 100 MHz): δ 161.87, 157.38, 154.55, 141.09, 130.09, 127.02, 120.30, 
106.50, 106.16, 69.95, 62.13, 42.01, 28.28, 14.63, 11.82. Calculated exact mass for the 
protonated molecule (C17H22NO4): 304.1549; measured accurate mass (ESI): 304.1561. 
LC-MS purity: 100%, tR = 11.39 min.  
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Ethyl-3-methyl-4-(piperidin-3-yloxy)benzofuran-2-carboxylate(110)  
Prepared from a solution of compound 3 (20 mg, 0.09 mmol), 
compound 104 (46 mg, 0.22 mmol), triphenylphosphine (60 mg, 
0.22 mmol) and DIAD (44 µL, 0.22 mmol) in anhydrous THF (2 mL), 
according to the preparation of compound 106,  the N-Boc precursor was obtained. After 
that, the deprotection in DCM (1 mL) containing TFA (100 µL) was carried out according 
to the preparation of compound 109, the title compound was obtained as a white solid 
(17 mg, 45% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.42 (t, J=8.4 Hz, 1H), 7.18 (d, 
J=8.4 Hz, 1H), 6.86 (d, J=8.0 Hz, 1H), 4.98-4.91 (m, 1H), 4.42 (q, J=7.2 Hz, 2H), 3.62-3.45 
(m, 2H), 3.28-3.20 (m, 2H), 2.81 (s, 3H), 2.28-2.07 (m, 3H), 2.00-1.86 (m, 1H), 1.43 (t, 
J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 161.86, 157.39, 154.60, 141.18, 130.04, 
127.22, 120.40, 106.65, 106.51, 70.48, 62.14, 46.79, 44.96, 28.36, 19.83, 14.63, 11.80. 
Calculated exact mass for the protonated molecule (C17H22NO4): 304.1549; measured 
accurate mass (ESI): 304.1560. LC-MS purity: 96%, tR = 11.44 min.  
 
Ethyl-4-(3-amino-2,2-dimethylpropoxy)-3-methylbenzofuran-2-
carboxylate(111) 
Prepared from a solution of compound 3 (10 mg, 0.045 mmol), 
compound 105 (23 mg, 0.11 mmol), triphenylphosphine (30 mg, 
0.11 mmol) and DIAD (22 µL, 0.11 mmol) in anhydrous THF (2 mL), the N-Boc precursor 
was obtained. After that, the deprotection in DCM (1 mL) containing TFA (100 µL) was 
carried out according to the preparation of compound 110, to give the title compound as 
a white solid (2.7 mg, 14% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.41 (t, J=8.0 Hz, 1H), 
7.15 (d, J=8.4 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 3.99 (s, 2H), 3.12 (s, 
2H), 2.80 (s, 3H), 1.43 (t, J=7.2 Hz, 3H), 1.25 (s, 6H). 13C-NMR (CD3OD, 100 MHz): δ 
161.88, 157.12, 156.51, 140.97, 130.13, 126.86, 119.67, 106.12, 105.48, 74.97, 62.12, 
47.90, 35.43, 22.53, 14.63, 12.16. Calculated exact mass for the protonated molecule 
(C17H24NO4): 306.1705; measured accurate mass (ESI): 306.1708. LC-MS purity: 100%, tR 
= 12.06 min. 
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Ethyl 3-methyl-4-(1-methylpiperidin-4-yloxy)benzofuran-2-
carboxylate (112) 
A mixture of compound 109 (30 mg, 0.07 mmol), formaldehyde 
(37% aqueous, 17.5 µL, 0.21 mmol), acetic acid (24 µL, 0.42 mmol) 
in THF/DMF (2 mL, 1:1) was stirred at room temperature for 2 hours, followed by the 
addition of sodium triacetoxyborohydride (74 mg, 0.35 mmol). The resulting mixture was 
further stirred at room temperature for 12 hours. After that, the reaction mixture was 
diluted with ethyl acetate (20 mL) and sequentially washed with 5% NaHCO3, water and 
brine (each 15 mL). The organic layer was concentrated in vacuo and the residue was 
purified by semi-preparative reverse phase HPLC, with no TFA in the mobile phase, to 
give the title compound as colourless oil (17 mg, 77% yield). 1H-NMR (CDCl3, 400 MHz): δ 
7.30 (t, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 4.61-4.51 (m, 1H), 
4.45 (q, J=7.2 Hz, 2H), 2.79 (s, 3H), 2.67 (brs, 2H), 2.42 (brs, 2H), 2.34 (s, 3H), 2.14-2.05 
(m, 2H), 2.02-1.94 (m, 2H), 1.45 (t, J=7.2 Hz, 3H). 13C-NMR (CDCl3, 100 MHz): δ 160.58, 
155.94, 154.09, 139.61, 128.41, 126.75, 119.45, 104.93, 104.69, 71.56, 60.92, 52.31, 
46.31, 30.54, 14.40, 11.61. Calculated exact mass for the protonated molecule 
(C18H24NO4): 318.1705; measured accurate mass (ESI): 318.1718. LC-MS purity: 100%, tR 
= 11.25 min.  
 
Ethyl 4-(1-ethylpiperidin-4-yloxy)-3-methylbenzofuran-2-
carboxylate (113)  
Prepared from a solution of compound 109 (30 mg, 0.07 mmol), 
acetalaldehyde (11.8 µL, 0.21 mmol), acetic acid (24 µL, 0.42 
mmol) and sodium triacetoxyborohydride (74 mg, 0.35 mmol) in THF/DMF (2 mL, 1:1), 
according to the preparation of compound 112, the title compound was obtained as 
colourless oil (18 mg, 78% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.30 (t, J=8.0 Hz, 1H), 7.11 
(d, J=8.0 Hz, 1H), 6.65 (d, J=8.0 Hz, 1H), 4.63-4.53 (m, 1H), 4.45 (q, J=7.2 Hz, 2H), 2.78 (s, 
3H), 2.72 (brs, 2H), 2.48 (q, J=7.2 Hz, 2H), 2.45 (brs, 2H), 2.16-2.06 (m, 2H), 2.04-1.94 (m, 
2H), 1.45 (t, J=7.2 Hz, 3H), 1.14 (t, J=7.2 Hz, 3H). 13C-NMR (CDCl3, 100 MHz): δ 160.60, 
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155.96, 154.13, 139.62, 128.42, 126.78, 119.47, 104.95, 104.67, 72.28, 60.92, 52.43, 
49.85, 30.52, 14.41, 12.17, 11.60. Calculated exact mass for the protonated molecule 
(C19H26NO4): 332.1862; measured accurate mass (ESI): 332.1865. LC-MS purity: 100%, tR 
= 11.34 min.  
 
Ethyl 4-(1-isopropylpiperidin-4-yloxy)-3-methylbenzofuran-2-
carboxylate (114)  
Prepared from a solution of compound 109 (30 mg, 0.07 mmol), 
acetone (15.9 µL, 0.21 mmol), acetic acid (24 µL, 0.42 mmol) and 
sodium triacetoxyborohydride (74 mg, 0.35 mmol) in THF/DMF (2 mL, 1:1), according to 
the preparation of compound 112, the title compound was obtained as colourless oil (21 
mg, 87% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.30 (t, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 
6.65 (d, J=8.0 Hz, 1H), 4.60-4.53 (m, 1H), 4.46 (q, J=7.2 Hz, 2H), 2.84-2.75 (m, 3H), 2.79 (s, 
3H), 2.51 (brs, 2H), 2.14-2.07 (m, 2H), 2.02-1.93 (m, 2H), 1.45 (t, J=7.2 Hz, 3H), 1.10 (d, 
J=6.8 Hz, 6H). 13C-NMR (CDCl3, 100 MHz): δ 160.61, 155.96, 154.16, 139.59, 128.43, 
126.82, 119.46, 104.92, 104.60, 72.51, 60.92, 54.58, 45.32, 30.86, 18.37, 14.42, 11.55. 
Calculated exact mass for the protonated molecule (C20H28NO4): 346.2018; measured 
accurate mass (ESI): 346.2019. LC-MS purity: 100%, tR = 11.51 min.  
 
Ethyl 4-(1-benzylpiperidin-4-yloxy)-3-methylbenzofuran-2-
carboxylate (115)  
Prepared from a solution of compound 109 (20 mg, 0.048 
mmol), benzaldehyde (15.2 µL, 0.15 mmol), acetic acid (16.5 µL, 
0.29 mmol) and sodium triacetoxyborohydride (51 mg, 0.24 mmol) in THF/DMF (2 mL, 
1:1), according to the preparation of compound 112, the title compound was obtained 
as colourless oil (11 mg, 58% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.36-7.29 (m, 6H), 7.11 
(d, J=8.4 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 4.62-4.53 (m, 1H), 4.47 (q, J=7.2 Hz, 2H), 3.59 (s, 
2H), 2.77 (s, 3H), 2.74-2.67 (m, 2H), 2.51-2.39 (m, 2H), 2.14-2.03 (m, 2H), 2.03-1.91 (m, 
2H), 1.47 (t, J=7.2 Hz, 3H). 13C-NMR (CDCl3, 100 MHz): δ 160.63, 155.97, 154.18, 139.60, 
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138.15, 129.19, 128.45, 128.25, 127.11, 126.86, 119.45, 104.90, 104.65, 72.38, 63.18, 
60.94, 50.11, 30.56, 14.44, 11.60. Calculated exact mass for the protonated molecule 
(C24H28NO4): 394.2018; measured accurate mass (ESI): 394.2010. LC-MS purity: 100%, tR 
= 12.12 min.  
 
Ethyl-4-({1-[(4-fluorophenyl)methyl]piperidin-4-yl}oxy)-3-
methyl-1-benzofuran-2-carboxylate (116) 
Prepared from a solution of compound 109 (50 mg, 0.12 
mmol), 4-fluoro-benzaldehyde (38.6 µL, 0.36 mmol), acetic 
acid (41.2 µL, 0.72 mmol) and sodium triacetoxyborohydride (127 mg, 0.6 mmol) in 
THF/DMF (2 mL, 1:1), according to the preparation of compound 112, the title 
compound was obtained as colourless oil (26 mg, 48% yield). 1H-NMR (CDCl3, 400 MHz): 
δ 7.38-7.28 (m, 3H), 7.11 (d, J=8.0 Hz, 1H), 7.07-7.01 (m, 2H), 6.64 (d, J=8.0 Hz, 1H), 4.62-
4.52 (m, 1H), 4.47 (q, J=7.2 Hz, 2H), 3.54 (s, 2H), 2.77 (s, 3H), 2.08 (brs, 2H), 2.44 (brs, 2H), 
2.13-1.90 (m, 4H), 1.46 (t, J=7.2 Hz, 3H). 13C-NMR (CDCl3, 100 MHz): δ 163.25, 160.63, 
155.97, 154.14, 139.62, 133.90, 130.64, 128.45, 126.79, 119.44, 115.03, 104.79, 62.34, 
60.96, 50.01, 30.52, 14.42, 11.61. Calculated exact mass for the protonated molecule 
(C24H27NO4F): 412.1924; measured accurate mass (ESI): 412.1940. LC-MS purity: 100%, tR 
= 12.19 min.  
 
(3-Methyl-4-(piperidin-4-yloxy)benzofuran-2-yl)(phenyl) 
methanone (117) 
Prepared from a solution of compound 70 (17 mg, 0.068 mmol), 
compound 103 (34 mg, 0.17 mmol), triphenylphosphine (44 mg, 
0.17 mmol) and DIAD (32 µL, 0.17 mmol) in anhydrous THF (1 mL), the N-Boc precursor 
was obtained. After that, the deprotection in DCM containing 5% TFA (2 mL) was carried 
out according to the preparation of compound 110, to afford the title compound as an 
off-white solid (17.3 mg, 84% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.01 (d, J=7.2 
Hz, 2H), 7.66 (t, J=7.6 Hz, 1H), 7.56 (t, J=7.6 Hz, 2H), 7.46 (t, J=8.4 Hz, 1H), 7.18 (d, J=8.4 
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Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 5.02-4.95 (m, 1H), 3.51-3.42 (m, 2H), 3.38-3.30 (m, 2H), 
2.84 (s, 3H), 2.38-2.28 (m, 2H), 2.25-2.14 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 186.00, 
155.91, 153.53, 147.07, 137.86, 132.42, 129.35, 129.19, 128.05, 127.20, 119.12, 105.23, 
104.91, 68.60, 40.57, 26.84, 11.08. Calculated exact mass for the protonated molecule 
(C21H22NO3): 336.1600; measured accurate mass (ESI): 336.1603. LC-MS purity: 100%, tR 
= 12.37 min.  
 
(3-Methyl-4-(1-methylpiperidin-4-yloxy)benzofuran-2-yl)(phenyl) 
methanone (118)  
Prepared from a solution of compound 117 (15 mg, 0.033 mmol), 
formaldehyde (37% aqueous, 8.1 µL, 0.1 mmol), acetic acid (11.5 
µL, 0.2 mmol) and sodium triacetoxyborohydride (35 mg, 0.17 mmol) in THF/DMF (1 mL, 
1:1), according to the preparation of compound 112, the title compound was obtained 
as colourless oil (9 mg, 78% yield). 1H-NMR (CDCl3, 400 MHz): δ 8.06 (d, J=7.2 Hz, 2H), 
7.61 (t, J=7.2 Hz, 1H), 7.53 (t, J=7.2 Hz, 2H), 7.36 (t, J=8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 
6.68 (d, J=8.0 Hz, 1H), 4.66-4.56 (m, 1H), 2.84 (s, 3H), 2.69 (brs, 2H), 2.45 (brs, 2H), 2.36 
(s, 3H), 2.15-2.08 (m, 2H), 2.05-1.95 (m, 2H). 13C-NMR (CDCl3, 100 MHz): δ 185.87, 
155.89, 154.54, 147.21, 138.15, 132.37, 129.64, 128.95, 128.23, 128.00, 119.74, 105.00, 
104.65, 71.60, 52.25, 46.31, 30.50, 12.23. Calculated exact mass for the protonated 
molecule (C22H24NO3): 350.1756; measured accurate mass (ESI): 350.1752. LC-MS purity: 
100%, tR = 12.26 min.  
 
(4-(1-Benzylpiperidin-4-yloxy)-3-methylbenzofuran-2-yl) 
(phenyl)-methanone (119)  
Prepared from a solution of compound 117 (15 mg, 0.033 
mmol), benaldehyde (10 µL, 0.1 mmol), acetic acid (11.5 µL, 0.2 
mmol) and sodium triacetoxyborohydride (35 mg, 0.17 mmol) in THF/DMF (1 mL, 1:1), 
according to the preparation of compound 112, the title compound was obtained as 
colourless oil (7 mg, 50% yield). 1H-NMR (CDCl3, 400 MHz): δ 8.06 (d, J=7.2 Hz, 2H), 7.62 
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(t, J=7.2 Hz, 1H), 7.53 (t, J=7.2 Hz, 2H), 7.37-7.30 (m, 6H), 7.09 (d, J=8.0 Hz, 1H), 6.67 (d, 
J=8.0 Hz, 1H), 4.65-4.56 (m, 1H), 3.59 (s, 2H), 2.81 (s, 3H), 2.74 (brs, 2H), 2.46 (brs, 2H), 
2.16-2.08 (m, 2H), 2.02-1.93 (m, 2H). 13C-NMR (CDCl3, 100 MHz): δ 185.89, 155.91, 
154.64, 147.20, 138.19, 132.38, 129.67, 129.18, 128.97, 128.11, 127.10, 119.72, 104.95, 
104.57, 72.40, 63.17, 50.08, 30.56, 12.21. Calculated exact mass for the protonated 
molecule (C28H28NO3): 426.2069; measured accurate mass (ESI): 426.2079. LC-MS purity: 
100%, tR = 12.76 min.  
 
4-({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)-3-methyl-1-
benzofuran-2-carboxylic acid (120)  
Prepared from a solution of compound 106 (1.85 g, 4.6 mmol) and 
LiOH·H2O (1.16 g, 27.5 mmol) in THF/MeOH (40 mL, 1:1) according 
to the preparation of compound 55, the title compound was obtained as a while solid 
(1.51 g, 88% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.12 (d, J=8.0 Hz, 
1H), 6.65 (d, J=8.0 Hz, 1H), 4.74-4.69 (m, 1H), 3.69-3.62 (m, 2H), 3.56-3.50 (m, 2H), 2.76 
(s, 3H), 2.06-1.99 (m, 2H), 1.94-1.86 (m, 2H), 1.50 (s, 3H). 
 
N-isopropyl-3-methyl-4-(piperidin-4-yloxy)benzofuran-2-
carboxamide(121) 
Prepared from a solution of compound 120 (30 mg, 0.08 mmol) 
in DMF/DCM (2 mL, 1:1) was sequentially added DIPEA (15 µL, 
0.088 mmol), PyBOP (46 mg, 0.088  mmol) and isopropylamine (7.6 µL, 0.088 mmol) 
according to the preparation of compound 59, the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 109, to afford the title compound as a white solid (11.5 mg, 34% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.37 (t, J=8.4 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 
6.87 (d, J=8.4 Hz, 1H), 4.98-4.93 (m, 1H), 4.30-4.96 (m, 1H), 3.46-3.40 (m, 2H), 3.32-3.29 
(m, 2H), 2.80 (s, 3H), 2.32-2.25 (m, 2H), 2.21-2.13 (m, 2H), 1.29 (d, J=6.4 Hz, 6H). 13C-
NMR (CD3OD, 100 MHz): δ 161.52, 156.45, 154.30, 143.11, 129.19, 123.31, 120.78, 
106.62, 106.05, 69.78, 42.32, 41.92, 28.23, 22.58, 11.52. Calculated exact mass for the 
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protonated molecule (C18H25N2O3): 317.1865; measured accurate mass (ESI): 317.1867. 
LC-MS purity: 100%, tR = 10.75 min.  
 
N-cyclopropyl-3-methyl-4-(piperidin-4-yloxy)benzofuran-2-
carboxamide (122) 
Prepared from a solution of compound 120 (30 mg, 0.08 mmol) 
in DMF/DCM (2 mL, 1:1) was sequentially added DIPEA (15 µL, 
0.088 mmol), PyBOP (46 mg, 0.088 mmol) and cyclopropylamine (6.2 µL, 0.088 mmol), 
the N-Boc precursor was obtained. After that, the deprotection in DCM containing 5% 
TFA (2 mL) was carried out according to the preparation of compound 121, to afford the 
title compound as a white solid (11 mg, 32% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.37 (t, J=8.4 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.87 (d, J=8.0 Hz, 1H), 4.98-4.93 (m, 1H), 
3.46-3.40 (m, 2H), 3.32-3.29 (m, 2H), 2.88-2.82 (m, 1H), 2.81 (s, 3H), 2.32-2.25 (m, 2H), 
2.21-2.13 (m, 2H), 0.86-0.82 (m, 2H), 0.71-0.67 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 
163.90, 156.51, 154.34, 142.95, 129.26, 123.51, 120.76, 106.65, 106.05, 69.82, 41.94, 
28.25, 23.25, 11.51, 6.63. Calculated exact mass for the protonated molecule 
(C18H23N2O3): 315.1709; measured accurate mass (ESI): 315.1702. LC-MS purity: 100%, tR 
= 10.25 min.  
 
N-tert-butyl-3-methyl-4-(piperidin-4-yloxy)benzofuran-2-
carboxamide(123) 
Prepared from a solution of compound 120 (30 mg, 0.08 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added DIPEA 
(15 µL, 0.088 mmol), PyBOP (46 mg, 0.088  mmol) and tert-butylamine (9.2 µL, 0.088 
mmol), the N-Boc precursor was obtained. After that, the deprotection in DCM 
containing 5% TFA (2 mL) was carried out according to the preparation of compound 121, 
to afford the title compound as a white solid (13 mg, 37% overall yield). 1H-NMR (CD3OD, 
400 MHz): δ 7.37 (t, J=8.4 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 6.86 (d, J=8.4 Hz, 1H), 4.97-4.93 
(m, 1H), 3.49-3.38 (m, 2H), 3.32-3.26 (m, 2H), 2.78 (s, 3H), 2.34-2.24 (m, 2H), 2.21-2.13 
(m, 2H), 1.50 (s, 9H). 13C-NMR (CD3OD, 100 MHz): δ 161.83, 156.23, 154.27, 143.47, 
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129.10, 122.83, 120.82, 106.67, 106.06, 69.81, 52.64, 41.93, 29.12, 28.25, 11.52. 
Calculated exact mass for the protonated molecule (C19H27N2O3): 331.2022; measured 
accurate mass (ESI): 331.2021. LC-MS purity: 100%, tR = 11.75 min.  
 
N-cyclohexyl-3-methyl-4-(piperidin-4-yloxy)benzofuran-2- 
carboxamide (124) 
Prepared from a solution of compound 120 (50 mg, 0.13 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added 
DIPEA (26 µL, 0.15 mmol), PyBOP (76 mg, 0.15 mmol) and cyclohexylamine (17 µL, 0.15 
mmol), the N-Boc precursor was obtained. After that, the deprotection in DCM 
containing 5% TFA (2 mL) was carried out according to the preparation of compound 121, 
to afford the title compound as a white solid (13.4 mg, 22% overall yield). 1H-NMR 
(CD3OD, 400 MHz): δ 7.37 (t, J=8.4 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 6.87 (d, J=8.4 Hz, 1H), 
4.97-4.92 (m, 1H), 3.94-3.86 (m, 1H), 3.49-3.38 (m, 2H), 3.32-3.29 (m, 2H), 2.80 (s, 3H), 
2.35-2.23 (m, 2H), 2.23-2.12 (m, 2H), 2.00-1.91 (m, 2H), 1.91-1.76 (m, 2H), 1.76-1.66 (m, 
1H), 1.50-1.35 (m, 4H), 1.35-1.19 (m, 1H). 13C-NMR (CD3OD, 100 MHz): δ 161.46, 156.45, 
154.30, 143.11, 129.18, 123.36, 120.80, 106.64, 106.05, 69.79, 49.72, 41.93, 33.76, 
28.25, 26.57, 26.44, 11.54. Calculated exact mass for the protonated molecule 
(C21H29N2O3): 357.2178; measured accurate mass (ESI): 357.2162. LC-MS purity: 100%, tR 
= 12.20 min.  
 
N-adamantyl-3-methyl-4-(piperidin-4-yloxy)benzofuran-2-
carboxamide (125) 
Prepared from a solution of compound 120 (30 mg, 0.08 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added 
DIPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088  mmol) and 1-adamantylamine (13.3 
mg, 0.088 mmol), the N-Boc precursor was obtained. After that, the deprotection in 
DCM containing 5% TFA (2 mL) was carried out according to the preparation of 
compound 121, to afford the title compound as a white solid (15 mg, 36% overall yield). 
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1H-NMR (CD3OD, 400 MHz): δ 7.36 (t, J=8.4 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.86 (d, J=8.0 
Hz, 1H), 4.97-4.90 (m, 1H), 3.48-3.40 (m, 2H), 3.33-3.28 (m, 2H), 2.77 (s, 3H), 2.34-2.24 
(m, 2H), 2.19 (brd, 7H), 2.14 (brd, 4H), 1.79 (brd, 6H). 13C-NMR (CD3OD, 100 MHz): δ 
161.48, 156.18, 154.26, 143.37, 129.12, 122.92, 120.82, 106.68, 106.05, 69.81, 53.52, 
42.51, 41.92, 37.45, 30.99, 28.24, 11.54. Calculated exact mass for the protonated 
molecule (C25H33N2O3): 409.2491; measured accurate mass (ESI): 409.2497. LC-MS purity: 
100%, tR = 13.40 min.  
 
3-Methyl-N-phenyl-4-(piperidin-4-yloxy)benzofuran-2-
carboxamide (126) 
Prepared from a solution of compound 120 (15 mg, 0.04 
mmol) in DMF/DCM (1 mL, 1:1) was sequentially added 
DIPEA (7.4 µL, 0.044 mmol), PyBOP (23 mg, 0.044 mmol) and aniline (4 µL, 0.044 mmol), 
the N-Boc precursor was obtained. After that, the deprotection in DCM containing 5% 
TFA (1 mL) was carried out according to the preparation of compound 121, to afford the 
title compound as an off-white solid (5 mg, 37% overall yield). 1H-NMR (CDCl3, 400 MHz): 
δ 8.32 (s, 1H, CONH), 7.72 (d, J=7.2 Hz, 2H), 7.40 (t, J=7.2 Hz, 2H), 7.33 (t, J=8.0 Hz, 1H), 
7.17 (t, J=7.2 Hz, 1H), 7.09 (d, J=8.0 Hz, 1H), 6.69 (d, J=8.0 Hz, 1H), 4.67-4.58 (m, 1H), 
3.23-3.17 (m, 2H), 2.89 (s, 3H), 2.87-2.81 (m, 2H), 2.15-2.08 (m, 2H), 1.89-1.81 (m, 2H). 
13C-NMR (CDCl3, 100 MHz): δ 158.18, 154.82, 154.17, 141.00, 137.59, 129.08, 128.13, 
124.89, 124.39, 119.91, 105.44, 104.11, 73.08, 43.53, 31.89, 11.20. Calculated exact 
mass for the protonated molecule (C21H23N2O3): 351.1709; measured accurate mass (ESI): 
351.1696. LC-MS purity: 92%, tR = 11.74 min.  
 
3-Methyl-4-(piperidin-4-yloxy)-N-(1,2,4-trimethyl-1H-
imidazol-5-yl)benzofuran-2-carboxamide (127)  
Prepared from a solution of compound 120 (30 mg, 0.08 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added 
DIPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088 mmol) and 4-amino-1,3,5-
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trimethylpyrazole (11 mg, 0.088 mmol), the N-Boc precursor was obtained. After that, 
the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 121, to afford the title compound as a white solid (29 mg, 73% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.43 (t, J=8.4 Hz, 1H), 7.21 (d, J=8.0 Hz, 1H), 
6.91 (d, J=8.0 Hz, 1H), 4.97-4.91 (m, 1H), 3.81 (s, 3H), 3.5-3.39 (m, 2H), 3.38-3.30 (m, 2H), 
2.84 (s, 3H), 2.37-2.27 (m, 2H), 2.25 (s, 3H), 2.21 (s, 3H), 2.21-2.15 (m 2H). 13C-NMR 
(CD3OD, 100 MHz): δ 161.78, 156.73, 154.49, 144.74, 142.68, 139.07, 129.71, 125.02, 
120.75, 115.88, 106.79, 106.11, 69.96, 41.94, 36.26, 28.26, 11.62, 10.86, 9.30. Calculated 
exact mass for the the protonated molecule (C21H27N4O3): 383.2083; measured accurate 
mass (ESI): 383.2068. LC-MS purity: 100%, tR = 10.03 min.  
 
N-benzyl-3-methyl-4-(piperidin-4-yloxy)benzofuran-2-
carboxamide(128) 
Prepared from a solution of compound 120 (30 mg, 0.08 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added 
DiPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088  mmol) and benzylamine (9.6 µL, 0.088 
mmol), the N-Boc precursor was obtained. After that, the deprotection in DCM 
containing 5% TFA (2 mL) was carried out according to the preparation of compound 121, 
to afford the title compound as a white solid (12.5 mg, 33% overall yield). 1H-NMR 
(CD3OD, 400 MHz): δ 7.40-7.32 (m, 5H), 7.26 (t, J=7.2 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.85 
(d, J=8.4 Hz, 1H), 4.92-4.87 (m, 1H), 4.58 (s, 2H), 3.45-3.39 (m, 2H), 3.32-3.28 (m, 2H), 
2.80 (s, 3H), 2.34-2.24 (m, 2H), 2.20-2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 162.32, 
156.54, 154.34, 142.97, 140.18, 129.55, 129.33, 128.51, 128.20, 123.78, 120.76, 106.64, 
106.06, 69.79, 43.54, 41.90, 28.22, 11.56. Calculated exact mass for the the protonated 
molecule (C22H25N2O3): 365.1865; measured accurate mass (ESI): 365.1875. LC-MS purity: 
100%, tR = 11.55 min.  
 
 
 
 
Chapter 6 – Experimental section 
-200- | P a g e  
 
3-Methyl-N-(naphthalen-1-yl)-4-(piperidin-4-yloxy) 
benzofuran-2-carboxamide (129) 
Prepared from a solution of compound 120 (30 mg, 0.08 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added 
DIPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088  mmol) and 1-naphthylamine (12.6 mg, 
0.088 mmol), the N-Boc precursor was obtained. After that, the deprotection in DCM 
containing 5% TFA (2 mL) was carried out according to the preparation of compound 121, 
to afford the title compound as an off-white solid (13.8 mg, 34% overall yield). 1H-NMR 
(CD3OD, 400 MHz): δ 8.06-8.04 (m, 1H), 7.97-7.95 (m, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.10 (d, 
J=7.2 Hz, 1H), 7.60-7.54 (m, 3H), 7.45 (t, J=8.4 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 6.92 (d, 
J=8.0 Hz, 1H), 4.98-4.94 (m, 1H), 3.47-3.40 (m, 2H), 3.31-3.28 (m, 2H), 2.87 (s, 3H), 2.34-
2.26 (m, 2H), 2.22-2.15 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 161.59, 156.76, 154.48, 
142.98, 135.81, 133.58, 130.71, 129.42, 128.19, 127.28, 126.53, 125.07, 124.86, 123.62, 
120.89, 106.81, 106.26, 69.92, 41.96, 28.27, 11.71. Calculated exact mass for the 
protonated molecule (C25H25N2O3): 401.1865; measured accurate mass (ESI): 401.1859. 
LC-MS purity: 100%, tR = 12.21 min.  
 
3-Methyl-N-(naphthalen-1-ylmethyl)-4-(piperidin-4-
yloxy)-benzofuran-2-carboxamide (130) 
Prepared from a solution of compound 120 (30 mg, 
0.08 mmol) in DMF/DCM (2 mL, 1:1) was sequentially 
added DIPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088 mmol) and 1-
naphthylmethylamine (12.9 µL, 0.088 mmol), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 121, to afford the title compound as a white solid (20.7 mg, 49% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.18 (d, J=8.4 Hz, 1H), 7.90 (d, J=8.4 Hz, 1H), 
7.82 (d, J=8.0 Hz, 1H), 7.58-7.44 (m, 4H), 7.33 (t, J=8.4 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 
6.80 (d, J=8.4 Hz, 1H), 5.05 (s, 2H), 4.89-4.84 (m, 1H), 3.43-3.37 (m, 2H), 3.32-3.26 (m, 
2H), 2.80 (s, 3H), 2.28-2.21 (m, 2H), 2.18-2.10 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 
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162.23, 156.51, 154.29, 142.92, 135.33, 134.98, 132.62, 129.79, 129.31, 129.13, 127.36 
126.86, 126.61, 126.44, 124.31, 123.85, 120.72, 106.61, 106.06, 69.75, 41.87, 41.59, 
28.19, 11.59. Calculated exact mass for the protonated molecule (C26H27N2O3): 415.2022; 
measured accurate mass (ESI): 415.2020. LC-MS purity: 100%, tR = 12.50 min.  
 
(3,4-Dihydroisoquinolin-2(1H)-yl)(3-methyl-4-(piperidin-
4-yloxy)-benzofuran-2-yl)methanone (131) 
Prepared from a solution of compound 120 (30 mg, 0.08 
mmol) in DMF/DCM (2 mL, 1:1) was sequentially added 
DIPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088 mmol) and 1,2,3,4-
tetrahydroisoquinoline (11 µL, 0.088 mmol), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 121, to afford the title compound as a white solid (17.6 mg, 44% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.37 (t, J=8.4 Hz, 1H), 7.22 (brd, 4H), 7.17 (d, 
J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 4.97-4.92 (m, 1H), 4.85 (s, 2H), 4.00-3.80 (m, 2H), 
3.46-3.40 (m, 2H), 3.33-3.28 (m, 2H), 3.02 (t, J=5.6 Hz, 2H), 2.61 (s, 3H), 2.32-2.25 (m, 
2H), 2.21-2.13 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 163.18, 162.04, 161.75, 156.77, 
154.02, 144.07, 135.63, 129.75, 128.80, 127.97, 127.63, 122.11, 120.10, 106.76, 106.06, 
69.80, 46.20, 41.91, 30.69, 29.22, 28.25, 11.47. Calculated exact mass for the protonated 
molecule (C24H27N2O3): 391.2022; measured accurate mass (ESI): 391.2029. LC-MS purity: 
100%, tR = 12.40 min.  
 
(4-Benzylpiperazin-1-yl)(3-methyl-4-(piperidin-4-
yloxy)-benzofuran-2-yl)methanone (132) 
Prepared from a solution of compound 120 (30 mg, 
0.08 mmol) in DMF/DCM (2 mL, 1:1) was 
sequentially added DIPEA (15 µL, 0.088 mmol), PyBOP (46 mg, 0.088 mmol) and 1-
benzylpiperazine (15.3 µL, 0.088 mmol), the N-Boc precursor was obtained. After that, 
the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
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preparation of compound 121, to afford the title compound as a white solid (27.2 mg, 62% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.58-7.54 (m, 2H), 7.54-7.52 (m, 3H), 7.39 (t, 
J=8.4 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 6.90 (d, J=8.4 Hz, 1H), 4.97-4.92 (m, 1H), 4.44 (s, 2H), 
3.46-3.40 (m, 6H), 3.32-3.29 (m, 2H), 2.64 (s, 3H), 2.33-2.26 (m, 2H), 2.20-2.12 (m, 2H). 
13C-NMR (CD3OD, 100 MHz): δ 162.34, 156.67, 154.17, 142.73, 132.40, 131.43, 130.45, 
129.93, 129.38, 124.61, 120.05, 106.85, 106.04, 69.96, 61.66, 52.60, 49.06, 41.94, 28.26, 
11.63. Calculated exact mass for the protonated molecule (C26H32N3O3): 434.2444; 
measured accurate mass (ESI): 434.2423. LC-MS purity: 100%, tR = 8.83 min.  
 
1-(Triphenylmethyl)piperidin-4-ol  (138)[189] 
4-Hydroxypiperidine (0.30 g, 3.0 mmol) and triphenylmethyl 
chloride (0.84 g, 3.0 mmol) were dissolved in DCM (5 mL). Triethylamine (0.84 mL, 6.0 
mmol) was added dropwise and the resulting mixture was stirred for 24 hours at room 
temperature. After that, the reaction was diluted with CHCl3 (20 mL) and partitioned 
with 5% NaHCO3 solution (30 mL). The aqueous layer was then extracted with CHCl3 (2 x 
15 mL). The combined organic layers were washed with brine and dried over anhydrous 
sodium sulphate, concentrated in vacuo, to give the title compound as a white solid 
(1.05 g, quantitative yield). 1H-NMR (CDCl3, 400 MHz): δ 7.49 (brs, 5H), 7.34-7.26 (m, 7H), 
7.20-7.16 (m, 3H), 2.91 (brs, 1H), 2.03-1.85 (m, 2H), 1.71-1.60 (m, 2H), 1.60-1.24 (m, 4H).  
 
 Ethyl 3-methyl-4-{[1-(triphenylmethyl)piperidin-4-yl]oxy}-1-
benzofuran-2-carboxylate (139)  
Prepared from compound 3 (100 mg, 0.45 mmol) and compound 
138 (386 mg, 1.1 mmol), triphenylphosphine (294 mg, 1.1 mmol) 
and DIAD (214 µL, 1.1 mmol) in anhydrous THF (4 mL) according to the preparation of 
compound 106, the title compound was obtained as a white solid (160 mg, 65% yield). 
1H-NMR (CDCl3, 400 MHz): δ 7.63-7.42 (m, 5H), 7.38-7.29 (m, 7H), 7.26-7.14 (m, 4H), 
7.05 (d, J=8.0 Hz, 1H), 6.55 (d, J=8.0 Hz, 1H), 4.46 (q, J=7.2 Hz, 2H), 2.28-2.13 (m, 3H), 
2.12 -1.98 (m, 3H), 1.64-1.53 (m, 2H), 1.47 (t, J=7.2 Hz, 3H).  
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 (3-Methyl-4-{[1-(triphenylmethyl)piperidin-4-yl]oxy}-1-
benzofuran-2-yl) methanol (140) 
Prepared from compound 139 (160 mg, 0.29 mmol) and LiAlH4 
(17 mg, 0.44 mmol) in anhydrous THF according to the 
preparation of compound 79, the title compound was obtained as colourless oil (150 mg, 
quantitative yield). 1H-NMR (CDCl3, 400 MHz): δ 7.68-7.41 (m, 5H), 7.38-7.30 (m, 6H), 
7.25-7.14 (m, 4H), 7.10 (t, J=8.0 Hz, 1H), 6.98 (d, J=8.0 Hz, 1H), 6.54 (d, J=8.0 Hz, 1H), 
4.70 (s, 2H), 4.06-3.94 (m, 1H), 2.24-2.11 (m, 2H), 2.12-1.97 (m, 4H), 1.91-1.83 (m, 2H).  
 
[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl]methanol (141)  
A solution of compound 140 (5 mg, 0.001 mmol) in DCM (1 mL), 
containing 0.1% of TFA and 0.2% of water, was stirred at room 
temperature for 12 hours. After that, the reaction mixture was 
concentrated in vacuo and the residue was purified by semi-preparative reverse phase 
HPLC, with no TFA in the mobile phases, to give the title compound as colourless oil (1.7 
mg, 59% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.21 (t, J=8.0 Hz, 1H), 7.07 (d, J=8.0 Hz, 1H), 
6.79 (d, J=8.0 Hz, 1H), 4.89-4.87 (m, 2H), 4.65 (s, 2H), 3.46-3.40 (m, 2H), 3.31-3.26 (m, 
2H), 2.46 (s, 3H), 2.31-2.22 (m, 2H), 2.20-2.11 (m, 2H). 13C-NMR (CD3OD, 125 MHz): 
δ157.36, 153.12, 152.29, 126.29, 120.88, 113.50, 106.26, 105.82, 69.51, 55.27, 41.98, 
28.53, 10.42. . Calculated exact mass for the protonated molecule (C15H20NO3): 262.1443; 
measured accurate mass (ESI): 262.1455. LC-MS purity: 89% (somewhat decomposition 
under weakly acidic or LC-MS conditions), tR = 9.29 min.  
 
4-{[3-Methyl-2-(phenoxymethyl)-1-benzofuran-4-yl]oxy} 
piperidine (142) 
Prepared from compound 140 (30 mg, 0.06 mmol), 
phenol (14.1 mg, 0.15 mmol), triphenylphosphine (39 mg, 
0.15 mmol) and DIAD (29 µL, 0.15 mmol) in anhydrous THF (2 mL) according to the 
preparation of compound 80, the N-trityl precursor was obtained. After that, the 
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deprotection in DCM (1mL) containing 0.1% of TFA and 0.2% of water was carried out 
according to the preparation of compound 141, to afford the title compound as 
colourless oil (0.4 mg, 2% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.32-7.28 (m, 2H), 
7.24 (t, J=8.0 Hz, 1H), 7.09 (d, J=8.0 Hz, 1H), 7.04 (d, J=8.0 Hz, 2H), 6.98 (t, J=8.0 Hz, 1H), 
6.81 (d, J=8.0 Hz, 1H), 5.15 (s, 2H), 4.96-4.89 (m, 1H), 3.43-3.38 (m, 2H), 3.30-3.26 (m, 
2H), 2.48 (s, 3H), 2.30-2.22 (m, 2H), 2.20-2.11 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 
159.96, 153.18, 148.70, 138.03, 130.54, 126.75, 122.40, 120.63, 116.18, 115.81, 106.33, 
105.89, 69.55, 61.90, 41.98, 28.34, 10.50. Calculated exact mass for the protonated 
molecule (C21H24NO3): 338.1756; measured accurate mass (ESI): 338.1772. LC-MS purity: 
100%, tR = 12.44 min.  
 
4-{[2-(Methoxymethyl)-3-methyl-1-benzofuran-4-yl]oxy} 
piperidine (143) 
A solution of compound 140 (30 mg, 0.06 mmol) and sodium 
hydride (60% w/w, 7.2 mg, 0.18 mmol) in anhydrous DMF was 
stirred at room temperature for 30 minutes, then treated with methyl iodide (9.4 µL, 
0.15 mmol). The resulting mixture was further stirred at room temperature for 12 hours. 
After that, the reaction mixture was quenched with 100 µL of cold water, diluted with 
EtOAc (20 mL) and sequentially washed with water and brine (each for 20 mL). The 
organic layer was concentrated in vacuo and the residue was purified by column 
chromatography over silica gel, eluting with hexane:ethyl acetate, 8:1, to give the N-trityl 
precursor. The compound was further deprotected in DCM (1mL), containing 0.1% of TFA 
and 0.2% of water, according to the preparation of compound 141, to afford the title 
compound as yellow oil (7.8 mg, 28% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.22 (t, 
J=8.0 Hz, 1H), 7.06 (d, J=8.0 Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 4.90-4.87 (m, 1H), 4.55 (s, 2H), 
3.46-3.37 (m, 2H), 3.40 (s, 3H), 3.32-3.27 (m, 2H), 2.45 (s, 3H), 2.31-2.23 (m, 2H), 2.20-
2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 157.42, 153.16, 149.55, 126.61, 120.58, 
115.58, 106.25, 105.78, 69.53, 65.16, 58.07, 41.92, 28.31, 10.49. Calculated exact mass 
for the protonated molecule (C16H22NO3): 276.1600; measured accurate mass (ESI): 
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276.1606. LC-MS purity: 100%, tR = 10.96 min.  
 
4-{[2-(Ethoxymethyl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine 
(144) 
Prepared from a solution of compound 140 (20 mg, 0.04 mmol), 
sodium hydride (60% w/w, 4.8 mg, 0.12 mmol) and ethyl iodide 
(6.4 µL, 0.08 mmol) in anhydrous DMF, the N-trityl precursor was obtained. After that, 
the deprotection in DCM (1mL) containing 0.1% of TFA and 0.2% of water was carried 
out according to the preparation of compound 143, to afford the title compound as 
yellow oil (1.7 mg, 15% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.22 (t, J=8.0 Hz, 1H), 
7.07 (d, J=8.0 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 4.88-4.85 (m, 1H), 4.60 (s, 2H), 3.61 (q, J=7.2 
Hz, 2H), 3.46-3.40 (m, 2H), 3.32-3.25 (m, 2H), 2.47 (s, 3H), 2.32-2.23 (m, 2H), 2.23-2.11 
(m, 2H), 1.23 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ 157.41, 153.14, 149.92, 
126.55, 120.64, 115.19, 106.26, 105.82, 69.51, 66.77, 63.42, 41.94, 28.34, 15.38, 10.51. 
Calculated exact mass for the protonated molecule (C17H24NO3): 290.1756; measured 
accurate mass (ESI): 290.1761. LC-MS purity: 87% (somewhat decomposition under 
weakly acidic or LC-MS conditions), tR = 11.39 min. 
 
4-({2-[(Benzyloxy)methyl]-3-methyl-1-benzofuran-4-yl}oxy) 
-piperidine (145)  
Prepared from a solution of compound 140 (30 mg, 0.06 
mmol), sodium hydride (60% w/w, 7.2 mg, 0.18 mmol) 
and benzyl bromide (10.7 µL, 0.09 mmol) in anhydrous DMF, the N-trityl precursor was 
obtained. After that, the deprotection in DCM (1mL) containing 0.1% of TFA and 0.2% of 
water was carried out according to the preparation of compound 143, to afford the title 
compound as colourless oil (2 mg, 10% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.40-
7.28 (m, 5H), 7.23 (t, J=8.0 Hz, 1H), 7.09 (d, J=8.0 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 4.91-
4.85 (m, 1H), 4.64 (s, 2H), 4.60 (s, 2H), 3.46-3.39 (m, 2H), 3.30-3.27 (m, 2H), 2.43 (s, 3H), 
2.30-2.22 (m, 2H), 2.20-2.12 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 156.06, 151.72, 
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148.30, 137.87, 128.02, 127.62, 127.45, 125.19, 119.22, 114.14, 104.84, 104.45, 71.65, 
68.06, 61.44, 40.53, 26.90, 9.14. Calculated exact mass for the protonated molecule 
(C22H26NO3): 352.1913; measured accurate mass (ESI): 352.1909. LC-MS purity: 100%, tR 
= 12.34 min.  
 
t-Butyl 4-[(2-formyl-3-methyl-1-benzofuran-4-yl)oxy]piperidine-1-
carboxylate (153)  
To a solution of compound 135 (50 mg, 0.13 mmol) in anhydrous 
DCM was added activated manganese dioxide (560 mg, 6.5 mmol) 
at room temperature, and the resulting mixture was stirred at the same temperature for 
24 hours. After that, the reaction mixture was filtered over a celite pad and the filtrate 
was concentrated in vacuo, to afford the title compound as yellow oil (37 mg, 77% yield). 
1H-NMR (CDCl3, 400 MHz): δ 9.96 (s, 1H), 7.38 (t, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 
6.66 (d, J=8.0 Hz, 1H), 4.74-4.69 (m, 1H), 3.69-3.62 (m, 2H), 3.56-3.50 (m, 2H), 2.76 (s, 
3H), 2.06-1.99 (m, 2H), 1.94-1.86 (m, 2H), 1.50 (s, 3H).  
 
Benzyl({[3-methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-
yl]methyl})-amine (154) 
A mixture of compound 153 (18 mg, 0.05 mmol), 
benzylamine (6.2 µL, 0.055 mmol) and acetic acid (18 µL, 
0.3 mmol) in THF (1 mL) was stirred at room temperature for 2 hours, followed by the 
addition of sodium triacetoxyborohydride (53 mg, 0.25 mmol). The resulting mixture was 
further stirred at room temperature for 12 hours. After that, the reaction mixture was 
diluted with ethyl acetate (20 mL) and sequentially washed with 5% NaHCO3, water and 
brine (each 15 mL). The organic layer was concentrated in vacuo, to give the N-Boc 
protected title compound without further purification. After that, the deprotection in 
DCM (1 mL) containing 5% TFA was carried out according to the preparation of 
compound 109, to afford the title compound as a yellow solid (5.5 mg, 24% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.54-7.46 (m, 5H), 7.31 (t, J=8.0 Hz, 1H), 7.14 (d, J=8.0 Hz, 
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1H), 6.87 (d, J=8.0 Hz, 1H), 4.92-4.86 (m, 1H), 4.44 (s, 2H), 4.31 (s, 2H), 3.47-3.40 (m, 2H), 
3.32-3.28 (m, 2H), 2.47 (s, 3H), 2.33-2.25 (m, 2H), 2.19-2.11 (m, 2H). 13C-NMR (CD3OD, 
125 MHz): δ 157.81, 153.48, 142.85, 132.31, 131.00, 130.75, 130.33, 127.81, 120.08, 
118.86, 106.74, 105.85, 69.88, 51.81, 42.13, 42.01, 28.36, 10.62. Calculated exact mass 
for the protonated molecule (C22H27N2O2): 351.2073; measured accurate mass (ESI): 
351.2061. LC-MS purity: 100%, tR = 8.87 min.   
 
{[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl] 
methyl}-(naphthalen-1-ylmethyl)amine (155) 
Prepared from a solution of compound 153 (18 mg, 
0.05 mmol), 1-naphthylmethylamine (8.1 µL, 0.055 
mmol), acetic acid (18 µL, 0.3 mmol) and sodium triacetoxyborohydride (53 mg, 0.25 
mmol) in THF (1 mL), the N-Boc precursor was obtained. After that, the deprotection in 
DCM (1 mL) containing 5% TFA was carried out according to the preparation of 
compound 154, to afford the title compound as a white solid (14.5 mg, 56% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 8.02-7.97 (m, 3H), 7.69 (d, J=6.8 Hz, 1H), 7.62-7.54 (m, 3H), 
7.33 (t, J=8.0 Hz, 1H), 7.16 (d, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 4.91-4.85 (m, 1H), 
4.78 (s, 2H), 4.57 (s, 2H), 3.46-3.40 (m, 2H), 3.32-3.28 (m, 2H), 2.48 (s, 3H), 2.33-2.26 (m, 
2H), 2.19-2.11 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 157.81, 153.52, 142.77, 135.46, 
132.64, 131.70, 130.17, 128.43, 128.26, 127.91, 127.60, 126.49, 123.59, 120.10, 119.24, 
106.79, 105.88, 69.90, 48.31, 42.53, 42.01, 28.37, 10.62. Calculated exact mass for the 
protonated molecule (C26H29N2O4): 401.2229; measured accurate mass (ESI): 401.2221. 
LC-MS purity: 100%, tR = 10.02 min.  
 
[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl] methanamine 
(156) 
A solution of compound 154 (10 mg, 0.022 mmol), palladium on 
carbon (10% w/w, 7 mg, 0.006 mmol) and 1,4-cyclohexadiene 
(50 µL) in ethanol (1 mL) was stirred at 80 ˚C for 6 hours. After that, the reaction mixture 
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was concentrated in vacuo and the residue was purified by semi-preparative reverse 
phase HPLC to give the title compound as yellow oil (3.1 mg, 38% yield). 1H-NMR (CD3OD, 
400 MHz): δ 7.28 (t, J=8.0 Hz, 1H), 7.12 (d, J=8.0 Hz, 1H), 6.85 (d, J=8.0 Hz, 1H), 4.87-4.85 
(m, 1H), 4.30 (s, 2H), 3.46-3.40 (m, 2H), 3.30-3.27 (m, 2H), 2.49 (s, 3H), 2.32-2.25 (m, 2H), 
2.18-2.10 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 157.00, 153.43, 144.54, 127.52, 120.20, 
117.07, 106.70, 105.81, 69.89, 42.07, 35.06, 28.42, 10.43. Calculated exact mass for the 
protonated molecule (C15H21N2O4): 261.1603; measured accurate mass (ESI): 261.1606. 
LC-MS purity: 100%, tR = 1.17 min.  
 
3-Methyl-N-(2-phenylethyl)-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxamide (157) 
Prepared from a solution of compound 120 (50 mg, 
0.13 mmol) in DMF/DCM (2 mL, 1:1) was sequentially 
added DIPEA (26 µL, 0.15 mmol), PyBOP (76 mg, 0.15 mmol) and 2-phenethylamine 
(18.4 µL, 0.15 mmol), the N-Boc precursor was obtained. After that, the deprotection in 
DCM containing 5% TFA (2 mL) was carried out according to the preparation of 
compound 121, to afford the title compound as a white solid (25.9 mg, 41% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.36 (t, J=8.0 Hz, 1H), 7.34-7.32 (m, 4H), 7.23-7.19 (m, 1H), 
7.12 (d, J=8.0 Hz, 1H), 6.85 (d, J=8.0 Hz, 1H), 4.93-4.89 (m, 1H), 3.60 (t, J=7.6 Hz, 2H), 
3.46-3.39 (m, 2H), 3.31-3.28 (m, 2H), 2.93 (t, J=7.6 Hz, 2H), 2.79 (s, 3H), 2.32-2.24 (m, 
2H), 2.20-2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 162.31, 156.46, 154.31, 143.01, 
140.44, 129.82, 129.51, 129.24, 127.38, 123.44, 120.74, 106.64, 105.99, 69.80, 41.89, 
41.78, 36.76, 28.21, 11.50. Calculated exact mass for the protonated molecule 
(C23H27N2O3): 379.2022; measured accurate mass (ESI): 379.2022. LC-MS purity: 100%, tR 
= 11.91 min.  
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3-Methyl-N-(3-phenylpropyl)-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxamide (158) 
Prepared from a solution of compound 120 (50 mg, 
0.13 mmol) in DMF/DCM (2 mL, 1:1) was sequentially 
added DIPEA (26 µL, 0.15 mmol), PyBOP (76 mg, 0.15 mmol) and 3-phenylpropylamine 
(20.8 µL, 0.15 mmol), the N-Boc precursor was obtained. After that, the deprotection in 
DCM (2 mL) containing 5% TFA was carried out according to the preparation of 
compound 121, to afford the title compound as a white solid (35.1 mg, 54% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.36 (t, J=8.0 Hz, 1H), 7.28-7.21 (m, 4H), 7.17-7.13 (m, 1H), 
7.14 (d, J=8.0 Hz, 1H), 6.85 (d, J=8.0 Hz, 1H), 4.92-4.88 (m, 1H), 3.45-3.38 (m, 2H), 3.42 (t, 
J=7.2 Hz, 2H), 3.32-3.27 (m, 2H), 2.79 (s, 3H), 2.70 (t, J=7.2 Hz, 2H), 2.31-2.24 (m, 2H), 
2.19-2.12 (m, 2H), 1.98-1.91 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 162.35, 156.44, 
154.30, 143.05, 143.00, 129.39, 129.20, 126.88, 123.34, 120.76, 106.64, 106.01, 69.81, 
41.88, 39.86, 34.36, 32.45, 28.21, 11.52. Calculated exact mass for the protonated 
molecule (C24H29N2O3): 393.2178; measured accurate mass (ESI): 393.2166. LC-MS purity: 
100%, tR = 12.27 min. 
 
Methyl 3-methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-
carboxylate (160) 
A mixture of compound 120 (30 mg, 0.08 mmol), EDCI (16.8 mg, 
0.088 mmol), hydroxybenzotriazole (13.6 mg, 0.11 mmol) in 
anhydrous acetonitrile (3 mL) was stirred at room temperature for 30 minutes, and then 
treated with methanol (3.6 µL, 0.088 mmol) and DIPEA (28 µL, 0.16 mmol). The resulting 
mixture was further stirred at room temperature for another 12 hours. After that, the 
solution was evaporated to dryness in vacuo. The residue was re-dissolved in ethyl 
acetate (20 mL) and washed with brine, 5% NaHCO3 and water (each 20 mL). The organic 
layer was dried over anhydrous sodium sulphate and concentrated in vacuo, to produce 
the N-Boc precursor without further purification. This compound was further 
deprotected in DCM (2 mL) containing 5% TFA according to the preparation of 
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compound 109, to afford the title compound as a white solid (16.1 mg, 50% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.87 (d, J=8.0 
Hz, 1H), 4.96-4.94 (m, 1H), 3.95 (s, 3H), 3.48-3.41 (m, 2H), 3.41-3.33 (m, 2H), 2.78 (s, 3H), 
2.36-2.24 (m, 2H), 2.23-2.11 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 162.27, 157.39, 
154.56, 140.89, 130.15, 127.20, 120.22, 106.48, 106.08, 69.95, 52.32, 41.96, 37.87, 
28.25, 11.82. Calculated exact mass for the protonated molecule (C16H20NO4): 290.1392; 
measured accurate mass (ESI): 290.1395. LC-MS purity: 100%, tR = 10.76 min.  
 
Phenyl 3-methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-
carboxylate(161) 
Prepared from a mixture of compound 120 (44 mg, 0.12 
mmol), EDCI (25 mg, 0.13 mmol), hydroxybenzotriazole (20.5 
mg, 0.13 mmol), phenol (12.1 mg, 0.13 mmol) and DIPEA (41 µL, 0.24 mmol) in 
anhydrous acetonitrile (3 mL), the N-Boc precursor was obtained. After that, the 
deprotection in DCM (2 mL) containing 5% TFA was carried out according to the 
preparation of compound 160, to afford the title compound as a white solid (28.1 mg, 51% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.50-7.43 (m, 3H), 7.32 (t, J=7.6 Hz, 1H), 7.26 
(d, J=7.6 Hz, 2H), 7.18 (d, J=8.0 Hz, 1H), 6.90 (d, J=8.0 Hz, 1H), 4.94-4.90 (m, 1H), 3.48-
3.41 (m, 2H), 3.35-3.29 (m, 2H), 2.85 (s, 3H), 2.35-2.27 (m, 2H), 2.22-2.14 (m, 2H). 13C-
NMR (CD3OD, 100 MHz): δ 160.02, 157.66, 154.69, 151.71, 140.26, 130.67, 130.62, 
129.16, 127.21, 122.79, 120.29, 106.62, 106.19, 70.09, 41.99, 28.26, 12.05. Calculated 
exact mass for the protonated molecule (C21H22NO4): 352.1549; measured accurate mass 
(ESI): 352.1545. LC-MS purity: 100%, tR = 12.17 min.  
 
Benzyl 3-methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-
carboxylate(162) 
Prepared from a mixture of compound 120 (15 mg, 0.04 
mmol), EDCI (8.4 mg, 0.044 mmol), hydroxybenzotriazole 
(6.8 mg, 0.05 mmol), benzyl alcohol (4.5 µL, 0.044 mmol) and DIPEA (14 µL, 0.08 mmol) 
in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After that, the 
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deprotection in DCM (2 mL) containing 5% TFA was carried out according to the 
preparation of compound 160, to afford the title compound as a white solid (8.5 mg, 44% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.50 (d, J=8.0 Hz, 2H), 7.44-7.35 (m, 4H), 
7.14 (d, J=8.0 Hz, 1H), 6.86 (d, J=8.0 Hz, 1H), 5.40 (s, 2H), 4.95-4.91 (m, 1H), 3.45-3.39 (m, 
2H), 3.31-3.27 (m, 2H), 2.78 (s, 3H), 2.33-2.23 (m, 2H), 2.15-2.10 (m, 2H). 13C-NMR 
(CD3OD, 100 MHz): δ 161.59, 157.47, 154.57, 140.88, 137.29, 130.21, 129.67, 129.46, 
127.48, 120.29, 106.53, 106.20, 69.95, 67.70, 41.98, 28.25, 24.21, 11.94. Calculated 
exact mass for the protonated molecule (C22H24NO4): 366.1705; measured accurate mass 
(ESI): 366.1708. LC-MS purity: 100%, tR = 12.38 min.  
 
Cyclohexylmethyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (163) 
Prepared from a mixture of compound 120 (20 mg, 0.055 
mmol), EDCI (11.3 mg, 0.06 mmol), hydroxybenzotriazole 
(9.4 mg, 0.07 mmol), cyclohexanemethanol (7.3 µL, 0.06 mmol) and DIPEA (18.5 µL, 0.11 
mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After that, 
the deprotection in DCM (2 mL) containing 5% TFA was carried out according to the 
preparation of compound 160, to afford the title compound as a white solid (2.7 mg, 10% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.42 (t, J=8.0 Hz, 1H), 7.16 (d, J=8.0 Hz, 1H), 
6.88 (d, J=8.0 Hz, 1H), 5.00-4.94 (m, 1H), 4.19 (d, J=6.4 Hz, 2H), 3.50-3.41 (m, 2H), 3.32-
3.27 (m, 2H), 2.81 (s, 3H), 2.35-2.26 (m, 2H), 2.24-2.12 (m, 2H), 1.93-1.69 (m, 6H), 1.42-
1.25 (m, 3H), 1.21-1.07 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 161.99, 157.46, 154.56, 
141.14, 130.10, 126.94, 120.31, 106.52, 106.20, 71.15, 69.94, 41.99, 38.63, 30.83, 28.27, 
27.45, 26.83, 11.96. Calculated exact mass for the protonated molecule (C22H30NO4): 
372.2175; measured accurate mass (ESI): 372.2167. LC-MS purity: 100%, tR = 12.46 min.  
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Naphthalen-1-ylmethyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzo-furan-2-carboxylate (164)  
Prepared from a mixture of compound 120 (15 mg, 0.04 
mmol), EDCI (8.4 mg, 0.044 mmol), 
hydroxybenzotriazole (6.8 mg, 0.05 mmol), 1-naphthalenemethanol (7 mg, 0.044 mmol) 
and DIPEA (14 µL, 0.08 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was 
obtained. After that, the deprotection in DCM c(2 mL) ntaining 5% TFA was carried out 
according to the preparation of compound 160, to afford the title compound as a white 
solid (4.3 mg, 20% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.19 (d, J=8.0 Hz, 1H), 
7.96 (t, J=7.2 Hz, 2H), 7.69 (d, J=7.2 Hz, 1H), 7.63-7.51 (m, 3H), 7.38 (t, J=8.0 Hz, 1H), 7.12 
(d, J=8.0 Hz, 1H), 6.83 (d, J=8.0 Hz, 1H), 4.92-4.86 (m, 1H), 3.42-3.35 (m, 2H), 3.31-3.25 
(m, 2H), 2.71 (s, 3H), 2.30-2.21 (m, 2H), 2.17-2.10 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 
161.62, 157.50, 154.53, 140.90, 135.34, 132.61, 130.18, 128.96, 127.42, 126.36, 124.70, 
120.25, 106.47, 106.20, 69.84, 66.01, 41.92, 28.19, 11.92. Calculated exact mass for the 
protonated molecule (C26H26NO4): 416.1862; measured accurate mass (ESI): 416.1854. 
LC-MS purity: 99%, tR = 13.10 min. 
 
3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-carboxylic acid 
(165) 
Prepared from a solution of compound 120 (10 mg, 0.027mmol) 
in DCM containing 5% TFA (1 mL), according to the method of 
compound 109, the title compound was obtained as a white solid (2.3 mg, 22% yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.38 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.85 (d, J=8.0 
Hz, 1H), 4.94-4.92 (m, 1H), 3.48-3.38 (m, 2H), 3.30-3.24 (m, 2H), 2.78 (s, 3H), 2.33-2.23 
(m, 2H), 2.15-2.11 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 163.47, 157.39, 154.52, 129.88, 
126.64, 120.47, 106.45, 106.20, 69.88, 42.02, 28.29, 11.92. Calculated exact mass for the 
protonated molecule (C15H18NO4): 276.1236; measured accurate mass (ESI): 276.1234. 
LC-MS purity: 100%, tR = 9.54 min.  
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2-Phenylethyl-3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (166) 
Prepared from a mixture of compound 120 (20 mg, 
0.055 mmol), EDCI (11.3 mg, 0.06 mmol), 
hydroxybenzotriazole (9.4 mg, 0.07 mmol), phenethyl alcohol (7.1 µL, 0.06 mmol) and 
DIPEA (18.5 µL, 0.11 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was 
obtained. After that, the deprotection in DCM containing 5% TFA (2 mL) was carried out 
according to the preparation of compound 160, to afford the title compound as a white 
solid (2.4 mg, 9% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.41 (t, J=8.0 Hz, 1H), 7.34-
7.30 (m, 4H), 7.27-7.22 (m, 1H), 7.14 (d, J=8.0 Hz, 1H), 6.87 (d, J=8.0 Hz, 1H), 5.02-4.92 
(m, 1H), 4.59 (t, J=6.8 Hz, 2H), 3.49-3.40 (m, 2H), 3.32-3.25 (m, 2H), 3.11 (t, J=6.8 Hz, 2H), 
2.71 (s, 3H), 2.35-2.26 (m, 2H), 2.23-2.10 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 161.79, 
157.46, 154.57, 140.99, 139.22, 130.14, 130.00, 129.56, 127.64, 127.14, 120.27, 106.50, 
106.16, 69.97, 66.71, 42.03, 36.09, 28.28, 11.87. Calculated exact mass for the 
protonated molecule (C23H26NO4): 380.1862; measured accurate mass (ESI): 380.1856. 
LC-MS purity: 100%, tR = 12.78 min.  
 
3-Phenylpropyl-3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (167) 
Prepared from a mixture of compound 120 (20 mg, 
0.055 mmol), EDCI (11.3 mg, 0.06 mmol), 
hydroxybenzotriazole (9.4 mg, 0.07 mmol), 3-phenyl-1-propanol (8 µL, 0.06 mmol) and 
DIPEA (18.5 µL, 0.11 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was 
obtained. After that, the deprotection in DCM containing 5% trifluoroacetic acid (2 mL) 
was carried out according to the preparation of compound 160, to afford the title 
compound as an off-white solid (2.3 mg, 8% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.43 (t, J=8.0 Hz, 1H), 7.32-7.19 (m, 5H), 7.17 (d, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 
5.01-4.92 (m, 1H), 4.37 (t, J=6.4 Hz, 2H), 3.50-3.39 (m, 2H), 3.32-3.28 (m, 2H), 2.82 (t, 
J=7.6 Hz, 2H), 2.82 (s, 3H), 2.36-2.25 (m, 2H), 2.25-2.07 (m, 4H). 13C-NMR (CD3OD, 125 
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MHz): δ 161.89, 157.45, 154.56, 142.48, 141.07, 130.14, 129.49, 127.07, 120.31, 106.53, 
106.21, 69.95, 65.42, 42.01, 33.21, 31.55, 28.28, 11.94. Calculated exact mass for the 
protonated molecule (C24H28NO4): 394.2018; measured accurate mass (ESI): 394.2018. 
LC-MS purity: 100%, tR = 13.14 min.  
 
(4-Chlorophenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (173) 
Prepared from a mixture of compound 120 (15 mg, 0.04 
mmol), EDCI (8.4 mg, 0.044 mmol), hydroxybenzotriazole 
(6.8 mg, 0.05 mmol), 4-chloro-benzyl alcohol (6.3 mg, 0.044 mmol) and DIPEA (14 µL, 
0.08 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as a white solid (1.5 mg, 7% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.51 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.4 Hz, 2H), 
7.42 (t, J=8.0 Hz, 1H), 7.16 (d, J=8.0 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 5.40 (s, 2H), 4.96-4.94 
(m, 1H), 3.46-3.40 (m, 2H), 3.31-3.26 (m, 2H), 2.80 (s, 3H), 2.34-2.25 (m, 2H), 2.16-2.13 
(m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 160.04, 156.11, 153.17, 138.28, 134.75, 129.69, 
128.88, 128.39, 126.28, 113.40, 105.15, 104.84, 68.55, 65.40, 40.61, 26.87, 22.79, 10.52. 
Calculated exact mass for the protonated molecule (C22H23NO4Cl): 400.1316; measured 
accurate mass (ESI): 400.1300. LC-MS purity: 100%, tR = 12.91 min.  
 
(4-Methylphenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (174) 
Prepared from a mixture of compound 120 (15 mg, 0.04 
mmol), EDCI (8.4 mg, 0.044 mmol), hydroxybenzotriazole 
(6.8 mg, 0.05 mmol), 4-methyl-benzyl alcohol (5.4 mg, 0.044 mmol) and DIPEA (14 µL, 
0.08 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as a white solid (4 mg, 21% 
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overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.43-7.37 (m, 3H), 7.24 (d, J=8.0 Hz, 2H), 
7.15 (d, J=8.0 Hz, 1H), 6.87 (d, J=8.0 Hz, 1H), 5.36 (s, 2H), 4.96-4.94 (m, 1H), 3.46-3.39 (m, 
2H), 3.31-3.28 (m, 2H), 2.78 (s, 3H), 2.38 (s, 3H), 2.32-2.24 (m, 2H), 2.22-2.13 (m,  2H). 
13C-NMR (CD3OD, 100 MHz): δ 161.65, 157.46, 154.55, 140.94, 139.48, 134.24, 130.25, 
130.18, 129.63, 127.36, 120.29, 106.51, 106.20, 69.91, 67.66, 41.97, 28.24, 24.21, 21.23, 
11.94. Calculated exact mass for the protonated molecule (C23H26NO4): 380.1862; 
measured accurate mass (ESI): 380.1857. LC-MS purity: 100%, tR = 12.83 min.  
 
(3-Chlorophenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (175) 
Prepared from a mixture of compound 120 (40 mg, 0.11 
mmol), EDCI (22.6 mg, 0.12 mmol), hydroxybenzotriazole 
(18.8 mg, 0.14 mmol), 3-chloro-benzyl alcohol (13.9 µL, 0.12 mmol) and DIPEA (37 µL, 
0.22 mmol) in anhydrous acetonitrile (3 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as a yellow solid (23.6 mg, 
42% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.51 (s, 1H), 7.43-7.35 (m, 4H), 7.11 (d, 
J=8.0 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 5.36 (s, 2H), 4.91-4.88 (m, 1H), 3.45-3.39 (m, 2H), 
3.32-3.28 (m, 2H), 2.75 (s, 3H), 2.32-2.24 (m, 2H), 2.20-2.12 (m, 2H). 13C-NMR (CD3OD, 
100 MHz): δ 159.96, 156.05, 153.17, 139.22, 138.22, 134.08, 129.86, 128.90, 128.07, 
127.89, 126.41, 126.28, 118.83, 105.10, 104.75, 68.56, 65.31, 40.53, 26.82, 10.57. 
Calculated exact mass for the protonated molecule (C22H23NO4Cl): 400.1316; measured 
accurate mass (ESI): 400.1319. LC-MS purity: 100%, tR = 13.26 min.  
 
(3-Methylphenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (176) 
Prepared from a mixture of compound 120 (20 mg, 0.055 
mmol), EDCI (11.3 mg, 0.06 mmol), hydroxybenzotriazole 
(9.4 mg, 0.07 mmol), 3-methyl-benzyl alcohol (7.1 µL, 0.06 mmol) and DIPEA (18.5 µL, 
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0.11 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as an off-white solid (9.4 mg, 
35% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.33-7.28 (m, 3H), 
7.22-7.17 (m, 2H), 7.14 (d, J=8.0 Hz, 1H), 6.86 (d, J=8.0 Hz, 1H), 5.36 (s, 2H), 4.96-4.91 (m, 
1H), 3.46-3.40 (m, 2H), 3.33-3.28 (m, 2H), 2.78 (s, 3H), 2.39 (s, 3H), 2.33-2.25 (m, 2H), 
2.21-2.13 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 160.22, 156.05, 153.16, 139.48, 138.11, 
135.77, 128.79, 128.71, 128.17, 126.04, 125.14, 118.88, 105.10, 104.77, 68.53, 66.35, 
40.55, 26.83, 20.00, 10.54. Calculated exact mass for the protonated molecule 
(C23H26NO4): 380.1862; measured accurate mass (ESI): 380.1858. LC-MS purity: 100%, tR 
= 13.10 min.  
 
(3-Methoxyphenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-
1-benzofuran-2-carboxylate (177) 
Prepared from a mixture of compound 120 (20 mg, 0.055 
mmol), EDCI (11.3 mg, 0.06 mmol), hydroxybenzotriazole 
(9.4 mg, 0.07 mmol), 3-methoxyl-benzyl alcohol (7.4 µL, 0.06 mmol) and DIPEA (18.5 µL, 
0.11 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as an off-white solid (10.9 
mg, 39% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.40 (t, J=8.0 Hz, 1H), 7.33 (t, J=8.0 
Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 7.07-7.05 (m, 2H), 6.95-6.92 (m, 1H), 6.85 (d, J=8.0 Hz, 
1H), 5.37 (s, 2H), 4.94-4.91 (m, 1H), 3.83 (s, 3H), 3.46-3.40 (m, 2H), 3.33-3.28 (m, 2H), 
2.78 (s, 3H), 2.32-2.25 (m, 2H), 2.20-2.13 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 160.17, 
159.98, 156.06, 153.17, 139.44, 137.33, 129.34, 128.81, 126.10, 120.10, 118.87, 113.54, 
113.42, 105.11, 104.77, 68.54, 66.16, 54.32, 40.55, 26.83, 10.56. Calculated exact mass 
for the protonated molecule (C23H26NO5): 396.1811; measured accurate mass (ESI): 
396.1798. LC-MS purity: 100%, tR = 12.65 min.  
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(2-Chlorophenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (178) 
Prepared from a mixture of compound 120 (40 mg, 0.11 
mmol), EDCI (22.6 mg, 0.12 mmol), hydroxybenzotriazole 
(18.8 mg, 0.14 mmol), 2-chloro-benzyl alcohol (16.8 mg, 0.12 mmol) and DIPEA (37 µL, 
0.22 mmol) in anhydrous acetonitrile (3 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as a white solid (25.2 mg, 45% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.62-7.59 (m, 1H), 7.50-7.48 (m, 1H), 7.41-
7.36 (m, 3H), 7.13 (d, J=8.0 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 5.49 (s, 2H), 4.96-4.91 (m, 1H), 
3.46-3.40 (m, 2H), 3.33-3.28 (m, 2H), 2.76 (s, 3H), 2.33-2.25 (m, 2H), 2.21-2.13 (m, 2H). 
13C-NMR (CD3OD, 100 MHz): δ 159.94, 156.10, 153.19, 139.26, 133.55, 133.34, 130.26, 
129.80, 129.30, 128.89, 126.93, 126.36, 118.84, 105.12, 104.77, 68.55, 63.60, 40.53, 
26.82, 10.56. Calculated exact mass for the protonated molecule (C22H23NO4Cl): 
400.1316; measured accurate mass (ESI): 400.1317. LC-MS purity: 100%, tR = 13.15 min.  
 
(2-Methylphenyl) methyl 3-methyl-4-(piperidin-4-yloxy)-1-
benzofuran-2-carboxylate (179) 
Prepared from a mixture of compound 120 (20 mg, 0.055 
mmol), EDCI (11.3 mg, 0.06 mmol), hydroxybenzotriazole 
(9.4 mg, 0.07 mmol), 2-methyl-benzyl alcohol (7.2 mg, 0.06 mmol) and DIPEA (18.5 µL, 
0.11 mmol) in anhydrous acetonitrile (2 mL), the N-Boc precursor was obtained. After 
that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according to the 
preparation of compound 160, to afford the title compound as an off-white solid (8.4 mg, 
31% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.44 (d, J=7.2 Hz, 1H), 7.40 (t, J=8.0 Hz, 
1H), 7.31-7.21 (m, 3H), 7.14 (d, J=8.0 Hz, 1H), 6.85 (d, J=8.0 Hz, 1H), 5.44 (s, 2H), 4.97-
4.91 (m, 1H), 3.46-3.39 (m, 2H), 3.31-3.28 (m, 2H), 2.77 (s, 3H), 2.45 (s, 3H), 2.32-2.24 (m, 
2H), 2.20-2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 160.19, 156.07, 153.16, 139.48, 
137.03, 133.69, 130.04, 129.26, 128.81, 128.45, 126.02, 125.71, 118.88, 105.12, 104.79, 
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68.52, 64.74, 40.54, 26.83, 17.61, 10.51. Calculated exact mass for the protonated 
molecule (C23H26NO4): 380.1862; measured accurate mass (ESI): 380.1855. LC-MS purity: 
100%, tR = 13.02 min.  
 
Benzyl 3-methyl-4-{[1-(propan-2-yl) piperidin-4-yl]oxy}-1-
benzofuran-2-carboxylate (180) 
Prepared from a mixture of compound 162 (20 mg, 0.042 
mmol), acetone (10 µL, 0.13 mmol), acetic acid (15 µL, 0.26 
mmol) and sodium triacetoxyborohydride (45 mg, 0.21 mmol) in THF (2 mL), according 
to the preparation of compound 112, the title compound was obtained as colourless oil 
(11 mg, 64% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.50 (d, J=7.2 Hz, 2H), 7.44-7.35 (m, 3H), 
7.31 (t, J=8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 5.44 (s, 2H), 4.60-4.51 
(m, 1H), 2.84-2.74 (m, 3H), 2.78 (s, 3H), 2.50 (brs, 2H), 2.14-2.04 (m, 2H), 2.01-1.90 (m, 
2H), 1.09 (d, J=6.8 Hz, 6H). 13C-NMR (CDCl3, 100 MHz): δ 160.43, 156.09, 154.22, 139.38, 
135.81, 128.62, 128.36, 127.33, 125.88, 119.44, 104.94, 104.63, 72.52, 66.52, 54.59, 
45.34, 30.85, 18.40, 11.65. Calculated exact mass for the protonated molecule 
(C25H30NO4): 408.2175; measured accurate mass (ESI): 408.2168. LC-MS purity: 100%, tR 
= 12.41 min.  
 
Benzyl-4-[3-(t-butylamino)propoxy]-3-methyl-1-
benzofuran-2 carboxylate (181) 
From a mixture of compound 55 (40 mg, 0.13 mmol), EDCI 
(27 mg, 0.14 mmol), hydroxybenzotriazole (22 mg, 0.17 mmol) benzyl alcohol (14.6 µL, 
0.14 mmol) and DIPEA (45 µL, 0.26 mmol) in anhydrous acetonitrile (3 mL) according to 
the preparation of compound 160, the brominated precursor was obtained. This 
compound was further reacted with t-butylamine (11.5 µL, 0.11 mmol) in DMF (1 mL) 
according to the preparation of compound 1, to afford the title compound as an off-
white solid (5.7 mg, 11% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.50 (d, J=7.2 Hz, 
2H), 7.45-7.36 (m, 4H), 7.14 (d, J=8.0 Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 5.40 (s, 2H), 4.27 (t, 
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J=6.0 Hz, 2H), 3.26 (t, J=8.0 Hz, 2H), 2.75 (s, 3H), 2.30-2.23 (m, 2H), 1.42 (s, 9H). 13C-NMR 
(CD3OD, 100 MHz): δ 161.68, 157.19, 156.49, 140.69, 137.21, 130.30, 129.67, 129.46, 
127.59, 119.57, 106.05, 105.42, 67.72, 66.02, 58.09, 39.97, 27.78, 25.80, 11.82. 
Calculated exact mass for the protonated molecule (C24H30NO4): 396.2175; measured 
accurate mass (ESI): 396.2190. LC-MS purity: 97%, tR = 12.68 min.  
 
[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl]methyl 
benzoate (182) 
Prepared from a mixture of benzoic acid (7.3 mg, 0.06 
mmol), EDCI (12.6 mg, 0.066 mmol), hydroxybenzotriazole 
(10.5 mg, 0.08 mmol), compound 140 (30 mg, 0.06 mmol) and DIPEA (21 µL, 0.12 mmol) 
in anhydrous acetonitrile (3 mL) according to the preparation of compound 160, the N-
trityl precursor was obtained. This compound was further deprotected in DCM 
containing 0.1% of trifluoroacetic acid and 0.2% of water (1 mL), according to the 
preparation of compound 141, to afford the title compound as colourless oil (2.3 mg, 11% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 8.05 (d, J=7.2 Hz, 2H), 7.63 (t, J=7.2 Hz, 1H), 
7.50 (t, J=7.2 Hz, 2H), 7.26 (t, J=8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 
5.48 (s, 2H), 4.96-4.86 (m, 1H), 3.46-3.40 (m, 2H), 3.32-3.28 (m, 2H), 2.56 (s, 3H), 2.30-
2.23 (m, 2H), 2.21-2.13 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 166.15, 156.22, 151.86, 
146.33, 133.02, 129.68, 129.18, 128.23, 125.62, 119.07, 115.27, 104.96, 104.47, 68.12, 
56.47, 40.53, 26.89, 9.19. Calculated exact mass for the protonated molecule (C22H24NO4): 
366.1705; measured accurate mass (ESI): 366.1707. LC-MS purity: decompose under 
weakly acidic or LC-MS conditions. 
 
4-{[3-Methyl-2-(2-phenylethyl)-1-benzofuran-4-yl]oxy} 
piperidine(186) 
A mixture of compound 189 (13 mg, 0.039 mmol), palladium 
on carbon (10% w/w, 5 mg, 0.008 mmol) and 1,4-
cyclohexadiene (70 µL) in ethanol (1 mL) was stirred at 80 ˚C for 4 hours. The reaction 
mixture was then concentrated in vacuo and the residue was purified by semi-
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preparative reverse phase HPLC to give the title compound as colourless oil (6.6 mg, 38% 
yield). 1H-NMR (CD3OD, 500 MHz): δ 7.23 (t, J=8.0 Hz, 2H), 7.18-7.11 (m, 4H), 7.03 (d, 
J=8.0 Hz, 1H), 6.74 (d, J=8.0 Hz, 1H), 4.85-4.81 (m, 1H), 3.40-3.35 (m, 2H), 3.30-3.25 (m, 
2H), 3.00 (brs, 4H), 2.25-2.19 (m, 2H), 2.15-2.09 (m, 2H), 2.11 (s, 3H). 13C-NMR (CD3OD, 
125 MHz): δ 157.06, 153.11, 152.38, 142.37, 129.55, 129.31, 127.08, 125.06, 121.20, 
111.15, 106.34, 105.55, 69.41, 41.90, 35.44, 29.07, 28.31, 10.17. Calculated exact mass 
for the protonated molecule (C22H26NO2): 336.1964; measured accurate mass (ESI): 
336.1964. LC-MS purity: 100%, tR = 13.30 min.  
 
4-({3-Methyl-2-[(E)-2-phenylethenyl]-1-benzofuran-4-yl}oxy) 
piperidine(188) 
To a mixture of compound 153 (50 mg, 0.14 mmol) and 
benzyltriphenyl phosphonium bromide (65 mg, 0.15 mmol) 
in DCM/water (2 mL, 1:1), 10M of NaOH solution (50 µL) was added. The resulting 
mixture was stirred at room temperature for 1 hour. After that, the reaction mixture was 
diluted with DCM (20 mL) and washed sequentially with water and brine (15 mL each). 
The organic layer was concentrated to give the mixture of the cis/trans N-Boc precursors. 
After that, the deprotection in DCM containing 5% TFA (2 mL) was carried out according 
to the method of ICL41, to isolate the title compound as the 1st major fraction from 
preparative HPLC (white solid, 4.9 mg, 8% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.41 (d, J=8.0 Hz, 2H), 7.34-7.26 (m, 3H), 7.17 (t, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 
6.78 (d, J=8.0 Hz, 1H), 6.72 (d, J=12.4 Hz, 1H), 6.51 (d, J=12.4 Hz, 1H), 4.89-4.85 (m, 1H), 
3.44-3.37 (m, 2H), 3.31-3.26 (m, 2H), 2.54 (s, 3H), 2.32-2.22 (m, 2H),  2.19-2.11 (m, 2H). 
13C-NMR (CD3OD, 125 MHz): δ 156.93, 152.96, 150.05, 138.72, 132.03, 130.13, 128.88, 
128.52, 127.58, 126.68, 120.99, 116.34, 106.39, 105.56, 69.57, 41.95, 28.32, 11.06. 
Calculated exact mass for the protonated molecule (C22H24NO2): 334.1807; measured 
accurate mass (ESI): 334.1813. LC-MS purity: 96% (trans:cis = 3:1), tR = 13.22 min.  
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4-({3-methyl-2-[(Z)-2-phenylethenyl]-1-benzofuran-4-yl}oxy)piperidine  
(189) 
The title compound was isolated as the 2nd major fraction from above 
preparative HPLC (off-white solid, 14.6 mg, 23% overall yield). 1H-NMR 
(CD3OD, 400 MHz): δ 7.58 (d, J=7.2 Hz, 2H), 7.38 (t, J=8.0 Hz, 2H), 7.27 
(t, J=7.2 Hz, 1H), 7.23-7.18 (m, 3H), 7.07 (d, J=8.0 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.90-
4.82 (m, 1H), 3.46-3.40 (m, 2H), 3.32-3.27 (m, 2H), 2.53 (s, 3H), 2.35-2.22 (m, 2H), 2.21-
2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 157.20, 153.02, 150.95, 138.43, 129.81, 
129.62, 128.88, 127.58, 126.80, 121.67, 115.10, 114.66, 106.55, 105.43, 69.62, 41.94, 
28.34, 10.52. Calculated exact mass for the protonated molecule (C22H24NO2): 334.1807; 
measured accurate mass (ESI): 334.1799. LC-MS purity: 97%, tR = 13.64 min.  
 
1-[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl]-3- 
phenylpropan-1-one (190) 
Prepared from a solution of compound 193 (8 mg, 0.017 
mmol), palladium on carbon (10% w/w, 7 mg, 0.004 mmol) 
and 1,4-cyclohexadiene (60 µL) in ethanol (1 mL), according to the preparation of 
compound 186, the title compound was obtained as a white solid (3.3 mg, 41% yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.44 (t, J=8.0 Hz, 1H), 7.29-7.28 (m, 4H), 7.22-7.18 (m, 1H), 
7.17 (d, J=8.0 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 4.98-4.95 (m, 1H), 3.46-3.38 (m, 2H), 3.33-
3.27 (m, 2H), 3.30 (t, J=7.6 Hz, 2H), 3.04 (t, J=7.6 Hz, 2H), 2.82 (s, 3H), 2.34-2.25 (m, 2H), 
2.23-2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 194.25, 157.00, 154.95, 148.16, 142.45, 
130.56, 129.42, 127.10, 126.01, 125.94, 120.65, 106.52, 106.33, 69.94, 42.50, 42.00, 
30.75, 28.27, 11.90. Calculated exact mass for the protonated molecule (C23H26NO3): 
364.1913; measured accurate mass (ESI): 364.1904. LC-MS purity: 100%, tR = 13.10 min.  
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 t-Butyl 4-[(2-acetyl-3-methyl-1-benzofuran-4-yl)oxy]piperidine-1-
carboxylate (192)  
Prepared from compound 71 (190 mg, 1.0 mmol), compound 103 
(500 mg, 2.5 mmol), triphenylphosphine (657 mg, 2.5 mmol) and 
DIAD (0.48 mL, 2.5 mmol) in anhydrous THF according to the preparation of compound 
106, the title compound was obtained as a light yellow solid (318 mg, 84% yield). 1H-
NMR (CDCl3, 400 MHz): δ 7.35 (t, J=8.0 Hz, 1H), 7.08 (d, J=8.0 Hz, 1H), 6.65 (d, J=8.0 Hz, 
1H), 4.77-4.66 (m, 1H), 3.71-3.62 (m, 2H), 3.56-3.50 (m, 2H), 2.79 (s, 3H), 2.60 (s, 3H), 
2.06-1.96 (m, 2H), 1.95-1.86 (m, 2H), 1.50 (s, 9H).  
 
(2E)-1-[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl]-3- 
phenylprop-2-en-1-one (193) 
To a mixture of compound 192 (50 mg, 0.13 mmol) and 
benzaldehyde (15 µL, 0.15 mmol) in ethanol (1 mL) was 
added 0.25M NaOH solution (1 mL). The resulting mixture was stirred at room 
temperature for 3 hours. The reaction mixture was then diluted with 20 mL EtOAc, 
followed by the wash with water and brine (20 mL each). The organic layer was dried 
over anhydrous sodium sulphate and concentrated in vacuo. And the residue was 
purified by column chromatography over silica gel, eluting with hexane:ethyl acetate, 6:1, 
to give the N-Boc precursor. This compound was  further deprotected in DCM containing 
5% TFA (2 mL) according to the preparation of compound 109, to afford the title 
compound as a yellow solid (14.7 mg, 24% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.86-7.75 (m, 4H), 7.51-7.45 (m, 4H), 7.24 (d, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 5.02-
4.93 (m, 1H), 3.50-3.39 (m, 2H), 3.33-3.27 (m, 2H), 2.88 (s, 3H), 2.36-2.24 (m, 2H), 2.24-
2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 183.19, 157.14, 154.95, 148.89, 145.04, 
136.18, 131.91, 130.81, 130.14, 129.73, 127.50, 123.26, 120.94, 106.64, 106.38, 70.04, 
41.99, 28.26, 12.17. Calculated exact mass for the protonated molecule (C23H24NO3): 
362.1756; measured accurate mass (ESI): 362.1750. LC-MS purity: 97%, tR = 13.17 min.  
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N'-1-(2,6-dihydroxyphenyl)ethylidene-ethoxycarbohydrazide 
(197) 
To a solution of 2, 6-dihydroxyacetophenone (0.5 g, 3.3 mmol) 
in ehanol/water (8 mL, 1:1), ethyl carbazate (340 mg, 3.3 mmol) was added. The 
resulting mixture was refluxed for 24 hours and allowed to stay overnight in fridge. The 
precipitate was filtered off, washed with diethyl ether and dried under vacuum, to afford 
the title compound as a yellow solid (180 mg, 24% yield). 1H-NMR (CD3SOCD3, 400 MHz): 
δ 10.76 (s, 2H), 6.98 (t, J=8.0 Hz, 1H), 6.33 (d, J=8.0 Hz, 2H), 4.19 (q, J=7.2 Hz, 2H), 2.26 (s, 
3H), 1.26 (t, J=7.2 Hz, 3H).  
 
2-(1, 2, 3-Thiadiazol-4-yl)benzene-1,3-diol (199) 
To the solution of compound 197 (200 mg, 0.84 mmol) in DMF (2 mL) 
was added thionyl chloride (1.2 mL) at the temperature of -20 ˚C. After 
the liberation of gas ceased, the reaction mixture was warmed up to room temperature 
and maintained for a further 3 hours. The excess of thionyl chloride and DMF were 
removed under pressure. The residue was re-dissolved by EtOAc (20 mL) and partitioned 
with 5% NaHCO3 (20 mL). The aqueous layer was further extracted by EtOAc (2 x 15 mL). 
The combined organic layers were sequentially washed by water and brine, dried over 
anhydrous sodium sulphate, concentrated in vacuo, to afford the title compound without 
further purification as a yellow solid (87 mg, 54% yield). 1H-NMR (CD3COCD3, 400 MHz): 
δ 10.52 (brs, 2H), 9.77 (s, 1H), 7.20 (t, J=8.0 Hz, 1H), 6.64 (d, J=8.0 Hz, 2H). m/z (ESI) 
195.0 (M+H+). 
 
2-(Benzylsulfanyl)-1-benzofuran-4-ol (200)  
A mixture of the compound 199 (50 mg, 0.26 mmol), benzyl 
chloride (33 µL, 0.28 mmol) and potassium carbonate (54 mg, 
0.38 mmol) in dry acetone (3 mL) was stirred at 60 ˚C for 6 hours. After that, the reaction 
mixture was evaporated under pressure to dryness and the residue was purified by 
column chromatography over silica gel, eluting with hexane:ethyl acetate 91:9, 89:11, 
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86:14, to afford the title compound as a white solid (15 mg, 24% yield). 1H-NMR 
(CD3COCD3, 400 MHz): δ 7.34-7.23 (m, 5H), 7.14 (t, J=8.0 Hz, 1H), 7.01 (d, J=8.0 Hz, 1H), 
6.86 (s, 1H), 6.68 (d, J=8.0 Hz, 1H), 4.23 (s, 2H). m/z (ESI) 257.1 (M+H+) 
 
 t-Butyl 4-{[2-(benzylsulfanyl)-1-benzofuran-4-yl]oxy} 
piperidine-1-carboxylate (205)  
Prepared from a solution of compound 200 (9 mg, 0.035 
mmol), compound 103 (18 mg, 0.088 mmol), 
triphenylphosphine (24 mg, 0.088 mmol) and DIAD (17 µL, 0.088 mmol) in anhydrous 
THF (1 mL), according to the preparation of compound 106, the title compound was 
obtained as colourless oil (6 mg, 40% yield). 1H-NMR (CDCl3, 400 MHz): δ 7.33-7.25 (m, 
5H), 7.21 (t, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 6.79 (s, 1H), 6.68 (d, J=8.0 Hz, 1H), 4.67-
4.56 (m, 1H), 4.16 (s, 2H), 3.71-3.65 (m, 2H), 3.44-3.38 (m, 2H), 2.00-1.89 (m, 2H), 1.89-
1.77 (m, 2H), 1.51 (s, 9H).  
 
4-{[2-(Benzylsulfanyl)-1-benzofuran-4-yl]oxy}piperidine (208) 
Prepared from a solution of compound 205 (10 mg, 0.023 
mmol) in DCM containing 5% TFA (1 mL), according to the 
preparation of compound 109, the title compound was 
obtained as colourless oil (9.7 mg, 93% yield). 1H-NMR (CD3OD, 400 MHz): δ 7.27-7.18 (m, 
6H), 7.14 (d, J=8.0 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 6.79 (s, 1H), 4.87-4.79 (m, 1H), 4.17 (s, 
2H), 3.47-3.37 (m, 2H), 3.29-3.19 (m, 2H), 2.26-2.16 (m, 2H), 2.12-2.04 (m, 2H). 13C-NMR 
(CD3OD, 100 MHz): δ 157.90, 149.48, 148.69, 137.54, 128.54, 128.04, 126.91, 125.25, 
119.76, 108.89, 106.51, 104.41, 68.78, 40.37, 38.59, 26.95. Calculated exact mass for the 
protonated molecule (C20H22NO2S): 340.1371; measured accurate mass (ESI): 340.1369. 
LC-MS purity: 100%, tR = 12.80 min.  
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4-{[2-(Phenylmethane)sulfonyl-1-benzofuran-4-yl]oxy} 
piperidine(209) 
A mixture of compound 205 (20 mg, 0.046 mmol) and 3-
chloroperbenzoic acid (77% w/w, 16 mg, 0.07 mmol) in DCM 
(1 mL) was stirred at room temperature for 1 hour. The reaction mixture was 
concentrated in vacuo, to give the N-Boc precursor without further purification. This 
compound was further deprotected in DCM containing 5% TFA (2 mL), to afford the title 
compound as pink oil (8.0 mg, 36% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.52 (t, 
J=8.0 Hz, 1H), 7.46 (s, 1H), 7.35-7.21 (m, 6H), 6.99 (d, J=8.0 Hz, 1H), 4.98-4.92 (m, 1H), 
4.72 (s, 2H), 3.48-3.39 (m, 2H), 3.29-3.19 (m, 2H), 2.28-2.18 (m, 2H), 2.14-2.07 (m, 2H). 
13C-NMR (CD3OD, 100 MHz): δ 157.59, 151.61, 148.00, 130.60, 129.39, 128.55, 128.22, 
127.77, 117.35, 112.47, 106.75, 105.11, 68.95, 60.60, 40.31, 26.78. Calculated exact 
mass for the protonated molecule (C20H22NO4S): 372.1270; measured accurate mass (ESI): 
372.1263. LC-MS purity: 100%, tR = 10.91 min.  
 
4-{[3-Methyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-
benzofuran-4-yl]oxy}piperidine (213) 
A mixture of compound 120 (25 mg, 0.066 mmol), EDCI (14 
mg, 0.073 mmol), hydroxybenzotriazole (12 mg, 0.086 
mmol) in anhydrous acetonitrile (2 mL) was stirred at room temperature for 30 minutes, 
and then treated with N'-hydroxybenzenecarboximidamide (10 mg, 0.073 mmol) and 
DIPEA (24 µL, 0.13 mmol). The resulting mixture was further stirred at room temperature 
for 12 hours. After that, the solution was evaporated to dryness in vacuo. The residue 
was re-dissolved in ethyl acetate (20 mL) and washed with brine, 5% NaHCO3 and water 
(each 20 mL). The organic layer was dried over anhydrous sodium sulphate and 
concentrated in vacuo. The residue was then dissolved in dry toluene over 4Å molecular 
sieve and the resulting mixture was stirred at 110 ˚C for 4 hours. After that, the reaction 
mixture was filtered off and the filtration was concentrated in vacuo, to give the N-Boc 
precursor without further purification. This compound was further deprotected in DCM 
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containing 5% TFA (1 mL) according to the preparation of compound 109, to afford the 
title compound as a white solid (6.3 mg, 20% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
8.14 (d, J=7.6 Hz, 2H), 7.62-7.53 (m, 3H), 7.43 (t, J=8.0 Hz, 1H), 7.22 (d, J=8.0 Hz, 1H), 
6.90 (d, J=8.0 Hz, 1H), 4.99-4.95 (m, 1H), 3.50-3.44 (m, 2H), 3.37-3.31 (m, 2H), 2.94 (s, 
3H), 2.38-2.26 (m, 2H), 2.26-2.13 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 170.00, 169.76, 
158.24, 154.51, 137.38, 132.64, 130.37, 130.10, 128.46, 127.83, 126.01, 120.24, 106.94, 
106.12, 70.09, 42.02, 28.30, 11.78. Calculated exact mass for the protonated molecule 
(C22H22N3O3): 376.1661; measured accurate mass (ESI): 376.1659. LC-MS purity: 100%, tR 
= 13.33 min.  
 
4-{[2-(3-Benzyl-1,2,4-oxadiazol-5-yl)-3-methyl-1-
benzofuran-4-yl]oxy}piperidine (215) 
Prepared from a mixture of compound 120 (30 mg, 0.08 
mmol), EDCI (16.9 mg, 0.088 mmol), 
hydroxybenzotriazole (14 mg, 0.1 mmol), N'-hydroxybenzyl carboximidamide (13.2 mg, 
0.088 mmol) and DIPEA (28 µL, 0.16 mmol) in anhydrous acetonitrile (2 mL), the ester 
was formed, followed by the thermal dehydration under refluxing toluene conditions to 
give the N-Boc precursor. This compound was further deprotected in DCM containing 5% 
TFA (1 mL) according to the preparation of compound 213, to afford the title compound 
as a white solid (11.6 mg, 29% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.46-7.24 (m, 
6H), 7.18 (d, J=8.0 Hz, 1H), 6.86 (d, J=8.0 Hz, 1H), 4.99-4.90 (m, 1H), 4.17 (s, 2H), 3.49-
3.38 (m, 2H), 3.33-3.26 (m, 2H), 2.83 (s, 3H), 2.36-2.26 (m, 2H), 2.19-2.09 (m, 2H). 13C-
NMR (CD3OD, 100 MHz): δ 171.17, 169.92, 158.18, 154.46, 137.34, 137.04, 130.30, 
130.06, 129.72, 128.16, 125.85, 120.21, 106.91, 106.09, 70.04, 41.97, 32.86, 28.25, 
11.67. Calculated exact mass for the protonated molecule (C23H24N3O3): 390.1818; 
measured accurate mass (ESI): 390.1819. LC-MS purity: 100%, tR = 12.86 min. 
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6.2   Biology 
 
6.2.1   General Methods 
 
The purities of all the molecules used for biological assays were at least 95% 
(except for three ether compounds), which were determined by analytical LC-MS 
(Section 6.1.1). The stock solutions for test molecules were either 50 mM or 10 mM in 
anhydrous DMSO.  
The enzymes PfNMT and LdNMT were expressed by Dr James Brannigan at 
University of York and stored as 0.98 mg/mL 0.58 mg/mL respectively, in a solution of 25% 
glycerol, 40 mM Tris pH 7.5, 1.25 mM NaCl, 2 mM dithiothreitol (DTT), 2 mM ethylene 
glycol tetraacetic acid (EGTA) and 2 mM ethylenediaminetetraacetic acid (EDTA). The 
enzymes HsNMT1 and HsNMT2 were expressed by Dr Franziska Meier, a past member of 
our group, and stored as 9.8 mg/mL and 1.33 mg/mL respectively, in a solution of 20% 
glycerol, 30 mM Tris pH 7.4, 2.5 mM DTT, 0.5 mM EGTA and 0.5 mM EDTA. The peptide 
substrate GLYVSRLFNRLFQKK(Biotin)-NH2 was synthesized by Dr Paul Bowyer, another 
past member of our group, and stored as 20 mM in anhydrous DMSO. Both [9,10(n)-
3H]myristoyl CoA (3.51 µM @ 57 Ci/mmol in 0.01 M sodium acetate, pH 5.6:ethanol (1:1) 
solution) and streptavidin PVT beads were purchased from GE Healthcare (The 
radioactive department now belongs to Perkin Elmer). All the other chemicals were 
obtained from Sigma-Aldrich. Enzyme assays were carried out in white opaque 96-well 
microplates, which were purchased from Perkin Elmer.   
Plasmodium falciparum inhibition assays were performed by Dr David Moss at 
the National Institute of Medical Research (NIMR). Hydroethidine (HE) fluorescent stain 
was obtained from Polyscience. 2% Haematocrit are 2% red blood cells in media, i.e. 2 
mL erythrocytes in 100 mL media. 70% Percoll was purchased from Amersham 
Biosciences (formerly known as GE Healthcare). Albumax was purchased from GIBCO 
and Giesma from BDH. 
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Leishmania Donovani ex-vivo amastigote inhibition and macrophage toxicity 
assays were carried out by Dr Daniel Paape at University of York. Alama blue was 
purchased from Trek Diagnostics; DMEM medium was obtained from Invitrogen 
(catalogue number: 41966029); All the other chemicals, including RPMI1640 medium, 
were purchased from Sigma Aldrich. 
 
6.2.2   Biological Assays 
 
6.2.2.1   Standard procedure for enzyme inhibition assay 
 
Enzyme inhibition assay (in total 100 µL for each well) for NMTs contained 
variable amounts of an inhibitor, 9.4 ng of purified PfNMT (4.8 ng for LdNMT, 5.1 ng for 
HsNMT1 and 20.8 ng for HsNMT2), 62.5 nM 3H-Myristoyl-CoA (8 Ci/mmol) and 500 nM 
of peptide substrate in 4% DMSO buffer 1 (Table 6.1). Incubation was allowed to proceed 
for 30 min at 37 °C, followed by the addition of 100 µL bead-stop solution (buffer 3, 
Table 6.1) to terminate the reaction. Overnight settling of the beads resulted in an 
accurate reading, with signal-to-noise ratio at least 20. The instrument used for counting 
is a Plate Chameleon multilabel reader (Hidex Oy, Finland). Final concentration of 100 
µM and 10 µM of inhibitors are used for the single-point assay. The readout of [3H]-
myristoylated peptide in the reaction lacking an inhibitor was defined as 100% activity 
(positive control), and that from the reaction with no enzyme was defined as 0% 
(negative control). The effect of an inhibitor at the single concentration was calculated as 
a percentage of the enzyme activity left (% activity left = (readout-negative) / (positive-
negative) X 100%). In terms of the IC50 determination, the inhibitory activity of an 
inhibitor was measured according to the method described above with the 
concentrations ranging from 500 µM to 2 nM and the 50% inhibitory concentration (IC50) 
of an inhibitor was calculated by a nonlinear regression analysis using GraFit 7.0.1 
version (Erithacus Software Limited, UK). Single point assays were performed in triplicate 
and IC50 determination assays were carried out in duplicate.  
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Table 6.1  Components of the assay buffer system 
Buffer 1 Buffer 2 Buffer 3 
30 mM Tris 
0.5mM EGTA 
0.5 mM EDTA 
2.5 mM DTT 
Adjust to pH 7.4 with HCl 
0.1% Triton X-100 
0.2 M phosphoric acid 
 Adjust to pH 4.0 with NaOH 
0.75 mM MgCl2 
0.05% (w/V) BSA 
0.01% (w/V) NaN3 
Streptavidin PVT beads in 
PBS/0.05% NaN3(50 
mg/mL); diluted 50 times 
using buffer 2 
 
6.2.2.2   Km determination of substrates in enzyme assays 
 
The KM for myristoyl-CoA was evaluated by varying the concentration of [
3H]-
myristoyl-CoA between 500 nM and 0.23 nM, at a fixed 500 nM concentration of the 
assay peptide. The KM with respect to the peptide was evaluated by varying its 
concentration over the range 10-0.04 µM, at a fixed concentration of [3H]-myristoyl-CoA 
of 62.5 nM. The amount of beads added in stop solution was proportional to the amount 
of the assay peptide. Other substrates were kept the same to the inhibition assay 
described above except that there was no inhibitor involved. The reactions were 
quenched after 1, 3 and 5 min, and the initial reaction velocities were derived. Data were 
analyzed by nonlinear regression (Michaelis-Menten) and linear regression of a double-
reciprocal plot (Lineweaver-Burk) using GraFit 7.0.1 version (Erithacus Software Limited, 
UK). Assays were performed once due to safety and cost considerations. 
 
6.2.2.3   P. falciparum inhibition assay  
 
P. falciparum parasites were routinely cultured in 2% haematocrit at 37 °C in 
RPMI 1640 containing albumax and glutamine. To synchronise parasites, heterogeneous 
populations containing late stages were first centrifuged onto a 70% Percoll cushion to 
separate late trophozoite/schizont from rings. Late trophozoite/schizonts were then 
harvested from the Percoll cushion, pelleted and washed twice in media to remove 
remaining Percoll. These parasites were re-cultured for 3-5 hours with fresh red blood 
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cells, allowing invasion to occur, and assessed using Giemsa-stained smears. Following 
invasion the culture was pelleted and incubated in a final concentration of 90% sorbitol 
at 37 °C for 10 min to remove remaining schizonts. Post sorbitol treatment, the culture 
was pelleted and washed twice in fresh media prior to re-suspension in media to 2% 
haematocrit for culturing.  
For each assay, a 90 µL culture was placed into a well of a 96-well plate. And for 
each compound, a 10x serial dilution was made using a 10x stock of DMSO media (5% 
DMSO) so that in each case the final DMSO concentration was maintained at 0.5%. To 
each well 10 µL of this 10x stock was added to above 90 µL culture. Therefore, the final 
assay volume was 100 µL in each well.  
Synchronous cultures of late trophozoite-stage parasites (1% parasitemia in 2% 
haematocrit) were grown with experimental inhibitors at different concentrations, with 
the range of 20-0.62 µM. Cultures were incubated at 37 ˚C for another cycle, which is 48 
hours. Aliquots of 50 µL were removed from each well then, and added to 500 μL freshly 
diluted HE (1:200 dilution of 10 mg/mL DMSO stock in PBS) and incubated for 20 min at 
37 °C. Samples were then diluted with 1 mL PBS to enable appropriate counts (5000 
counts/s). Staining was stopped by storing samples on ice. Parasites cultured in medium 
in the absence of an inhibitor and non-infected red blood cells were used as positive and 
negative controls respectively.  
Parasitemia was calculated using a FACSCalibur flow cytometer. When expressed 
as a histogram of HE intensity vs. number of erythrocytes, a distinct peak representing 
late trophozoite/schizont infected erythrocytes is evident and can be used to calculate 
parasitemia of cultures. And the growth inhibition at each concentration is calculated as % 
inhibition = [1-(readout-negative)/(positive-negative)] x 100%. All assays were carried 
out in triplicate.  
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6.2.2.4   L. donovani ex vivo amastigote inhibition assay  
 
L. donovani amastigotes (5 X 105/well of 96-well plate) were incubated with test 
compounds, with the concentrations ranging from 75 μM to 0.034 µM in 200 μL RPMI 
1640 medium supplemented with 20% heat-inactivated FCS, 100 µM adenine, 20 mM 2-
[N-morpholino]ethanesulphonic acid (pH 5.5), 5 µM hemin, 3 µM biopterin, 1 µM biotin, 
100 U penicillin and 100 µg streptomycin. After 72 hour incubation at 26 ˚C, alamar blue 
(10% v/v) was added to each well and the resulting mixture was incubated for additional 
4 hours prior to measuring the fluorescence (excitation wavelength was 560 nm and 
emission was recorded with a 590nm±10nm bandpass filter, POLARstar Optima). 
Parasites cultured in medium alone were used as a positive control and medium without 
cells containing corresponding concentration of a compound was used as a medium 
control. Growth inhibition at each concentration was calculated as % inhibition of 
normalized data = [1-(readout-medium)/(positive-medium)] x 100%. Assays were carried 
out in triplicate. 
 
6.2.2.5   Macrophage toxicity test 
 
Bone marrow-derived macrophage (BMDM, 4.2 X 104/well of 96-well plate) were 
incubated with the same concentrations of test compounds as mentioned above in 
DMEM medium containing 4% L929 cell and 10% FCS (fetal calf serum). Cells were 
incubated at 37˚ C and 5% CO2 for 72 hours. Aalamar blue (10% v/v) was added to each 
well and the resulting mixture was incubated for additional 4 hours prior to measuring 
the fluorescence. Medium without cells containing the corresponding concentration of a 
compound was used as a medium control. Assays were performed in duplicate. 
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6.2.3   Crystallography 
 
Protein-ligand complex crystallisation  
45 µL PvNMT (6 mg/mL in 10 mM Tris pH 7.0, 125 mM NaCl) was incubated 
overnight at 4°C with 5 µL of S-(2-oxo)pentadecyl-CoA (10 mM in 50% DMSO) and 1 mg 
of solid ligand. Crystals were grown by the vapour diffusion method. Hanging drops 
consisting of 1 µL protein mixture (after centrifugation to pellet any solid material) and 1 
µL of reservoir solution containing 0.2 M ammonium sulphate, 25% (w/v) PEG 3350, 5% 
(v/v) DMF in 0.1 M Bis-Tris buffer, pH 6.0 were equilibrated against 0.8 mL reservoir 
solution at 20°C. Preliminary X-ray analysis established that the crystals belong to the 
orthorhombic space group P212121 with cell dimensions a = 57.36 Å, b = 121.63 Å, c = 
179.05 Å. With three molecules per asymmetric unit, the Matthew’s coefficient is 2.08 
Å3/Da corresponding to a solvent content of 41 %. Crystals were flash-vitrified directly in 
liquid nitrogen before storage. 
Data collection, processing and structure solution 
X-ray diffraction data were collected on synchrotron beamline I04-1 (λ = 0.9173 
Å) at the Diamond Light Source (Oxford) and processed using HKL2000[190] implemented 
in the CCP4 suite[191]. All data were used in molecular replacement calculations in the 
program MOLREP[192] using the coordinate set corresponding to a monomer of PvNMT 
(without associated waters) as the search model. The output trimeric model found by 
molecular replacement was refined using maximum likelihood methods implemented in 
REFMAC5[193]. 5% of the data were excluded for R-free calculations. The model was 
refined by iterative cycles of REFMAC5 using anisotropic temperature factors, 
interspersed with manual modelling and adjustments carried out in COOT[194]. 
Refinement was concluded with an R-factor of 19.9 % (Rfree 26.9 %) for data in the range 
30 - 2.2 Å.  
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Appendix – Full biological data of test compounds 
 
Reference 
Number 
Structure 
IC50 against 
NMTs 
P. falciparum 
EC50 
L. donovani 
ex-vivo 
amastigote 
EC50  
Toxicity 
d
 
1 
 
Pf: 51.4 µM
a
 
Ld: (2%)
b
 
Hs1: (0%) 
Hs2: (1.3%) 
   
13 
 
Pf: (31.0%) 
Ld: (60.0%) 
   
14 
 
Pf: (0%) 
Ld: (0%) 
   
15 
 
Pf: 9.0 µM 
Ld: (37.5%) 
Hs1: (0%) 
Hs2: (37.5%) 
16.9 ± 2.7 µM; 
prediction
c
 
  
16 
 
Pf: 8.5 µM 
Ld: (44.1%) 
Hs1: (0%) 
Hs2: (34.3%) 
6.8 ± 0.7 µM; 
Hill slope: 4.4 
  
17 
 
Pf: 54.5 µM 
Ld: (61.6%) 
Hs1: (0%) 
Hs2: (0%) 
   
18 
 
Pf: 84.4 µM 
Ld: (20.4%) 
   
19 
 
Pf: (48.1%) 
Ld: (46.6%) 
   
20 
 
Pf: (48.4%) 
Ld: (0%) 
   
21 
 
Pf: (21.2%) 
Ld: (0%) 
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22 
 
Pf: (35.6%) 
Ld: (22.4%) 
   
23 
 
Pf: 102 µM 
Ld: (34.3%) 
   
24 
 
Pf: 51.0 µM 
Ld: (65.5%) 
   
25 
 
Pf: 13.0 µM 
Ld: (21.5%) 
Hs1: (14.9%) 
Hs2: (27.2%)  
   
26 
 
Pf: 31.6 µM 
Ld: (63.4%) 
Hs1: (17.6%) 
Hs2: (46.4%) 
   
27 
 
Pf: (56.7%) 
Ld: (15.2%) 
   
28 
 
Pf: (59.1%) 
Ld: (37.0%) 
   
29 
 
Pf: (17.0%) 
Ld: >100 µM  
   
30 
 
Pf: (43.8%) 
Ld: (21.9%) 
   
31 
 
Pf: (25.0%) 
Ld: (4%) 
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32 
 
Pf: (41.4%) 
Ld: (37.3%) 
   
33 
 
Pf: (40.7%) 
Ld: (0%) 
   
34 
 
Pf: (31.2%) 
Ld: (43.5%) 
   
35 
 
Pf: (0%) 
Ld: (0%) 
   
36 
 
Pf: (0%) 
Ld: (8.5%) 
7.3 ± 0.9 µM; 
Hill slope: 3.1 
3.3 ± 0.1 µM; 
Hill slope: 2.6 
Between 25 
and 75 µM 
48 
 
Pf: (35.7%) 
Ld: (0%) 
   
49 
 
Pf: (0%) 
Ld: (0%) 
   
51 
 
Pf: (50.5%) 
Ld: (0%) 
   
52 
 
Pf: (22.6%) 
Ld: (0%) 
   
53 
 
Pf: (28.9%) 
Ld: (0%) 
   
59 
 
Pf: 9.2 µM 
Ld: (43.1%) 
Hs1: (18.3%) 
Hs2: (56.6%) 
1.2 ± 0.6 µM; 
prediction 
c
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60 
 
Pf: (0%) 
Ld: (44.3%) 
92% parasite 
death at 5 µM 
2.6 ± 0.2 µM; 
Hill slope: 1.1 
Between 8.3 
and 25 µM 
61 
 
Pf: 15.5 µM 
Ld: (64.4%) 
Hs1: (24.4%) 
Hs2: 70.7 µM 
   
62 
 
Pf: 30.0 µM 
Ld: (18.6%) 
Hs1: (0%) 
Hs2: (35.2%) 
   
63 
 
Pf: 63.6 µM 
Ld: (43.2%) 
   
64 
 
Pf: 56.9 µM 
Ld: (21.8%) 
Hs1: (40.0%) 
Hs2: (60.9%) 
   
65 
 
Pf: (13.5%) 
Ld: (39.1%) 
   
72 
 
Pf: 10.6 µM 
Ld: 32.6 µM 
Hs1: (40.3%) 
Hs2: 81.9 µM 
99% parasite 
death at 10 µM; 
43% parasite 
death at 5 µM 
  
73 
 
Pf: (0%) 
Ld: (53.4%) 
1.3 ± 0.5 µM; 
Prediction 
c
 
  
74 
 
Pf: 53.2 µM 
Ld: (10.2%) 
   
75 
 
Pf: 71.5 µM 
Ld: (55.9%) 
   
80 
 
Pf: 1.4 µM 
Ld: 56.0 µM 
Hs1: (61.4%) 
Hs2: 44.4 µM 
87% parasite 
death at 10 µM; 
36% parasite 
death at 5 µM 
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81 
 
Pf: 98.3 µM 
Ld: (61.1%) 
83% parasite 
death at 10 µM; 
44% parasite 
death at 5 µM 
  
82 
 
Pf: 2.3 µM 
Ld: 27.8 µM 
Hs1: 35.7 µM 
Hs2: 41.6 µM 
   
83 
 
Pf: 8.4 µM 
Ld: 35.9 µM 
Hs1: (63.0%) 
Hs2: (63.7%) 
   
84 
 
Pf: 2.1 µM 
Ld: 19.1 µM 
   
85 
 
Pf: 8.2 µM 
Ld: 36.4 µM 
   
86 
 
Pf: (29.9%) 
Ld: (34.8%) 
   
87 
 
Pf: 30.0 µM 
Ld: (24.5%) 
Hs1: (0%) 
Hs2: (28.3%) 
   
88 
 
Pf: (37.1%) 
Ld: (9.4%) 
   
91 
 
Pf: (0%) 
Ld: (10.9%) 
   
92 
 
Pf: (0%) 
Ld: (50.5%) 
   
93 
 
Pf: (0%) 
Ld: (24.0%) 
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94 
 
Pf: (45.4%) 
Ld: 98.6 µM 
Hs1: (0%) 
Hs2: (31.9%) 
   
95 
 
Pf: (32.6%) 
Ld: >100 µM 
Hs1: (0%) 
Hs2: (60.8%) 
   
96 
 
Pf: (31.7%) 
Ld: (50.6%) 
   
97 
 
Pf: 17.2 µM 
Ld: 35.4 µM 
Hs1: (38.1%) 
Hs2: 23.8 µM 
   
98 
 
Pf: 6.8 µM 
Ld: (58.4%) 
Hs1: (0%) 
Hs2: (52.0%) 
   
99 
 
Pf: 9.7 µM 
Ld: (61.5%) 
Hs1: (0%) 
Hs2: (64.9%) 
   
100 
 
Pf: 14.0 µM 
Ld: 65.4 µM 
Hs1: (36.9%) 
Hs2: (50.7%) 
   
101 
 
Pf: 6.8 µM 
Ld: (62.2%) 
Hs1: (18.5%) 
Hs2: (49.2%) 
   
102 
 
Pf: 28.9 µM 
Ld: 29.8 µM 
Hs1: (57.8%) 
Hs2: 49.0 µM 
   
109 
 
Pf: 16.5 µM 
Ld: 22.9 µM 
Hs1: (37.0%) 
Hs2: (0%) 
97% parasite 
death at 20 µM; 
33% parasite 
death at 10 µM 
4.6 ± 0.5 µM; 
prediction 
c
 
Between 25 
and 75 µM 
110 
 
Pf: (0%) 
Ld: (24.8%) 
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111 
 
Pf: (7.1%) 
Ld: (12.7%) 
   
112 
 
Pf: 50.0 µM 
Ld: (51.5%) 
16.6 ± 0.4 µM; 
Hill slope: 5.2 
  
113 
 
Pf: 27.0 µM 
Ld: (46.4%) 
Hs1: (41.9%) 
Hs2: (5.1%) 
23.7 ± 1.4 µM; 
Hill slope: 3.4 
  
114 
 
Pf: 8.0 µM 
Ld: 117 µM 
Hs1: (44.9%) 
Hs2: (27.2%) 
17% parasite 
death at 20 µM 
  
115 
 
Pf: (32.5%) 
Ld: (0%) 
 
4.1 ± 0.2 µM; 
Hill slope: 1.8 
Between 25 
and 75 µM 
116 
 
Pf: (14.7%) 
Ld: (0%) 
   
117 
 
Pf: 22.0 µM 
Ld: 8.6 µM 
Hs1: (56.0%) 
Hs2: (52.8%) 
5.3 ± 0.6 µM; 
Hill slope: 3.2 
  
118 
 
Pf: (43.0%) 
Ld: 68.8 µM 
Hs1: (39.4%) 
Hs2: (42.8%) 
   
119 
 
Pf: (0%) 
Ld: (0%) 
75% parasite 
death at 10 µM; 
0% parasite 
death at 5 µM 
6.1 ± 0.3 µM; 
Hill slope: 1.6 
Between 25 
and 75 µM 
121 
 
Pf: (19.6%) 
Ld: (31.7%) 
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122 
 
Pf: (25.4%) 
Ld: (44.2%) 
   
123 
 
Pf: (25.5%) 
Ld: (38.3%) 
   
124 
 
Pf: (43.5%) 
Ld: (57.8%) 
4.0 ± 0.7 µM; 
prediction 
c
 
  
125 
 
Pf: (40.7%) 
Ld: 59.9 µM 
   
126 
 
Pf: 28.8 µM 
Ld: 94.8 µM 
Hs1: (21.0%) 
Hs2: (19.1%) 
5.3 ± 1.1 µM; 
prediction 
c
 
  
127 
 
Pf: (23.9%) 
Ld: (29.3%) 
   
128 
 
Pf: 13.0 µM 
Ld: 13.5 µM 
Hs1: (30.5%) 
Hs2: (40.5%) 
7.8 ± 0.8 µM; 
Hill slope: 3.1; 
20% parasite 
inhibition left 
even at 0.6 µM 
97% parasite 
death at 25 
µM; 20% 
parasite death 
at 8.3 µM 
Between 8.3 
and 25 µM 
129 
 
Pf: >100 µM 
Ld: 48.8 µM 
Hs1: (48.9%) 
Hs2: (68.1%) 
   
130 
 
Pf: 2.3 µM 
Ld: 5.3 µM 
Hs1: (63.2%) 
Hs2: 50.0 µM 
2.4 ± 0.1 µM; 
Hill slope: 12.4 
  
131 
 
Pf: 21.0 µM 
Ld: 7.5 µM 
Hs1: (50.7%) 
Hs2: (61.5%) 
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132 
 
Pf: (42.1%) 
Ld: (56.3%) 
   
141 
 
Pf: (3.9%) 
Ld: (29.4%) 
   
142 
 
Pf: 6.6 µM 
Ld: 2.6 µM 
Hs1: (39.6%) 
Hs2: (52.1%) 
 
1.9 ± 0.1 µM; 
prediction 
c
 
Between 8.3 
and 25 µM 
143 
 
Pf: (14.1%) 
Ld: (53.8%) 
   
144 
 
Pf: (19.3%) 
Ld: (50.1%) 
   
145 
 
Pf: 7.1 µM 
Ld: 2.5 µM 
Hs1: (53.6%) 
Hs2: (53.0%) 
4.5 ± 1.9 µM; 
Hill slope: 2.1 
11.0 ± 2.0 µM; 
prediction 
c
 
Between 8.3 
and 25 µM 
154 
 
Pf: (44.6%) 
Ld: 9.0 µM 
Hs1: (35.4%) 
Hs2: (25.0%) 
 
44% parasite 
death at 25 
µM 
Between 8.3 
and 25 µM 
155 
 
Pf: 50.0 µM 
Ld: 5.3 µM 
Hs1: (48.8%) 
Hs2: (62.9%) 
   
156 
 
Pf: (0%) 
Ld: (15.8%) 
   
157 
 
Pf: 37.2 µM 
Ld: 13..5 µM 
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158 
 
Pf: (40.9%) 
Ld: 64.0 µM 
   
160 
 
Pf: (50.6%) 
Ld: (40.8%) 
   
161 
 
Pf: 24.4 µM 
Ld: 19.8 µM 
Hs1: (1.7%) 
Hs2: (17.4%) 
34% parasite 
death at 10 µM 
4.9 ± 1.1 µM; 
Hill slope: 0.9 
Between 25 
and 75 µM 
162 
 
Pf: 0.27 µM 
Ld: 4.7 µM 
Hs1: (41.7%) 
Hs2: (53.4%) 
1.2 ± 0.2 µM; 
prediction
c
 
1.4 ± 0.3 µM; 
Hill slope: 1.1 
Between 8.3 
and 25 µM 
163 
 
Pf: 9.7 µM 
Ld: 15.6 µM 
Hs1: 25.7 µM 
Hs2: 50.2 µM 
3.2 ± 0.8 µM; 
Hill slope: 2.5 
3.6 ± 0.7 µM; 
Hill slope: 5.1 
Between 2.8 
and 8.3  
164 
 
Pf: 1.4 µM 
Ld: 1.9 µM 
Hs1: (48.5%) 
Hs2: (52.6%) 
 
1.5 ± 0.2 µM; 
Hill slope: 1.5 
Between 2.8 
and 8.3 µM 
165 
 
Pf: (18.4%) 
Ld: (2.7%) 
   
166 
 
Pf: 4.1 µM 
Ld: 12.6 µM 
   
167 
 
Pf: 36.2 µM 
Ld: 81.7 µM 
   
173 
 
Pf: 5.6 µM 
Ld: 16.4 µM 
Hs1: (40.0%) 
Hs2: (54.2%) 
89% parasite 
death at 5 µM; 
18% parasite 
death at 2.5 µM 
100% parasite 
death at 8.3 
µM; 30% 
parasite death 
at 2.8 µM 
Between 8.3 
and 25 µM 
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174 
 
Pf: 2.1 µM 
Ld: 21.1 µM 
Hs1: (42.4%) 
Hs2: (57.8%) 
93% parasite 
death at 5 µM; 
34% parasite 
death at 2.5 µM 
  
175 
 
Pf: 0.99 µM 
Ld: 4.1 µM 
Hs1: (55.8%) 
Hs2: (56.5%) 
   
176 
 
Pf: 0.62 µM 
Ld: 2.8 µM 
Hs1: (50.1%) 
Hs2: (52.1%) 
   
177 
 
Pf: 0.68 µM 
Ld: 2.2 µM 
Hs1: >100 µM 
Hs2: 182 µM 
 
7.4 ± 2.9 µM; 
Hill slope: 1.2 
Between 8.3 
and 25 µM 
178 
 
Pf: 0.98 µM 
Ld: 7.9 µM 
Hs1: (31.2%) 
Hs2: (40.4%) 
   
179 
 
Pf: 1.9 µM 
Ld: 6.1 µM 
Hs1: (29.5%) 
Hs2: (57.6%) 
   
180 
 
Pf: 1.4 µM 
Ld: 12.5 µM 
Hs1: (53.4%) 
Hs2: (55.2%) 
4.7 ± 0.2 µM; 
Hill slope: 4.5 
1.8 ± 0.4 µM; 
Hill slope: 0.9 
Between 8.3 
and 25 µM 
181 
 
Pf: 1.5 µM 
Ld: 14.6 µM 
Hs1: 37.6 µM 
Hs2: 34.0 µM 
89% parasite 
death at 5 µM; 
25% parasite 
death at 2.5 µM 
  
182 
 
Pf: 9.6 µM 
Ld: 3.3 µM 
Hs1: (49.1%) 
Hs2: (54.2%) 
 
75% parasite 
death at 25 
µM; 
0% parasite 
death at 8.3 
µM 
Between 25 
and 75 µM 
186 
 
Pf: 131 µM 
Ld: 30.9 µM 
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188 
 
Pf: 26.1 µM 
Ld: 20.8 µM 
   
189 
 
Pf: 72.0 µM 
Ld: 68.8 µM 
   
190 
 
Pf: 10.2 µM 
Ld: 18.2 µM 
Hs1: (15.9%) 
Hs2: (45.7%) 
4.0 ± 0.3 µM; 
Hill slope: 4.7 
99% parasite 
death at 8.3 
µM; 
8% parasite 
death at 2.8 
µM 
Between 8.3 
and 25 µM 
193 
 
Pf: 3.5 µM 
Ld: 9.7 µM 
Hs1: 43.9 µM 
Hs2: 39.5 µM 
2.5 ± 0.1 µM; 
Hill slope: 3.6 
1.3 ± 0.02 µM; 
Hill slope: 4.4 
Between 8.3 
and 25 µM 
208 
 
Pf: 38.2 µM 
Ld: 25.1 µM 
   
209 
 
Pf: (44.0%) 
Ld: (63.1%) 
   
213 
 
Pf: 17.9 µM 
Ld: 26.8 µM 
   
215 
 
Pf: 2.0 µM 
Ld: 10.2 µM 
Hs1: (36.9%) 
Hs2: (40.2%) 
2.1 ± 0.1 µM; 
Hill slope: 4.8 
1.5 ± 0.02 µM; 
Hill slope: 4.2 
Between 8.3 
and 25 µM 
a  
The IC50 values were averaged from two independent dose-response curves; the variation was 
generally <15%. 
b
 The numbers in parenthese were the percentage inhibition values of 
compounds at 100 µM in triplicate; the variation was generally <10%. 
c
 The value was calculated 
from the two single points of inhibitory data, using GraFit (version 7.0.1). 
d
 Bone marrow derived 
macrophage was used in the assay.
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